: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.

Bladder Cancer, January 2023
Free Subscription

Abstracts
Retrieve all available abstracts of the following 2497 articles:
HTML format

Single Articles

CHAU M, Thia I, Viswambaram P, Hawks C, et al
Lymph node assessment technique matters in radical cystectomy for bladder cancer.
ANZ J Surg. 2023 Mar 3. doi: 10.1111/ans.18292.
Abstract

IMAMVERDIYEV S, Qasimov E, Naghiyev R
COMPARATIVE RESULTS OF MODERN EXAMINATION METHODS IN EARLY DIAGNOSIS OF BLADDER CANCER, DETERMINATION OF THE DEGREE OF INVASION AND SELECTION OF RADICAL TREATMENT TACTICS.
Georgian Med News. 2023;:98-102.
Abstract

XU H, Liu Z, Weng S, Ren Y, et al
Epigenetically regulated gene expression profiles recognized three molecular classifications with prognostic and therapeutic implications in bladder cancer.
Clin Transl Med. 2023;13:e1145.
Abstract

IKEDA M, Uemura K, Araki Y, Iribe Y, et al
[A Case of Long-Term Survival Following Multidisciplinary Therapy for Small Intestinal Metastasis of Bladder Cancer].
Hinyokika Kiyo. 2023;69:55-58.
Abstract

DE HAAR-HOLLEMAN A, van Hoogstraten LMC, C C M Hulshof M, Tascilar M, et al
Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study.
Radiother Oncol. 2023 Feb 28:109584. doi: 10.1016/j.radonc.2023.109584.
Abstract

TACAR SY, Yilmaz M, Baytekin HF, Tural D, et al
Evaluation of predictive factors in patients with bladder cancer undergoing atezolizumab treatment: Case reports.
Indian J Cancer. 2022;59:556-559.
Abstract

Retraction: CircRNA circPDSS1 promotes bladder cancer by downregulating miR-16.
Biosci Rep. 2023;43:BSR-2019-1961.
Abstract

AN HW, Hou DY, Yang J, Wang ZQ, et al
A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.
Sci Adv. 2023;9:eabq8225.
Abstract

YU Z, Lu C, Lai Y
A serum miRNAs signature for early diagnosis of bladder cancer.
Ann Med. 2023;55:736-745.
Abstract

MAZZASCHI G, Giudice GC, Coriano M, Campobasso D, et al
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.
Technol Cancer Res Treat. 2023;22:15330338231159753.
Abstract

LI X, Fu C, Li G, He H, et al
RNA-seq reveals novel mechanistic targets of Livin in bladder cancer.
BMC Urol. 2023;23:26.
Abstract

LI SH, Zhai GQ, He RQ, Chen G, et al
Down-regulation and clinical significance of Sorbin and SH3 domain-containing protein 1 in bladder cancer tissues.
IET Syst Biol. 2023 Feb 28. doi: 10.1049/syb2.12060.
Abstract

WANG XF, Liu DL, Geng L
The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder Cancer: A Meta-Analysis.
Genet Test Mol Biomarkers. 2023;27:44-55.
Abstract

MCELREE IM, Steinberg RL, Mott SL, O'Donnell MA, et al
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
JAMA Netw Open. 2023;6:e230849.
Abstract

YOUSSIEF MOHAMMED AA, Gamal DA, Abd Elzaher AR, Hasaballah A, et al
Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:517-524.
Abstract

FENG R, Li Z, Ge G, Wang C, et al
Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1/PD-1 expression.
Endocr Metab Immune Disord Drug Targets. 2023.
Abstract

WANG W, Chen L, Yang J, Hu D, et al
Apatinib Inhibits Bladder Cancer through Suppression of The VEGFR2-PI3K-AKT Signaling Pathway as revealed by Network Pharmacology and In Vitro Experimental Verification.
Comb Chem High Throughput Screen. 2023.
Abstract

KOKURA K, Watanabe J, Takuma T, Uketa S, et al
A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer.
Urol Case Rep. 2023;47:102358.
Abstract

LIU Y, Zhao YC, Lu Y, Goodarz D, et al
The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States.
Urol Oncol. 2023 Feb 25:S1078-1439(23)00051.
Abstract

KERIOUI M, Bertrand J, Desmee S, Le Tourneau C, et al
Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?
JCO Precis Oncol. 2023;7:e2200368.
Abstract

DUQUESNE I, Benamran D, Masson-Lecomte A, De La Taille A, et al
Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification.
World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04340.
Abstract

FRANCO N, Godono A, Clari M, Ciocan C, et al
Occupational asbestos exposure and urinary bladder cancer: a systematic review and meta-analysis.
World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04327.
Abstract

GUPTA P, Sarangi SS, Singh M, Pandey H, et al
To determine correlation between VIRADS scoring and pathological staging in bladder cancer: A prospective study and review of literature.
Urologia. 2023 Feb 27:3915603231151738. doi: 10.1177/03915603231151738.
Abstract

WOLF P
Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer.
Front Oncol. 2023;13:1124600.
Abstract

MAJA SG, Slavica KK, Suad A, Rubens J, et al
Bladder mucinous adenocarcinoma as a diagnostic challenge: a case report.
Pan Afr Med J. 2022;42:221.
Abstract

WANG Z, Wang J, Zhang W, Wang D, et al
Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature.
Pathol Oncol Res. 2023;29:1610856.
Abstract

GUERRERO-RAMOS F
BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
Actas Urol Esp (Engl Ed). 2023 Feb 24:S2173-5786(23)00018.
Abstract

HE HL, Lai HY, Chan TC, Hsing CH, et al
Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder.
World J Surg Oncol. 2023;21:62.
Abstract

LIU Z, Song L, Xie J, Wu XR, et al
Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
Molecules. 2023;28:1666.
Abstract

LEMINSKI A, Michalski W, Masojc B, Kaczmarek K, et al
Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.
J Clin Med. 2023;12:1560.
Abstract

WEN P, Wen J, Huang X, Wang F, et al
Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.
J Clin Med. 2023;12:1314.
Abstract

BOSCHI F, Malatesta M
Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review.
Int J Mol Sci. 2023;24:3812.
Abstract

SANGUEDOLCE F, Zanelli M, Palicelli A, Bisagni A, et al
HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Int J Mol Sci. 2023;24:3720.
Abstract

YANG CC, Chuang FC, Chang CL, Huang CR, et al
Melatonin-Assisted Cisplatin Suppresses Urinary Bladder Cancer Cell Proliferation and Growth through Inhibiting PrP(C)-Regulated Cell Stress and Cell Proliferation Signaling.
Int J Mol Sci. 2023;24:3353.
Abstract

LIN PT, Hung WK, Chang YH, Hsieh ML, et al
Replacement Instead of Discontinuation of Bacillus Calmette-Guerin Instillation in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:1345.
Abstract

LEE MC, Wang SY, Pan CT, Chien MY, et al
Development of Deep Learning with RDA U-Net Network for Bladder Cancer Segmentation.
Cancers (Basel). 2023;15:1343.
Abstract

LEE HW, Kwon WA, Nguyen NT, Phan DTT, et al
Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations.
Cancers (Basel). 2023;15:1323.
Abstract

ABOUDARAM A, Chaltiel L, Pouessel D, Graff-Cailleaud P, et al
Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.
Cancers (Basel). 2023;15:1161.
Abstract

GAO Y, Cao H, Huang D, Zheng L, et al
RNA-Binding Proteins in Bladder Cancer.
Cancers (Basel). 2023;15:1150.
Abstract

WANG H, Feng Y, Zheng X, Xu X, et al
The Diagnostic and Therapeutic Role of snoRNA and lincRNA in Bladder Cancer.
Cancers (Basel). 2023;15:1007.
Abstract

KOLL FJ, Metzger E, Hamann J, Ramos-Triguero A, et al
Overexpression of KMT9alpha Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer.
Cells. 2023;12:589.
Abstract

SHI Y, Mathis BJ, He Y, Yang X, et al
The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.
Biomedicines. 2023;11:539.
Abstract

JAIN M, Tivtikyan A, Kamalov D, Avdonin S, et al
Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies.
Biomedicines. 2023;11:495.
Abstract

GALINIAK S, Molon M, Biesiadecki M, Mokrzynska A, et al
Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer.
Antioxidants (Basel). 2023;12:277.
Abstract

ZONA A, Fazzo L, Benedetti M, Bruno C, et al
[SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
Epidemiol Prev. 2023;47.
Abstract

CINAR NB, Yilmaz H, Avci IE, Cakmak K, et al
Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria.
World J Surg Oncol. 2023;21:58.
Abstract

MARTINEZ-VIDAL L, Chighizola M, Berardi M, Alchera E, et al
Micro-mechanical fingerprints of the rat bladder change in actinic cystitis and tumor presence.
Commun Biol. 2023;6:217.
Abstract

JOSHI M, Tuanquin L, Zhu J, Walter V, et al
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
J Immunother Cancer. 2023;11:e006551.
Abstract

TANG Q, Zuo W, Wan C, Xiong S, et al
Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Front Immunol. 2023;13:1097730.
Abstract

ALRADHI M, Wen S, Safi M, Al-Danakh A, et al
Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.
Cancer Med. 2023;12:3931-3951.
Abstract

RASPOLLINI MR, Comperat EM, Lopez-Beltran A, Montironi R, et al
News in the classification of WHO 2022 bladder tumors.
Pathologica. 2022;115:32-40.
Abstract

BOULEFTOUR W, Sargos P, Magne N
Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
Curr Oncol Rep. 2023;25:181-188.
Abstract

HU X, Wang K, Sun M, Li C, et al
Quantitative MRI in distinguishing bladder paraganglioma from bladder leiomyoma.
Abdom Radiol (NY). 2023;48:1051-1061.
Abstract

PEREZ-MONTIEL D, Olivares-Mundo A, Jimenez-Rios MA, Morera CS, et al
Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
Ann Diagn Pathol. 2023;63:152081.
Abstract

BABAN F, Auen T, Eschbacher KL, Swanson AA, et al
Invasive urothelial carcinoma with squamous differentiation and associated high-risk human papilloma virus infection: Clinical, cytologic, and histologic features of a rare entity.
Ann Diagn Pathol. 2023;63:152103.
Abstract

FUJIKI T, Sakai Y, Ikawa Y, Takenaka M, et al
Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib.
Pediatr Blood Cancer. 2023;70:e30172.
Abstract

PETEINARIS A, Kallidonis P, Tsaturyan A, Pagonis K, et al
The feasibility of robot-assisted radical cystectomy: an experimental study.
World J Urol. 2023;41:477-482.
Abstract

SYED M, Mushtaq S, Loya A, Hassan U, et al
Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
Ann Diagn Pathol. 2023;63:152079.
Abstract

GAO S, Zhou XQ, Wu Q, Chen XD, et al
Effects of Holliday Junction-Recognition Protein-Mediated C-Jun N-Terminal Kinase/ Signal Transducer and Activator of Transcription 3 Signaling Pathway on Cell Proliferation, Cell Cycle and Cell Apoptosis in Bladder Urothelial Carcinoma.
Tohoku J Exp Med. 2023;259:209-219.
Abstract

HEKMAN MCH, Wijn SRW, Lotan Y, Govers TM, et al
Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
World J Urol. 2023;41:471-476.
Abstract

BALAR AV, Castellano DE, Grivas P, Vaughn DJ, et al
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
Ann Oncol. 2023;34:289-299.
Abstract

BREHMER M
Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on "Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 20
Scand J Urol. 2023;57.
Abstract

BALAWENDER K, Wawrzyniak A, Walocha J, Mazur M, et al
Leiomyoma: a case of a rare benign mesenchymal neoplasm of the urinary bladder.
Pol Arch Intern Med. 2023;133:16381.
Abstract

KARTTUNEN E, Hervonen P, Hosseini Aliabad A, Oldenburg J, et al
Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019.
Scand J Urol. 2023;57.
Abstract

BOROWCZAK J, Szczerbowski K, Maniewski M, Zdrenka M, et al
The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma.
Clin Transl Oncol. 2023;25:830-840.
Abstract

ALTIERI MA, Sarmiento-Machado LM, Romualdo GR, de Moura NA, et al
Dietary Capsaicin Reduces Chemically Induced Rat Urinary Bladder Carcinogenesis.
Plant Foods Hum Nutr. 2023;78:93-99.
Abstract

MOEEN AM, Behnsawy HM, Faragallah MA, Gadelkareem RA, et al
Functional evaluation of a spiral neobladder with an angled chimney; A prospective randomized comparative study.
Eur J Surg Oncol. 2023;49:491-496.
Abstract

LIMONNIK V, Samiei A, Abel S, Wegner RE, et al
Urachal carcinoma: A novel staging system utilizing the National Cancer Database.
Cancer Med. 2023;12:2752-2760.
Abstract

MATSUBARA N, Yonese J, Kojima T, Azuma H, et al
Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
Cancer Med. 2023;12:2761-2771.
Abstract

SONPAVDE GP, Maughan BL, McGregor BA, Wei XX, et al
Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
Cancer Immunol Immunother. 2023;72:775-782.
Abstract

HUANG J, Huang D, Ruan X, Huang J, et al
Association between cannabis use with urological cancers: A population-based cohort study and a mendelian randomization study in the UK biobank.
Cancer Med. 2023;12:3468-3476.
Abstract

WU Y, Zhu W, Wang J, Liu L, et al
Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials.
Cancer Med. 2023;12:3744-3757.
Abstract

ITO K, Kita Y, Yokomizo A, Miki J, et al
Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
Cancer Med. 2023;12:2325-2332.
Abstract

BORET S, Lambert E, Charles VP, Philippe T, et al
Vulvar pagetoid urothelial intraepithelial neoplasia: a case report.
Acta Chir Belg. 2023;123:174-177.
Abstract

LENTZSCH AM, Siggel R, Schnorr C, Holtick U, et al
LONG-TERM FOLLOW-UP OF ASYMMETRIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION IN A PATIENT WITH METASTASIZED UROTHELIAL CARCINOMA.
Retin Cases Brief Rep. 2023;17:105-110.
Abstract

COCKRELL DC, Rose TL
Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.
Curr Oncol Rep. 2023 Mar 10. doi: 10.1007/s11912-023-01390.
Abstract

YANAGISAWA T, Matsukawa A, Iwatani K, Sato S, et al
En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
Ann Surg Oncol. 2023 Mar 10. doi: 10.1245/s10434-023-13227.
Abstract

GRABE-HEYNE K, Henne C, Odeyemi I, Pohlmann J, et al
Evaluating the cost-utility of intravesical bacillus calmette-guerin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
J Med Econ. 2023 Mar 10:1-19. doi: 10.1080/13696998.2023.2189860.
Abstract

HU X, Sun C, Ren X, Ge S, et al
Contrast-enhanced Ultrasound Combined With Elastography for the Evaluation of Muscle-invasive Bladder Cancer in Rats.
J Ultrasound Med. 2023 Mar 10. doi: 10.1002/jum.16216.
Abstract

YAMAMOTO Y, Kawashima A, Morishima T, Uemura T, et al
Comparative Effectiveness of Radiation Versus Radical Cystectomy for Localized Muscle-Invasive Bladder Cancer.
Adv Radiat Oncol. 2022;8:101157.
Abstract

WANG H, Li J, Zi X, Yuan X, et al
Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis, tumor microenvironment invasion, and drug sensitivity.
Front Oncol. 2023;13:1116305.
Abstract

WU S, Hong G, Xu A, Zeng H, et al
Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
Abstract

MANDRIK O, Hahn AI, Catto JWF, Zauber AG, et al
Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.
Pharmacoeconomics. 2023 Mar 8. doi: 10.1007/s40273-023-01256.
Abstract

ZUKOV RA, Savchenko AA, Slepov EV, Semenov EV, et al
Phenotype of Urine Sediment Cells in Patients with Bladder Cancer.
Bull Exp Biol Med. 2023 Mar 9. doi: 10.1007/s10517-023-05732.
Abstract

CARAMELO B, Zagorac S, Corral S, Marques M, et al
Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
Eur Urol Oncol. 2023 Mar 6:S2588-9311(23)00043-3. doi: 10.1016/j.euo.2023.
Abstract

YAMADA Y, Kume H
[Frailty and surgical tolerability in elderly patients undergoing robot-assisted radical cystectomy (RARC)].
Nihon Ronen Igakkai Zasshi. 2023;60:38-42.
Abstract

JIN D, Qian L, Xia J, Zhang R, et al
In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
Med Oncol. 2023;40:113.
Abstract

FAN X, Yu H, Ni X, Chen G, et al
Systematic radiomics analysis based on multiparameter MRI to preoperatively predict the expression of Ki67 and histological grade in patients with bladder cancer.
Br J Radiol. 2023 Mar 8:20221086. doi: 10.1259/bjr.20221086.
Abstract

PASSALACQUA MI, Squeri A, Sciume C, Ieni A, et al
Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient.
Acta Biomed. 2023;94.
Abstract

SHU TD, Schumacher FR, Conroy B, Ponsky L, et al
Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.
Cancer Causes Control. 2023 Mar 8. doi: 10.1007/s10552-023-01679.
Abstract

TAPPERO S, Barletta F, Piccinelli ML, Cano Garcia C, et al
Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer.
Urol Oncol. 2023 Mar 5:S1078-1439(23)00015-7. doi: 10.1016/j.urolonc.2023.
Abstract

AKDEMIR E, Sweegers MG, Vrieling A, Rundqvist H, et al
EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.
BMJ Open. 2023;13:e071304.
Abstract

JEONG SH, Ku JH
Treatment strategies for the Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
Investig Clin Urol. 2023;64:103-106.
Abstract

NAGAHISA C, Iizuka J, Kobari Y, Minoda R, et al
Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases.
In Vivo. 2023;37:912-915.
Abstract

CHEN L, Dong W, Zhou M, Yang C, et al
PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
Cell Biosci. 2023;13:45.
Abstract

CIARAMELLA A, Di Nardo E, Terracciano D, Conte L, et al
A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer prognosis by a machine learning based methodology.
BMC Bioinformatics. 2023;23.
Abstract

LEE YS, Ha MS, Tae JH, Chang IH, et al
Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study.
Sci Rep. 2023;13:3682.
Abstract

SCHMOKEL SS, Nordentoft I, Lindskrog SV, Lamy P, et al
Improved protocol for single-nucleus RNA-sequencing of frozen human bladder tumor biopsies.
Nucleus. 2023;14:2186686.
Abstract

JIN D, Qian L, Xia J, Zhang R, et al
In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy.
Cell Oncol (Dordr). 2023 Mar 6. doi: 10.1007/s13402-023-00785.
Abstract

In brief: Adstiladrin - a gene therapy for bladder cancer.
Med Lett Drugs Ther. 2023;65:e40-e41.
Abstract

YOSHIOKA F, Kato T, Shima Y, Hatano K, et al
Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin administration for bladder cancer with scleroderma.
IJU Case Rep. 2023;6:133-136.
Abstract

COLLACOTT H, Krucien N, Heidenreich S, Catto JWF, et al
Patient Preferences for Treatment of Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.
Eur Urol Open Sci. 2023;49:92-99.
Abstract

WU Y, Xu Y, He S, Li Y, et al
Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
Heliyon. 2023;9:e13707.
Abstract

LI T, Jiang N, Bai Y, Liu T, et al
Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature.
Heliyon. 2023;9:e13661.
Abstract

CHEN R, Jiang M, Hu B, Fu B, et al
Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.
Int J Gen Med. 2023;16:707-722.
Abstract

ST-LAURENT MP, Suderman J, Black PC
Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer.
Eur Urol Oncol. 2023 Mar 3:S2588-9311(23)00035-4. doi: 10.1016/j.euo.2023.
Abstract

ANDRIKOS I, Stefanou K, Bellos C, Stergios G, et al
EDIT Software: A tool for the semi-automatic 3D reconstruction of bladder cancer and urinary bladder of animal models.
Comput Methods Programs Biomed. 2023;232:107448.
Abstract

WHYNOT EG, Tomko AM, Dupre DJ
Anticancer properties of cannabidiol and Delta(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines.
J Cannabis Res. 2023;5:7.
Abstract

CARVALHO LB, Martinez JLC, Lodeiro C, Bento R, et al
Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients.
J Proteomics. 2023 Mar 2:104865. doi: 10.1016/j.jprot.2023.104865.
Abstract

IZAWA M, Tanaka N, Murakami T, Anno T, et al
Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
Lab Invest. 2023;103:100040.
Abstract

AMEEN YA, Badary DM, Abonnoor AEI, Hussain KF, et al
Which data subset should be augmented for deep learning? a simulation study using urothelial cell carcinoma histopathology images.
BMC Bioinformatics. 2023;24:75.
Abstract

BUKAVINA L, Isali I, Ginwala R, Sindhani M, et al
Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
Eur Urol Oncol. 2023 Mar 1:S2588-9311(23)00036-6. doi: 10.1016/j.euo.2023.
Abstract

LI KD, Chu CE, Patel M, Meng MV, et al
Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
Urol Oncol. 2023 Mar 1:S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.
Abstract

HERZOG RW, Suzuki M
Adenoviral gene therapy for bladder cancer.
Cell. 2023;186:893.
Abstract

ZENG SP, Sun YF, Ye JB, Zeng K, et al
Transurethral en bloc resection of a bladder perivascular epithelioid cell tumor (PEComa): a case report.
BMC Urol. 2023;23:28.
Abstract

FONTUGNE J, Wong J, Cabel L, Neyret-Kahn H, et al
Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis.
J Pathol. 2023;259:455-467.
Abstract

GERALD T, Margulis V, Meng X, Bagrodia A, et al
Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
Urol Oncol. 2023;41:148.
Abstract

SETYO LC, Donahoe SL, Shearer PL, Wang P, et al
Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-beta, and CDK4 in canine urothelial carcinoma.
J Vet Diagn Invest. 2023;35:109-115.
Abstract

MIYAKE M, Shimizu T, Oda Y, Tachibana A, et al
Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
Jpn J Clin Oncol. 2023;53:253-262.
Abstract

BARLETTA F, Tappero S, Panunzio A, Incesu RB, et al
Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
Urol Oncol. 2023;41:147.
Abstract

WOLDU SL, Labbate C, Murray KS, Rose K, et al
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Urol Oncol. 2023;41:147.
Abstract

MIYAKE M, Oda Y, Owari T, Iida K, et al
Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
Cancer Sci. 2023;114:1118-1130.
Abstract

CHEN Y, Fu J, Li Z, Chen Q, et al
Cutoff values of PD-L1 expression in urinary cytology samples for predicting response to immune checkpoint inhibitor therapy in upper urinary tract urothelial carcinoma.
Cancer Cytopathol. 2023;131:179-187.
Abstract

MATUTE GUERRERO A, Abanses Moreno P, Villasmil Chaparro I
Pulmonary thrombotic microangiopathy caused by neoplastic urothelial carcinoma cells.
Med Clin (Barc). 2023;160:226-227.
Abstract

QIWEI C, Jiajun S, Cheng L, Shengbo H, et al
Comparison between renal pelvic and ureteral tumors in muscle-invasive upper tract urothelial carcinoma.
Cancer Sci. 2023;114:984-994.
Abstract

PIERCONTI F, Rossi ED, Cenci T, Carlino A, et al
DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group.
Cancer Cytopathol. 2023;131:158-164.
Abstract

SEKINE Y, Iwasaki Y, Hakozaki N, Endo M, et al
Prevalence and risk estimation of cancer-predisposing genes for upper urinary tract urothelial carcinoma in Japanese.
Jpn J Clin Oncol. 2022;52:1441-1445.
Abstract

BLINOVA E, Samishina E, Deryabina O, Blinov D, et al
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
Int J Mol Sci. 2021;22:9856.
Abstract

LEE HW, Seo HK
Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
Int J Mol Sci. 2021;22:9526.
Abstract

LOPEZ-CORTES R, Gomez BB, Vazquez-Estevez S, Perez-Fentes D, et al
Blood-based protein biomarkers in bladder urothelial tumors.
J Proteomics. 2021;247:104329.
Abstract

MARANDINO L, Raggi D, Calareso G, Alessi A, et al
Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
Clin Genitourin Cancer. 2021;19:457-465.
Abstract

POND GR, Agarwal A, Ornstein M, Garcia J, et al
Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
Clin Genitourin Cancer. 2021;19:425-433.
Abstract

STOKKEL LE, Stokkel MPM, Donswijk ML, Lahaye MJ, et al
The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
Clin Genitourin Cancer. 2021;19:373-380.
Abstract

RUNDO F, Bersanelli M, Urzia V, Friedlaender A, et al
Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy.
Clin Genitourin Cancer. 2021;19:396-404.
Abstract

CH'NG ES
Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
Sci Rep. 2021;11:6765.
Abstract

LEE Y, Kim YS, Hong B, Cho YM, et al
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
J Cancer Res Clin Oncol. 2021;147:3421-3429.
Abstract

AGNIHOTRI MA, Sathe PA
Coexistent urothelial papilloma and ureteric calculus in an 8-year-old child: A rare co-occurrence.
J Postgrad Med. 2021;67:182-183.
Abstract

HUANG Y, Xie C, Li Q, Huang X, et al
Prognostic factors and nomogram for the overall survival of bladder cancer bone metastasis: A SEER-based study.
Medicine (Baltimore). 2023;102:e33275.
Abstract

SEMENIUK-WOJTAS A, Poddebniak-Strama K, Modzelewska M, Baryla M, et al
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
Cancer Immunol Immunother. 2023 Mar 16. doi: 10.1007/s00262-023-03376.
Abstract

KE M, Sun N, Lin Z, Zhang P, et al
SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein.
Cancer Cell Int. 2023;23:48.
Abstract

JARIMBA R, Quaresma V, Pedroso Lima J, Eliseu M, et al
Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study.
Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11026.
Abstract

TZELVES L, Katsimperis S, Bellos T, Berdempes M, et al
Anthropometric characteristics and relationship with non-muscle invasive bladder cancer in Greece: A case-control study.
Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11266.
Abstract

LI Z, Zhao J, Huang X, Wang J, et al
An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer.
Sci Rep. 2023;13:4302.
Abstract

VAN GINKEL N, van Gennep EJ, Oosterbaan L, Greidanus J, et al
Added Clinical Value of (18)F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
Clin Genitourin Cancer. 2023 Feb 22:S1558-7673(23)00037.
Abstract

ZHANG W, Zhang Z, Xiao W, Wang Y, et al
Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67 correlation in bladder cancer in 3.0-T MRI.
Cancer Med. 2023 Mar 14. doi: 10.1002/cam4.5782.
Abstract

ZHU J, Livasy C, Donahue EE, Symanowski JT, et al
Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.
Transl Androl Urol. 2023;12:228-240.
Abstract

TAN Z, Chen Z, Yao G, Mumin MA, et al
Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER databas
Transl Androl Urol. 2023;12:330-346.
Abstract

YING Y, Wang Z, Tan Y, Cao H, et al
Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.
Transl Androl Urol. 2023;12:176-186.
Abstract

YUAN F, Yin XY, Huang Y, Cai XW, et al
Exosomal miR-93-5p as an important driver of bladder cancer progression.
Transl Androl Urol. 2023;12:286-299.
Abstract

WANG SS, Zhai GQ, Huang ZG, Luo JY, et al
Nitidine chloride regulates cell function of bladder cancer in vitro through downregulating Lymphocyte antigen 75.
Naunyn Schmiedebergs Arch Pharmacol. 2023.
Abstract

VAN HOOGSTRATEN LMC, Vrieling A, van der Heijden AG, Kogevinas M, et al
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.
Nat Rev Clin Oncol. 2023 Mar 13. doi: 10.1038/s41571-023-00744.
Abstract

ZHANG X, Liu H, Zhang J, Wang Z, et al
Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscleâ€‘Invasive Bladder Cancer.
Arch Esp Urol. 2023;76:70-83.
Abstract

CATA ED, Andras I, Popa A, Medan P, et al
Robotic Radical Cystectomy with Intracorporeal Urinary Diversion - Tips and Tricks.
Chirurgia (Bucur). 2023;118:63-72.
Abstract

XU Y, Xia Z, Sun X, Wei B, et al
Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer.
Front Immunol. 2023;14:1111319.
Abstract

HU B, Chen R, Chen G, Zheng P, et al
Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy.
Front Surg. 2023;10:1121184.
Abstract

ILLIAS AM, Yu KJ, Wu SC, Cata JP, et al
Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: A meta-analysis of observational studies.
Front Oncol. 2023;13:1097637.
Abstract

BORDELEAU F, Brownell D, Chabaud S, Huot ME, et al
Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression.
Stem Cell Investig. 2023;10:5.
Abstract

TIAN YQ, Yang JC, Hu JJ, Ding R, et al
Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019.
Front Public Health. 2023;11:1119374.
Abstract

YANAGISAWA T, Miki J, Matsukawa A, Iwatani K, et al
ASO Author Reflections: Is T1HG Bladder Cancer a Good Candidate for En Bloc Resection?
Ann Surg Oncol. 2023 Mar 12. doi: 10.1245/s10434-023-13291.
Abstract

LI J, Qiu Z, Cao K, Deng L, et al
Predicting muscle invasion in bladder cancer based on MRI: A comparison of radiomics, and single-task and multi-task deep learning.
Comput Methods Programs Biomed. 2023;233:107466.
Abstract

GROBET-JEANDIN E, Lenfant L, Mir C, Giannarini G, et al
A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Mar 9:S2588-9311(23)00040-8. doi: 10.1016/j.euo.2023.
Abstract

PHILIPPS L, Porta N, James N, Huddart R, et al
Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
Clin Oncol (R Coll Radiol). 2023 Feb 11:S0936-6555(23)00052.
Abstract

ZHANG P, Sun Y, Shi L, Sun D, et al
Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of bladder cancer by activating PPARgamma/PTEN/AKT pathway.
Tissue Cell. 2023;82:102048.
Abstract

ZHU H, Chen Q, Zhang Y, Zhao L, et al
Glutathione S-transferase zeta 1 alters the HMGB1/GPX4 axis to drive ferroptosis in bladder cancer cells.
Hum Exp Toxicol. 2023;42:9603271231161606.
Abstract

HANNA DH, Aziz MM, Shafee EE
Effective-by-method for the preparation of folic acid coated TiO(2) nanoparticles with high targeting potential for apoptosis induction against bladder cancer cells (T24).
Biotechnol Appl Biochem. 2023 Mar 11. doi: 10.1002/bab.2456.
Abstract

PEREIRA IOA, da Silva GN, Almeida TC, Lima APB, et al
LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells.
Molecules. 2023;28:2412.
Abstract

WANG Z, Wang T, Wu G, Zhu L, et al
Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer.
J Clin Med. 2023;12:1892.
Abstract

FLAMMIA RS, Tufano A, Chierigo F, Wurnschimmel C, et al
The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer.
J Clin Med. 2023;12:1776.
Abstract

MURAKAMI K, Furuya H, Hokutan K, Goodison S, et al
Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer.
Int J Mol Sci. 2023;24:4943.
Abstract

MA L, Chen H, Yang W, Ji Z, et al
Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Int J Mol Sci. 2023;24:4760.
Abstract

TORTORA F, La Civita E, Trivedi P, Febbraio F, et al
Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers.
Int J Mol Sci. 2023;24:4601.
Abstract

ZUCCHI A, Claps F, Pastore AL, Perotti A, et al
Focus on the Use of Resveratrol in Bladder Cancer.
Int J Mol Sci. 2023;24:4562.
Abstract

ZHU J, Li Y, Luo Y, Xu J, et al
Correction: Zhu et al. A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-like Properties and Invasion in Human Bladder Cancer. Cancers 2019, 11, 349.
Cancers (Basel). 2023;15:1403.
Abstract

HURLE R, Soria F, Contieri R, Avolio PP, et al
Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial.
Cancers (Basel). 2023;15:1618.
Abstract

CELADA LUIS G, Albers Acosta E, de la Fuente H, Velasco Balanza C, et al
A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:1364.
Abstract

HU X, Xue Y, Zhu G
Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma.
Diagnostics (Basel). 2023;13:1004.
Abstract

VAROL N, Keles I, Yildiz H, Karaosmanoglu C, et al
Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene expression in bladder cancer.
Gene. 2023;866:147352.
Abstract

ASCIONE CM, Napolitano F, Esposito D, Servetto A, et al
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
Cancer Treat Rev. 2023;115:102530.
Abstract

WANG J, Meng X, Yu M, Li X, et al
A novel microfluidic system for enrichment of functional circulating tumor cells in cancer patient blood samples by combining cell size and invasiveness.
Biosens Bioelectron. 2023;227:115159.
Abstract

KUMAR R, Harilal S, Abdelgawad MA, Ghoneim MM, et al
Urachal carcinoma: The journey so far and the road ahead.
Pathol Res Pract. 2023;243:154379.
Abstract

WANG P, Shi Y, Zhang J, Shou J, et al
UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA.
EBioMedicine. 2023;89:104437.
Abstract

WANG L, Shi G, Zhao G, He W, et al
Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
Anticancer Drugs. 2023;34:473-478.
Abstract

JIN J, Yang Q, Yu Y, Chen L, et al
Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
Anticancer Drugs. 2023;34:595-598.
Abstract

FATIMA A, Russell DH, Epstein JI
Nested Subtype of Urothelial Carcinoma in the Upper Urinary Tract: A Series of 15 Cases.
Am J Surg Pathol. 2023;47:461-468.
Abstract

CALEN L, Mesnard B, Hedhli O, Broudeur L, et al
Robot-assisted laparoscopic cystectomy with non-continent urinary diversion for neurogenic lower urinary tract dysfunction: Midterm outcomes.
Neurourol Urodyn. 2023;42:586-596.
Abstract

ZHAO Q, Wu L, Yang F, Han S, et al
Application of Transvaginal Natural Orifice Specimen Extraction Surgery in Urological Surgery.
J Laparoendosc Adv Surg Tech A. 2023;33:231-235.
Abstract

WU W, Jing Y, Xu Q, Hao J, et al
MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway.
Panminerva Med. 2023;65:114-115.
Abstract

STARRETT GJ, Yu K, Golubeva Y, Lenz P, et al
Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients.
Elife. 2023;12:e82690.
Abstract

GOLMOHAMMADI M, Elmaghraby DA, Ramirez-Coronel AA, Rakhimov N, et al
A Comprehensive View on the Quercetin Impact on Bladder Cancer: Focusing on Oxidative stress, Cellular, and Molecular Mechanisms.
Fundam Clin Pharmacol. 2023 Mar 24. doi: 10.1111/fcp.12896.
Abstract

WANG C, Cao Q, Zhang S, Liu H, et al
Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line.
Pharmgenomics Pers Med. 2023;16:219-228.
Abstract

ZHAO Z, Liu S, Sun R, Zhu W, et al
The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
Front Immunol. 2023;14:1085476.
Abstract

ARRABAL POLO MA, Melgarejo Segura MT, Yanez Castillo Y, Morales Martinez A, et al
Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
J Cancer Res Clin Oncol. 2023 Mar 23:1-7. doi: 10.1007/s00432-023-04688.
Abstract

BASILE G, de Angelis M, Leni R, Re C, et al
Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review.
Minerva Urol Nephrol. 2023 Mar 22. doi: 10.23736/S2724-6051.23.05091.
Abstract

Corrigendum to "The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer".
Int J Surg Pathol. 2023 Mar 22:10668969231164482. doi: 10.1177/10668969231164482
Abstract

CHENG F, Hansson VC, Georgolopoulos G, Mani K, et al
Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
Oncotarget. 2023;14:219-235.
Abstract

LI X, Li Y, Liu B, Chen L, et al
P4HA2-mediated HIF-1alpha stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
FASEB J. 2023;37:e22840.
Abstract

LEPARA Z, Alic J, Lepara O, Spahovic H, et al
Antioxidant status in patients with bladder cancer regarding cancer stage and grade.
Asian J Urol. 2023;10:182-188.
Abstract

ARSUFFI S, Cambianica A, Di Filippo E, Ripamonti D, et al
Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature.
J Clin Tuberc Other Mycobact Dis. 2023;31:100360.
Abstract

CHANG LW, Hung SC, Chen CS, Li JR, et al
Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy.
Sci Rep. 2023;13:4554.
Abstract

DAZA J, Grauer R, Chen S, Lavallee E, et al
Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer.
Urol Oncol. 2023 Mar 18:S1078-1439(23)00047.
Abstract

EL SHARKAWI FZ, El Sabah M, Atya HB, Khaled HM, et al
Urinary BLACAT1 as a non-invasive biomarker for bladder cancer.
Mol Biol Rep. 2023 Mar 20. doi: 10.1007/s11033-023-08370.
Abstract

DROBNER JC, Lichtbroun BJ, Singer EA, Ghodoussipour S, et al
Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma.
Technol Cancer Res Treat. 2023;22:15330338231164196.
Abstract

HU W, Zhang Y, Ning J, Li M, et al
Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages.
Heliyon. 2023;9:e14272.
Abstract

ZHAO Y, Sun W, Ji Z, Liu X, et al
Serum metabolites as early detection markers of non-muscle invasive bladder cancer in Chinese patients.
Front Oncol. 2023;13:1061083.
Abstract

ALSHAHWAN MI, Bin Dukhi MM, Alotaibi SN, Aldarrab R, et al
Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior.
Cureus. 2023;15:e36278.
Abstract

LIU J, Cheng C, Qi T, Xiao J, et al
ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts.
Front Genet. 2023;14:1148437.
Abstract

ANRAKU T, Hashidate H, Nakahara A, Imai T, et al
Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
BMC Urol. 2023;23:38.
Abstract

FAN J, Ding Y, Huang H, Xiong S, et al
High expression of ABCF1 is an independent predictor of poor prognosis in bladder cancer.
BMC Urol. 2023;23:37.
Abstract

BOLGEO T, Ruta F, Gatti D, Gambalunga F, et al
Management of the patient with urostomy: Caregiver needs during the three months after discharge. A qualitative study.
Arch Ital Urol Androl. 2023;95.
Abstract

LEONARDI R, Vecco F, Iacona G, Calarco A, et al
TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting.
Arch Ital Urol Androl. 2023;95.
Abstract

LAGARDE-LENON MS, Aron M
Reprint of: Female Urethral Carcinoma: A contemporary review of the clinicopathologic features, with emphasis on the histo-anatomic landmarks and potential staging issues.
Hum Pathol. 2023;133:126-135.
Abstract

DE FALCO F, Cuccaro B, De Tullio R, Alberti A, et al
Possible etiological association of ovine papillomaviruses with bladder tumors in cattle.
Virus Res. 2023;328:199084.
Abstract

YOKOTA Y, Suzuki S, Gi M, Yanagiba Y, et al
o-Toluidine metabolism and effects in the urinary bladder of humanized-liver mice.
Toxicology. 2023;488:153483.
Abstract

SHENG Y, Wu J, Li X, Qiu J, et al
iATMEcell: identification of abnormal tumor microenvironment cells to predict the clinical outcomes in cancer based on cell-cell crosstalk network.
Brief Bioinform. 2023;24:bbad074.
Abstract

LEE A
Nadofaragene Firadenovec: First Approval.
Drugs. 2023;83:353-357.
Abstract

ZHAO L, Qi X, Chen Y, Qiao Y, et al
Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network.
Brief Bioinform. 2023;24:bbad023.
Abstract

RYSANKOVA K, Hanzlikova P, Zidlik V, Vrtkova A, et al
Is high accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) sufficient for its implementation in the urological practice?
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167:85-90.
Abstract

WU J, Gao Y, Xiong Z, Xiao X, et al
Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: A systematic review and network meta-analysis.
Cancer Med. 2023;12:5420-5435.
Abstract

GOUDOURIS E, Aranda CS, Sole D
Implications of the non-specific effect induced by Bacillus Calmette-Guerin (BCG) vaccine on vaccine recommendations.
J Pediatr (Rio J). 2023;99 Suppl 1:S22-S27.
Abstract

FUKUOKAYA W, Yanagisawa T, Hashimoto M, Yamamoto S, et al
Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
Cancer Immunol Immunother. 2023;72:841-849.
Abstract

MULLANE P, Joshi S, Bilen M, Osunkoya AO, et al
Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology.
J Clin Pathol. 2023;76:256-260.
Abstract

WU W, Jing Y, Xu Q, Hao J, et al
MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway.
Panminerva Med. 2023;65:114-115.
Abstract

SONG Q, Zhou Z, Bai J, Liu N, et al
A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
Clin Transl Oncol. 2023 Mar 31. doi: 10.1007/s12094-023-03143.
Abstract

POURKERMAN M, Hajjar M, Naja F, Yunus F, et al
Nutrient Patterns and Bladder Cancer: A Case-Control Study in Iran.
Nutr Cancer. 2023 Mar 31:1-7. doi: 10.1080/01635581.2023.2191383.
Abstract

GHOLAMI L, Momtazi-Borojeni AA, Malaekeh-Nikouei B, Nikfar B, et al
Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC Liposome Nanoparticles on Human Bladder Cancer Cells.
Curr Pharm Des. 2023 Mar 31. doi: 10.2174/1381612829666230331084848.
Abstract

REN C, Li Y, Cong Z, Li Z, et al
Bioengineered bacterial outer membrane vesicles encapsulated Polybia-mastoparan I fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory chemotherapy.
Front Immunol. 2023;14:1129771.
Abstract

SEITO T, Ishikawa A, Tsuru I, Hikatsu M, et al
Bladder Preservation After Bilateral Kidney Loss and Bladder Cancer After Renal Transplantation: A Case Report.
Transplant Proc. 2023 Mar 28:S0041-1345(23)00087.
Abstract

TOLSTRUP LK, Als AB, Carus A, Dahlrot R, et al
The iBLAD app protocol - a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care.
Acta Oncol. 2023 Mar 30:1-5. doi: 10.1080/0284186X.2023.2194031.
Abstract

CUI X, Zhang C, Zhang L, Yan H, et al
The prognostic and immunological role of MYB: from bladder cancer validation to pan-cancer analysis.
Biosci Rep. 2023 Mar 30:BSR20222627. doi: 10.1042/BSR20222627.
Abstract

ZHAO H, Liu K, Giannakopoulos S, Yuruk E, et al
Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma.
BMC Urol. 2023;23:49.
Abstract

AHLSCHLAGER L, McCabe S, Deal AM, Guo A, et al
The effect of treatment on work productivity in patients with bladder cancer.
Urol Oncol. 2023 Mar 27:S1078-1439(23)00056.
Abstract

YU D, Chen C, Sun L, Wu S, et al
KRT13-expressing epithelial cell population predicts better response to chemotherapy and immunotherapy in bladder cancer: Comprehensive evidences based on BCa database.
Comput Biol Med. 2023;158:106795.
Abstract

Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Poster Presentations.
Can Urol Assoc J. 2023;17.
Abstract

Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Podium Presentations.
Can Urol Assoc J. 2023;17.
Abstract

UFUK F, Yagci AB
Letter to the Editor: "Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results".
Diagn Interv Radiol. 2023;29:412-413.
Abstract

PAN SY, Lai CZ, Chen WC, Chen YH, et al
Chondrosarcoma of Ureter in an Elderly Patient: A Case Report.
Medicina (Kaunas). 2023;59:454.
Abstract

HEIDAR NA, Bhat TA, Shabir U, Hussein AA, et al
The Urinary Microbiome and Bladder Cancer.
Life (Basel). 2023;13:812.
Abstract

BARONE B, Finati M, Cinelli F, Fanelli A, et al
Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence.
J Pers Med. 2023;13:512.
Abstract

OFNER H, Laukhtina E, Hassler MR, Shariat SF, et al
Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.
Int J Mol Sci. 2023;24:5846.
Abstract

WANG Q, Ke S, Liu Z, Shao H, et al
HSPA5 Promotes the Proliferation, Metastasis and Regulates Ferroptosis of Bladder Cancer.
Int J Mol Sci. 2023;24:5144.
Abstract

MEUNIER S, Frontczak A, Balssa L, Blanc J, et al
Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.
Cancers (Basel). 2023;15:1886.
Abstract

THOMPSON D, Lawrentschuk N, Bolton D
New Approaches to Targeting Epigenetic Regulation in Bladder Cancer.
Cancers (Basel). 2023;15:1856.
Abstract

ENGELMANN SU, Pickl C, Haas M, Kaelble S, et al
Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer: Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors for Mortality.
Cancers (Basel). 2023;15:1778.
Abstract

CULINE S, Harter V, Krucker C, Gravis G, et al
Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Cancers (Basel). 2023;15:1742.
Abstract

SARKAR S, Min K, Ikram W, Tatton RW, et al
Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach.
Cancers (Basel). 2023;15:1673.
Abstract

WOOLBRIGHT BL, Rajendran G, Abbott E, Martin A, et al
Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer.
Cancers (Basel). 2023;15:1654.
Abstract

JHUO YC, Cha TL, Kao CC, Tsai YT, et al
Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study.
Diagnostics (Basel). 2023;13:1032.
Abstract

OZDEN-YILMAZ G, Savas B, Bursali A, Eray A, et al
Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
Cells. 2023;12:836.
Abstract

KUDELSKI J, Tokarzewicz A, Gudowska-Sawczuk M, Mroczko B, et al
The Significance of Matrix Metalloproteinase 9 (MMP-9) and Metalloproteinase 2 (MMP-2) in Urinary Bladder Cancer.
Biomedicines. 2023;11:956.
Abstract

NOWAK L, Krajewski W, Dejnaka E, Malkiewicz B, et al
Ubiquitin-Specific Proteases as Potential Therapeutic Targets in Bladder Cancer-In Vitro Evaluation of Degrasyn and PR-619 Activity Using Human and Canine Models.
Biomedicines. 2023;11:759.
Abstract

XU X, Tian X, Song L, Xie J, et al
Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation.
Biomolecules. 2023;13:521.
Abstract

LIU S, Chen H, Zheng Z, He Y, et al
Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer.
Bioengineering (Basel). 2023;10:318.
Abstract

KO WS, Kim SJ
Predictive Value of 18F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
Clin Nucl Med. 2023 Mar 27. doi: 10.1097/RLU.0000000000004639.
Abstract

KARABURUN MC, Ozkaya MF, Erguder BI, Suer E, et al
Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
J Med Syst. 2023;47:41.
Abstract

PRATA F, Anceschi U, Taffon C, Rossi SM, et al
Real-Time Urethral and Ureteral Assessment during Radical Cystectomy Using Ex-Vivo Optical Imaging: A Novel Technique for the Evaluation of Fresh Unfixed Surgical Margins.
Curr Oncol. 2023;30:3421-3431.
Abstract

MURTHY PB, Naidu S, Davaro F, Spiess PE, et al
Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension.
Curr Oncol. 2023;30:3223-3231.
Abstract

PRIJOVIC N, Acimovic M, Santric V, Stankovic B, et al
Predictive Value of Inflammatory and Nutritional Indexes in the Pathology of Bladder Cancer Patients Treated with Radical Cystectomy.
Curr Oncol. 2023;30:2582-2597.
Abstract

Retraction: MiR-301b promotes the proliferation, mobility, and epithelial-to-mesenchymal transition of bladder cancer cells by targeting EGR1.
Biochem Cell Biol. 2023 Mar 28. doi: 10.1139/bcb-2023-0074.
Abstract

TAN Z, Chen X, Zuo J, Fu S, et al
Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
J Transl Med. 2023;21:223.
Abstract

LI C, Xie W
Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer.
BMC Bioinformatics. 2023;24:118.
Abstract

RENNER S, Loussikian P, Foulquie P, Marrel A, et al
Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments: Infodemiology Study Based on Social Media Data.
JMIR Cancer. 2023;9:e45011.
Abstract

JIANG L, Sun G, Zou L, Guan Y, et al
Noncoding RNAs as a potential biomarker for the prognosis of bladder cancer: a systematic review and meta-analysis.
Expert Rev Mol Diagn. 2023 Mar 27. doi: 10.1080/14737159.2023.2195554.
Abstract

JHUANG JR, Chiu PC, Hsieh TC, Chen CH, et al
Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
Front Public Health. 2023;11:1072864.
Abstract

ZHU X, Qin R, Qu K, Wang Z, et al
Corrigendum to 'Atomic force microscopy-based assessment of multimechanical cellular properties for classification of graded bladder cancer cells and cancer early diagnosis using machine learning analysis' Acta Biomaterialia 2023, 158, 358â€’373.
Acta Biomater. 2023 Mar 23:S1742-7061(23)00152.
Abstract

LONG G, Hu Z, Liu Z, Ye Z, et al
Partial and radical cystectomy provides equivalent oncologic outcomes in bladder cancer when combined with adequate lymph node dissection: A population-based study.
Urol Oncol. 2023 Mar 23:S1078-1439(23)00078.
Abstract

QIU Y, Wang X, Fan Y, Bao Y, et al
A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next-generation sequencing prospect.
Thorac Cancer. 2023 Mar 25. doi: 10.1111/1759-7714.14864.
Abstract

KRISHNATRY R, Maitre P, Kumar A, Telkhade T, et al
Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer.
Cancer Med. 2023 Mar 25. doi: 10.1002/cam4.5840.
Abstract

TUONG MNE, Prillaman GE, Culp SH, Nelson M, et al
India Ink Tattooing of Ureteroenteric Anastomoses.
Tomography. 2023;9:449-458.
Abstract

GRIMM MO, Grun CB, Niegisch G, Pichler M, et al
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2023;24:347-359.
Abstract

KOMATSU M, Funakoshi T, Aki T, Unuma K, et al
Aristolochic acid induces an inflammatory response with prostaglandin E2 production and apoptosis in NRK-52E proximal tubular cells.
Toxicol Lett. 2023;378:39-50.
Abstract

BERGENGREN O, Belozerov A, Bill-Axelson A, Garmo H, et al
Short term outcomes after robot assisted and open cystectomy - A nation-wide population-based study.
Eur J Surg Oncol. 2023;49:868-874.
Abstract

LEIBRANDT RC, Tu MJ, Yu AM, Lara PN, et al
ATR Inhibition in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2023;21:203-207.
Abstract

MAKRAKIS D, Bakaloudi DR, Talukder R, Lin GI, et al
Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer. 2023;21:286-294.
Abstract

HARRIS KT, Villela NA, Alam R, Wu WJ, et al
The exstrophy experience: A national survey assessing urinary continence, bladder management, and oncologic outcomes in adults.
J Pediatr Urol. 2023;19:178.
Abstract

RAMAHI YO, Shiekh M, Shah AA, Houenstein H, et al
Uretero-enteric Strictures After Robot Assisted Radical Cystectomy: Prevalence and Management Over Two Decades.
Clin Genitourin Cancer. 2023;21:e19-e26.
Abstract

NECCHI A, Joshi M, Bangs R, Makaroff L, et al
Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly.
Clin Genitourin Cancer. 2023;21:301-308.
Abstract

HALD OC, Phan YC, Carter CJM, Klatte T, et al
Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG.
Clin Genitourin Cancer. 2023;21:e70-e77.
Abstract

LI DX, Feng DC, Shi X, Wu RC, et al
Identification of endothelial-related molecular subtypes for bladder cancer patients.
Front Oncol. 2023;13:1101055.
Abstract

MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.
BJUI Compass. 2023;4:305-313.
Abstract

CONROY S, Pang K, Jubber I, Hussain SA, et al
Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
BJUI Compass. 2022;4:314-321.
Abstract

WOODCOCK VK, Chen JL, Purshouse K, Butcher C, et al
PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.
BJUI Compass. 2023;4:322-330.
Abstract

MINAMI T, Fujita K, Hashimoto M, Nishimoto M, et al
External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy.
World J Urol. 2023 Apr 6. doi: 10.1007/s00345-023-04380.
Abstract

HAN S, Ji Z, Jiang J, Fan X, et al
Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
Cancer Med. 2023 Apr 6. doi: 10.1002/cam4.5900.
Abstract

FAN Y, Hao Y, Zhu C, Hu B, et al
PLCepsilon promotes the Warburg effect and tumorigenesis through AKT/GSK3beta/Cdc25a in bladder cancer.
Biotechnol Genet Eng Rev. 2023 Apr 5:1-15. doi: 10.1080/02648725.2023.2199188.
Abstract

JIN S, Shang Z, Wang W, Gu C, et al
Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
J Immunother. 2023;46:154-159.
Abstract

VANARSA K, Castillo J, Wang L, Lee KH, et al
Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.
BMC Med. 2023;21:133.
Abstract

LI S, Xin K, Pan S, Wang Y, et al
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.
Cell Mol Biol Lett. 2023;28:28.
Abstract

LOK W, Zhang J, Zheng X, Lin T, et al
Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: a propensity score-matched study.
Chin Med J (Engl). 2023 Apr 5. doi: 10.1097/CM9.0000000000002512.
Abstract

LING Y, Li J, Zhou L
Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer.
Int J Immunopathol Pharmacol. 2023;37:3946320231166774.
Abstract

HUANG KC, Chandra D, McGrath S, Dixit V, et al
Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
Mol Cancer Ther. 2023;22:551.
Abstract

LI L, Zhang J, Zhe X, Chang H, et al
An MRI-based radiomics nomogram in predicting histologic grade of non-muscle-invasive bladder cancer.
Front Oncol. 2023;13:1025972.
Abstract

CHEMI J, Villoldo GM
Should continuous bladder irrigation be recommended when single instillation of intravesical chemotherapy cannot be used after transurethral resection in low-risk non-muscle invasive bladder cancer?
Bladder (San Franc). 2023;10:e21200002.
Abstract

WANG X, Bai Y, Zhang F, Li D, et al
Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
Front Immunol. 2023;14:955949.
Abstract

JAKUS D, Cepin P, Vrhovac I, Jakus IA, et al
Influence of the grade and invasiveness of bladder cancer on disease course severity in patients with bladder tamponade resulting from a bleeding bladder cancer.
Urol Ann. 2023;15:27-30.
Abstract

ZHENG Q, Guo L, Yang R, Chen Z, et al
Identification of essential genes and drug discovery in bladder cancer and inflammatory bowel disease via text mining and bioinformatics analysis.
Curr Comput Aided Drug Des. 2023 Mar 30. doi: 10.2174/1573409919666230330154008.
Abstract

KOOL R, Marcq G, Breau RH, Black PC, et al
Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
Eur Urol Oncol. 2023 Mar 31:S2588-9311(23)00068.
Abstract

GONTERO P, Livoti S, Soria F
A Restaging Transurethral Resection of the Bladder Is Always Necessary for High-grade T1 Non-muscle-invasive Bladder Cancer: Con.
Eur Urol Focus. 2023 Mar 31:S2405-4569(23)00076.
Abstract

YING X, Huang Y, Liu B, Hu W, et al
Targeted m(6)A demethylation of ITGA6 mRNA by a multisite dCasRx-m(6)A editor inhibits bladder cancer development.
J Adv Res. 2023 Mar 30:S2090-1232(23)00092-9. doi: 10.1016/j.jare.2023.
Abstract

GERETTO P, DE Cillis S, Phe V
Voiding patterns following radical cystectomy and orthotopic neobladder: is intermittent self-catheterization worth the hype?
Minerva Urol Nephrol. 2023;75:246-247.
Abstract

SORIA F, Delacruz JE, Aznar-Cervantes SD, Aranda J, et al
Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma.
Minerva Urol Nephrol. 2023;75:194-202.
Abstract

CANCRINI F, Osman N, Doizi S, Guillot-Tantay C, et al
Incidence of urological cancers in neurological patients: a review of the literature from the EAU Young Academic Urologist Functional Group.
Minerva Urol Nephrol. 2023;75:163-171.
Abstract

FALLARA G, Maida FD, Bravi CA, DE Groote R, et al
A systematic review and meta-analysis of robot-assisted vs. open radical cystectomy: where do we stand and future perspective.
Minerva Urol Nephrol. 2023;75:134-143.
Abstract

CO JL, Goco MLL, So JS
Paraganglioma in The Urinary Bladder: A Pitfall in Histopathologic Diagnosis.
Acta Med Indones. 2023;55:95-100.
Abstract

SCHLACK K
[Perioperative systemic treatment of urothelial cancer].
Urologie. 2023;62:407-417.
Abstract

COLE K, Al-Kadhimi Z, Talmadge JE
Highlights into historical and current immune interventions for cancer.
Int Immunopharmacol. 2023;117:109882.
Abstract

HUANG C, Li Y, Ling Q, Wei C, et al
Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration.
FEBS Open Bio. 2023;13:736-750.
Abstract

EGGER M, Seiler R
Which Patients To Consider for Bladder Preservation After a Complete Response to Neoadjuvant Chemotherapy.
Eur Urol Focus. 2023;9:229-231.
Abstract

KAWADA T, Yanagisawa T, Mostafaei H, Sari Motlagh R, et al
Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2023;9:264-274.
Abstract

SUGIYAMA Y, Naiki T, Tasaki Y, Mimura Y, et al
GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
Oncology. 2023;101:224-233.
Abstract

LANGE S, Calleris G, Matin SF, Roupret M, et al
Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.
Eur Urol Focus. 2023;9:280-282.
Abstract

DENG Q, Xie J, Kong S, Tang T, et al
Long-Term Retention Microbubbles with Three-Layer Structure for Floating Intravesical Instillation Delivery.
Small. 2023;19:e2205630.
Abstract

FELSNER M, Grubmuller B
[One clip too many].
Urologie. 2023;62:389-391.
Abstract

IACOVELLI R, Cicala CM, Ciccarese C, Sacco E, et al
Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Urologia. 2023;90:3-10.
Abstract

KAWADA T, Laukhtina E, Quhal F, Yanagisawa T, et al
Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis.
Eur Urol Focus. 2023;9:236-240.
Abstract

ZHAO H, Peng P, Luo Z, Liu H, et al
Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
Photodiagnosis Photodyn Ther. 2023;41:103220.
Abstract

INGERSOLL MA
Does immune cell exhaustion lie at the heart of BCG-unresponsive disease?
Nat Rev Urol. 2023;20:201-202.
Abstract

LAUKHTINA E, Kawada T, Quhal F, Yanagisawa T, et al
Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2023;9:258-263.
Abstract

HASUI KI, Kawakami Y, Miyake T, Hirai Y, et al
Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin.
J Dermatol. 2022 Nov 22. doi: 10.1111/1346-8138.16646.
Abstract

CHEN CJ, Hang JF, Chen YA, Lin SJ, et al
The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
Cancer Cytopathol. 2023;131:226-233.
Abstract

SCHONE M, Uhthoff H, Schone S
[Cystoscopy in the outpatient clinical routine: things to keep in mind].
Aktuelle Urol. 2023;54:129-134.
Abstract

AMBEGODA M, Shiyanth S, Vidanapathirana S, Kumara S, et al
Outcome of transurethral resection of bladder tumour under spinal anaesthesia combined with obturator nerve block in Sri Lanka.
Urologia. 2023;90:80-82.
Abstract

LOKESHWAR SD, Rahman SN, Choksi A, Press BH, et al
Patient tolerability during office cystoscopy and bladder tumor cauterization: a multivariate analysis of risk factors.
Actas Urol Esp (Engl Ed). 2023;47:165-171.
Abstract

PENG J, Zhang X, Meng Y, Yang X, et al
Urachal mucinous cystadenocarcinoma: A case report.
Asian J Surg. 2023;46:1759-1760.
Abstract

CONTIERI R, Hurle R, Paciotti M, Casale P, et al
Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
Minerva Urol Nephrol. 2023;75:180-187.
Abstract

SUBIELA JD, Rodriguez Faba O, Aumatell J, Gonzalez-Padilla DA, et al
Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guerin: Implications for Risk-adapted Follow-up.
Eur Urol Focus. 2023;9:325-332.
Abstract

NI RAGHALLAIGH H, Pineda-Turner A, Mather K, Chetwood A, et al
Melanosis of the urinary bladder.
Ann R Coll Surg Engl. 2023;105:386-387.
Abstract

IPPOLITI S, Bhatt NR, Ilie CP
Transurethral resection of bladder tumour (TURBT) as a day-case: A real-world practice and patients' perspective from a district general hospital (DGH).
Urologia. 2023;90:68-74.
Abstract

W AC, Gj N, T M, A A, et al
The impact of socio-economic deprivation on recovery following robotic assisted radical cystectomy.
Urologia. 2023;90:136-140.
Abstract

BICCI E, Mastrorosato M, Danti G, Lattavo L, et al
Dual-Energy CT applications in urinary tract cancers: an update.
Tumori. 2023;109:148-156.
Abstract

OK F, Durmus E
Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature.
Urologia. 2023;90:195-197.
Abstract

TRENTI E, Palermo S, Pycha A, Comploj E, et al
[Sigmoid colon conduit volvulus: an extremely rare complication of a sigmoid colon conduit].
Aktuelle Urol. 2023;54:148-150.
Abstract

THOLOMIER C, Martini A, Mokkapati S, Dinney CP, et al
The current status of gene therapy in bladder cancer.
Expert Rev Anticancer Ther. 2023 Apr 13. doi: 10.1080/14737140.2023.2203385.
Abstract

ELAYAT G, Punev I, Selim A
An Overview of Angiogenesis in Bladder Cancer.
Curr Oncol Rep. 2023 Apr 13. doi: 10.1007/s11912-023-01421.
Abstract

WU X, Xu Q, Li T, Wei Y, et al
Correction to: Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2â€‘Antisense RNA 1/microRNAâ€‘93â€‘5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis.
Appl Biochem Biotechnol. 2023 Apr 13. doi: 10.1007/s12010-023-04478.
Abstract

SHIN HM, Lee J, Lee DH, Kim SH, et al
CT Evaluation of the Findings of Nutcracker Syndrome in Patients with Bladder Cancer after Radical Cystectomy and Ileal Neobladder Formation: A Correlation with Hematuria.
J Korean Soc Radiol. 2023;84:409-417.
Abstract

TEIXEIRA-MARQUES A, Lourenco C, Oliveira MC, Henrique R, et al
Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
Int J Mol Sci. 2023;24:6757.
Abstract

SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;24:6610.
Abstract

GREBOWSKI R, Saluk J, Bijak M, Szemraj J, et al
Variability, Expression, and Methylation of IL-6 and IL-8 Genes in Bladder Cancer Pathophysiology.
Int J Mol Sci. 2023;24:6266.
Abstract

NEUHAUS J, Rabien A, Reinhold A, Koehler L, et al
3D Tumor Models in Urology.
Int J Mol Sci. 2023;24:6232.
Abstract

HU CY, Wu HT, Shan YS, Wang CT, et al
Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione Peroxidase 4 and Induction of Ferroptosis.
Int J Mol Sci. 2023;24:6021.
Abstract

BLANCA A, Lopez-Beltran A, Lopez-Porcheron K, Gomez-Gomez E, et al
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype.
Cancers (Basel). 2023;15:2149.
Abstract

BERTUCCI A, Cartier L, Rollet A, Boustany R, et al
Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020.
Cancers (Basel). 2023;15:2069.
Abstract

DEL GIUDICE F, Asero V, Bologna E, Scornajenghi CM, et al
Efficacy of Different Bacillus of Calmette-Guerin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
Cancers (Basel). 2023;15:1937.
Abstract

KIMURA K, Yoshida S, Tsuchiya J, Kitazume Y, et al
Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer.
Eur Radiol. 2023 Apr 13. doi: 10.1007/s00330-023-09627.
Abstract

GHALI F, Wright JL, Grivas P
The Pursuit of Intravesical and Systemic Therapies in Non-muscle-invasive Bladder Cancer: Challenges and Opportunities.
Eur Urol Oncol. 2023 Apr 10:S2588-9311(23)00071.
Abstract

WANG Z, Kwan ML, Haque R, Goniewicz M, et al
Associations of dietary isothiocyanate exposure from cruciferous vegetable consumption with recurrence and progression of non-muscle invasive bladder cancer: Findings from The Be-Well Study.
Am J Clin Nutr. 2023 Apr 10:S0002-9165(23)46835.
Abstract

ZHANG H, Liu J, Zheng Z
Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer.
PeerJ. 2023;11:e15088.
Abstract

YANAGISAWA T, Matsukawa A, Iwatani K, Sato S, et al
ASO Visual Abstract: En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
Ann Surg Oncol. 2023 Apr 11. doi: 10.1245/s10434-023-13395.
Abstract

XIA Y, Xu DF, Huang T, Zhao CH, et al
Exploring the application of bladder-preservation treatment in patients with T2N0M0 bladder cancer and establish a nomogram model: A SEER-based study.
Asian J Surg. 2023 Apr 8:S1015-9584(23)00486.
Abstract

BILE-SILVA A, Lopez-Beltran A, Blanca A, Lopez-Rios F, et al
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
Expert Opin Biol Ther. 2023 Apr 10:1-12. doi: 10.1080/14712598.2023.2201371.
Abstract

QUIGNOT N, Jiang H, Doobaree IU, Lehmann J, et al
Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.
Clinicoecon Outcomes Res. 2023;15:227-237.
Abstract

BAI X, Chen G, Shang S, Li S, et al
Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study.
Front Surg. 2023;10:1121357.
Abstract

FRESHOUR SL, Chen THP, Fisk B, Shen H, et al
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
bioRxiv. 2023 Mar 29:2023.03.28.534561. doi: 10.1101/2023.03.28.534561.
Abstract

ZHANG X, Zhang A, Hu L, Xiong W, et al
An innovative risk index based on neutrophils and macrophages can effectively predict prognosis and immunotherapy response in patients with muscle-invasive bladder cancer.
Transl Cancer Res. 2023;12:536-549.
Abstract

PYRGIDIS N, Sokolakis I, Haltmair G, Hatzichristodoulou G, et al
The Short- and Long-Term Effect of Radical Cystectomy in Frail Patients With Bladder Cancer.
Clin Genitourin Cancer. 2023 Mar 11:S1558-7673(23)00063.
Abstract

DONG ZX, Chan SH, Chen SN, Li M, et al
TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression and transcriptional activity through TWIST1.
Transl Oncol. 2023;32:101666.
Abstract

MONTORSI F, Moschini M, Briganti A
Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505-16.
Eur Urol Oncol. 2023 Apr 6:S2588-9311(23)00073-1. doi: 10.1016/j.euo.2023.
Abstract

WU J, He D, Yu F, Huang Y, et al
Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia patient.
BMC Infect Dis. 2023;23:219.
Abstract

GAFFNEY CD, Katims A, D'Souza N, Bjurlin MA, et al
Bladder Cancer Carcinogens: Opportunities for Risk Reduction.
Eur Urol Focus. 2023 Apr 5:S2405-4569(23)00086-X. doi: 10.1016/j.euf.2023.
Abstract

ZHANG Y, Li Z, Zhang Y, Shen C, et al
circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the miR-200a-3p/PTEN Axis and Participating in the Immune Response.
Cell Transplant. 2023;32:9636897231165874.
Abstract

SHEN D, Deng Z, Liu W, Zhou F, et al
Melatonin inhibits bladder tumorigenesis by suppressing PPARgamma/ENO1-mediated glycolysis.
Cell Death Dis. 2023;14:246.
Abstract

PHILIPPS L, Porta N, James N, Huddart R, et al
Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
Clin Oncol (R Coll Radiol). 2023;35:331-338.
Abstract

GONZALEZ-FIERRO A, Romo-Perez A, Chavez-Blanco A, Dominguez-Gomez G, et al
Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
Clin Drug Investig. 2023;43:227-239.
Abstract

JAIN RK, Singh AM, Wang X, Guevara-Patino JA, et al
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
Expert Opin Emerg Drugs. 2023;28:17-26.
Abstract

MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
Open vs robotic intracorporeal Padua ileal bladder: functional outcomes of a single-centre RCT.
World J Urol. 2023;41:739-746.
Abstract

YAMADA Y, Nakagawa T, Miyakawa J, Kawai T, et al
Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.
World J Urol. 2023;41:767-776.
Abstract

BAHLINGER V, Hartmann A, Eckstein M
Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
Adv Anat Pathol. 2023;30:203-210.
Abstract

GAYA JM, Territo A, Basile G, Gallioli A, et al
Optimizing decision-making process of benign uretero-enteric anastomotic stricture treatment after radical cystectomy.
World J Urol. 2023;41:733-738.
Abstract

BLACKMUR JP, Chew E, Trail M, Brodie K, et al
Assessment of association between lower ureteric excision technique and oncological outcomes for upper urinary tract urothelial carcinoma: retrospective analysis from the Scottish Renal Cancer Consortium.
World J Urol. 2023;41:757-765.
Abstract

KIM H, Jeong BC, Hong J, Kwon GY, et al
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
Cancer Res Treat. 2023;55:636-642.
Abstract

FAN B, Zheng X, Wang Y, Hu X, et al
Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer.
Pathol Oncol Res. 2023;29:1611117.
Abstract

TAN D, Jiang W, Hu R, Li Z, et al
Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR.
Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5879.
Abstract

CATTO JWF, Rogers Z, Downing A, Mason SJ, et al
Lifestyle Factors in Patients with Bladder Cancer: A Contemporary Picture of Tobacco Smoking, Electronic Cigarette Use, Body Mass Index, and Levels of Physical Activity.
Eur Urol Focus. 2023 Apr 18:S2405-4569(23)00101.
Abstract

SONG SH, Lee J, Ko YH, Kim JW, et al
TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer : Stage-Matched Analysis of a Large Multicenter National Cohort.
Cancer Res Treat. 2023 Apr 17. doi: 10.4143/crt.2023.
Abstract

COCKRELL DC, Rose TL
Correction to: Current Status of Perioperative Therapy in Muscleâ€‘Invasive Bladder Cancer and Future Directions.
Curr Oncol Rep. 2023 Apr 20. doi: 10.1007/s11912-023-01409.
Abstract

YOSHINO H, Yokoyama S, Tamai M, Okamura S, et al
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
FEBS Open Bio. 2023 Apr 20. doi: 10.1002/2211-5463.13616.
Abstract

VERRI P, Baboudjian M, Diana P, Gallioli A, et al
Reduced- vs full-dose BCG in bladder cancer: A systematic review and meta-analysis.
Actas Urol Esp (Engl Ed). 2023;47:4-14.
Abstract

MORENO-CORTES JC, Herranz-Amo F, Bataller-Monfort V, Esteban-Labrador L, et al
Development of an immune-nutritional prognostic index in patients with muscle-infiltrating bladder cancer candidates for radical cystectomy.
Actas Urol Esp (Engl Ed). 2023;47:34-40.
Abstract

SHEENU VS, Paul RS, Pushpa M, Ami EM, et al
Histopathological spectrum of adult renal tumours: A single center experience and review of literature.
Indian J Pathol Microbiol. 2023;66:307-313.
Abstract

SCHALLENBERG S, Dragomir MP, Anders P, Ebner B, et al
Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Eur Urol Focus. 2023 Apr 17:S2405-4569(23)00080.
Abstract

SANZ GOMEZ I, Huguet J, Bravo A, Robalino J, et al
Sequential Treatment With Bacillus Calmette-Guerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
Clin Genitourin Cancer. 2023 Mar 17:S1558-7673(23)00061.
Abstract

YAN CL, Gallo RA, Pandiri M, Gallo SJ, et al
Bladder squamous cell carcinoma in situ in the background of condyloma acuminatum in a kidney transplant recipient.
Can J Urol. 2023;30:11505-11508.
Abstract

WANG W, Jiang X, Xia F, Chen X, et al
Correction to: HYOU1 promotes cell proliferation, migration, and invasion via the PI3K/AKT/FOXO1 feedback loop in bladder cancer.
Mol Biol Rep. 2023 Apr 18. doi: 10.1007/s11033-023-08325.
Abstract

CHEN J, Huang CP, Quan C, Zu X, et al
The androgen receptor in bladder cancer.
Nat Rev Urol. 2023 Apr 18. doi: 10.1038/s41585-023-00761.
Abstract

MINOLI M, Cantore T, Hanhart D, Kiener M, et al
Bladder cancer organoids as a functional system to model different disease stages and therapy response.
Nat Commun. 2023;14:2214.
Abstract

STORMOEN DR, Taarnhoj GA, Friis RB, Johansen C, et al
Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial.
Acta Oncol. 2023 Apr 18:1-6. doi: 10.1080/0284186X.2023.2199461.
Abstract

SU Y, Wang B, Huang J, Huang M, et al
YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer.
Cell Prolif. 2023 Apr 17:e13404. doi: 10.1111/cpr.13404.
Abstract

JIANG Y, Zhang M, Wang L, Zhang L, et al
Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation.
BMC Complement Med Ther. 2023;23:122.
Abstract

STONE L
Going in circles: circMGA-HNRNPL feedback loop in bladder cancer.
Nat Rev Urol. 2023 Apr 17. doi: 10.1038/s41585-023-00771.
Abstract

MASONE MC
Using AI to assist pathologists in bladder cancer metastases detection.
Nat Rev Urol. 2023 Apr 14. doi: 10.1038/s41585-023-00769.
Abstract

YU X, Li W, Feng Y, Gao Z, et al
The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics.
Sci Rep. 2023;13:6241.
Abstract

MOHAMMED SA, Hetta HF, Zahran AM, Tolba MEM, et al
T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt.
PLoS Negl Trop Dis. 2023;17:e0011258.
Abstract

JAHAN M, Mittal A, Rao S, Kishore S, et al
Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCell technology: Potential as a simple cytology test.
Diagn Cytopathol. 2023 Apr 17. doi: 10.1002/dc.25141.
Abstract

WANG Y, Chen S, Zhang W, Xiao W, et al
Image quality evaluation of diffusion-weighted imaging in bladder cancer: a comparison between integrated slice-specific dynamic shimming and single-shot echo-planar imaging.
Quant Imaging Med Surg. 2023;13:2526-2537.
Abstract

JAKUS D, Situm M, Cepin P, Vrhovac I, et al
The impact of antithrombotic therapy on the time of detection of bladder cancer.
Cent European J Urol. 2023;76:33-37.
Abstract

XIONG X, Chen C, Li X, Yang J, et al
Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Front Oncol. 2023;13:972558.
Abstract

CASTANEDA PR, Theodorescu D, Rosser CJ, Ahdoot M, et al
Identifying novel biomarkers associated with bladder cancer treatment outcomes.
Front Oncol. 2023;13:1114203.
Abstract

CHEN H, Yang W, Ji Z
Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
Front Immunol. 2023;14:1171420.
Abstract

HE Z, Chen K, An Y, He J, et al
BSA modification of bacterial surface: a promising anti-cancer therapeutic strategy.
BMC Microbiol. 2023;23:105.
Abstract

YANG J, Li K, Zhang Y, Hu J, et al
Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors.
Cancer Med. 2023 Apr 16. doi: 10.1002/cam4.5895.
Abstract

WISHAHI M, Hassan S, Hassan M, Badawy M, et al
Telocytes and ezrin expression in normal-appearing tissues adjacent to urothelial bladder carcinoma as predictors of invasiveness and recurrence.
Sci Rep. 2023;13:6179.
Abstract

CHANDRA M, Li R, Parwani A, Carson WE 3rd, et al
Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.
Urol Oncol. 2023 Apr 13:S1078-1439(23)00094.
Abstract

WU R, Li D, Feng D, Han P, et al
Transmembrane protein 132A (TMEM132A) predicts overall survival for bladder cancer patients.
Asian J Surg. 2023 Apr 13:S1015-9584(23)00423.
Abstract

GARCIA-PORRERO G, Paricio Martinez JJ, Alvarez Gigli L, Abengozar Muela M, et al
Osteoclast-rich undifferentiated carcinoma of the bladder and the diagnostic usefulness of immunohistochemistry. A case report.
Rev Esp Patol. 2023;56:132-135.
Abstract

CONTIERI R, Lazzeri M, Hurle R
When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2023 Apr 12:S2405-4569(23)00095.
Abstract

SUN A, Luo Y, Xiao W, Zhu Z, et al
Androgen receptor transcriptionally inhibits programmed death ligand-1 (PD-L1) expression and influences immune escape in bladder cancer.
Lab Invest. 2023 Apr 12:100148. doi: 10.1016/j.labinv.2023.100148.
Abstract

MAMTANI R, Zhang H, Parikh RB, Patel K, et al
Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer.
JAMA Netw Open. 2023;6:e238395.
Abstract

CHANG YL, Chen YT, Wang HH, Chiang PH, et al
The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis.
Medicine (Baltimore). 2023;102:e33485.
Abstract

ZHANG X, G Dapar ML, Zhang X, Chen Y, et al
A pan-cancer analysis of the oncogenic role of YKT6 in human tumors.
Medicine (Baltimore). 2023;102:e33546.
Abstract

JOENSEN UN, Kingo PS, Stormoen D, Carus A, et al
[Not Available].
Ugeskr Laeger. 2023;185:V02230082.
Abstract

OLIUSHINA EM, Zavalishina LE, Alekseenok EY, Oskina NA, et al
[Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
Arkh Patol. 2023;85:5-12.
Abstract

JIN X, Wang Q, Luo F, Pan J, et al
Single-cell transcriptomic analysis of tumor heterogeneity and intercellular networks in human urothelial carcinoma.
Chin Med J (Engl). 2023;136:690-706.
Abstract

YAJIMA S, Nakanishi Y, Yasujima R, Hirose K, et al
Rapid geriatric screening tools predict inability to manage stoma by oneself after urinary diversion: G8 and IADL-modified G8.
J Geriatr Oncol. 2023;14:101468.
Abstract

ZHU A, Berends JE, Daignault-Newton S, Kaye DR, et al
Use of a physical activity monitor to track perioperative activity of radical cystectomy patients. Our first glimpse at what our patients are doing before and after surgery.
Urol Oncol. 2023;41:206.
Abstract

SONG E, Suek T, Davaro F, Hamilton Z, et al
Variant histology in upper tract carcinomas: Analysis of the National Cancer Database.
Urol Oncol. 2023;41:206.
Abstract

ROSENZWEIG SJ, Ranti D, Mehrazin R, Sfakianos JP, et al
Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy.
Urol Oncol. 2023;41:207.
Abstract

MORA RM, Ghoreifi A, Ladi-Seyedian SS, Sheybaee Moghaddam F, et al
Radical cystectomy and urinary diversion outcomes in patients with single vs. double renal unit: A 2:1 matched-pair analysis.
Urol Oncol. 2023;41:207.
Abstract

SHORE ND, Gavaghan MB
Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
Urol Oncol. 2023;41:207.
Abstract

HAO Z, Dang W, Zhu Q, Xu J, et al
Long non-coding RNA UCA1 regulates MPP(+)-induced neuronal damage through the miR-671-5p/KPNA4 pathway in SK-N-SH cells.
Metab Brain Dis. 2023;38:961-972.
Abstract

DE JONG JJ, Pijpers OM, van Kessel KEM, Boormans JL, et al
A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
Eur Urol Oncol. 2023;6:183-189.
Abstract

KOBAYASHI G, Hayashi T, Sentani K, Ikeda K, et al
ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
Pathobiology. 2023;90:94-103.
Abstract

CASAGRANDE G, Ibrahimi M, Semproni F, Iacovacci V, et al
Hydraulic Detrusor for Artificial Bladder Active Voiding.
Soft Robot. 2023;10:269-279.
Abstract

GAUTAM KA, Raghav A, Sankhwar SN, Singh R, et al
Genetic Polymorphisms of Gene Methionine Synthase Reductase (MTRR) and Risk of Urinary Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:1137-1141.
Abstract

ECKE TH, Wirtz RM, Friedersdorff F, Fussel S, et al
[Research in bladder cancer: translation into the clinic-report of 13th annual meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].
Urologie. 2023 Apr 28. doi: 10.1007/s00120-023-02093.
Abstract

PENG C, Guo S, Yang Z, Li X, et al
A prognostic model for bladder cancer based on cytoskeleton-related genes.
Medicine (Baltimore). 2023;102:e33538.
Abstract

WU M, Zheng X, Wang X, Li X, et al
The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study.
Cancer Control. 2023;30:10732748231173475.
Abstract

AL-AZAB R, Al-Zubi M, Al Demour S, Khaled Al-Jamal S, et al
Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer among urology trainers and trainees in Jordan: a cross-sectional study.
Ann Med Surg (Lond). 2023;85:763-766.
Abstract

KANG Y, Park C, Lee H, Kang S, et al
Natural Products as New Approaches for Treating Bladder Cancer: From Traditional Medicine to Novel Drug Discovery.
Pharmaceutics. 2023;15:1117.
Abstract

ZHANG-YIN J, Girard A, Marchal E, Lebret T, et al
PET Imaging in Bladder Cancer: An Update and Future Direction.
Pharmaceuticals (Basel). 2023;16:606.
Abstract

WILCZAK M, Surman M, Przybylo M
Altered Glycosylation in Progression and Management of Bladder Cancer.
Molecules. 2023;28:3436.
Abstract

HU B, Chen R, Jiang M, Xiong S, et al
MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.
Int J Mol Sci. 2023;24:7608.
Abstract

ZHU J, Tong H, Sun Y, Li T, et al
YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
Int J Mol Sci. 2023;24:6905.
Abstract

PANEBIANCO V
VI-RADS for the diagnosis and management of urinary bladder cancer.
Eur Radiol. 2023 Apr 28. doi: 10.1007/s00330-023-09677.
Abstract

WANG Y, Ju L, Wang G, Qian K, et al
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC.
Nat Commun. 2023;14:2421.
Abstract

ROBERTSON AG, Meghani K, Cooley LF, McLaughlin KA, et al
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
Nat Commun. 2023;14:2126.
Abstract

MAGEE DE, Cheung DC, Hird AE, Chung P, et al
Cost of Bladder Cancer Care: A Single Centre Comparison of Radical Cystectomy and Trimodal Therapy.
Urol Pract. 2023 Apr 4:101097UPJ0000000000000403.
Abstract

SORIA F, D'Andrea D, Barale M, Gust KM, et al
Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guerin: Implications for Decision-making?
Eur Urol Open Sci. 2023;50:17-23.
Abstract

FU Y, Liu K, Zhao L, Jiang X, et al
Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496.
Eur Urol Open Sci. 2023;50:31-42.
Abstract

LI J, Qi Y, Li B, Liu Y, et al
STIL/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer.
J Transl Med. 2023;21:281.
Abstract

HOLTEDAHL K, Borgquist L, Donker GA, Buntinx F, et al
Symptoms and signs of urogenital cancer in primary care.
BMC Prim Care. 2023;24:107.
Abstract

ADAMS-MARDI C, Sparks A, Whalen M
Impact of Minimally Invasive Approach to Radical Cystectomy in Bladder Cancer Patients with Malnutrition.
Nutr Cancer. 2023 Apr 26:1-6. doi: 10.1080/01635581.2023.2202432.
Abstract

GU S, Yang C
Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients.
BMC Urol. 2023;23:65.
Abstract

LEONG SW, Wang J, Okuda KS, Su Q, et al
Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells.
Eur J Med Chem. 2023;254:115335.
Abstract

HAGGSTROM C, Rowley M, Liedberg F, Coolen ACC, et al
Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe).
Cancer Med. 2023 Apr 25. doi: 10.1002/cam4.5981.
Abstract

XU H, Lin T, Ai J, Zhang J, et al
Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy.
J Inflamm Res. 2023;16:1733-1744.
Abstract

HALSTUCH D, Lotan P, Karchever I, Rubinshtein D, et al
Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
Clin Genitourin Cancer. 2023 Mar 23:S1558-7673(23)00066.
Abstract

LIN Y, Li T, Li Z, Shen C, et al
Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
Front Genet. 2023;14:1097179.
Abstract

JAMES C, Gomez K, Desai S, Patel HD, et al
Impact of intravesical Bacillus Calmette-Guerin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.
Front Cell Infect Microbiol. 2023;13:1125809.
Abstract

ZHAO Y, Li M, Wu W, Miao W, et al
Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization.
Front Immunol. 2023;14:1161273.
Abstract

MARSH GM, Kruchten A
A reevaluation of selected mortality risks in the updated NCI/NIOSH acrylonitrile cohort study.
Front Public Health. 2023;11:1122346.
Abstract

JOYCE DD, Sharma V, Williams SB
Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature.
Pharmacoeconomics. 2023 Apr 23. doi: 10.1007/s40273-023-01273.
Abstract

WU Q, Zhang H, You S, Xu Z, et al
NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway.
Environ Toxicol. 2023 Apr 23. doi: 10.1002/tox.23796.
Abstract

MODOS O, Varadi M, Der B, Keszthelyi A, et al
[Current diagnostic and treatment strategies for urachal cancer].
Orv Hetil. 2023;164:602-609.
Abstract

CAI T, Lu J, Lin Z, Lup M, et al
[Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:488-494.
Abstract

LU YT, Plets M, Morrison G, Cunha AT, et al
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074.
Abstract

ASTUDILLO C, Garcia-Perdomo HA
Electronic cigarette: is it a risk factor for the development of bladder cancer?
Actas Urol Esp (Engl Ed). 2023 Apr 20:S2173-5786(23)00047.
Abstract

CHEN N, Li P, Liu L, Zhang J, et al
Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and Mitochondrial Apoptotic Pathway.
Plant Foods Hum Nutr. 2023 Apr 22. doi: 10.1007/s11130-023-01058.
Abstract

YILDIZ AK, Ozgur BC, Bayraktar AS, Demir DO, et al
How has the COVID-19 pandemic affected patients with primary bladder cancer?
Cir Cir. 2023;91:204-211.
Abstract

YASUI M, Cui L, Miyamoto H
Recent advances in the understanding of urothelial tumorigenesis.
Expert Rev Anticancer Ther. 2023;23:485-493.
Abstract

SHERMAN E, Lee JL, Debruyne PR, Keam B, et al
Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
ESMO Open. 2023;8:100877.
Abstract

JING W, Chen C, Wang G, Han M, et al
Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanoporter-Encased Hydrogel Eradicates Bladder Carcinoma.
Adv Sci (Weinh). 2023;10:e2206893.
Abstract

GUO J, Liang X, Zheng Y, Ma J, et al
Progress in the treatment of urethral adenocarcinoma.
J Cancer Res Clin Oncol. 2023;149:2693-2698.
Abstract

SUN MY, Peng Y, Liu DW, Wang K, et al
Ectopic prostate tissue at the bladder trigone accompanied by cystitis glandularis and hemorrhage detected by multiparametric MRI.
Asian J Androl. 2023;25:438-439.
Abstract

ABDELRAHMAN I, Aboulkassem H, Elazab A, Abdallah AY, et al
Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
J Egypt Natl Canc Inst. 2023;35:13.
Abstract

REESINK DJ, van Melick HHE, van der Nat PB, Los M, et al
Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
World J Urol. 2023 May 5. doi: 10.1007/s00345-023-04408.
Abstract

DU KL, Ji WT, Jiang QH, Wang Y, et al
Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
Clin Lab. 2023;69.
Abstract

JIN Y, Li J, Tang C, He K, et al
A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
Medicine (Baltimore). 2023;102:e33664.
Abstract

NOVA-CAMACHO LM, Val-Carreres Castellote A, Villafruela Mateos A
Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder Cancer.
Int J Surg Pathol. 2023 May 4:10668969231169049. doi: 10.1177/10668969231169049.
Abstract

JIANG YK, Situai YJ, Deng HM, Zhang H, et al
ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
Curr Med Sci. 2023 May 5. doi: 10.1007/s11596-023-2731.
Abstract

FAULK A, Avulova S, Bree KK, Baak-Kukreja J, et al
Pelvic Organ Preservation in Non-muscle-invasive Bladder Cancer: Less Is More.
Eur Urol Focus. 2023 May 2:S2405-4569(23)00103-7. doi: 10.1016/j.euf.2023.
Abstract

PLAIS H, Dumont C, Gauthier H, Culine S, et al
Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
Immunotherapy. 2023 May 4. doi: 10.2217/imt-2022-0283.
Abstract

LI Q, Qing L, Xu W, Yang Y, et al
Berberine Affects the Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis of Bladder Cancer Cells T24 and 5637 by Down-Regulating the HER2/PI3K/AKT Signaling Pathway.
Arch Esp Urol. 2023;76:152-160.
Abstract

OKUCU E, Yucetas U, Karsiyakali N, Koseoglu H, et al
Higher Serum Endothelial-Specific Molecule-1 (ESM-1/Endocan) Levels are Associated with Poor Pathological Outcomes in Primary Bladder Cancer: A Non-randomized, Prospective, Case-Control Study.
Arch Esp Urol. 2023;76:132-138.
Abstract

SANCHEZ VERDES P, Fernandez-Pello Montes S, Gonzalez Rodriguez I, Suarez Sal PJ, et al
Impact of a One-Stop Hematuria Clinic on Overall Survival and Bladder Tumor Recurrence.
Arch Esp Urol. 2023;76:114-122.
Abstract

LU Y, Jiang S, Yin X, Guo J, et al
Long-term effect of transurethral partial cystectomy with a 2-micrometer continuous-wave laser for non-muscle-invasive bladder cancer.
Front Surg. 2023;10:1117997.
Abstract

SHI ZD, Han XX, Song ZJ, Dong Y, et al
Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression.
Biomark Res. 2023;11:47.
Abstract

LONG F, Wang W, Li S, Wang B, et al
The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer.
J Transl Med. 2023;21:298.
Abstract

KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
Urol Oncol. 2023 May 1:S1078-1439(23)00118-7. doi: 10.1016/j.urolonc.2023.
Abstract

MARTINS PR, Santos TPMD, Menezes LM, Froede AG, et al
Association of human papillomavirus (HPV), p16, p53 and p63 expression with non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm construction for histopathological grading prediction.
Einstein (Sao Paulo). 2023;21:eAO0109.
Abstract

RASTI A, Khalili M, Fakhr Yasseri AM, Nasirian N, et al
Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer.
Rep Biochem Mol Biol. 2023;11:710-719.
Abstract

XIAO D, Xu S, Zhou X, Li D, et al
Synergistic augmentation of osimertinib-induced autophagic death by proguanil or rapamycin in bladder cancer.
MedComm (2020). 2023;4:e236.
Abstract

RAAD E, Helou S, Hage K, Daou M, et al
Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling study.
Int J Equity Health. 2023;22:77.
Abstract

LIU F, Han Z, Lu J, Zhong W, et al
Development and validation of a tobacco smoking-related index for predicting overall survival and immunotherapy response in bladder cancer.
Environ Sci Pollut Res Int. 2023 May 2. doi: 10.1007/s11356-023-27132.
Abstract

STANIMIR M, Lorge F, D'Hondt L, Nollevaux MC, et al
Metastasis to the penis from a bladder carcinoma invading only the lamina propria: case report and description of the morphological aspects.
Rom J Morphol Embryol. 2023;64:89-94.
Abstract

BUKAVINA L, Bell S, Packiam VT, Smaldone M, et al
Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
Urol Oncol. 2023 Apr 29:S1078-1439(23)00119.
Abstract

YAN R, Shen Y, Zhang X, Xu P, et al
Histopathological bladder cancer gene mutation prediction with hierarchical deep multiple-instance learning.
Med Image Anal. 2023;87:102824.
Abstract

SHAHIDI M, Abazari O, Dayati P, Reza JZ, et al
Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer.
Nanomedicine (Lond). 2023 Apr 26. doi: 10.2217/nnm-2022-0198.
Abstract

ZHANG Z, Chen P, Yun J
Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer.
Front Genet. 2023;14:1156095.
Abstract

LI T, Hu W, Jin L, Yin X, et al
Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
Front Oncol. 2023;13:1164368.
Abstract

CHEN X, He F, Zhang W, Fu Y, et al
Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
Front Oncol. 2023;13:1092969.
Abstract

HUANG H, Zhang Y, Chen Z, Zeng X, et al
Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
Heliyon. 2023;9:e15157.
Abstract

SUN X, Dai T, Xu L
Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions.
Front Surg. 2023;10:1143219.
Abstract

GAO W, Zhang J, Tian T, Fu Z, et al
Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
PeerJ. 2023;11:e15284.
Abstract

MUNGMUNPUNTIPANTIP R, Wiwanitkit V
Comment on "telomerase reverse transcriptase rs2736098 and rs2736100 in bladder cancer".
Rep Pract Oncol Radiother. 2023;28:135.
Abstract

VANCAVAGE R, Siddiqui S, Bernstein A, Avulova S, et al
Why has sexuality research in women with bladder cancer undergoing radical cystectomy been ignored for so long?
J Sex Med. 2023;20:580-583.
Abstract

DE VRIES EGE, Ruschoff J, Lolkema M, Tabernero J, et al
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Cancer Med. 2023 Apr 29. doi: 10.1002/cam4.5893.
Abstract

MA X, Zhang L, Liu L, Ruan D, et al
Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and Metastasis.
Appl Biochem Biotechnol. 2023 Apr 29. doi: 10.1007/s12010-023-04512.
Abstract

PARAMANANTHAM Y, B M Said NA, Mun KS
The correlation of EMT and p53 immunohistochemical markers with cisplatin resistance in muscle invasive bladder cancer patients: A single-centred study.
Malays J Pathol. 2023;45:19-29.
Abstract

DU C, Zheng M, Wang Z, Zhang J, et al
Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center.
BMC Urol. 2023;23:71.
Abstract

ZHOU L, Xu G, Huang F, Chen W, et al
Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
BMC Med Genomics. 2023;16:88.
Abstract

LAI HW, Yamamoto S, Fukuhara H, Ogura SI, et al
Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer.
Photodiagnosis Photodyn Ther. 2023 Apr 26:103581.
Abstract

SOBHANI S, Ghoreifi A, Douglawi A, Ahmadi H, et al
Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center.
Int Braz J Urol. 2023;49:351-358.
Abstract

PRIJOVIC N, Santric V, Babic U, Stankovic B, et al
Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man-A Case Report of an Unusual Localization of a Rare Tumour.
Medicina (Kaunas). 2023;59:791.
Abstract

LUO HL, Chang YL, Liu HY, Wu YT, et al
VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma.
Int J Mol Sci. 2023;24:7486.
Abstract

QIAO L, Zhang L, Wang H
SPAG9 Expression Predicts Good Prognosis in Patients with Clear-Cell Renal Cell Carcinoma: A Bioinformatics Analysis with Experimental Validation.
Genes (Basel). 2023;14:944.
Abstract

KHANJANI N, Moradabadi A, Najafi E, Hayati B, et al
Geographic variation in urinary tract and genital cancers in Iran: a hypothesis involving exposure to solar radiation.
BMC Res Notes. 2023;16:65.
Abstract

XIAO XY, Zhao H, Guo HQ, Wang C, et al
[Tumor cell-based glycolytic metabolism and single-cell sequencing of urinary exfoliated cells for the diagnosis and molecular profiling of urothelial carcinoma].
Zhonghua Bing Li Xue Za Zhi. 2023;52:472-479.
Abstract

ALTINTAS TASLICAY C, Sivrioglu AK
Urinary Bladder Masslike Lesions.
Radiographics. 2023;43:e230012.
Abstract

FARAG CM, Akosman S, Luu J, Haji-Momenian S, et al
Hemoglobin, Albumin, Lymphocyte, and Platelet Count is a Significant Biomarker Surrogate for Nutritional Status to Predict Overall Survival in Patients Post-radical Cystectomy.
Urol Pract. 2023;10:262-269.
Abstract

SHU TD, Prunty MC, Pominville R, Omil-Lima D, et al
Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65.
Urol Pract. 2023;10:59-65.
Abstract

ALTINTAS TASLICAY C, Cam I, Civriz AH, Kara O, et al
18F-FDG PET-Positive Large Pelvic Granuloma Mimicking Malignant Bladder Tumor.
Clin Nucl Med. 2023 Apr 25. doi: 10.1097/RLU.0000000000004676.
Abstract

JACKSON-SPENCE F, Toms C, O'Mahony LF, Choy J, et al
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
Future Oncol. 2023;19:509-515.
Abstract

BAJORIN DF, Witjes JA, Gschwend JE, Schenker M, et al
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
Future Oncol. 2023;19:413-426.
Abstract

GRIVAS P, Veeranki P, Chiu K, Pawar V, et al
Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
Future Oncol. 2023;19:369-383.
Abstract

GUZMAN SJ, Kleinschmidt-DeMasters BK
Urothelial carcinoma metastases impacting the CNS: A 20-year retrospective series.
Ann Diagn Pathol. 2023;64:152109.
Abstract

PEREZ-AIZPURUA X, Monzo-Gardiner JI, Maqueda-Arellano J, Buendia-Gonzalez E, et al
BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours.
Actas Urol Esp (Engl Ed). 2023;47:250-258.
Abstract

VARADI M, Nagy N, Reis H, Hadaschik B, et al
Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
Cancer Med. 2023;12:9041-9054.
Abstract

JIANG Y, Peng Y, Ding S, Zheng Y, et al
Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy and preliminary experiences in 22 patients.
Cancer Med. 2023;12:7835-7843.
Abstract

XU YK, Bai J
Multiple urinary bladder tumors: A case report.
Asian J Surg. 2023;46:2221-2222.
Abstract

DOMINGUEZ GARCIA A, Munoz Rodriguez J, Prats Lopez J, Almirall Daly J, et al
Metabolic acidosis after ileal urinary diversion and radical cystectomy. Do we know as much as we think we do? A systematic review.
Actas Urol Esp (Engl Ed). 2023;47:195-210.
Abstract

TERRITO A, Fontanet S, Meneghetti I, Gallioli A, et al
Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
Actas Urol Esp (Engl Ed). 2023;47:221-228.
Abstract

ALLAEYS C, De Backer P, Decaestecker K, Berquin C, et al
Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guerin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report.
Acta Clin Belg. 2023;78:257-260.
Abstract

TANG YC, Yang CS, Liang MX, Zhang Y, et al
Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients.
Medicine (Baltimore). 2023;102:e33719.
Abstract

SEILER R, Egger M, De Menna M, Wehrli S, et al
Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
BMC Urol. 2023;23:89.
Abstract

ZHANG B, Liu T, He Y, Han D, et al
Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer.
BMC Urol. 2023;23:91.
Abstract

ZHENG Y, Wang X, Yang X, Xing N, et al
Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer.
Cell Oncol (Dordr). 2023 May 11. doi: 10.1007/s13402-023-00820.
Abstract

NURMINEN P, Nummi A, Kesti O, Ettala O, et al
Comparison of Bacillus Calmette-Guerin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2023 May 9:S2405-4569(23)00110-4. doi: 10.1016/j.euf.2023.
Abstract

KENNELLEY GE, Amaye-Obu T, Foster BA, Tang L, et al
Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.
Am J Clin Exp Urol. 2023;11:103-120.
Abstract

BAZARGANI S, Lall C, Gopireddy DR, Liu S, et al
Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.
Am J Clin Exp Urol. 2023;11:185-193.
Abstract

ZHANG S, Li L, Yu P, Wu C, et al
A deep learning model for drug screening and evaluation in bladder cancer organoids.
Front Oncol. 2023;13:1064548.
Abstract

OHTSU A, Arai S, Fujizuka Y, Fukuda R, et al
Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a case report.
BMC Urol. 2023;23:88.
Abstract

HINDERBERGER P, Winters N
Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical Route.
Altern Ther Health Med. 2023;29:18-19.
Abstract

TIAN G, Li Y, Nie L, Liu S, et al
Cervical lymph node metastasis of bladder cancer: a case report and review of literature.
Aging Male. 2023;26:2205935.
Abstract

JIANG T, Jin P, Huang G, Li SC, et al
The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics.
Math Biosci Eng. 2023;20:9511-9529.
Abstract

YU J, Lee J, Ha S, Baek JW, et al
Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
Ann Surg Oncol. 2023 May 9. doi: 10.1245/s10434-023-13565.
Abstract

WANG L, Huang S, Zhang P, Li H, et al
The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
J Cancer Res Clin Oncol. 2023 May 9. doi: 10.1007/s00432-023-04739.
Abstract

HAJEBRAHIMI S, Talebpour A, Kabiri N, Ahmadian N, et al
Promoting post-discharge telephone follow-up of patients with transurethral resection for bladder cancer: a best practice implementation project.
JBI Evid Implement. 2023 May 10. doi: 10.1097/XEB.0000000000000374.
Abstract

REN L, Yang X, Liu J, Wang W, et al
An innovative model based on N7-methylguanosine-related lncRNAs for forecasting prognosis and tumor immune landscape in bladder cancer.
Cancer Cell Int. 2023;23:85.
Abstract

LUO Y, Zhang Y, Pang S, Min J, et al
PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation.
Mol Carcinog. 2023 May 8. doi: 10.1002/mc.23533.
Abstract

MOU Z, Chen Y, Zhang Z, Chen X, et al
Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour-specific immunity.
Clin Transl Med. 2023;13:e1255.
Abstract

ABUGOMAA A, Elbadawy M, Ishihara Y, Yamamoto H, et al
Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids.
Front Pharmacol. 2023;14:1159516.
Abstract

SHEN J, Hou H, Liang B, Guo X, et al
Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Front Immunol. 2023;14:1155104.
Abstract

DU Y, Liu Y, Cao J, Jiang X, et al
LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
Front Immunol. 2023;14:1113756.
Abstract

ZHAO S, Wang L, Ding W, Ye B, et al
Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Front Endocrinol (Lausanne). 2023;14:1180404.
Abstract

ANWAR M, Ejaz M, Ijaz M, Ahmad G, et al
Association of IL-17A promoter region SNP-rs2275913 with urinary bladder cancer.
Int J Health Sci (Qassim). 2023;17:33-38.
Abstract

REVESZ J, Posfai B, Pajor L, Papdan T, et al
Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.
Pathol Oncol Res. 2023;29:1611077.
Abstract

WANG H, Gao Y, Qin L, Zhang M, et al
Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis.
Orphanet J Rare Dis. 2023;18:107.
Abstract

LORENZO JF, Lopez Arquillo IM, Rey JV
Primary aortoenteric fistula after intravesical instillation of Bacillus Calmette-Guerin for bladder cancer.
Vascular. 2023 May 6:17085381231174923. doi: 10.1177/17085381231174923.
Abstract

NAIK M, Rao BV, Challa S, Fonseca D, et al
Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
J Cancer Res Ther. 2023;19.
Abstract

AHMAD U, Abdullah S, Chau M, Chia SL, et al
Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
Sci Rep. 2023;13:7323.
Abstract

CZECH AK, Gronostaj K, Fronczek J, Frydrych J, et al
Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing cystectomy: A prospective study.
Urol Oncol. 2023 May 3:S1078-1439(23)00122-9. doi: 10.1016/j.urolonc.2023.
Abstract

HSIEH TY, Sung WW, Chang YC, Yu CY, et al
Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma.
Aging (Albany NY). 2023;15:3107-3119.
Abstract

JANA S, Brahma S, Arora S, Wladyka CL, et al
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
Cancer Cell. 2023;41:853-870.
Abstract

BOLENZ C, Zengerling F
[Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
Urologie. 2023;62:522-524.
Abstract

DAVIS D, Seely D, Morash C, Armstrong J, et al
Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
Altern Ther Health Med. 2023;29:6-17.
Abstract

ROUPRET M, Brouquet A, Colrat F, Diez-Andreu P, et al
Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
World J Urol. 2023;41:1069-1075.
Abstract

VAN WIJNGAARDEN C, Bus MTJ, Ruiter AEC, Lagerveld BW, et al
A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
World J Urol. 2023;41:1077-1083.
Abstract

DENG Y, Fu Y, Chua SL, Khoo BL, et al
Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a 3D Multi-Faceted Tumor Model.
Small. 2023;19:e2205904.
Abstract

KE C, Hu Z, Yang C
Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
Cancer Med. 2023;12:9106-9115.
Abstract

MORI K, Yanagisawa T, Katayama S, Laukhtina E, et al
Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
World J Urol. 2023;41:909-919.
Abstract

DICKMAN KG, Chen CH, Grollman AP, Pu YS, et al
Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
World J Urol. 2023;41:899-907.
Abstract

MURTHY V, Maitre P, Singh M, Pal M, et al
Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
Clin Oncol (R Coll Radiol). 2023 May 5:S0936-6555(23)00178.
Abstract

YANG Y, Bai Y, Wang X, Guo Y, et al
Clock gene NR1D1 might be a novel target for the treatment of bladder cancer.
Urol Oncol. 2023 May 18:S1078-1439(23)00141.
Abstract

KUSMARTSEV S, Ku JH, Grizzi F
Editorial: Tumor microenvironment in bladder cancer.
Front Oncol. 2023;13:1208196.
Abstract

WANG Y, Xie K, Chen W, Fang Y, et al
Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic acid modified metal-organic frameworks.
Bioeng Transl Med. 2023;8:e10515.
Abstract

WEINBERG MS, Zafar A, Magdamo C, Chung SY, et al
Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer.
JAMA Netw Open. 2023;6:e2314336.
Abstract

CHANTAPRASOPSUK S, Rees-Punia E, Patel AV
Physical activity, obesity, and bladder cancer incidence.
Cancer Causes Control. 2023 May 18. doi: 10.1007/s10552-023-01711.
Abstract

DAVARO F, Jain R, Li R
Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know.
Eur Urol Focus. 2023 May 16:S2405-4569(23)00109.
Abstract

REN D, Li L, Wang S, Zuo Y, et al
The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells.
Tissue Cell. 2023;82:102096.
Abstract

ZHAO F, Yang T, Zhou L, Li R, et al
Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing beta-integrin.
Aging (Albany NY). 2023;15.
Abstract

WARRICK JI, Al-Ahmadie H, Berman DM, Black PC, et al
International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
Am J Surg Pathol. 2023 May 18. doi: 10.1097/PAS.0000000000002053.
Abstract

WANG J, Shi H, Fan Z, Yang J, et al
Prognostic nutritional index combined with NLR to construct a survival prediction model and decision analysis of patients with muscle-invasive bladder cancer after surgery.
Cancer Med. 2023 May 18. doi: 10.1002/cam4.6088.
Abstract

DAS S, Gu L, Eve CT, Parrish J, et al
The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
Clin Genitourin Cancer. 2023 Apr 28:S1558-7673(23)00098.
Abstract

HEINZELBECKER J, Spieler N, Kuehn M, Fischer C, et al
Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
Urol Oncol. 2023 May 15:S1078-1439(23)00134.
Abstract

ZHANG C, Xiao J, Yuan T, He Y, et al
Molecular vasculogenic mimicry-Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts.
Front Pharmacol. 2023;14:1163115.
Abstract

SHADAB R, Nerli RB, Bidi SR, Ghagane SC, et al
Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients.
J Cancer Allied Spec. 2023;9:485.
Abstract

KIMURA T, Ishikawa H, Nagumo Y, Sekino Y, et al
Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase II trial.
Int J Radiat Oncol Biol Phys. 2023 May 15:S0360-3016(23)00461.
Abstract

LIN J, Zhan X, Chen R, Chen T, et al
Increased Burden of Second Bladder Cancer and Rectal Cancer in Prostate Cancer Treated With Radiotherapy: Results From Surveillance, Epidemiology, and End Results.
Cancer Control. 2023;30:10732748231177544.
Abstract

BOU ZERDAN M, Bratslavsky G, Jacob J, Ross J, et al
Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
Mol Diagn Ther. 2023 May 17. doi: 10.1007/s40291-023-00647.
Abstract

VAN STRATEN CGJI, Bruins MH, Dijkstra S, Cornel EB, et al
The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients.
World J Urol. 2023 May 17. doi: 10.1007/s00345-023-04428.
Abstract

CELIK S, Gokbayrak O, Erol A, Yorukoglu K, et al
Anna Karenina principle in personalized treatment of bladder cancer according to oncogram: which drug for which patient?
Per Med. 2023 May 17. doi: 10.2217/pme-2022-0134.
Abstract

STRAUSS D, Kaplunov B, Kutikov A, Geynisman DM, et al
Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy.
Urol Case Rep. 2023;48:102399.
Abstract

AN MH, Kim MS, Kim C, Noh TI, et al
Association of 5alpha-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
JAMA Netw Open. 2023;6:e2313667.
Abstract

RELOUW S, Dugbartey GJ, Sener A
Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer.
Cancers (Basel). 2023;15:2381.
Abstract

LEDDEROSE S, Rodler S, Eismann L, Ledderose G, et al
P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:2321.
Abstract

EL AZZOUZI M, El Ahanidi H, Hafidi Alaoui C, Chaoui I, et al
The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer.
Diagnostics (Basel). 2023;13:1471.
Abstract

LI X, Li L, Xiong X, Kuang Q, et al
Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer.
Diagnostics (Basel). 2023;13:1393.
Abstract

VANEMAN J, van Beekhuizen HJ, Boormans JL, Ewing-Graham PC, et al
Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value.
Virchows Arch. 2023 May 15. doi: 10.1007/s00428-023-03559.
Abstract

LINDSKROG SV, Schmokel SS, Nordentoft I, Lamy P, et al
Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer.
Eur Urol Open Sci. 2023;51:78-88.
Abstract

VON DEIMLING M, Mertens LS, van Rhijn BWG, Lotan Y, et al
Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.
Eur Urol Open Sci. 2023;51:39-46.
Abstract

ZLOTTA AR, Ballas LK, Niemierko A, Lajkosz K, et al
Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
Lancet Oncol. 2023 May 12:S1470-2045(23)00170.
Abstract

ARAYA M, Ishikawa H, Nishioka K, Maruo K, et al
Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database.
J Radiat Res. 2023 Apr 25:rrad027. doi: 10.1093.
Abstract

BLOUDEK L, Wright P, McKay C, Derleth CL, et al
Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
Curr Oncol. 2023;30:3637-3647.
Abstract

YU J, Lee J, Ha S, Baek JW, et al
ASO Visual Abstract: Impact of Chart-Derived Frailty Index (CFI) on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
Ann Surg Oncol. 2023 May 15. doi: 10.1245/s10434-023-13618.
Abstract

Chen, Y, Zhang, W, Kadier, A, Zhang, H, Yao, X. MicroRNA-769-5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer. J Clin Lab Anal. 2020; 34:e23193.
J Clin Lab Anal. 2023 May 14:e24893. doi: 10.1002/jcla.24893.
Abstract

ISHII M, Yamamoto Y, Yoshimura A, Hayashi T, et al
[A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing Effectiveness of Chemotherapy with Gemcitabine and Cisplatin].
Hinyokika Kiyo. 2023;69:107-112.
Abstract

HU B, Chen R, Jiang M, Xiong S, et al
EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
PeerJ. 2023;11:e15309.
Abstract

GU L, Guo H, Wu LX, Yuan JB, et al
Prognostic analysis and validation of lncRNAs in bladder cancer on the basis of neutrophil extracellular traps.
J Gene Med. 2023 May 13:e3525. doi: 10.1002/jgm.3525.
Abstract

GUDOWSKA-SAWCZUK M, Kudelski J, Olkowicz M, Mlynarczyk G, et al
The Clinical Significance of Serum Free Light Chains in Bladder Cancer.
J Clin Med. 2023;12:3294.
Abstract

MALKIEWICZ B, Jedrzejuk D, Gurwin A, Wilk K, et al
Diagnostic Value of the Sentinel Lymph Node Technique in Patients with Muscle-Invasive Bladder Cancer.
J Clin Med. 2023;12:3092.
Abstract

RYU D, Kim TM, Lee YH, Ha US, et al
Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer.
Int J Mol Sci. 2023;24:8418.
Abstract

SZYDLAK R, Ovreeide IH, Luty M, Zielinski T, et al
Bladder Cancer Cells Interaction with Lectin-Coated Surfaces under Static and Flow Conditions.
Int J Mol Sci. 2023;24:8213.
Abstract

PACKEISER EM, Engels L, Nolte I, Goericke-Pesch S, et al
MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines.
Int J Mol Sci. 2023;24:8136.
Abstract

GANDIN V, Hoeschele JD, Margiotta N
Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0".
Int J Mol Sci. 2023;24:7917.
Abstract

KUBIK A, das Virgens IPA, Szabo A, Varadi M, et al
Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis.
Int J Mol Sci. 2023;24:7859.
Abstract

GRANT SR, Tang L, Wei L, Foster BA, et al
Mutation Hotspots Found in Bladder Cancer Aid Prediction of Carcinogenic Risk in Normal Urothelium.
Int J Mol Sci. 2023;24:7852.
Abstract

MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder Cancer.
Cancers (Basel). 2023;15:2565.
Abstract

NIE Z, Gao Y, Chen M, Peng Y, et al
Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
Cancers (Basel). 2023;15:2487.
Abstract

WANG Z, Zhao C, Li Y, Wang J, et al
Photostable Cascade Activatable Peptide Self-assembly on a Cancer Cell Membrane for High-Performance Identification of Human Bladder Cancer.
Adv Mater. 2023 May 12:e2210732. doi: 10.1002/adma.202210732.
Abstract

LI TY, Zhang B, Zhang J
A case report and literature review on primary solitary fibrous tumor of the bladder.
Medicine (Baltimore). 2023;102:e33708.
Abstract

HABIL MR, Hein DW
Effects of dose and human N-acetyltransferase 1 genetic polymorphism in benzidine metabolism and genotoxicity.
Arch Toxicol. 2023;97:1765-1772.
Abstract

PENG L, Mehmud I, Meng C, Tang D, et al
ASO Author Reflections: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
Ann Surg Oncol. 2023;30:3817-3818.
Abstract

EGGER V, Hutterer GC, Mischinger J, Seles M, et al
Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.
World J Urol. 2023;41:1359-1364.
Abstract

LEE JL, Desai C, Park SH, Tsuchiya N, et al
Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Urol Oncol. 2023;41:256.
Abstract

BUSETTO GM, Finati M, Chirico M, Cinelli F, et al
Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
World J Urol. 2023;41:1329-1335.
Abstract

KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
The efficacy of ultrasonography for the detection of upper tract urothelial carcinoma.
J Med Ultrason (2001). 2023;50:197-203.
Abstract

PYCHA S, Trenti E, Mian C, Schwienbacher C, et al
Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
World J Urol. 2023;41:1323-1328.
Abstract

PENG L, Mehmud I, Meng C, Tang D, et al
ASO Visual Abstract: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
Ann Surg Oncol. 2023;30:3819.
Abstract

PENG L, Mehmud I, Meng C, Tang D, et al
Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
Ann Surg Oncol. 2023;30:3805-3816.
Abstract

PARIMI V, Choi W, Feng M, Fong M, et al
Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
Histopathology. 2023;82:991-1002.
Abstract

JIN J, Li J, Peng C, Chen J, et al
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
Anticancer Drugs. 2023;34:797-802.
Abstract

ROUMIGUIE M, Wong A, Belanger E, Wang G, et al
Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design.
Urol Oncol. 2023;41:254.
Abstract

MIURA H, Hatakeyama S, Tanaka T, Fujita N, et al
Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction.
Urol Oncol. 2023;41:254.
Abstract

MORTON E, Kaul S, Fleishman A, Korets R, et al
Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection.
Urol Oncol. 2023;41:255.
Abstract

MAISCH P, Koll F, Bolenz C, Chun FK, et al
Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
Urol Oncol. 2023;41:219-232.
Abstract

KUCKUCK EC, Hennenlotter J, Todenhofer T, Brunn LA, et al
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria.
Urol Oncol. 2023;41:254.
Abstract

NEUMANN I, Borrelli M, Al Kallaa M, Parker RT, et al
Rare periorbital, pseudocystic metastasis of squamous cell carcinoma of the bladder: Case report and review of the literature.
Orbit. 2023;42:336-342.
Abstract

TYAGI P, Moon CH, Connell M, Ganguly A, et al
Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging.
Curr Oncol. 2023;30:4632-4647.
Abstract

BITAM S, Hamadache M, Hanini S
Targeting bladder cancer with Trigonella foenum-graecum: a computational study using network pharmacology and molecular docking.
J Biomol Struct Dyn. 2023 May 26:1-8. doi: 10.1080/07391102.2023.2217926.
Abstract

ZHAO J, Li J, Zhang R
Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer.
Biochim Biophys Acta Rev Cancer. 2023 May 23:188926.
Abstract

LI W, Wang Z, Jiang Z, Yan Y, et al
MiR-3960 inhibits bladder cancer progression via targeting of DEXI.
Biochem Biophys Res Commun. 2023;668:8-18.
Abstract

OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
Targeted and untargeted urinary metabolic profiling of bladder cancer.
J Pharm Biomed Anal. 2023;233:115473.
Abstract

WIRTZ HS, Hepp Z, Grewal S, Wright P, et al
Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
Am J Manag Care. 2023;29:e136-e142.
Abstract

BENABDALLAH W, Ben Othmane M, Ouahchi I, Mestiri S, et al
Plasmacytoid bladder cancer: a rare case report.
Ann Med Surg (Lond). 2023;85:1885-1887.
Abstract

MIRTO BF, Scafuri L, Sicignano E, Luca C, et al
Nature's hidden gem: quercitrin's promising role in preventing prostate and bladder cancer.
Future Sci OA. 2023;9:FSO867.
Abstract

BAUDEWYNS A, Jabbour T, Bourgeno HA, Peltier A, et al
Late-onset enteric fistula following radical cystectomy for bladder cancer: A case report.
Urol Case Rep. 2023;49:102431.
Abstract

HRBACEK J, Hanacek V, Kadleckova D, Cirbusova A, et al
Urinary shedding of common DNA viruses and their possible association with bladder cancer: a qPCR-based study.
Neoplasma. 2023;70:311-318.
Abstract

UCHIDA H, Obinata D, Takada S, Yoshizawa T, et al
Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.
J Int Med Res. 2023;51:3000605231173319.
Abstract

MAAS M, Todenhofer T, Black PC
Urine biomarkers in bladder cancer - current status and future perspectives.
Nat Rev Urol. 2023 May 24. doi: 10.1038/s41585-023-00773.
Abstract

HUDDART R, Hafeez S, Omar A, Alonzi R, et al
Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
Clin Oncol (R Coll Radiol). 2023 May 9:S0936-6555(23)00180.
Abstract

JOHANNSEN M, Klier J, Konig F, Schonfelder R, et al
[National Registries for Urothelial Cancer (UroNAT) and Prostate Cancer (ProNAT) by d-uo].
Aktuelle Urol. 2023;54:202-207.
Abstract

DOEHN C, Johannsen M, Eichenauer R, Klier J, et al
[The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)].
Aktuelle Urol. 2023;54:189-195.
Abstract

[Not Available].
Aktuelle Urol. 2023;54:185.
Abstract

DE JONG FC, Laajala TD, Hoedemaeker RF, Jordan KR, et al
Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin.
Sci Transl Med. 2023;15:eabn4118.
Abstract

DENG Z, Dong W, Xiong S, Jin D, et al
Machine learning models combining computed tomography semantic features and selected clinical variables for accurate prediction of the pathological grade of bladder cancer.
Front Oncol. 2023;13:1166245.
Abstract

LONATI C, Soria F, Pradere B, D'Andrea D, et al
Comment on: "Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG".
Minerva Urol Nephrol. 2023;75:407-409.
Abstract

ASERO V, Scornajenghi CM, Krajewski W, Szydelko T, et al
Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma".
Minerva Urol Nephrol. 2023;75:401-403.
Abstract

KHODADADI F, Khorashadizadeh M, Ghasemi F
Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro.
Mol Biol Rep. 2023 May 23. doi: 10.1007/s11033-023-08472.
Abstract

DE LIMA CSA, Rial-Hermida MI, de Freitas LF, Pereira-da-Mota AF, et al
Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels containing gemcitabine and papain for bladder cancer treatment.
Int J Biol Macromol. 2023 May 20:124957. doi: 10.1016/j.ijbiomac.2023.124957.
Abstract

LIU SS, Li JS, Xue M, Wu WJ, et al
LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
Int J Biol Sci. 2023;19:2599-2612.
Abstract

XIE S, He J, Feng B, Rao D, et al
A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer.
Heliyon. 2023;9:e15897.
Abstract

SCHELTES DA, van der Steen-Banasik EM, Smits GAHJ
Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study.
J Contemp Brachytherapy. 2023;15:110-116.
Abstract

WANG X, Zhang Y, Wu Y, Cheng H, et al
The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy.
Front Immunol. 2023;14:1202633.
Abstract

LIU H, Xiang P, Miao W, Liu H, et al
Analysis of the Regulatory Effect of ACTG2 on Biological Behavior of Bladder Cancer Cells Based on Database Screening.
Cell Mol Biol (Noisy-le-grand). 2023;69:125-130.
Abstract

LIU H, Wang X, Guo Z, Sun G, et al
LncRNA BCLET variant confers bladder cancer susceptibility through alternative splicing of MSANTD2 exon 1.
Cancer Med. 2023 May 21. doi: 10.1002/cam4.6072.
Abstract

SARAVANABAVAN S, Prakash GJ, Joshi A, Pal M, et al
Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center.
Clin Genitourin Cancer. 2023 Apr 11:S1558-7673(23)00082.
Abstract

CHUNG R, Moran GW, Movassaghi M, Pohl D, et al
Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy.
Urol Oncol. 2023 May 18:S1078-1439(23)00137.
Abstract

SANYA DRA, Onesime D
Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
Hum Cell. 2023 May 20. doi: 10.1007/s13577-023-00915.
Abstract

YUAN H, Xiu Y, Liu T, Fan Y, et al
The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma.
Front Immunol. 2023;14:1126247.
Abstract

HUA X, Li J, Shang M, He W, et al
Pathogenesis of psoriasis via miR-149-5p/AKT1axis by long noncoding RNA BLACAT1.
Skin Res Technol. 2023;29:e13339.
Abstract

WIECZOREK E, Wolniakowska A, Roszak J, Rodrigues RM, et al
Gene-occupation interactions: a review of the literature on bladder and prostate cancer.
Med Pr. 2023;74:127-144.
Abstract

TAPPERO S, Cano Garcia C, Incesu RB, Piccinelli ML, et al
Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy.
Surg Oncol. 2023;48:101947.
Abstract

TAN WS, Tan MY, Alhalabi O, Campbell MT, et al
Evolving systemic management of urothelial cancers.
Curr Opin Oncol. 2023;35:186-199.
Abstract

HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
Regional differences in total hospital costs for radical cystectomy in the United States.
Surg Oncol. 2023;48:101924.
Abstract

LO YC, Bauer AH, Odintsov I, Siegmund SE, et al
Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.
Mod Pathol. 2023;36:100126.
Abstract

MUSANGILE FY, Matsuzaki I, Iwamoto R, Sagan K, et al
Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
Mod Pathol. 2023;36:100120.
Abstract

BASU M, Mukhopadhyay D, Chakraborty B, Ghosh S, et al
Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
Mol Cell Biochem. 2023;478:1599-1610.
Abstract

BRAVI CA, Piazza P, Mazzone E, Dell'Oglio P, et al
Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up.
J Robot Surg. 2023;17:1143-1150.
Abstract

VISWAMBARAM P, McCombie SP, Hawks C, Wallace DMA, et al
Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database.
Asia Pac J Clin Oncol. 2023;19:290-295.
Abstract

YAMADA Y, Ikeda M, Hirayama T, Murakami Y, et al
Noninferior oncological outcomes in adults aged 80 years or older compared with younger patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma.
Asia Pac J Clin Oncol. 2023;19:305-311.
Abstract

GELLRICH AL, Eraky A, Hamann C, Hugelmann K, et al
[Cystectomy of a young patient with squamous cell metaplasia of the bladder and manifestation of condyloma].
Aktuelle Urol. 2023;54:223-227.
Abstract

BAIRD B, Bilgili A, Anderson A, Carames G, et al
Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer.
Int Braz J Urol. 2023;49:479-489.
Abstract

ELSAYED DH, Elfarargy OM, Elderey MS, Mandour D, et al
Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
Contemp Oncol (Pozn). 2023;27:1-9.
Abstract

YANG C, Li Q, Chen X, Zhang Z, et al
Correction for: Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation.
Aging (Albany NY). 2023;undefined.
Abstract

RETZ M, Kirchhoff FP, von Amsberg G, De Santis M, et al
[Sequential therapy of advanced bladder cancer after prior perioperative systemic treatment : Recommendations from the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the DKG e.â€¯V.].
Urologie. 2023 Jun 1. doi: 10.1007/s00120-023-02098.
Abstract

LIU Y, Hu B, Pei X, Li J, et al
A non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.
Adv Healthc Mater. 2023 Jun 1:e2300791. doi: 10.1002/adhm.202300791.
Abstract

MACDONALD A, Mehrnoush V, Ismail A, Di Matteo L, et al
History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer.
Arch Ital Urol Androl. 2023 May 31:11380. doi: 10.4081/aiua.2023.11380.
Abstract

ZHANG L, Liu B, Deng QH, Li JX, et al
Retraction Note: LncRNA BRE-AS1 acts as a tumor suppressor factor in bladder cancer via mediating STAT3.
Eur Rev Med Pharmacol Sci. 2023;27:4326.
Abstract

VAN HOOGSTRATEN LMC, Man CCO, Witjes JA, Meijer RP, et al
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
World J Urol. 2023 May 31:1-9. doi: 10.1007/s00345-023-04443.
Abstract

YAN B, Li X, Peng M, Zuo Y, et al
The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression.
Exp Mol Med. 2023 Jun 1. doi: 10.1038/s12276-023-00997.
Abstract

CHAPPIDI MR, Escobar D, Meng MV, Washington SL 3rd, et al
Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
Urol Oncol. 2023 May 29:S1078-1439(23)00172.
Abstract

WANG D, Liu Y
Comment on "The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer".
Rev Assoc Med Bras (1992). 2023;69:e20230295.
Abstract

SIREGAR GP, Parwati I, Noegroho BS, Safridai F, et al
The association between serum hypoxia inducible factor-1alpha level and urothelial bladder cancer: A preliminary study.
Arch Ital Urol Androl. 2023 May 29:11292. doi: 10.4081/aiua.2023.11292.
Abstract

SOHNGEN C, Thomas DJ, Skowron MA, Bremmer F, et al
CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
FEBS J. 2023 May 31. doi: 10.1111/febs.16880.
Abstract

ZHANGHUANG C, Zhang Z, Wang J, Yao Z, et al
Surveillance of prognostic risk factors in patients with SCCB using artificial intelligence: a retrospective study.
Sci Rep. 2023;13:8727.
Abstract

ZENG N, Xu MY, Sun JX, Liu CQ, et al
Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.
Front Oncol. 2023;13:1164932.
Abstract

DU Y, Miao W, Jiang X, Cao J, et al
Corrigendum: The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis.
Front Oncol. 2023;13:1185029.
Abstract

UEMATSU R, Teishima J, Sakata H, Mita Y, et al
Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette-Guerin for bladder cancer.
Int Cancer Conf J. 2023;12:221-225.
Abstract

KONO S, Hashimoto Y, Shirai Y, Kunihiro Y, et al
A long-term survival case of bladder cancer with distant metastases: abscopal effect of brain metastases after stereotactic radiotherapy with immune checkpoint blockade therapy to lung metastases.
Int Cancer Conf J. 2023;12:205-209.
Abstract

DOLNY M, Czajkowski M, Czajkowska K, Sokolowska-Wojdylo M, et al
Penile metastasis secondary to urothelial bladder cancer.
Urol Case Rep. 2023;49:102428.
Abstract

TORTORA D, Roberts ME, Kumar G, Kotapalli SS, et al
A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer.
iScience. 2023;26:106525.
Abstract

COSTA L, Alexandre T, Mansinho A, Sousa R, et al
Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal.
Front Public Health. 2023;11:1133959.
Abstract

ZHANG ZC, Zhao HF, Sun Z, Li Y, et al
Tripartite motif-containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2/3 axis.
J Cell Commun Signal. 2023 May 30. doi: 10.1007/s12079-023-00766.
Abstract

LIU Y, Yu H, Zeng B, Gou X, et al
miR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT signaling pathway.
Cancer Biomark. 2023 May 18. doi: 10.3233/CBM-220379.
Abstract

ZHU PY, Wang L, Li KP, Yin S, et al
Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and pooled analysis of comparative outcomes.
World J Surg Oncol. 2023;21:163.
Abstract

MALALASEKERA A, Neththikumara N, Somasundaram P, Pathirana S, et al
Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer Patients from Sri Lanka.
Asian Pac J Cancer Prev. 2023;24:1533-1542.
Abstract

CHEN Y, Zhang Y, Wang X, Qiao S, et al
Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway.
J Biochem Mol Toxicol. 2023 May 29:e23387. doi: 10.1002/jbt.23387.
Abstract

DOWNES MR, Hartmann A, Shen S, Tsuzuki T, et al
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance.
Am J Surg Pathol. 2023 May 29. doi: 10.1097/PAS.0000000000002059.
Abstract

ZHANG N, Bian Q, Gao Y, Wang Q, et al
The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?
Technol Cancer Res Treat. 2023;22:15330338231175733.
Abstract

GALLUZZO A, Danti G, Bicci E, Mastrorosato M, et al
The Role of Dual-Energy CT in the Study of Urinary Tract Tumors: Review of Recent Literature.
Semin Ultrasound CT MR. 2023;44:136-144.
Abstract

SHI X, Dong A, Yang Y, Zheng G, et al
Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
J Cancer Res Clin Oncol. 2023 May 27. doi: 10.1007/s00432-023-04881.
Abstract

CLAPS F, Rossin G, van Rhijn BWG, Mir MC, et al
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer.
Medicina (Kaunas). 2023;59:926.
Abstract

MOHANTY SK, Lobo A, Mishra SK, Cheng L, et al
Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
J Pers Med. 2023;13:756.
Abstract

EINERHAND SMH, Zuur LG, Wondergem MJ, Boellaard TN, et al
The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the Detection and Characteristics of Occult Nodal Metastases at Upfront Radical Cystectomy?
J Clin Med. 2023;12:3367.
Abstract

SZALLASI A
"ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and Prognosis (Practical Approach by a Pathologist).
Int J Mol Sci. 2023;24:9098.
Abstract

WATANABE R, Miura N, Kurata M, Kitazawa R, et al
Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
Int J Mol Sci. 2023;24:8955.
Abstract

SMITH V, Lee D, Reardon M, Shabbir R, et al
Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;24:8956.
Abstract

OKUNO Y, Hattori-Kato M, Tanaka H, Tonooka A, et al
Relationship between the Reduced Expression of Zinc Finger Protein 668 in Bladder Cancer and Its Invasiveness.
Int J Mol Sci. 2023;24:8668.
Abstract

WANG BR, Chang WS, Liao CH, Wang YC, et al
Impacts of Mir146a Genotypes on Bladder Cancer Risk in Taiwan.
Biomedicines. 2023;11:1396.
Abstract

SPIRITO L, Maturi R, Credendino SC, Manfredi C, et al
Differential Expression of LncRNA in Bladder Cancer Development.
Diagnostics (Basel). 2023;13:1745.
Abstract

STRAUSS J, Deville JL, Sznol M, Ravaud A, et al
First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
J Immunother Cancer. 2023;11:e005813.
Abstract

JIANG LJ, Guo SB, Huang ZY, Li XL, et al
PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/beta-catenin signaling pathway.
Pathol Res Pract. 2023;247:154536.
Abstract

YANG CH, Hsu CY, Lin YS, Tung MC, et al
One-Step Robot-Assisted Complete Urinary Tract Extirpation in Man with End-Stage Renal Disease on Dialysis: The First Case Report.
Curr Oncol. 2023;30:5093-5102.
Abstract

DAI S, Liu C, Jiang Z, Teng X, et al
Three-port approach vs conventional laparoscopic radical cystectomy with orthotopic neobladder: a single-center retrospective study.
World J Surg Oncol. 2023;21:160.
Abstract

SAVELEVA MS, Lobanov ME, Gusliakova OI, Plastun VO, et al
Mucoadhesive Emulsion Microgels for Intravesical Drug Delivery: Preparation, Retention at Urothelium, and Biodistribution Study.
ACS Appl Mater Interfaces. 2023;15:25354-25368.
Abstract

TANG Q, Li S, Huang G, Liu H, et al
Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
Int Immunopharmacol. 2023;119:110158.
Abstract

ANIS O, Yogev D, Dotan A, Tsur AM, et al
Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review.
Autoimmun Rev. 2023;22:103329.
Abstract

ZHONG B, Wang Y, Liao Y, Liang J, et al
MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
Apoptosis. 2023;28.
Abstract

BAHCECI D, Nguyen JK, Sangoi AR, Stohr BA, et al
Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
Hum Pathol. 2023;136:56-62.
Abstract

GONZALEZ N, Rao N, Dean M, Lee D, et al
Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors.
Cancer Epidemiol Biomarkers Prev. 2023;32:840-847.
Abstract

SU R, Chen Z, Hong D, Jiang S, et al
Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
Cancer Med. 2023;12:10587-10596.
Abstract

MOON JH, Nikas IP, Moon KC, Kim B, et al
Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: A prospective, single institute study.
Cancer Med. 2023;12:10363-10370.
Abstract

TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
Clin Genitourin Cancer. 2023;21:334-341.
Abstract

PATEL KN, Salunke A, Sharma M, Puj K, et al
Development and Internal Validation of a Nomogram Predicting Overall Survival Based on Log ODDS of Positive Lymph-Nodes for Post Radical Cystectomy Patients in Muscle Invasive Carcinoma of Bladder.
Clin Genitourin Cancer. 2023;21:e153-e165.
Abstract

GELLINGS P, Galeas-Pena M, Morici LA
Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
Clin Exp Med. 2023;23:519-527.
Abstract

ZHENG P, Wu K, Gao Z, Li H, et al
[Retracted] KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.
Int J Mol Med. 2023;52:62.
Abstract

VAN DER KWAST TH, Bubendorf L, Cheng L
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Progresses and Challenges.
Am J Surg Pathol. 2023 Jun 8. doi: 10.1097/PAS.0000000000002066.
Abstract

ZHOU H, Wang P, Qin X, Zhang X, et al
Comparative transcriptomic analysis and mechanistic characterization revealed the use of formononetin for bladder cancer treatment.
Food Funct. 2023 Jun 8. doi: 10.1039/d2fo03962.
Abstract

VOLZ Y, Trappmann R, Ebner B, Eismann L, et al
Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk?
BMC Urol. 2023;23:106.
Abstract

ERDIK A, Cimen HI, Kose O, Ates OF, et al
Can pelvic diameter measurement have an effect on surgical outcomes in radical cystectomy?
BMC Urol. 2023;23:105.
Abstract

LU J, Li X, Chen M, Yang P, et al
Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response to Adjuvant Chemotherapy in T3 Stage Bladder Cancer.
Clin Genitourin Cancer. 2023 May 7:S1558-7673(23)00105.
Abstract

PETRAUSCH U, Spahn M, Schneider M, Hayoz S, et al
Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol
BMJ Open. 2023;13:e067634.
Abstract

ZHANG W, Mao S, Shi D, Zhang J, et al
Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.
Front Oncol. 2023;13:1208728.
Abstract

XU C, Zou W, Zhang L, Xu R, et al
Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
Front Immunol. 2023;14:1162580.
Abstract

WU W, Chen L, Jia G, Tang Q, et al
Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
Cancer Med. 2023 Jun 7. doi: 10.1002/cam4.6172.
Abstract

XU C, Chen A, Mao C, Cui B, et al
Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:139-147.
Abstract

LINDNER AK, Lackner F, Tymoszuk P, Barth DA, et al
Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Biol Sex Differ. 2023;14:38.
Abstract

WU R, Teng X, Song Q, Chen S, et al
Single-cell RNA sequencing reveals sexual diversity in the human bladder and its prospective impacts on bladder cancer and urinary tract infection.
BMC Med Genomics. 2023;16:122.
Abstract

ZHENG J, Miao F, Wang Z, Ma Y, et al
Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Life Sci. 2023 Jun 3:121832. doi: 10.1016/j.lfs.2023.121832.
Abstract

YANG CJ, Tan ZL, Yang JD, Hsu FT, et al
Fluoxetine inactivates STAT3/NF-kappaB signaling and promotes sensitivity to cisplatin in bladder cancer.
Biomed Pharmacother. 2023;164:114962.
Abstract

DONG Y, Xu C, Su G, Li Y, et al
Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation.
Front Immunol. 2023;14:1122570.
Abstract

HERRANZ R, Oto J, Hueso M, Plana E, et al
Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
Front Immunol. 2023;14:1171065.
Abstract

DERGAMOUN H, El Gdaouni A, Taoufik A, Ziouziou I, et al
Inflammatory myofibroblastic tumor of the urinary bladder: a case report.
Pan Afr Med J. 2023;44:119.
Abstract

LIU X, Li X, Kuang Q, Luo H, et al
Screening of immunotherapy-related genes in bladder cancer based on GEO datasets.
Front Oncol. 2023;13:1176637.
Abstract

KAGAMI LP, Goncalves IL, da Silva AC, Silva AC, et al
LaSOM 335, active against bladder cancer cells, interferes with Let-60 (hRas) and reduces CD73 expression/activity.
Chem Biol Drug Des. 2023 Jun 5. doi: 10.1111/cbdd.14273.
Abstract

SODA T, Tashiro Y, Koike S, Ikeuchi R, et al
Evaluation of incidence, predictive factors and treatment considerations for asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin therapy.
Actas Urol Esp (Engl Ed). 2023;47:317-326.
Abstract

WANG S, Ge C
High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid.
J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04867.
Abstract

LICHTBROUN B, Srivastava A, Ghodoussipour S
A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer.
Eur Urol Focus. 2023 Jun 1:S2405-4569(23)00121-9. doi: 10.1016/j.euf.2023.
Abstract

WU S, Hong G, Lin T
Artificial intelligence-based model for lymph node metastases detection in bladder cancer - Authors' reply.
Lancet Oncol. 2023;24:e234.
Abstract

MAI Z, Zhou Y, Zhou Z, Yan W, et al
Artificial intelligence-based model for lymph node metastases detection in bladder cancer.
Lancet Oncol. 2023;24:e233.
Abstract

ZOU K, Lu M, Peng Y, Tang X, et al
Artifical intelligence-based model for lymph node metastases detection in bladder cancer.
Lancet Oncol. 2023;24:e232.
Abstract

WANG C, Liu T, Wang J, Cheng C, et al
CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1 complex in bladder cancer.
Discov Oncol. 2023;14:86.
Abstract

SUN YF, Chen L, Xia QJ, Wang TH, et al
Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04886.
Abstract

CHEN C, Chao Y, Zhang C, Hu W, et al
TROP2 translation mediated by dual m(6)A/m(7)G RNA modifications promotes bladder cancer development.
Cancer Lett. 2023 May 31:216246. doi: 10.1016/j.canlet.2023.216246.
Abstract

HUANG EY, Tai MC, Chung HJ, Chang YH, et al
Effects of different combinations of radical nephroureterectomy and bladder cuff excision procedures for upper tract urothelial carcinoma on bladder recurrence.
Int Braz J Urol. 2023;49:469-478.
Abstract

KRANZ J, Hoffmann M, Alexa R, Kuppe C, et al
[Urothelial carcinoma of the upper urinary tract].
Urologie. 2023;62:640-650.
Abstract

GAVRILOVSKA-BRZANOV A, Seidi S, Stavridis S, Ivanovski O, et al
Obturator Nerve Block for Transurethral Resection of Bladder Tumors.
Med Arch. 2023;77:118-122.
Abstract

KARTTUNEN E, Oldenburg J, Thoresen S, Ullen A, et al
Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic count
Scand J Urol. 2023;58:20.
Abstract

CHEN X, Cheng Y, Tian X, Li J, et al
Urinary microbiota and metabolic signatures associated with inorganic arsenic-induced early bladder lesions.
Ecotoxicol Environ Saf. 2023;259:115010.
Abstract

SONG Y, Xu T
Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder.
World J Urol. 2023;41:1697-1698.
Abstract

MAGOON R, Jose J, Suresh V
Assessing postradical cystectomy outcomes in the enhanced recovery era: "enhancing" the corresponding research outlook.
Urol Oncol. 2023;41:292.
Abstract

VAHLENSIECK W
[Interstitial cystitis/bladder pain syndrome (IC/BPS)].
Urologie. 2023;62:582-589.
Abstract

KUMAR R, Matulewicz R, Mari A, Moschini M, et al
Impact of smoking on urologic cancers: a snapshot of current evidence.
World J Urol. 2023;41:1473-1479.
Abstract

BRUCH PG, Plage H, Hofbauer S, Kornienko K, et al
Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
Exp Mol Pathol. 2023;131:104860.
Abstract

DIAMANTOPOULOS LN, Makrakis D, Korentzelos D, Alevizakos M, et al
Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma.
Urol Oncol. 2023;41:296.
Abstract

ZHU Y, Geng Z, Lin Q
Primary intestinal adenocarcinoma after orthotopic ileal neobladder.
Asian J Surg. 2023;46:2321-2322.
Abstract

HARVEY SE, VandenBussche CJ
Nuclear membrane irregularity in high-grade urothelial carcinoma cells can be measured by using circularity and solidity as morphometric shape definitions in digital image analysis of urinary tract cytology specimens.
Cancer Cytopathol. 2023;131:351-359.
Abstract

CHIN CP, Smith WH, Cesaretti J, Terk M, et al
Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
Urol Oncol. 2023;41:296.
Abstract

BAI SJ, Chen XB, Zeng TB
Treatment progress of cystitis glandularis.
Asian J Surg. 2023;46:2444.
Abstract

SHEN H, Lv C
Multiple primary trans-systemic triple carcinoma: A rare case report.
Asian J Surg. 2023;46:2466-2467.
Abstract

BAIRD BA, Taylor T, Brennan E, Borkar S, et al
Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida.
Urol Oncol. 2023;41:294.
Abstract

FONTANET S, Gallioli A, Baboudjian M, Huguet J, et al
Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: A single institution series and systematic review.
Urol Oncol. 2023;41:274-283.
Abstract

DUDINEC JV, Ortiz-Melo DI, Lipkin ME, Abern MR, et al
Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.
Urol Oncol. 2023;41:295.
Abstract

TAI P, Wang Z, Chen X, Chen A, et al
Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
Cancer Med. 2023;12:11941-11959.
Abstract

VELEZ TORRES JM, Gonzalez ML, Duarte EM, Zein-Sabatto B, et al
Urine Cytology Findings in Cases of Pseudocarcinomatous Urothelial Hyperplasia of the Bladder Often Represent a Diagnostic Challenge.
Arch Pathol Lab Med. 2023;147:716-721.
Abstract

YOO Y, Kim JM, Choi E, Park HS, et al
The Effect of Complete Prostate Examination of Radical Cystoprostatectomy Specimen on the Final Stage of Urothelial Carcinoma of the Urinary Bladder and the Detection of Prostate Cancer.
Arch Pathol Lab Med. 2023;147:665-675.
Abstract

SHI T, Yuan Z, He Y, Zhang D, et al
Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer.
Cell Oncol (Dordr). 2023 Jun 16. doi: 10.1007/s13402-023-00823.
Abstract

LIU X, Wu Y, Zhou Z, Huang M, et al
[Corrigendum] Celecoxib inhibits the epithelialâ€‘toâ€‘mesenchymal transition in bladder cancer via the miRNAâ€‘145/TGFBR2/Smad3 axis.
Int J Mol Med. 2023;52:64.
Abstract

CHEN H, Yang W, Li Y, Ma L, et al
Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.
Front Immunol. 2023;14:1198878.
Abstract

XUE Y, Zhao G, Pu X, Jiao F, et al
Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA.
Front Oncol. 2023;13:1196802.
Abstract

BOOT IWA, Wesselius A, Yu EYW, White E, et al
Dietary vitamin D intake and the bladder cancer risk: A pooled analysis of prospective cohort studies.
Clin Nutr. 2023 May 22:S0261-5614(23)00152-8. doi: 10.1016/j.clnu.2023.
Abstract

YANG X, Zhang S, He J, Zhao L, et al
Brazilin inhibits bladder cancer by promoting cell necroptosis.
Clin Exp Pharmacol Physiol. 2023 Jun 15. doi: 10.1111/1440-1681.13800.
Abstract

GALLAGHER K, Bhatt N, Clement K, Zimmermann E, et al
Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study W
JMIR Res Protoc. 2023;12:e42254.
Abstract

LIU S, Liu Z, Shang A, Xun J, et al
CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis.
Sci Rep. 2023;13:9657.
Abstract

STEELE TM, Tsamouri MM, Siddiqui S, Lucchesi CA, et al
Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer.
Sci Rep. 2023;13:9617.
Abstract

STONE BV, Labban M, Filipas DK, Beatrici E, et al
The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States.
Clin Genitourin Cancer. 2023 May 27:S1558-7673(23)00135.
Abstract

LU XS, Huang ML, Chen LB, Liu SC, et al
SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer.
Genomics. 2023 Jun 12:110667. doi: 10.1016/j.ygeno.2023.110667.
Abstract

JIANG C, Perimbeti S, Deng L, Xing J, et al
Medicaid Expansion and Racial Disparity in Timely Multidisciplinary Treatment in Muscle Invasive Bladder Cancer.
J Natl Cancer Inst. 2023 Jun 14:djad112. doi: 10.1093.
Abstract

WANG L, Qi F, Bi L, Yan J, et al
Targeted hollow pollen silica nanoparticles for enhanced intravesical therapy of bladder cancer.
Biomater Sci. 2023 Jun 14. doi: 10.1039/d3bm00631.
Abstract

DALJIT T, Melgandi W, Ansari FA, Rathi AK, et al
Cutaneous metastasis in bladder cancer.
J Cancer Res Ther. 2023;19:501-504.
Abstract

ALAM MN, Agrawal S, Rastogi N, Saxena R, et al
Chemotherapy or chemotherapy followed by consolidation chemoradiation in postoperative (simple cholecystectomy) gall bladder cancer with residual disease, unsuitable for revision surgery? Risk stratification and outcomes.
J Cancer Res Ther. 2023;19:259-264.
Abstract

WU C, Duan L, Li H, Liu X, et al
PD1(hi) CD200(hi) CD4(+) exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial-mesenchymal transition in bladder cancer.
Clin Transl Med. 2023;13:e1303.
Abstract

AL-HUMAIRI RMA, Hashim Mohammad T, Thanoon Ahmed S, Ad'hiah AH, et al
Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guerin and Mitomycin C in Superficial Bladder Cancer.
Arch Razi Inst. 2023;78:353-360.
Abstract

NAMIKI S, Ueda S, Takeuchi Y, Kawase M, et al
[A Case of Refractory Lymphatic Leakage after Robot-Assisted Radical Cystectomy].
Hinyokika Kiyo. 2023;69:137-142.
Abstract

WANG Y, Song Y, Qin C, Zhang C, et al
Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysis of eight retrospective cohort studies.
BMC Anesthesiol. 2023;23:201.
Abstract

ROUPRET M, Burger M, Stenzl A
Letter to the Editor on the systematic review "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer".
World J Urol. 2023 Jun 13. doi: 10.1007/s00345-023-04435.
Abstract

KIM JY, Yoon JH, Yoo KB, Lee WR, et al
Disparity of Bladder Cancer Incidence among Male Workers across Industries: A Population-based Cohort Study from South Korea.
J Occup Environ Med. 2023 Jun 12. doi: 10.1097/JOM.0000000000002907.
Abstract

WANG H, Ma X, Li S, Su J, et al
KIF20A as a potential biomarker of renal and bladder cancers based on bioinformatics and experimental verification.
Aging (Albany NY). 2023;15.
Abstract

CHEN Y, Huang M, Lu J, Zhang Q, et al
Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.
Environ Toxicol. 2023 Jun 13. doi: 10.1002/tox.23860.
Abstract

KUKREJA JB
Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.
Eur Urol Focus. 2023 Jun 10:S2405-4569(23)00115.
Abstract

CHEN Y, Yin L, Hao M, Xu W, et al
Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells.
Acta Pharm. 2023;73:211-225.
Abstract

LIU B, Dan W, Wei Y, Zhang Y, et al
beta-asarone inhibits the migration, invasion, and EMT of bladder cancer through activating ER stress.
Cancer Med. 2023 Jun 12. doi: 10.1002/cam4.6059.
Abstract

LIU YS, Thaliffdeen R, Han S, Park C, et al
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review.
Expert Rev Pharmacoecon Outcomes Res. 2023.
Abstract

HONG KU, Hein DW
N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer.
Pharmacogenet Genomics. 2023 May 29. doi: 10.1097/FPC.0000000000000500.
Abstract

FAN X, He W, Huang J
Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
Transl Androl Urol. 2023;12:802-808.
Abstract

HAO L, Fang J, Xu R, Liu S, et al
Significance of the FGFR3 mutation in Chinese patients with bladder cancer.
Transl Androl Urol. 2023;12:761-769.
Abstract

HU W, Zhang Y, Ning J, Li M, et al
Corrigendum to "Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages" [Heliyon 9(3) (March 2023) e14272].
Heliyon. 2023;9:e15303.
Abstract

NASSIR A, Saada H, Bakry S, Al-Zahrani S, et al
Assessment of the knowledge and awareness of urinary bladder cancer among the general population in Western Saudi Arabia.
Urol Ann. 2023;15:220-225.
Abstract

ALBAKRI M, Abu-Hijlih R, Salah S, Al-Ibraheem A, et al
Bladder cancer in young adults: Disease and treatment characteristics of patients treated at a tertiary cancer center.
Urol Ann. 2023;15:207-210.
Abstract

VILLOLDO GM, Pombo MT, Aris M, Chemi J, et al
A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guerin in patients with non-muscle invasive bladder carcinoma: A retrospective study.
Oncol Res. 2023;31:207-220.
Abstract

ERIKSSON P, Berg J, Bernardo C, Bobjer J, et al
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection.
Eur Urol Open Sci. 2023;53:78-82.
Abstract

YIN J, Cai G, Wang H, Chen W, et al
SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder cancer growth by suppressing autophagy.
Cell Div. 2023;18:9.
Abstract

XU PH, Chen S, Wang Y, Jin S, et al
FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Comput Biol Med. 2023;162:106976.
Abstract

XIA Z, Wang Q, Lu P
LncRNA LINC00885 promotes bladder cancer progression by targeting the miR-98-5p/PBX3 axis.
Cell Mol Biol (Noisy-le-grand). 2023;69:163-168.
Abstract

KHOURY R, Saleh K, Khalife N, Saleh M, et al
Mechanisms of Resistance to Antibody-Drug Conjugates.
Int J Mol Sci. 2023;24:9674.
Abstract

PAPASAVVA M, Amvrosiou S, Pilala KM, Soureas K, et al
Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform.
Int J Mol Sci. 2023;24:9258.
Abstract

MEHUS AA, Jones M, Trahan M, Kinnunen K, et al
Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Cells.
Int J Mol Sci. 2023;24:9149.
Abstract

ZHENG Q, Jian J, Wang J, Wang K, et al
Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study.
Cancers (Basel). 2023;15:3000.
Abstract

BACCHIANI M, Salamone V, Massaro E, Sandulli A, et al
Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
Cancers (Basel). 2023;15:2951.
Abstract

SU YL, Xiao LY, Huang SY, Wu CC, et al
Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process.
Cells. 2023;12:1471.
Abstract

NOEL OD, Stewart E, Cress R, Dall'Era MA, et al
Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
Urol Oncol. 2023 Jun 8:S1078-1439(23)00194-1. doi: 10.1016/j.urolonc.2023.
Abstract

ALI MY, Aboelsaad AY, Abdel Gawad AM, Abouelgreed TA, et al
HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones.
Arch Ital Urol Androl. 2023;95:11313.
Abstract

GRIZZI F, Chiriva-Internati M, Miranda E, Zaharie R, et al
Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct.
Pathol Res Pract. 2023;247:154546.
Abstract

CISTERNINO A, Capone L, Rosati A, Latiano C, et al
New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
Arch Ital Urol Androl. 2023;95:11058.
Abstract

NAGAHISA C, Unagami K, Banno T, Oki R, et al
Kidney Transplantation After Multiple Urinary Tract Conversion with an Ileal Conduit: A Case Report.
Transplant Proc. 2023 May 14:S0041-1345(23)00252.
Abstract

HANZE J, Schulte-Herbruggen J, Hofmann R, Hegele A, et al
Modulation of immune checkpoint regulators in interferon gamma induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics.
Genes Immun. 2023;24:149-153.
Abstract

DELL'OGLIO P, Tappero S, Panunzio A, Antonelli A, et al
Age represents the main driver of surgical decision making in patients candidate to radical cystectomy.
J Surg Oncol. 2023;128:142-154.
Abstract

AMIR M, Javed S
Elucidation of binding dynamics of tyrosine kinase inhibitor tepotinib, to human serum albumin, using spectroscopic and computational approach.
Int J Biol Macromol. 2023;241:124656.
Abstract

SPARWASSER P, Frey L, Fischer ND, Thomas A, et al
First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted Nephroureterectomy with Bladder Cuff: A Single Center Study.
Ann Surg Oncol. 2023;30:4531-4539.
Abstract

MATSUKAWA A, Kimura S, Koike Y, Ajisaka S, et al
Feasibility of Novel Technique of Flexible Cystoscopic En Bloc Snare Resection of Bladder Tumor: f-ESRBT.
J Endourol. 2023;37:713-717.
Abstract

SAKUMO K, Morihashi K, Nakamura A, Nukaya T, et al
The usefulness of nuclear area in the diagnosis of high-grade urothelial carcinoma cells in voided urine cytology.
Cytopathology. 2023;34:295-301.
Abstract

CHEN M, Yao K, Cao M, Liu H, et al
HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
Cancer Immunol Immunother. 2023;72:2309-2318.
Abstract

NIELSEN TJ, Varga MG, Cronister CT, Ring BZ, et al
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
Cancer Immunol Immunother. 2023;72:2075-2086.
Abstract

YAMADA S, Miyata H, Isono M, Hori K, et al
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Cancer Immunol Immunother. 2023;72:2057-2065.
Abstract

CHOUDHURY S, Kamble V, Jana D, Pal DK, et al
Thulium laser enucleation of bladder tumour (Thulebt): Changing paradigm in the management of nonmuscle invasive urinary bladder carcinoma.
Urologia. 2023;90:266-271.
Abstract

SAMI MM, Sherief MH, El-Abaseri TB, El-Sakka AI, et al
Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.
Urologia. 2023;90:248-260.
Abstract

FISCHER AH, Wong JY, Baris D, Koutros S, et al
Urine pH and Risk of Bladder Cancer in Northern New England.
Cancer Epidemiol Biomarkers Prev. 2023 Jun 23:EPI-22-0801.
Abstract

DENG Z, Tang N, Xiong W, Lei X, et al
Inflammation-related research within the field of bladder cancer: a bibliometric analysis.
Front Oncol. 2023;13:1126897.
Abstract

WU Y, Deng Y, Dai Z, Ma Y, et al
Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019.
Cancer Med. 2023 Jun 23. doi: 10.1002/cam4.6219.
Abstract

ISALI I, Khooblall P, Helstrom E, Bukavina L, et al
Targeting bladder cancer: A sex sensitive perspective in mutations and outcomes.
Urol Oncol. 2023 Jun 20:S1078-1439(23)00166.
Abstract

DIEFENBACH MA, Marziliano A, Siembida EJ, Mistretta T, et al
Cancer Resource and Information Support (CRIS) for Bladder Cancer Survivors and Their Caregivers: Development and Usability Testing Study.
JMIR Form Res. 2023;7:e41876.
Abstract

AYDH A, Sari Motlagh R, Alamri A, Yanagisawa T, et al
Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.
World J Urol. 2023 Jun 22. doi: 10.1007/s00345-023-04478.
Abstract

HE L, Wang X, Chen P, Du C, et al
Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.
Histol Histopathol. 2023 Jun 13:18640. doi: 10.14670.
Abstract

ZHI Y, Cai C, Xu T, Sun F, et al
Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer by regulating PI3K/Akt and MAPK signaling pathways.
J Biochem Mol Toxicol. 2023 Jun 22:e23399. doi: 10.1002/jbt.23399.
Abstract

GEDERAAS OA, Sharma A, Mbarak S, Sporsheim B, et al
Proteomic analysis reveals mechanisms underlying increased efficacy of bleomycin by photochemical internalization in bladder cancer cells.
Mol Omics. 2023 Jun 22. doi: 10.1039/d2mo00337.
Abstract

LEE D, Lee W, Kim HP, Kim M, et al
Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA.
Cancers (Basel). 2023;15:2868.
Abstract

TICHANEK F, Forsti A, Hemminki A, Hemminki O, et al
Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century.
Cancers (Basel). 2023;15:2782.
Abstract

YOU C, Li Q, Yang Y, Qing L, et al
Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13744.
Abstract

BUNDELL S, Petric Howe N
Why bladder cancer cells that shed their Y chromosome become more aggressive.
Nature. 2023 Jun 21. doi: 10.1038/d41586-023-02069.
Abstract

MEI Y, Wu Y, Ma L, Zhang H, et al
Retraction Note: Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer.
Mamm Genome. 2023 Jun 21. doi: 10.1007/s00335-023-10002.
Abstract

MARK JR, Gomella LG, Lallas CD, Smentkowski KE, et al
Enhancing bladder cancer care through the multidisciplinary clinic approach.
Can J Urol. 2023;30:11526-11531.
Abstract

GHALI F, Vakar-Lopez F, Roudier MP, Garcia J, et al
Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
Clin Genitourin Cancer. 2023 May 25:S1558-7673(23)00132.
Abstract

CASTRO-ALONSO FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, et al
Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
Oncology (Williston Park). 2023;37:256-261.
Abstract

HANNA K
Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
Oncology (Williston Park). 2023;37:260-261.
Abstract

YOU C, Dong Z
ASO Author Reflections: A Safe and Feasible Procedure for Bladder Cancer-Extraperitoneal Radical Cystectomy.
Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13789.
Abstract

CHOI J, Jung TY, Kim JH, Maeng S, et al
Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model.
Investig Clin Urol. 2023;64:296-305.
Abstract

WANG S, Yuan X, Shen Z, Zhao J, et al
Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review.
Investig Clin Urol. 2023;64:229-241.
Abstract

KIM KH, Lee HW, Ha HK, Seo HK, et al
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
Investig Clin Urol. 2023;64:202-218.
Abstract

HU M, Pan D, Wei Y, Ye L, et al
Atypical Recurrent Renal Cell Carcinoma of the Ipsilateral Ureter Showing Typical Symptoms of Upper Urinary Tract Urothelial Carcinoma: A Case Report and Literature Review.
Arch Esp Urol. 2023;76:238-244.
Abstract

ZHOU Y, Yang H, Liang Z
Efficiency and Safety of Laparoscopic Radical Cystectomy for Muscle-Invasive Bladder Cancer, and Postoperative Recurrence.
Arch Esp Urol. 2023;76:196-202.
Abstract

LU X, Chen L, Liu S, Cao Y, et al
m(6)A-mediated upregulation of lncRNA RMRP boosts the progression of bladder cancer via epigenetically suppressing SCARA5.
Epigenomics. 2023 Jun 20. doi: 10.2217/epi-2023-0062.
Abstract

VERGHOTE F, Van Praet C, De Maeseneer D, Berquin C, et al
Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium.
Cancer Manag Res. 2023;15:511-521.
Abstract

LU Z, Lu Z, Lai Y, Zhou H, et al
A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer.
IET Syst Biol. 2023 Jun 19. doi: 10.1049/syb2.12067.
Abstract

WEI F, Li T, Li J, Zhang Y, et al
Prognostic and Immunological Role of Asporin across Cancers and Exploration in Bladder Cancer.
Gene. 2023 Jun 17:147573. doi: 10.1016/j.gene.2023.147573.
Abstract

LA MAESTRA S, Benvenuti M, D'Agostini F, Micale RT, et al
Comet-FISH analysis of urothelial cells. A screening opportunity for bladder cancer?
Expert Rev Mol Diagn. 2023 Jun 21:1-11. doi: 10.1080/14737159.2023.2227381.
Abstract

GRABE-HEYNE K, Henne C, Mariappan P, Geiges G, et al
Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.
Front Oncol. 2023;13:1170124.
Abstract

RADOSAVLJEVIC V, Milic N
Bladder cancer screening: The new selection and prediction model.
Open Med (Wars). 2023;18:20230723.
Abstract

MUKHERJEE D, Romano E, Walshaw R, Zeef LAH, et al
Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
Oncoimmunology. 2023;12:2223094.
Abstract

CRUPI E, de Padua TC, Marandino L, Raggi D, et al
Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Eur Urol Oncol. 2023 Jun 15:S2588-9311(23)00111.
Abstract

OH TJ, Lee JY, Seo Y, Woo MA, et al
Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
J Mol Diagn. 2023 Jun 15:S1525-1578(23)00131.
Abstract

VANNESTE M, van der Heij B, Christiaansen CE, Berendsen CL, et al
Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
World J Urol. 2023 Jun 17. doi: 10.1007/s00345-023-04469.
Abstract

ERYURUK U, Tasdemir MN, Aslan S
Comparison of the diagnostic performance of biparametric and multiparametric MRI in detecting muscle invasion of bladder cancer located at the ureteral orifice.
Abdom Radiol (NY). 2023 Jun 16. doi: 10.1007/s00261-023-03979.
Abstract

NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
Sci Rep. 2023;13:9802.
Abstract

TAN WS, Hall E, Kamat AM, Kelly JD, et al
Clinical trial design for non-muscle-invasive bladder cancer.
Nat Rev Urol. 2023 Jun 16. doi: 10.1038/s41585-023-00789.
Abstract

YANG L, Huang W, Bai X, Wang H, et al
Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling.
Cell Death Dis. 2023;14:363.
Abstract

SINGH P, Rotte A, Golsorkhi AA, Girish S, et al
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective.
Expert Rev Clin Pharmacol. 2023;16:533-548.
Abstract

HUGAR LA, Geiss C, Chavez MN, Gore LR, et al
Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis.
Urol Oncol. 2023;41:327.
Abstract

KHORSANDI N, Ding CC, VandenBussche CJ, Verduzco CS, et al
Urine cytology in patients with gender confirmation surgery and hormone therapy: evaluation of urine cytology performance in an underserved patient population.
J Am Soc Cytopathol. 2023;12:267-274.
Abstract

ZHANG C, Wang M, Ying Y, Meng F, et al
Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.
Cancer Med. 2023;12:12581-12592.
Abstract

COOK EE, Harrison BT, Hirsch MS
TRPS1 expression is sensitive and specific for primary extramammary Paget disease.
Histopathology. 2023;83:104-108.
Abstract

HENSLEY PJ, Seiler R, Herr H, Mouw KW, et al
Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
Urol Oncol. 2023;41:307-312.
Abstract

FERREIRA GM, Lima APB, Pereira GR, Silva GND, et al
Synthesis, characterization and antiproliferative effects of naphtho [2,3-b] thiophen-4,9-quinone on bladder tumor cells.
Nat Prod Res. 2023;37:2285-2292.
Abstract

CHI Z, Balani J, Gopal P, Hammer S, et al
GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
J Clin Pathol. 2023;76:474-479.
Abstract

ZHOU R, Zhou J, Muhuitijiang B, Zeng X, et al
Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

BHONGIR AV, Sampath S, Bonthapally RK, Gudivada KK, et al
Sequential Application and Post-Test Probability for Screening of Bladder Cancer Using Urinary Proteomic Biomarkers: A Review based Probabilistic Analysis.
Asian Pac J Cancer Prev. 2023;24:2021-2027.
Abstract

OFFICE FE
Retraction: Long noncoding RNA SNHG1 activates autophagy and promotes cell invasion in bladder cancer.
Front Oncol. 2023;13:1228367.
Abstract

BOGUMIL D, Cortessis VK, Wilkens LR, Le Marchand L, et al
Interethnic Differences in Bladder Cancer Incidence and the Association between Type 2 Diabetes and Bladder Cancer in the Multiethnic Cohort Study.
Cancer Res Commun. 2023;3:755-762.
Abstract

GUAN X, Lu D, Chen Z, Wang Z, et al
Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22.
Anal Methods. 2023 Jun 28. doi: 10.1039/d3ay00664.
Abstract

NIKULAINEN I, Salminen AP, Seikkula H, Hogerman M, et al
Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland.
Acta Oncol. 2023 Jun 28:1-7. doi: 10.1080/0284186X.2023.2228446.
Abstract

MYINT ZW, Chahine Z, Jayswal R, Bachert E, et al
Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer.
J Pers Med. 2023;13:885.
Abstract

GILYAZOVA I, Enikeeva K, Rafikova G, Kagirova E, et al
Epigenetic and Immunological Features of Bladder Cancer.
Int J Mol Sci. 2023;24:9854.
Abstract

JORDAENS S, Oeyen E, Willems H, Ameye F, et al
Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.
Biomolecules. 2023;13:932.
Abstract

LUI G, Minnar CM, Soon-Shiong P, Schlom J, et al
Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
Cells. 2023;12:1611.
Abstract

ABDELAZIZ A, Sultan M, Hammad MA, Martinez JR Jr, et al
Endophytic upper tract urothelial carcinoma in a solitary kidney treated by cryotherapy: an unorthodox case for successful management.
BMC Urol. 2023;23:111.
Abstract

LEE YJ, Kang SG, Kim CH
Over-expression of Long Non-coding RNA Urothelial Cancer-associated 1 as a Predictive Marker for Prostate Cancer.
In Vivo. 2023;37:1511-1516.
Abstract

WILLIAMS SB, Janes JL, Howard LE, Yang R, et al
Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans.
JAMA Netw Open. 2023;6:e2320593.
Abstract

SHIRONO Y, Bilim V, Anraku T, Kuroki H, et al
Targeting Pro-Survival Autophagy Enhanced GSK-3beta Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells.
Curr Oncol. 2023;30:5350-5365.
Abstract

PANUNZIO A, Gozzo A, Mazzucato G, Ornaghi PI, et al
Impairment in Activities of Daily Living Assessed by the Barthel Index Predicts Adverse Oncological Outcomes After Radical Cystectomy for Bladder Cancer.
Clin Genitourin Cancer. 2023 Jun 9:S1558-7673(23)00141.
Abstract

SHEN C, Zhang S, Zhang Z, Yang S, et al
Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Funct Integr Genomics. 2023;23:211.
Abstract

LEVY JJ, Chan N, Marotti JD, Rodrigues NJ, et al
Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.
Cancer Cytopathol. 2023 Jun 26. doi: 10.1002/cncy.22725.
Abstract

A BUENO AP, Clark O, Turnure M, Moreira ES, et al
Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact((R)) Survey 2020.
Future Oncol. 2023 Jun 26. doi: 10.2217/fon-2022-1066.
Abstract

CAGLAYAN A, Horsanali MO
Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?
Niger J Clin Pract. 2023;26:591-598.
Abstract

HONG BA, Zhao Q, Ji YP, Cao YD, et al
[The preliminary efficacy of "quadri-combination" therapy on the treatment of bladder cancer].
Zhonghua Yi Xue Za Zhi. 2023;103:1855-1859.
Abstract

CAYUELA L, Medina-Lopez R, Lendinez-Cano G, Cayuela A, et al
Bladder cancer mortality trends in Spain: 1980-2021.
Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00070.
Abstract

PYRGIDIS N, Sokolakis I, Haltmair G, Hatzichristodoulou G, et al
The perioperative and long-term outcomes of patients with variant histology bladder cancer undergoing radical cystectomy: A propensity score-matched analysis with pure urothelial carcinoma.
Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00071.
Abstract

ZHAO Y, Lu K, Yin ZX, Peng YH, et al
Systematic review and meta-analysis of completely retroperitoneoscopic nephroureterectomy versus traditional retroperitoneoscopic nephroureterectomy in upper tract urothelial carcinoma.
Medicine (Baltimore). 2023;102:e34112.
Abstract

SUN JX, Xia QD, Zhong XY, Liu Z, et al
The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
Front Cell Infect Microbiol. 2023;13:1182322.
Abstract

SINGH AM, Guevara-Patino JA, Wang X, Li R, et al
Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
BioDrugs. 2023;37:505-520.
Abstract

XIONG CC, Zhu SS, Yan DH, Yao YD, et al
Rapid and precise detection of cancers via label-free SERS and deep learning.
Anal Bioanal Chem. 2023;415:3449-3462.
Abstract

TAGUCHI S, Kawai T, Buti S, Bersanelli M, et al
Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
Immunotherapy. 2023;15:827-837.
Abstract

SHI R, Le Tan MT, Lim GH, Du J, et al
Prognostic Value of Tumor Budding in Urothelial Carcinoma: A Meta-Analysis and Systematic Review.
Lab Invest. 2023;103:100136.
Abstract

WONG MN, Wu DJ, Lee CT, Zynger DL, et al
Renal Pelvic Urothelial Carcinoma With Invasion Into Renal Medulla Can Be Redefined as pT2 to Improve Correlation With Survival.
Mod Pathol. 2023;36:100140.
Abstract

KOWALEWSKI KF, Wieland VLS, Kriegmair MC, Uysal D, et al
Robotic-assisted Versus Laparoscopic Versus Open Radical Cystectomy-A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Eur Urol Focus. 2023;9:480-490.
Abstract

WANG LJ, Liu ZX, Hu W, Liu Y, et al
[Research Progress in Preoperative Evaluation of Lymph Node Metastasis of Bladder Cancer].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:464-470.
Abstract

ECKE TH, Meisl CJ, Schlomm T Prof, Rabien A, et al
BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, and CancerCheck(R) UBC(R) rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
Urol Oncol. 2023 Jul 3:S1078-1439(23)00225-9. doi: 10.1016/j.urolonc.2023.
Abstract

ADOMI S, Fujita K, Kita H, Kuwahara K, et al
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
Cancer Diagn Progn. 2023;3:484-490.
Abstract

SUHARA Y, Urabe F, Hashimoto M, Nakazono M, et al
A case of eosinophilic cystitis coexisting of superficial bladder cancer, mimicking muscle-invasive cancer.
IJU Case Rep. 2023;6:230-234.
Abstract

MURATA Y, Shinojima T, Nakahira Y, Hamada M, et al
Recurrent urethral tumor with neuroendocrine differentiation in a female patient after radical cystectomy for bladder cancer.
IJU Case Rep. 2023;6:199-202.
Abstract

NIE J, Liu T, Mao T, Yang H, et al
Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer.
Front Immunol. 2023;14:1169588.
Abstract

SHAKHSSALIM N, Talebi A, Pahlevan-Fallahy MT, Sotoodeh K, et al
Lifestyle and occupational risks assessment of bladder cancer using machine learning-based prediction models.
Cancer Rep (Hoboken). 2023 Jul 5:e1860. doi: 10.1002/cnr2.1860.
Abstract

ALAMEDDINE R, Mallea P, Shahab F, Zakharia Y, et al
Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
Curr Treat Options Oncol. 2023 Jul 5. doi: 10.1007/s11864-023-01114.
Abstract

SHOAYDAROV MA, Martov AG, Andronov AS, Dutov SV, et al
[Experience in the use of confocal laser endomicroscopy for the diagnosis of bladder papillary tumors].
Urologiia. 2023;:99-106.
Abstract

GUIGNAND A, Bouleftour W, Vassal C, Tinquaut F, et al
The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study.
Clin Genitourin Cancer. 2023 Jun 15:S1558-7673(23)00145.
Abstract

RAFIEI S, Kheradkhah G, Kotronoulas G, Doustmehraban M, et al
Quality of life in bladder cancer: systematic review and meta-analysis.
BMJ Support Palliat Care. 2023 Jul 3:spcare-2023-004185.
Abstract

LI Y, Chen T, Fu B, Luo Y, et al
Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort.
Front Oncol. 2023;13:1164401.
Abstract

ZHANG M, Zhu J, Zhang P, Li L, et al
Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer.
Front Oncol. 2023;13:1174252.
Abstract

ZIANI I, Ibrahimi A, Zaoui Y, El Sayegh H, et al
Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
Pan Afr Med J. 2023;44:145.
Abstract

AGRAWAL M, Malvi G, Agrawal N, Narayanaswamy S, et al
Ileal neobladder adenocarcinoma occurring twenty-five years post ileocystoplasty: a case report.
Pan Afr Med J. 2023;44:149.
Abstract

ZHAN Y, Chen Z, Li Y, He A, et al
Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA.
J Exp Clin Cancer Res. 2023;42:157.
Abstract

LI Z, Fu H, Liu J, Song W, et al
LncRNA PVT1 promotes bladder cancer progression by forming a positive feedback loop with STAT5B.
Pathol Res Pract. 2023;248:154635.
Abstract

JU M, Wu W, Qu J, Sun Y, et al
Downregulation of circular RNA hsa_circ_0087856 sensitizes bladder cancer cells to cisplatin through targeting miR-1184/CITED2 signaling.
Environ Mol Mutagen. 2023 Jul 1. doi: 10.1002/em.22561.
Abstract

YANG L, Wu X, Zhou J, Song P, et al
Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis.
Eur J Med Res. 2023;28:206.
Abstract

CANO VELASCO J, Polanco Pujol L, Moreno Cortes JC, Lafuente Puentedura A, et al
Bladder Epicheck(R) for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience.
Actas Urol Esp (Engl Ed). 2023 Jun 28:S2173-5786(23)00075.
Abstract

QIU S, Qiu Y, Deng L, Nie L, et al
Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in a mice model of orthotopic bladder cancer.
Chin Med J (Engl). 2023 Jun 30. doi: 10.1097/CM9.0000000000002710.
Abstract

FENG J, Wang M, Du GS, Peng K, et al
Crosstalk between autophagy and bladder transitional cell carcinoma by autophagy-related lncRNAs.
Medicine (Baltimore). 2023;102:e34130.
Abstract

TERLEVIC R, Ulamec M, Stimac G, Murgic J, et al
Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
Biomol Biomed. 2023 Jun 21. doi: 10.17305/bb.2023.9242.
Abstract

DIXON S, Hill H, Flight L, Khetrapal P, et al
Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer.
JAMA Netw Open. 2023;6:e2317255.
Abstract

TANG Y, Lin L, Xiao Y, Meng L, et al
Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Clin Transl Oncol. 2023 Jun 30. doi: 10.1007/s12094-023-03264.
Abstract

SATCHITHANANTHAM V, Babiker T, Riding G, Banihani M, et al
A case of mycotic infrarenal abdominal aortic aneurysm after bacillus Calmette-Guerin immunotherapy for bladder cancer and a review of the literature.
J Vasc Surg Cases Innov Tech. 2023;9:101213.
Abstract

LONGEVITY OMAC
Retracted: LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress.
Oxid Med Cell Longev. 2023;2023:9812826.
Abstract

Y Chromosome Loss Drives Bladder Cancer Aggressiveness and Immune Evasion.
Cancer Discov. 2023 Jun 30:OF1. doi: 10.1158/2159-8290.CD-RW2023.
Abstract

YANG YJ, Xu XQ, Zhang YC, Hu PC, et al
Establishment of a prognostic model related to tregs and natural killer cells infiltration in bladder cancer.
World J Clin Cases. 2023;11:3444-3456.
Abstract

SONG W, Li Z, Yang K, Gao Z, et al
Antisense lncRNA-RP11-498C9.13 promotes bladder cancer progression by enhancing reactive oxygen species-induced mitophagy.
J Gene Med. 2023 Jun 29:e3527. doi: 10.1002/jgm.3527.
Abstract

ZHANG M, Qin J, Guo X, Li Z, et al
Recognition Imaging of Trace E-cadherins on the Bladder Cancer Cells Surface during Epithelial-Mesenchymal Transition by Force-Distance Curve-Based AFM.
Nano Lett. 2023 Jun 29. doi: 10.1021/acs.nanolett.3c01667.
Abstract

PANER GP, Kamat A, Netto GJ, Samaratunga H, et al
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non
Am J Surg Pathol. 2023 Jun 29. doi: 10.1097/PAS.0000000000002077.
Abstract

KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
The useful technique of laparoscopic segmental ureterectomy with ureteral reimplantation for distal upper tract urothelial carcinoma.
Asian J Endosc Surg. 2023;16:666-672.
Abstract

FRANZ A, Plage H, Fendler A, Schlomm T, et al
[Precision oncology options in urological cancers].
Urologie. 2023;62:696-704.
Abstract

GRIMM MO, Foller S, Leeder M, Leucht K, et al
[Antibody-drug conjugates as new therapeutic agents in uro-oncology].
Urologie. 2023;62:679-684.
Abstract

YAMAMOTO D, Kotake M, Ishibayashi K, Fujimori D, et al
Robot-assisted low anterior resection for a rectal cancer patient with ileal conduit: A case report.
Asian J Endosc Surg. 2023;16:608-612.
Abstract

GALFFY G, Lugowska I, Poddubskaya EV, Cho BC, et al
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer.
ESMO Open. 2023;8:101173.
Abstract

NAKAMURA K, Ishiyama Y, Nemoto Y, Ishihara H, et al
Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Int J Clin Oncol. 2023;28:913-921.
Abstract

NAKAGAWA R, Nohara T, Naito R, Kadomoto S, et al
Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.
Photodiagnosis Photodyn Ther. 2023;42:103574.
Abstract

MIYAKE M, Hori S, Fujii T, Nishimura N, et al
Clinical practice of UroVysion(R) urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette-Guerin.
Jpn J Clin Oncol. 2023;53:629-632.
Abstract

ROSE KM, Huelster HL, Meeks JJ, Faltas BM, et al
Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
Nat Rev Urol. 2023;20:406-419.
Abstract

CASTELLARNAU S, Gaya JM, Espinosa J, Sierra P, et al
Clinical impact of the suspension of the ERAS protocol on patients undergoing radical cystectomy during the COVID-19 pandemic.
Actas Urol Esp (Engl Ed). 2023;47:369-375.
Abstract

PANACH-NAVARRETE J, Devis-Peiro A, Lloret-Dura MA, Sanchez-Gimeno S, et al
Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment.
Actas Urol Esp (Engl Ed). 2023;47:360-368.
Abstract

CHUNG CJ, Lee HL, Chang CH, Wu CD, et al
Determination of potential sources of heavy metals in patients with urothelial carcinoma in central Taiwan: a biomonitoring case-control study.
Environ Geochem Health. 2023;45:5401-5414.
Abstract

MA J, Yu C, Li X, Zhang Y, et al
A rare case of perivascular epithelioid-cell tumor of the bladder.
Asian J Surg. 2023;46:2748-2749.
Abstract

CHING D, Chiu SK, Van Vliet C, Jasim A, et al
Primary ALK-Negative TP63-Rearranged Anaplastic Large Cell Lymphoma in the Bladder: Potential for Misdiagnosis.
Int J Surg Pathol. 2023;31:612-615.
Abstract

ELLERKAMP V, Schmidt A, Warmann SW, Eckert F, et al
Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.
J Cancer Res Clin Oncol. 2023;149:3161-3170.
Abstract

MELLGARD G, Patel VG, Zhong X, Joshi H, et al
Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
J Cancer Res Clin Oncol. 2023;149:2833-2841.
Abstract

GILES M, Crabb SJ
Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes.
Res Rep Urol. 2023;15:321-331.
Abstract

ZHU Z, Li X, Liu D, Li Z, et al
A novel signature of aging-related genes associated with lymphatic metastasis for survival prediction in patients with bladder cancer.
Front Oncol. 2023;13:1140891.
Abstract

TAN WS, Grajales V, Contieri R, Hensley P, et al
Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
Eur Urol Open Sci. 2023;53:16-22.
Abstract

YU G, Rice S, Heer R, Lewis R, et al
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Tr
Eur Urol Open Sci. 2023;53:67-77.
Abstract

NAKAMURA R, Hasegawa G, Ikeda Y, Hara N, et al
Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette-Guerin therapy.
SAGE Open Med Case Rep. 2023;11:2050313X231185444.
Abstract

Effect of SMYD3 on Biological Behavior and H3K4 Methylation in Bladder Cancer [Retraction].
Cancer Manag Res. 2023;15:625-626.
Abstract

YOU C, Li Q, Yang Y, Qing L, et al
ASO Visual Abstract: Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-analysis.
Ann Surg Oncol. 2023 Jul 12. doi: 10.1245/s10434-023-13855.
Abstract

ZHOU T, Chen H, Wang Y, Wen S, et al
Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy Efficacy: Further Exploration for CNTN1 and EMP1.
JCO Precis Oncol. 2023;7:e2200630.
Abstract

VISSING M, Munch Larsen L, Christensen AJ, Owall L, et al
Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report.
Acta Oncol. 2023 Jul 12:1-7. doi: 10.1080/0284186X.2023.2226330.
Abstract

SHAKHSSALIM N, Dadpour M, Sharifiaghdas F, Narouie B, et al
Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A Randomized Clinical Trial.
Clin Med Insights Oncol. 2023;17:11795549231184682.
Abstract

XIONG S, Dong W, Deng Z, Jiang M, et al
Value of the application of computed tomography-based radiomics for preoperative prediction of unfavorable pathology in initial bladder cancer.
Cancer Med. 2023 Jul 11. doi: 10.1002/cam4.6225.
Abstract

JIANG W, Pan C, Guo W, Xu Z, et al
Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.
Diagn Pathol. 2023;18:80.
Abstract

WANG Y, Zhu H, Xu H, Qiu Y, et al
Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity.
Aging (Albany NY). 2023;15.
Abstract

CHANG TC, Shkolyar E, Del Giudice F, Eminaga O, et al
Real-time Detection of Bladder Cancer Using Augmented Cystoscopy with Deep Learning: a Pilot Study.
J Endourol. 2023 Jul 11. doi: 10.1089/end.2023.0056.
Abstract

MIYAJIMA K, Suzuki H, Urabe F, Iwatani K, et al
Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
Int J Clin Oncol. 2023 Jul 11. doi: 10.1007/s10147-023-02383.
Abstract

FAROOQI AA, Venera R, Kapanova G, Tanbayeva G, et al
TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.
Med Oncol. 2023;40:236.
Abstract

PENG K, Ding D, Wang N, Du T, et al
ITIH5, as a predictor of prognosis and immunotherapy response for P53-like bladder cancer, is related to cell proliferation and invasion.
Mol Omics. 2023 Jul 11. doi: 10.1039/d2mo00322.
Abstract

SINGH A, Osbourne AS, Koshkin VS
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
Curr Treat Options Oncol. 2023 Jul 10. doi: 10.1007/s11864-023-01113.
Abstract

COBELLIS G, Torino G, Lisi G, Ilari M, et al
Pneumovesicoscopic management of bladder neoplasms in children: three case reports.
Pediatr Med Chir. 2023;45.
Abstract

GU Y, Zhuo H
Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
Aging Male. 2023;26:2233609.
Abstract

LI Z, Yao Y, Qi T, Wu Z, et al
ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
Front Pharmacol. 2023;14:1222512.
Abstract

ZENG J, Funk J, Lee BR, Hsu CH, et al
Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.
Transl Androl Urol. 2023;12:960-966.
Abstract

OKOBI TJ, Uhomoibhi TO, Akahara DE, Odoma VA, et al
Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence.
Cureus. 2023;15:e40031.
Abstract

ZHONG Q, Jiang K, Zhang F, Tian Y, et al
Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer.
Am J Cancer Res. 2023;13:2213-2233.
Abstract

HUANG CP, Lu HL, Shyr CR
Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.
Am J Cancer Res. 2023;13:2285-2306.
Abstract

WU L, Chen W, Cao Y, Chen B, et al
A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

JIANG Q, Zhou J, Chen Q, Huang Y, et al
Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer.
Funct Integr Genomics. 2023;23:228.
Abstract

ZENNAMI K, Takahara K, Nukaya T, Takenaka M, et al
The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy.
Clin Genitourin Cancer. 2023 Jun 28:S1558-7673(23)00155.
Abstract

JIANG H, Zhu S, Wu B, Su Y, et al
CDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer T24 cells.
Chem Biol Interact. 2023 Jul 7:110624. doi: 10.1016/j.cbi.2023.110624.
Abstract

XIAO K, Peng S, Lu J, Zhou T, et al
UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.
Cell Death Dis. 2023;14:408.
Abstract

KATES M, Chu X, Hahn N, Pietzak E, et al
Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guerin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
Eur Urol Focus. 2023 Jul 6:S2405-4569(23)00146-3. doi: 10.1016/j.euf.2023.
Abstract

LIU X, Liu L, Wang X, Jin Y, et al
Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
Phytomedicine. 2023;118:154943.
Abstract

ORJI P, Sun H, Isali I, Bell S, et al
Female sexual function evaluation and intraoperative vaginal reconstruction in bladder cancer.
World J Urol. 2023 Jul 7. doi: 10.1007/s00345-023-04502.
Abstract

KATES M
Doing Less with More: Towards a New Paradigm of Non-muscle-invasive Bladder Cancer Care.
Eur Urol Focus. 2023 Jul 5:S2405-4569(23)00147-5. doi: 10.1016/j.euf.2023.
Abstract

GUPTA S, Norgan AP, Erickson LA
Schistosomiasis of the Urinary Bladder.
Mayo Clin Proc. 2023;98:1100-1101.
Abstract

LEE J, Kim SH, Jeong SH, Han JH, et al
Pyuria as an independent predictor of intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
Investig Clin Urol. 2023;64:353-362.
Abstract

KIM D, Nam W, Kyung YS, You D, et al
Effect of decreased renal function on poor oncological outcome after radical cystectomy.
Investig Clin Urol. 2023;64:346-352.
Abstract

ESTEVES M, Duarte M, Oliveira PA, Gil da Costa RM, et al
SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.
Exp Oncol. 2023;45:107-119.
Abstract

GARMANCHUK LV, Yakovlev PG, Ostrovska GV, Stupak YA, et al
COMPARISON OF 2D AND 3D PRIMARY CELL CULTURES OBTAINED FROM EXPLANT OF HIGH-GRADE UROTHELIAL BLADDER CANCER.
Exp Oncol. 2023;45:130-136.
Abstract

TANG Z, Peng J, Wu S, Zhao F, et al
Combined use of a 980â€‘nm diode laser and preoperative intravesical instillation of pirarubicin for the prevention of shortâ€‘term recurrence of nonâ€‘muscle invasive bladder cancer: A pilot study.
Oncol Lett. 2023;26:322.
Abstract

SU Y, Chen L, Yang J
Network pharmacology and in vitro experiments reveal that Noscapine induces ROS-mediated apoptosis and cell cycle arrest via PI3K/Akt/FoxO3a signaling pathway in human bladder cancer cells.
Curr Cancer Drug Targets. 2023 Jul 6. doi: 10.2174/1568009623666230706153936.
Abstract

RODRIGUES L, Watson J, Feng Y, Lewis B, et al
Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics.
Sci Rep. 2023;13:10935.
Abstract

YU H, Bai K, Cheng Y, Lv J, et al
Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

RELPH K, Arif M, Pandha H, Annels N, et al
Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
Methods Mol Biol. 2023;2684:319-327.
Abstract

GRANDI P, Darilek A, Moscu A, Pradhan A, et al
Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer.
Methods Mol Biol. 2023;2684:303-317.
Abstract

NIEGISCH G
Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:293-301.
Abstract

BAHLINGER V, Eckstein M, Hartmann A, Stohr R, et al
Evaluation of FGFR Alteration Status in Urothelial Tumors.
Methods Mol Biol. 2023;2684:283-291.
Abstract

MENECEUR S, Grunewald CM, Niegisch G, Hoffmann MJ, et al
Epigenetic Priming and Development of New Combination Therapy Approaches.
Methods Mol Biol. 2023;2684:259-281.
Abstract

BAHLINGER V, Hartmann A, Eckstein M
Assessment of PD-L1 Status in Urothelial Cancer.
Methods Mol Biol. 2023;2684:249-255.
Abstract

NIKKOLA J, Black P
Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
Methods Mol Biol. 2023;2684:229-247.
Abstract

ZVEREVA M, Hosen MI, Forey N, Sheikh M, et al
Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
Methods Mol Biol. 2023;2684:213-228.
Abstract

ECKE TH, Benderska-Soder N, Bismarck E, van Rhijn BWG, et al
Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer.
Methods Mol Biol. 2023;2684:199-212.
Abstract

NORDENTOFT I, Birkenkamp-Demtroder K, Dyrskjot L
NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
Methods Mol Biol. 2023;2684:179-197.
Abstract

DONELAN W, Crispen PL, Kusmartsev S
Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:167-175.
Abstract

MANTWILL K, Nawroth R
Genome-Wide CRISPR Screening for the Identification of Therapy Resistance-Associated Genes in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:155-165.
Abstract

PARK Y, Lelo A, Harris B, Berry DL, et al
Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
Methods Mol Biol. 2023;2684:145-151.
Abstract

RAMPIAS T, Klinakis A
Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells.
Methods Mol Biol. 2023;2684:133-144.
Abstract

SEILLIER L, Peifer M
Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview.
Methods Mol Biol. 2023;2684:113-132.
Abstract

PETER C, Schulz WA, Whongsiri P
Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography.
Methods Mol Biol. 2023;2684:101-109.
Abstract

MOKOU M, Narayanasamy S, Stroggilos R, Balaur IA, et al
A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures.
Methods Mol Biol. 2023;2684:59-99.
Abstract

OLAH C, Szarvas T
A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer.
Methods Mol Biol. 2023;2684:27-43.
Abstract

BOSHERZ MS, Samarska IV, Gaisa NT
Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
Methods Mol Biol. 2023;2684:3-25.
Abstract

REIGNIER PL, Gauthier H, Hennequin C, Aussedat Q, et al
Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
World J Urol. 2023 Jul 6. doi: 10.1007/s00345-023-04506.
Abstract

KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis.
Immunotherapy. 2023;15:933-943.
Abstract

FARSHADPOUR F, Taherkhani R, Farzaneh M
Human papillomaviruses and bladder cancer risk: first report in south of Iran.
Virusdisease. 2023;34:257-262.
Abstract

BUDENBENDER B, Kother AK, Kriegmair MC, Grune B, et al
Getting specific: participation preference in urooncological decision-making.
BMC Med Inform Decis Mak. 2023;23:114.
Abstract

GU YM, Liang XL, Zhang YG, Zhao HY, et al
[Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:429-435.
Abstract

PARK JY, Baek JW, Yu J, Kim CS, et al
Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
J Clin Anesth. 2023;89:111191.
Abstract

ABDELBARY AM, Atwa HA, Elfarargy OM, Qasem ER, et al
Prognostic Implications of CD24, SOX2, and Nanog Expression in Invasive Urothelial Carcinoma.
Appl Immunohistochem Mol Morphol. 2023;31:421-428.
Abstract

KANNO T, Kobori G, Ito K, Nakagawa H, et al
Atypical Oncologic Failure After Laparoscopic Radical Nephroureterectomy in a Japanese Multicenter Study.
J Endourol. 2023;37:793-800.
Abstract

YU J, Lee J, Kim CS, Park JY, et al
ASO Author Reflections: Chart-Derived Frailty Index and 1-Year Mortality After Radical Cystectomy.
Ann Surg Oncol. 2023;30:5304-5305.
Abstract

MATTHEW-ONABANJO AN, Nortey G, Matulewicz RS, Basak R, et al
Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot.
Curr Probl Cancer. 2023;47:100958.
Abstract

HACKING SM, Pavlick D, Wang Y, Carneiro BA, et al
Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
Oncologist. 2023;28:e508-e519.
Abstract

SHI Y, Wang S, Liu W, Sherryn S, et al
Single-Position Complete Retroperitoneoscopic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Urinary Tract Urothelial Carcinoma.
J Endourol. 2023;37:768-774.
Abstract

ZHAO Q, Wu L, Yang F, Chen D, et al
A Modified and Practical Surgical Technique for Pure Transperitoneal Laparoscopic Radical Nephroureterectomy in a Single Position and Research Outcomes.
J Laparoendosc Adv Surg Tech A. 2023;33:691-697.
Abstract

SUN JX, An Y, Xu MY, Liu CQ, et al
Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intra
Front Oncol. 2023;13:1133161.
Abstract

CHAI J, Yin S, Feng W, Zhang T, et al
The Role of Hypoxia-inducible Factor-1 in Bladder Cancer.
Curr Mol Med. 2023 Jul 20. doi: 10.2174/1566524023666230720163448.
Abstract

ALBARAKATI N, Al-Ghamdi H, Al-Sowayan B, Alshareeda A, et al
Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.
Sci Rep. 2023;13:11738.
Abstract

CHEN G, Fan X, Wang T, Zhang E, et al
A machine learning model based on MRI for the preoperative prediction of bladder cancer invasion depth.
Eur Radiol. 2023 Jul 20. doi: 10.1007/s00330-023-09960.
Abstract

ANDRADE DL, Jalalizadeh M, Salustiano ACC, Reis LO, et al
Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guerin (BCG).
World J Urol. 2023 Jul 20. doi: 10.1007/s00345-023-04526.
Abstract

GOYAL S, Vias P, Periasamy K, Madan R, et al
Delineating and sparing the ileal conduit in adjuvant radiotherapy for bladder cancer with modulated radiotherapy.
J Cancer Res Ther. 2023;19:731-737.
Abstract

KUMAR A, Kumar M, Semwal MK, Singh U, et al
Management of surgically inoperable muscle-invasive bladder cancer in a resource constraint setting at a tertiary care center by bladder preservation protocol: Case series.
J Cancer Res Ther. 2023;19:725-730.
Abstract

MOHANTY P, Mohapatra AS, Sabat D, Nayak J, et al
Unusual histomorphological spectrum of urinary bladder cancers and their treatment modalities revisited: Our experience with series of five cases.
J Cancer Res Ther. 2023;19:617-623.
Abstract

AKBULUT F, Pazir Y, Esmeray A, Erbin A, et al
The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
Urologia. 2023 Jul 20:3915603231189022. doi: 10.1177/03915603231189022.
Abstract

ECKE TH, Lotan Y, Massfelder T
Editorial: Identifying novel biomarkers in bladder cancer.
Front Oncol. 2023;13:1191736.
Abstract

RAHMAN KMM, Foster BA, You Y
Preclinical evaluation of singlet oxygen-cleavable prodrugs in combination with protoporphyrin IX-photodynamic therapy in an orthotopic rat model of non-muscle-invasive bladder cancer(dagger).
Photochem Photobiol. 2023 Jul 20. doi: 10.1111/php.13838.
Abstract

TAN WS, McElree IM, Davaro F, Steinberg RL, et al
Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Jul 18:S2588-9311(23)00143.
Abstract

FARMANI F, Soleimani N, Razeghi M, Zamani A, et al
Uninvited guest, Balantidium coli in urine in a patient with bladder cancer: A case report and review of the literature.
Clin Case Rep. 2023;11:e7494.
Abstract

ZHAN Y, Chen Z, He S, Gong Y, et al
Correction: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2.
Mol Cancer. 2023;22:115.
Abstract

GUAN H, Wang G, Wang W, Zhou Y, et al
Postoperative adjuvant radiotherapy for patients with upper tract urothelial carcinoma (UTUC) who underwent kidney-sparing surgery (KSS): a single-center study.
Radiat Oncol. 2023;18:120.
Abstract

LIU W, Xiong J, Wang H, Li S, et al
Racial disparities in conditional survival of patients with bladder cancer: a population-based study.
BMC Urol. 2023;23:122.
Abstract

KOUHEN F, Dahbi Z, Afif M, Chihabeddine M, et al
Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report.
J Med Case Rep. 2023;17:320.
Abstract

LAUKHTINA E, Shariat SF
Smoking, ethnicity and bladder cancer - implications for public health and clinical practice.
Nat Rev Urol. 2023 Jul 18. doi: 10.1038/s41585-023-00804.
Abstract

WANG P, Joiner M, Dzul S, Miller SR, et al
Adenocarcinoma involving the urinary bladder.
BMJ Case Rep. 2023;16:e252747.
Abstract

SHEN C, Liu J, Jiao W, Zhang X, et al
A feed-forward loop based on aerobic glycolysis and TGF-beta between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape.
J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05164.
Abstract

RASTEGAR-POUYANI N, Montazeri V, Marandi N, Aliebrahimi S, et al
The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in Bladder Cancer: A comparison between recurrent and non-recurrent patient-derived CAFs.
Cancer Invest. 2023 Jul 18:1-16. doi: 10.1080/07357907.2023.2237576.
Abstract

ABE T, Yamada S, Kikuchi H, Sazawa A, et al
Impact of postoperative complications on long-term survival in bladder cancer patients.
Jpn J Clin Oncol. 2023 Jul 17:hyad079. doi: 10.1093.
Abstract

PING Q, Wang C, Cheng X, Zhong Y, et al
TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
J Transl Med. 2023;21:475.
Abstract

ARTYMOWICZ M, Struck-Lewicka W, Wiczling P, Markuszewski M, et al
Targeted quantitative metabolomics with a linear mixed-effect model for analysis of urinary nucleosides and deoxynucleosides from bladder cancer patients before and after tumor resection.
Anal Bioanal Chem. 2023 Jul 18. doi: 10.1007/s00216-023-04826.
Abstract

XIA T, Zhou F, Zhang D, Jin X, et al
Deep-profiling of phospholipidome via rapid orthogonal separations and isomer-resolved mass spectrometry.
Nat Commun. 2023;14:4263.
Abstract

MURAOKA K, Fukasawa M, Fukushima M, Kumagai M, et al
[The Effect of Naldemedine Tosylate on the Postoperative Course of Robot-Assisted Radical Cystectomy].
Hinyokika Kiyo. 2023;69:147-150.
Abstract

HE K, Wang J, Zhou Y, Huang Z, et al
Network pharmacology analysis of icariside II against bladder cancer.
Eur J Pharmacol. 2023 Jul 15:175914. doi: 10.1016/j.ejphar.2023.175914.
Abstract

MATAR M, Prince G, Hamati I, Baalbaky M, et al
Implication of KDM6A in bladder cancer.
Pharmacogenomics. 2023 Jul 17. doi: 10.2217/pgs-2023-0027.
Abstract

QI G, Liu J, Tao S, Fan W, et al
A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
PeerJ. 2023;11:e15675.
Abstract

ZHANG Y, Liu M, Wang J, Han K, et al
Bibliometric analysis of the association between drinking water pollution and bladder cancer.
Front Oncol. 2023;13:1170700.
Abstract

YI X, Pi J, Liu C, Xiong Y, et al
The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model.
Front Oncol. 2023;13:1189086.
Abstract

WANG XX, Wu HY, Yang Y, Ma MM, et al
CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.
Exp Ther Med. 2023;26:382.
Abstract

WANG Y, Kong Q, Li M, Gu J, et al
Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients.
Heliyon. 2023;9:e17690.
Abstract

SU Y, Ai J, Jia M, Yue G, et al
The Relationship between VEGF and AGT Gene Single Nucleotide Polymorphisms and Susceptibility to Renal and Bladder Cancers.
Arch Esp Urol. 2023;76:298-308.
Abstract

SHAHAIT M, Abu-Hijlih R, Farkouh A, Obeidat S, et al
Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
J Egypt Natl Canc Inst. 2023;35:21.
Abstract

TAPPERO S, Chierigo F, Parodi S, Bandini M, et al
Radical cystectomy in bladder cancer patients previously treated for prostate cancer: Insights from a large European multicentric series.
Surg Oncol. 2023;50:101973.
Abstract

CHEN H, Yang W, Li Y, Ji Z, et al
PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling.
Cell Death Dis. 2023;14:433.
Abstract

SUBRAMANYA SK, Li R, Wang Y, Miyamoto H, et al
Deep learning for histopathological segmentation of smooth muscle in the urinary bladder.
BMC Med Inform Decis Mak. 2023;23:122.
Abstract

GRASSAUER J, Schmidt J, Cowan A, Gilbert SM, et al
Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Jul 14:S2588-9311(23)00118.
Abstract

WISSING MD, O'Flaherty A, Dragomir A, Tanguay S, et al
Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Quebec, Canada.
BMC Urol. 2023;23:119.
Abstract

CHEN H, Xu C, Fang Z, Mao S, et al
Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in Prostate Cancer and Bladder Cancer.
Methods Mol Biol. 2023;2695:165-179.
Abstract

CUI Y, Cao M
Liquid Biopsy in Bladder Cancer.
Methods Mol Biol. 2023;2695:111-120.
Abstract

YUAN P, Li S, Xiong S, Zheng F, et al
Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer.
J Cancer Res Clin Oncol. 2023 Jul 14. doi: 10.1007/s00432-023-05067.
Abstract

BIERI U, Kranzbuhler B, Wettstein MS, Fankhauser CD, et al
Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.
Cureus. 2023;15:e40283.
Abstract

AVETA A, Cilio S, Contieri R, Spena G, et al
Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
Int J Mol Sci. 2023;24:10846.
Abstract

JAKUS D, Solic I, Juric I, Borovac JA, et al
The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics.
J Clin Med. 2023;12:4259.
Abstract

DANESHDOUST D, Yin M, Luo M, Sundi D, et al
Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
Cells. 2023;12:1714.
Abstract

FERRO M, Falagario UG, Barone B, Maggi M, et al
Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement.
Diagnostics (Basel). 2023;13:2308.
Abstract

BOCA B, Caraiani C, Telecan T, Pintican R, et al
MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment.
Diagnostics (Basel). 2023;13:2300.
Abstract

BORGHERESI A, Agostini A, Sternardi F, Cesari E, et al
Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer.
Diagnostics (Basel). 2023;13:2227.
Abstract

MCELREE IM, Orzel J, Stubbee R, Steinberg RL, et al
Sequential intravesical gemcitabine and docetaxel for treatment-naive and previously treated intermediate-risk nonmuscle invasive bladder cancer.
Urol Oncol. 2023 Jul 11:S1078-1439(23)00228.
Abstract

MA J, Roumiguie M, Hayashi T, Kohada Y, et al
Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
Eur Urol Focus. 2023 Jul 11:S2405-4569(23)00153.
Abstract

DAHL DM, Karrison TG, Michaelson MD, Pham HT, et al
Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
Eur Urol Oncol. 2023 Jul 11:S2588-9311(23)00115.
Abstract

MIR MA, Pandith AA, Mansoor S, Baba SM, et al
Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.
Gene. 2023;878:147583.
Abstract

ABDEL-HAFIZ HA, Schafer JM, Chen X, Xiao T, et al
Y chromosome loss in cancer drives growth by evasion of adaptive immunity.
Nature. 2023;619:624-631.
Abstract

GOBBO A, Fasulo V, Contieri R, Uleri A, et al
Clinical and pathological predictors of persistent T1 HG at second resection.
Urologia. 2023;90:482-490.
Abstract

TIAN BW, Han CL, Wang HC, Yan LJ, et al
Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
Clin Exp Metastasis. 2023;40:255-287.
Abstract

YONESE I, Ito M, Waseda Y, Kobayashi S, et al
Impact of diagnostic ureteral catheterization on intravesical tumour recurrence following radical nephroureterectomy for upper tract urothelial carcinoma.
World J Urol. 2023;41:1869-1875.
Abstract

YANAGISAWA T, Kawada T, Quhal F, Bekku K, et al
Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
World J Urol. 2023;41:1763-1774.
Abstract

MOAVRO DE, Andrini L, Iribarne A, Colaci P, et al
HLA-G expression in transitional bladder carcinoma. Relationship with tumor invasion level and patient survival: Experience in a public hospital in Argentina.
Hum Immunol. 2023;84:423-427.
Abstract

CHEN M, Jiang J, Chen J, Wang M, et al
The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors.
Curr Drug Targets. 2023;24:584-598.
Abstract

CERRATO C, Pandolfo SD, Autorino R, Panunzio A, et al
Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
World J Urol. 2023;41:1741-1749.
Abstract

CHAN TC, Pan CT, Hsieh HY, Vejvisithsakul PP, et al
The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGFbeta/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma.
Cell Oncol (Dordr). 2023;46:933-951.
Abstract

DJORDJEVIC D, Dragicevic S, Vukovic M
Mini-laparotomy radical cystectomy with limited bowel externalization during ileal conduit urinary diversion reduces the rate of postoperative complications: a match-paired, single centered analysis.
Acta Chir Belg. 2023;123:362-368.
Abstract

REBEZ G, Runti O, Rizzo M, Trombetta C, et al
Radical cystectomy and orthotopic neobladder in a patient with a preexisting three-components inflatable penile prosthesis.
Urologia. 2023;90:584-586.
Abstract

SYMVOULIDIS P, Tsioutis C, Zamboglou C, Agouridis AP, et al
The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
Curr Oncol. 2023;30:6648-6665.
Abstract

KODERA A, Mohammed M, Lim P, Abdalla O, et al
The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article.
Cureus. 2023;15:e40962.
Abstract

BUI TT, Jang E, Shin JH, Kim TH, et al
Feasibility of Raman spectroscopic identification of gall bladder cancer using extracellular vesicles extracted from bile.
Analyst. 2023 Jul 28. doi: 10.1039/d3an00806.
Abstract

TABAEI S, Haghshenas MR, Ariafar A, Gilany K, et al
Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.
Clin Proteomics. 2023;20:28.
Abstract

XUE XL, Zhao S, Xu MC, Li Y, et al
Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis.
Neoplasma. 2023;70:430-442.
Abstract

CAO T, Zhou X, Wu X, Zou Y, et al
Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
Front Immunol. 2023;14:1207544.
Abstract

WANG M, Zhang Z, Li Z, Zhu Y, et al
E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies.
Front Immunol. 2023;14:1226057.
Abstract

ZHANG J, Duan H, Feng Z, Han X, et al
Retraction Note: Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress.
Oncogenesis. 2023;12:39.
Abstract

YANAGISAWA T, Kawada T, von Deimling M, Bekku K, et al
Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
Eur Urol Focus. 2023 Jul 24:S2405-4569(23)00173.
Abstract

SINGH A, Choudhary A, Pai V, Viswanath K, et al
Uncovering the Uncommon: Institutional Insights Into the Clinical and Epidemiological Characteristics of Rarer Forms of Bladder Cancer Beyond Transitional Cell Carcinoma.
Cureus. 2023;15:e40879.
Abstract

HOSHINA H, Taguchi S, Suyama H, Kishitani K, et al
Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.
BMC Urol. 2023;23:125.
Abstract

BARAL BK, Poudel PR, Rajbhandari M, Karki AJ, et al
Ultrasound versus Nerve Stimulator Guided Obturator Nerve Block in Patients Undergoing Transurethral Resection of Bladder Tumor.
J Nepal Health Res Counc. 2023;20:998-1002.
Abstract

SASAKI Y, Daizumoto K, Fukuta K, Shiozaki K, et al
Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery.
Asian J Endosc Surg. 2023 Jul 25. doi: 10.1111/ases.13234.
Abstract

SHI ZD, Sun Z, Zhu ZB, Liu X, et al
Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial-fibroblast interactions in recurrent bladder cancer.
Clin Transl Med. 2023;13:e1338.
Abstract

ALAM SM, Larson M, Srinivasan P, Genz N, et al
Evaluation of sarcopenia in patients receiving intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer.
Urol Oncol. 2023 Jul 22:S1078-1439(23)00198.
Abstract

TANG NT, Robinson R, Snook RD, Brown M, et al
Classification of formalin-fixed bladder cancer cells with laser tweezer Raman spectroscopy.
Analyst. 2023 Jul 24. doi: 10.1039/d3an00119.
Abstract

SONG Y, Xu T
Letter to the editor for the article "Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer".
World J Urol. 2023 Jul 24. doi: 10.1007/s00345-023-04541.
Abstract

STEWART R, Richards HL, Houghton S, Sweeney P, et al
'I Had It. I Don't Think I Have It...But I Do Feel It Will Come Back Somewhere': A Qualitative Investigation of the Experience of People With Non-Muscle Invasive Bladder Cancer.
Qual Health Res. 2023 Jul 24:10497323231170089. doi: 10.1177/10497323231170089.
Abstract

YAMAMOTO K, Yamamoto K, Nakai G, Fujitani T, et al
Detection of the Vesical Arteries Using Three-dimensional Digital Subtraction Angiography Relevant to Intra-arterial Infusion Chemotherapy for Bladder Cancer Using Double-balloon Catheters.
Interv Radiol (Higashimatsuyama). 2023;8:64-69.
Abstract

XIAO X, Peng J, Chen Y, Lu X, et al
Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer.
Iran J Public Health. 2023;52:1225-1237.
Abstract

ERDIK A, Cimen HI, Atik YT, Gul D, et al
Sarcopenia is an independent predictor of survival in patients undergoing radical cystectomy for bladder cancer: a single-centre, retrospective study.
Cent European J Urol. 2023;76:81-89.
Abstract

WASFIE T, Atherton JM, Villegas SJ, Korbitz H, et al
Small bowel obstruction secondary to metastatic urothelial bladder cancer.
SAGE Open Med Case Rep. 2023;11:2050313X231176356.
Abstract

LI Y, Zheng H, Luo Y, Lin Y, et al
An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis.
Cancer Commun (Lond). 2023 Jul 22. doi: 10.1002/cac2.12470.
Abstract

ELMEKAWY S, Taha DE, Nabeeh HE, Ibrahim A, et al
Comparison of holmium laser, bipolar and conventional monopolar transurethral resection of bladder tumour in primary non-muscle invasive bladder cancer.
J Pak Med Assoc. 2023;73.
Abstract

AHMED NOR EM, Saied EM, Alshenawy HA, Shams Eldeen AA, et al
The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder Carcinoma Patients.
J Pak Med Assoc. 2023;73.
Abstract

MO R, Dawulieti J, Chi N, Wu Z, et al
Self-polymerized platinum (II)-Polydopamine nanomedicines for photo-chemotherapy of bladder Cancer favoring antitumor immune responses.
J Nanobiotechnology. 2023;21:235.
Abstract

BOONCHAI S, Tanthanuch M, Bejrananda T
Comparison of the Y-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and functional outcomes from a single-center series.
World J Surg Oncol. 2023;21:218.
Abstract

DE HERTOGH O
[Bladder preservation treatments for bladder cancer: Trimodality therapy, an overview of clinical practices in 2023].
Cancer Radiother. 2023 Jul 20:S1278-3218(23)00124.
Abstract

JIANG P, Ning J, Yu W, Rao T, et al
FLRT2 suppresses bladder cancer progression through inducing ferroptosis.
J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17855.
Abstract

LI L, Zhang Y, Hu W, Zou F, et al
MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17863.
Abstract

ZHU S, Li H, Fan Y, Tang C, et al
Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
BMC Urol. 2023;23:124.
Abstract

WANG Z, Muthusamy V, Petrylak DP, Anderson KS, et al
Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
NPJ Precis Oncol. 2023;7:70.
Abstract

WANG D, Wang C, Zhou FH
Identification of the diagnostic value of urine SLC1A5 in bladder cancer based on GEO database.
Asian J Surg. 2023 Jul 19:S1015-9584(23)01045.
Abstract

ZHANG B, Yang L, He Y, Han D, et al
Role and mechanisms of noncoding RNAs in the regulation of metabolic reprogramming in bladder cancer (Review).
Int J Mol Med. 2023;52:79.
Abstract

GHATALIA P, Kaur J, Sonpavde G
Muscle invasive bladder cancer: where is the field headed?
Expert Opin Biol Ther. 2023 Jul 21:1-15. doi: 10.1080/14712598.2023.2238607.
Abstract

LI B, Hu Y, Li QY, Tang YM, et al
Procoagulant genes may affect angiogenesis, epithelial-mesenchymal transition, survival prognosis and tumor immune microenvironment in patients with urothelial carcinoma.
Aging (Albany NY). 2023;15:6429-6444.
Abstract

SAINT-JACQUES N, Brown PE, Purcell J, Rainham DG, et al
The Nova Scotia Community Cancer Matrix: A geospatial tool to support cancer prevention.
Soc Sci Med. 2023;330:116038.
Abstract

GUERRA NL, Matas-Garcia A, Serra-Garcia L, Morgado-Carrasco D, et al
Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
Autoimmun Rev. 2023;22:103375.
Abstract

SAVIN Z, Kupershmidt A, Phollan D, Lazarovich A, et al
The role of malnutrition universal screening tool in predicting outcomes after radical cystectomy.
Surg Oncol. 2023;49:101962.
Abstract

RAMOS KS, Li J, Wijdeveld LFJ, van Schie MS, et al
Long Noncoding RNA UCA1 Correlates With Electropathology in Patients With Atrial Fibrillation.
JACC Clin Electrophysiol. 2023;9.
Abstract

CHOU LP, Hsu CW, Yang SF, Lee CT, et al
Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
Clin Genitourin Cancer. 2023;21:508.
Abstract

SEKAR RR, Diamantopoulos LN, Bakaloudi DR, Khaki AR, et al
Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
Clin Genitourin Cancer. 2023;21:507.
Abstract

BELLMUNT J, Chang J, Pavilack-Kirker M, Cappelleri JC, et al
Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
Clin Genitourin Cancer. 2023;21:459-466.
Abstract

SLOTMAN A, Xu M, Lindale K, Hardy C, et al
Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.
Lab Invest. 2023;103:100155.
Abstract

RAY CH, Davaro F, Hamilton ZA, Raza J, et al
Perioperative outcomes of open versus robot-assisted radical cystectomy in octogenarians: a population based analysis.
J Robot Surg. 2023;17:1629-1635.
Abstract

CHENG L, Lopez-Beltran A, Wang M, Whaley RD, et al
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
Mod Pathol. 2023;36:100151.
Abstract

LI KP, Chen SY, Wang CY, Wan S, et al
Comparison between robot-assisted versus open nephroureterectomy for upper tract urothelial carcinoma: outcomes from a pooled analysis.
J Robot Surg. 2023;17:1227-1238.
Abstract

GUPTA N, Kucirka L, Semerjian A, Pierorazio PM, et al
Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing Radical Cystectomy Among Urologic Oncologists in the United States.
Clin Genitourin Cancer. 2023;21:e236-e241.
Abstract

SUN ZJ, Zhao JW, Zhao M, Chen Y, et al
CD3 high and FoxP3 - tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder.
Anticancer Drugs. 2023;34:844-851.
Abstract

HEALTHCARE ENGINEERING JO
Retracted: Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.
J Healthc Eng. 2023;2023:9785158.
Abstract

SUN Z, Sun X, Qin G, Li Y, et al
FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.
Epigenetics. 2023;18:2242688.
Abstract

CHEN S, Ran J, Fan Z, Liu M, et al
Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
Sci Rep. 2023;13:12625.
Abstract

KLOSKOWSKI T, Fekner Z, Szeliski K, Paradowska M, et al
Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures.
Front Oncol. 2023;13:1222411.
Abstract

GIL DA COSTA RM, Levesque C, Bianchi-Frias D, Chatterjee P, et al
Pharmacological NF-kappaB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
Mol Oncol. 2023 Aug 3. doi: 10.1002/1878-0261.13504.
Abstract

ALI AH, Benterud A, Holmoy T, Myro AZ, et al
Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with anti-glycine receptor antibodies and urothelial carcinoma: a case report.
J Med Case Rep. 2023;17:330.
Abstract

FLEISCHMANN M, Rodel C
[Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer].
Strahlenther Onkol. 2023 Aug 2. doi: 10.1007/s00066-023-02134.
Abstract

ZHONG J, Xu A, Xu P, Su M, et al
Circ_0000235 targets MCT4 to promote glycolysis and progression of bladder cancer by sponging miR-330-5p.
Cell Death Discov. 2023;9:283.
Abstract

HAO Y, Zhu Y, Sun F, Xu D, et al
MicroRNA-30c-5p arrests bladder cancer G2/M phase and suppresses its progression by targeting PRC1-mediated blocking of CDK1/Cyclin B1 axis.
Cell Signal. 2023 Jul 31:110836. doi: 10.1016/j.cellsig.2023.110836.
Abstract

CHENG Y, Yu H, Li K, Lv J, et al
Hsa_circ_0003098 promotes bladder cancer progression via miR-377-5p/ACAT2 axis.
Genomics. 2023 Jul 31:110692. doi: 10.1016/j.ygeno.2023.110692.
Abstract

RIBEIRO DE SOUZA B, Brum Reis I, Cardoso de Arruda Camargo G, Oliveira G, et al
A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad(R) immunotherapy associated with platelet-rich plasma.
Int Immunopharmacol. 2023;123:110723.
Abstract

MEHMANDAR-OSKUIE A, Jahankhani K, Rostamlou A, Arabi S, et al
Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies.
Biomed Pharmacother. 2023;165:115242.
Abstract

DEMIRCI A, Ordu M
The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer.
Indian J Pathol Microbiol. 2023;66:502-510.
Abstract

LI Y, Kong Y, An M, Luo Y, et al
ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
J Exp Clin Cancer Res. 2023;42:191.
Abstract

CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1:EPI-23-0331.
Abstract

FAN Z, Shi H, Luo J, Guo X, et al
Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: A systematic review and network meta-analysis.
Int J Surg. 2023 Aug 1. doi: 10.1097/JS9.0000000000000592.
Abstract

KUANG X, Zhang Z, Li D, Bao W, et al
Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-kappaB activation via disrupting multiple-site ubiquitination of NEMO.
Cell Mol Biol Lett. 2023;28:62.
Abstract

CHABALLOUT BH, Chang EM, Parikh NR, Min Y, et al
Assessing utilities for muscle-invasive bladder cancer-related health states.
Urol Oncol. 2023 Jul 29:S1078-1439(23)00239.
Abstract

JIANG C, Xiao Y, Xu D, Huili Y, et al
Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a Comprehensive Analysis of Immunotherapy.
Crit Rev Eukaryot Gene Expr. 2023;33:73-86.
Abstract

MICHAEL SN, Masood PF, Sharma U, Bhat FI, et al
Giant right hydronephrosis with underlying double malignancy: a case report.
Pan Afr Med J. 2023;45:21.
Abstract

ELSAWY AA, Laymon M, Mansour I, Elghareeb A, et al
Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
Arab J Urol. 2023;21:142-149.
Abstract

AWAD M, Harraz AM, Farg H, Gabr HS, et al
Microscopic hematuria and pelvic ultrasonography could rule out flexible cystoscopy during surveillance for T1-low grade non-muscle invasive bladder cancer.
Arab J Urol. 2023;21:150-155.
Abstract

PICHLER R, Diem G, Hackl H, Koutnik J, et al
Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
Front Immunol. 2023;14:1202157.
Abstract

KOLAT D, Kaluzinska-Kolat Z, Kosla K, Orzechowska M, et al
LINC01137/miR-186-5p/WWOX: a novel axis identified from WWOX-related RNA interactome in bladder cancer.
Front Genet. 2023;14:1214968.
Abstract

JIN Y, Huang S, Wang Z
Identify and validate RUNX2 and LAMA2 as novel prognostic signatures and correlate with immune infiltrates in bladder cancer.
Front Oncol. 2023;13:1191398.
Abstract

DOU X, Ma X, Meng W, Zhang W, et al
HEATR3 involved in the cell proliferation, metastasis and cell cycle development of bladder cancer acts as a tumor suppressor.
Mol Genet Genomics. 2023 Jul 31. doi: 10.1007/s00438-023-02046.
Abstract

BRUCK K, Meijer RP, Boormans JL, Kiemeney LA, et al
Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study.
Int J Radiat Oncol Biol Phys. 2023 Jul 28:S0360-3016(23)07686.
Abstract

WIBERG E, Vega A, Eriksson V, Banday V, et al
A Validation Study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital.
J Pers Med. 2023;13:1163.
Abstract

HSU CY, Yang WT, Lin JH, Lu CH, et al
Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis In Vitro.
Int J Mol Sci. 2023;24:11852.
Abstract

LUCCHESI CA, Vasilatis DM, Mantrala S, Chandrasekar T, et al
Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.
Int J Mol Sci. 2023;24:11395.
Abstract

PARK EG, Lee DH, Kim WR, Lee YJ, et al
Human Endogenous Retrovirus-H-Derived miR-4454 Inhibits the Expression of DNAJB4 and SASH1 in Non-Muscle-Invasive Bladder Cancer.
Genes (Basel). 2023;14:1410.
Abstract

OSTROWSKI DA, Chelluri RR, Herzig M, Xia L, et al
Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.
Cancers (Basel). 2023;15:3746.
Abstract

DROSOS Y, Konstantakou EG, Bassogianni AS, Nikolakopoulos KS, et al
Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway.
Cancers (Basel). 2023;15:3730.
Abstract

LOZANO F, Raventos CX, Carrion A, Dinares C, et al
Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
Cancers (Basel). 2023;15:3683.
Abstract

MENG X, Li S, He K, Hu H, et al
Evaluation of Whole-Tumor Texture Analysis Based on MRI Diffusion Kurtosis and Biparametric VI-RADS Model for Staging and Grading Bladder Cancer.
Bioengineering (Basel). 2023;10:745.
Abstract

YU J, Wu S, Li R, Jiang Y, et al
Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
J Hematol Oncol. 2023;16:85.
Abstract

ZHAN Y, Lin J, Liu Y, Chen M, et al
Correction: Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer.
J Exp Clin Cancer Res. 2023;42:185.
Abstract

LI H, Zhou J, Chen R, Zhu J, et al
The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
Urol Oncol. 2023;41:356.
Abstract

D'ANDREA D, Shariat SF, Soria F, DI Trapani E, et al
Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.
Minerva Urol Nephrol. 2023;75:452-459.
Abstract

BURGESS EF, Livasy CA, Symanowski JT, Matulay JT, et al
Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites.
Urol Oncol. 2023;41:357.
Abstract

CLARK-GARVEY S, Damrauer JS, Milowsky MI
Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer.
Eur Urol Oncol. 2023;6:376-377.
Abstract

TAKASE R, Hagiya H, Fujimori T, Yokoyama Y, et al
Super acute-onset disseminated BCG infection: A case report.
J Infect Chemother. 2023;29:919-921.
Abstract

KAWAMURA K, Miyai K, Sato K, Matsukuma S, et al
Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma.
Cancer Sci. 2023;114:3411-3422.
Abstract

MORGANS AK, Galsky MD, Wright P, Hepp Z, et al
Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
Urol Oncol. 2023;41:357.
Abstract

NICOLETTI R, Gauhar V, Castellani D, Enikeev D, et al
Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A Hands-on Guide Through the Energy Landscape.
Eur Urol Focus. 2023;9:567-570.
Abstract

MAFFEZZOLI M, Campobasso D, Rebuzzi SE, Banna GL, et al
Prognostic models for patients with metastatic urothelial carcinoma: why use them?
Minerva Urol Nephrol. 2023;75:419-421.
Abstract

DRESSLER FF, Hinrichs S, Roesch MC, Perner S, et al
EpCAM tumor specificity and proteoform patterns in urothelial cancer.
J Cancer Res Clin Oncol. 2023;149:8913-8922.
Abstract

LIMA W, Wang Y, Miyamoto H
The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome.
Urol Oncol. 2023;41:357.
Abstract

WANG J, Zuo X, Zhang Y, Wang W, et al
The impact of histological variants in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
J Cancer Res Clin Oncol. 2023;149:8279-8288.
Abstract

LIAO CI, Fang HC, Lee PT, Hsu CY, et al
Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.
J Cancer Res Clin Oncol. 2023;149:8201-8211.
Abstract

CAO Y
A case of rare metachronous four primary carcinoma.
J Cancer Res Clin Oncol. 2023;149:7471-7477.
Abstract

CHEN T, Zheng Y, Roskos L, Mager DE, et al
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.
J Pharmacokinet Pharmacodyn. 2023;50:251-265.
Abstract

SJODAHL G, Bernardo C, Eriksson P, Hoglund M, et al
Tumor Biomarkers for Bacillus Calmette-Guerin Response: What We Get Is Not What We Want.
Eur Urol Focus. 2023;9:582-583.
Abstract

CELIK B, Kavas G
Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
Acta Cytol. 2023;67:425-433.
Abstract

MUILWIJK T, Akand M, Raskin Y, Jorissen C, et al
Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry.
Eur Urol Oncol. 2023;6:422-430.
Abstract

Correction to "G-protein-coupled receptor 137 accelerates proliferation of urinary bladder cancer cells in vitro".
Biotechnol Appl Biochem. 2023;70:1560.
Abstract

Retraction Statement: KLF8 is required for bladder cancer cell proliferation and migration.
Biotechnol Appl Biochem. 2023;70:1555.
Abstract

LIU L, Sun FZ, Zhang PY, Xiao Y, et al
Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study.
Eur J Med Res. 2023;28:279.
Abstract

DENG H, Deng L, Chao H, Yu Z, et al
RAB14 promotes epithelial-mesenchymal transition in bladder cancer through autophagyâ€‘dependent AKT signaling pathway.
Cell Death Discov. 2023;9:292.
Abstract

HOSOMI T, Shibasaki N, Otsuka H, Uketa S, et al
[Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
Hinyokika Kiyo. 2023;69:183-188.
Abstract

CONTIERI R, Hensley PJ, Tan WS, Grajales V, et al
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
Eur Urol Oncol. 2023 Aug 7:S2588-9311(23)00157-8. doi: 10.1016/j.euo.2023.
Abstract

FONTUGNE J, Xylinas E, Krucker C, Dixon V, et al
RNA-seq profiling of upper tract urothelial carcinoma: bladder cancer consensus classification relevance, molecular heterogeneity and differential immune signatures.
Mod Pathol. 2023 Aug 7:100300. doi: 10.1016/j.modpat.2023.100300.
Abstract

DUMONT C, Aregui A, Hauchecorne M, Lefevre M, et al
Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients.
World J Urol. 2023 Aug 9. doi: 10.1007/s00345-023-04561.
Abstract

SCANLON L, Canavan J, Babiker Z, Shilling C, et al
Leiomyoma of the Bladder: A case report and review.
Ir Med J. 2023;116:792.
Abstract

RASMUSSEN AM, Okholm TLH, Knudsen M, Vang S, et al
Circular stable intronic RNAs possess distinct biological features and are deregulated in bladder cancer.
NAR Cancer. 2023;5:zcad041.
Abstract

WANG J, Zhu J, Hu J, Wang Z, et al
A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells.
Genes Dis. 2022;10:2586-2596.
Abstract

TAN W, Gao L, Yuan Y, Huang H, et al
Relationship between testosterone and male bladder cancer.
Sci Rep. 2023;13:12881.
Abstract

FU Z, Tian Z, Chen Y, Jia Z, et al
Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous ureterostomy after radical cystectomy.
Eur J Med Res. 2023;28:273.
Abstract

GUO R, Wang L, Bai S, Kang D, et al
Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis.
Sci Rep. 2023;13:12801.
Abstract

LEOW JJ, Yong DZ, Chong YL
Value-based healthcare for bladder cancer patients undergoing robot-assisted radical cystectomy.
Eur J Surg Oncol. 2023;49:1329-1330.
Abstract

HSU FT, Liu WL, Lee SR, Jeng LB, et al
Unveiling nature's potential weapon: Magnolol's role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-delta/ERK axis.
Phytomedicine. 2023;119:154947.
Abstract

DEL GIUDICE F, Belladelli F, Glover F, Basran S, et al
5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
World J Urol. 2023 Aug 7. doi: 10.1007/s00345-023-04551.
Abstract

JIA X, Shkolyar E, Laurie MA, Eminaga O, et al
Tumor detection under cystoscopy with transformer-augmented deep learning algorithm.
Phys Med Biol. 2023;68.
Abstract

SUN C, Zhou X, Lou J
A Survival Model for Patients with Upper Tract Urothelial Carcinoma.
Arch Esp Urol. 2023;76:357-362.
Abstract

SHUMAN L, Pham J, Wildermuth T, Wu XR, et al
Urothelium-specific expression of mutationally activated Pik3ca initiates early lesions of non-invasive bladder cancer.
Am J Pathol. 2023 Aug 4:S0002-9440(23)00272-9. doi: 10.1016/j.ajpath.2023.
Abstract

HUANG L, Jia K, Yao K, Liu D, et al
Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade non-muscle-invasive bladder cancer who underwent radical cystectomy.
Medicine (Baltimore). 2023;102:e34501.
Abstract

WARE AP, Satyamoorthy K, Paul B
Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer.
Funct Integr Genomics. 2023;23:266.
Abstract

LIU H, Zhou Z, Yao H, Mao Q, et al
Robot-assisted radical cystectomy vs open radical cystectomy in patients with bladder cancer: a systematic review and meta-analysis of randomized controlled trials.
World J Surg Oncol. 2023;21:240.
Abstract

ZHAO X, Chen J, Zhang C, Xie G, et al
LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via regulating LRG1 mRNA stability.
Cell Signal. 2023 Aug 2:110839. doi: 10.1016/j.cellsig.2023.110839.
Abstract

ZLOTTA AR, Lajkosz K, Efstathiou JA
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' reply.
Lancet Oncol. 2023;24:e325-e326.
Abstract

JENA R, Issa R, Perry M
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed.
Lancet Oncol. 2023;24:e324.
Abstract

PANT S, Schuler M, Iyer G, Witt O, et al
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Lancet Oncol. 2023;24:925-935.
Abstract

[First-line maintenance therapy of adult patients with BCG-naive high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-2
Aktuelle Urol. 2023;54:272-273.
Abstract

CHEN J, Zhang Z, Nie Z, Qiu J, et al
Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study.
J Cancer Res Clin Oncol. 2023 Aug 4. doi: 10.1007/s00432-023-05206.
Abstract

ZHENG B, Wang S, Zhang J, Ge C, et al
Expression, Prognostic Value, and immune infiltration of MTHFD family in bladder cancer.
Curr Cancer Drug Targets. 2023 Aug 4. doi: 10.2174/1568009623666230804152603.
Abstract

ZENG Z, Wu X, Peng K, Ren D, et al
Robot-assisted laparoscopic enucleation in the treatment of leiomyosarcoma of urinary bladder: A case report.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48:782-788.
Abstract

SHIBUTANI K, Ishikawa K, Mori N
Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.
Am J Case Rep. 2023;24:e940375.
Abstract

JAIN K, Jain E, DiLena R, Saleeb R, et al
Urachal xanthogranuloma: a rare but important case presenting as a urachal mass.
BMC Urol. 2023;23:132.
Abstract

TRIPATHI A, Lerner SP
Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma.
JCO Precis Oncol. 2023;7:e2300293.
Abstract

TURNER R, Powari M, Stevenson T
From haematuria to nephroureterectomy via urine cytology-A case study.
Cytopathology. 2023;34:494-496.
Abstract

WANG S, Zhang D, Bai Y, Liu F, et al
Clinical Outcomes of Pelvic Lymph Node Dissection Before Versus After Robot-Assisted Laparoscopic Radical Cystectomy.
J Laparoendosc Adv Surg Tech A. 2023;33:776-781.
Abstract

BAGHERY F, Lau LDW, Mohamadi M, Vazirinejad R, et al
Risk of urinary tract cancers following arsenic exposure and tobacco smoking: a review.
Environ Geochem Health. 2023;45:5579-5598.
Abstract

ZHOU L, Shao Z, Liu Y, Yan X, et al
HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
Oncologist. 2023;28:e617-e624.
Abstract

XUE G, Liu Y, Ji X, Zhang H, et al
Wound dehiscence in enhanced recovery after open radical cystectomy: A meta-analysis.
Int Wound J. 2023;20:2634-2639.
Abstract

EUGENIA L, Giovanni A, Andrea M, Maria Rosaria R, et al
Mucinous appendiceal adenocarcinoma invading the bladder: not always an easy diagnosis. A case report.
Anticancer Drugs. 2023;34:967-969.
Abstract

SILVA JF, Pereira P, Macedo G
A rare case of ulcerative colitis following Bacillus Calmette-Guerin therapy.
Rev Esp Enferm Dig. 2023;115:403.
Abstract

MJAESS G, Diamand R, Aoun F, Assenmacher G, et al
Cost-analysis of robot-assisted radical cystectomy in Europe: A cross-country comparison.
Eur J Surg Oncol. 2023;49:1511-1518.
Abstract

GU L, Hu G, Hu J, Wen F, et al
Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer.
Heliyon. 2023;9:e18848.
Abstract

LIU C, Xu P, Shao S, Wang F, et al
The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer.
Mol Biol Rep. 2023 Aug 17. doi: 10.1007/s11033-023-08667.
Abstract

MERTENS LS, Psutka SP, Mir MC
Bladder cancer oligometastases - definition and treatment.
Nat Rev Urol. 2023 Aug 17. doi: 10.1038/s41585-023-00815.
Abstract

FONT A, Domenech M, Ramirez JL, Marques M, et al
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
Front Oncol. 2023;13:1155244.
Abstract

CHEN R, Hao X, Chen J, Zhang C, et al
Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1.
J Transl Med. 2023;21:549.
Abstract

XIA C, Zhao X, Li B, Qi B, et al
Loneliness, spiritual well-being, and death perception, as well as their risk factors in urological cancer patients.
Braz J Med Biol Res. 2023;56:e12915.
Abstract

XING Z, Ji M, Shan Y, Dong Z, et al
Using the Multidimensional Health Locus of Control Scale Form C to Investigate Health Beliefs About Bladder Cancer Prevention and Treatment Among Male Patients: Cross-Sectional Study.
JMIR Form Res. 2023;7:e43345.
Abstract

YANG C, Ou Y, Zhou Q, Liang Y, et al
Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.
Cell Death Dis. 2023;14:525.
Abstract

VANIN MORENO N, Whitehead M, Siemens DR
Real-life benchmarking bladder cancer care: A population-based study.
Can Urol Assoc J. 2023;17:268-273.
Abstract

LIU W, Chen R, Liu X, Zhou B, et al
Differentiation of bladder cancer stages using the vesical imaging -reporting and data system and apparent diffusion coefficient.
Quant Imaging Med Surg. 2023;13:4897-4907.
Abstract

LI HZ, Zhu J, Weng GJ, Li JJ, et al
Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery.
J Mater Chem B. 2023 Aug 15. doi: 10.1039/d3tb01323.
Abstract

ZHOU Q, Wu H, Miao F, Cao Y, et al
Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
Anticancer Drugs. 2023 Aug 15. doi: 10.1097/CAD.0000000000001528.
Abstract

SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis.
Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14051.
Abstract

LIN F, Ke ZB, Xue YT, Chen JY, et al
A novel CD8(+) T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer.
Inflamm Res. 2023 Aug 14. doi: 10.1007/s00011-023-01772.
Abstract

WONG MCS, Huang J, Wang HHX, Yau STY, et al
Risk prediction of bladder cancer among diabetes patients: a derivation and validation study.
Diabet Med. 2023 Aug 14:e15199. doi: 10.1111/dme.15199.
Abstract

CHANG S, Giannico GA, Haugen E, Jardaneh A, et al
Multiparameter interferometric polarization-enhanced imaging differentiates carcinoma in situ from inflammation of the bladder: an ex vivo study.
J Biomed Opt. 2023;28:102907.
Abstract

ROHITH G, Gaur AS, Nayak P, Mandal S, et al
Socio-economic, education, and insurance-related factors associated with the treatment completion rates in patients with nonmetastatic urinary bladder cancer: A Retrospective cohort study.
Indian J Urol. 2023;39:228-235.
Abstract

YAN D, He Q, Pei L, Yang M, et al
The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer.
Cell Death Dis. 2023;14:516.
Abstract

HSU CW, Cheng NC, Liao MY, Cheng TY, et al
Correction: Hsu et al. Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells. Nanomaterials 2020, 10, 1351.
Nanomaterials (Basel). 2023;13:2233.
Abstract

FIORENTINO V, Pizzimenti C, Franchina M, Rossi ED, et al
Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
Int J Mol Sci. 2023;24:12489.
Abstract

PATWARDHAN MV, Mahendran R
The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy.
Int J Mol Sci. 2023;24:12311.
Abstract

MURALISANKAR M, Chen JR, Haribabu J, Ke SC, et al
Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2' Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells.
Int J Mol Sci. 2023;24:11896.
Abstract

SERRANO M, Munoz-Unceta N, Alonso LA, Azueta A, et al
Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
Clin Transl Oncol. 2023 Aug 11. doi: 10.1007/s12094-023-03277.
Abstract

BASAK D, Mondal S, Srivastava SK, Sarkar D, et al
Intratumoral PD1(+)CD38(+)Tim3(+) CD8(+) T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer.
Cells. 2023;12:1939.
Abstract

RASTI A, Abazari O, Dayati P, Kardan Z, et al
Identification of Potential Key Genes Linked to Gender Differences in Bladder Cancer Based on Gene Expression Omnibus (GEO) Database.
Adv Biomed Res. 2023;12:157.
Abstract

LV J, Wu Q, Li K, Bai K, et al
Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
Int J Biol Sci. 2023;19:3744-3761.
Abstract

CHENG H, Liu Y, Chen G
Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis.
BMC Urol. 2023;23:135.
Abstract

STONE L
Subtypes in small cell bladder cancer.
Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00813.
Abstract

STONE L
Proteomic characterization of bladder cancer.
Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00814.
Abstract

ECKSTEIN M, Matek C, Wagner P, Erber R, et al
Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
Eur Urol Oncol. 2023 Aug 8:S2588-9311(23)00153-0. doi: 10.1016/j.euo.2023.
Abstract

LIU Z, Zheng X, Chen J, Zheng L, et al
NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.
Cell Rep. 2023;42:112963.
Abstract

FUNAKOSHI Y, Kanda S, Akihama S, Horikawa Y, et al
[A Case of Inflammatory Myofibroblastic Tumor of The Bladder Treated with Partial Cystectomy].
Hinyokika Kiyo. 2023;69:179-182.
Abstract

HASELAGER D, Dorigo-Zetsma W, Schroder M, Heidt J, et al
An 80-Year-Old Man With Respiratory Insufficiency After Intravesical Mycobacterium bovis BCG Immunotherapy.
Chest. 2023;164:e39-e43.
Abstract

SONG Y, Peng Y, Qin C
Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
World J Urol. 2023;41:2301-2302.
Abstract

BRUSASCO C, Di Domenico A, Ennas M, Benelli A, et al
Application of a protocol for enhanced recovery after radical cystectomy: a before-and-after cohort study.
World J Urol. 2023;41:2273-2280.
Abstract

CHANG YH, Hsu WL, Lee YK, Chiang CJ, et al
Trends and sex-specific incidence of upper urinary tract cancer in Taiwan: A birth cohort study.
Cancer Med. 2023;12:15350-15357.
Abstract

HE W, Chen C, Lin T, Xu Q, et al
Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review.
Cancer Med. 2023;12:15384-15403.
Abstract

WU S, Li R, Jiang Y, Yu J, et al
Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications.
Biomed Pharmacother. 2023;165:115027.
Abstract

JI J, Yao Y, Sun L, Yang Q, et al
Development and validation of a preoperative nomogram to predict lymph node metastasis in patients with bladder urothelial carcinoma.
J Cancer Res Clin Oncol. 2023;149:10911-10923.
Abstract

SANTONI M, Myint ZW, Buttner T, Takeshita H, et al
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
Cancer Immunol Immunother. 2023;72:2961-2970.
Abstract

LIN J, Ding M, Qin C, Song Y, et al
A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
J Cancer Res Clin Oncol. 2023;149:9877-9890.
Abstract

HUANG H, Li L, Cao Q, Tan H, et al
Ectopic prostate tissue at the bladder.
Am J Med Sci. 2023;366:e37.
Abstract

REISWICH V, Schmidt CE, Lennartz M, Hoflmayer D, et al
GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Pathobiology. 2023;90:219-232.
Abstract

ZIDAN ASA, Ibrahim ABM, Aly AAM, Mosbah HK, et al
Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against Cancer Cells.
Biol Trace Elem Res. 2023;201:4688-4696.
Abstract

LOBO J, Lobo C, Leca L, Rodrigues A, et al
Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center.
Pathobiology. 2023;90:233-240.
Abstract

ZHANG T, Chen L, Xu X, Shen C, et al
Knockdown of Long Noncoding RNA Urothelial Carcinoma-Associated 1 Represses Gallbladder Cancer Advancement by Regulating SPOCK1 Expression Through Sponging miR-613.
Cancer Biother Radiopharm. 2023;38:354-363.
Abstract

RYSANKOVA K, Gumulec J, Grepl M, Krhut J, et al
Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report.
World J Clin Cases. 2023;11:5338-5343.
Abstract

LI H, Jiang H, Huang Z, Chen Z, et al
Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
Aging (Albany NY). 2023;15.
Abstract

LI K, Li S, Tang S, Zhang M, et al
[Retracted] KIF22 promotes bladder cancer progression by activating the expression of CDCA3.
Int J Mol Med. 2023;52:92.
Abstract

SHEN J, Du M, Liang S, Wang L, et al
Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1.
Front Med (Lausanne). 2023;10:1222543.
Abstract

ALYUSUF Z, Hassan A, Maki R, Hasan W, et al
Intravesical urachal cyst masquerading as a bladder malignancy: a case report.
J Med Case Rep. 2023;17:364.
Abstract

ZHUANG J, Mo J, Huang Z, Yan Y, et al
Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3beta/beta-catenin signaling pathways: a network pharmacology-directed experimental investigation.
Chin Med. 2023;18:104.
Abstract

ZHANG D, Yin G, Zheng S, Chen Q, et al
Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023.
Abstract

KUMADA N, Nakane K, Yamada T, Tomioka-Inagawa R, et al
Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.
Minim Invasive Ther Allied Technol. 2023.
Abstract

JIANG PC, Xu LZ, Ning JZ, Cheng F, et al
GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.
World J Surg Oncol. 2023;21:255.
Abstract

TOREN P, Wilkins A, Patel K, Burley A, et al
The sex gap in bladder cancer survival - a missing link in bladder cancer care?
Nat Rev Urol. 2023 Aug 21. doi: 10.1038/s41585-023-00806.
Abstract

BASILE G, Pradere B, Bellmunt J, Roupret M, et al
A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials.
Eur Urol Oncol. 2023 Aug 19:S2588-9311(23)00147.
Abstract

FUKUHARA H, Hagiwara Y, Oba K, Inoue K, et al
Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan.
Photodiagnosis Photodyn Ther. 2023 Aug 19:103758.
Abstract

HAN D, Guan L, Zhang Y, Yang H, et al
FGF13A interacts with NPM1 and UBF and inhibits the invasion of bladder cancer cells.
Biochem Biophys Res Commun. 2023;678:1-10.
Abstract

WEI X, Chai Y, Li Z, Che X, et al
Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients.
Front Oncol. 2023;13:1233620.
Abstract

FANG D, He Y, Yi Y, Mei J, et al
Hub gene associated with prognosis in bladder cancer is a novel therapeutic target.
PeerJ. 2023;11:e15670.
Abstract

TAN Z, Chen X, Zuo J, Fu S, et al
Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer.
J Inflamm Res. 2023;16:3399-3417.
Abstract

SU W, Sui W, Cheng X, Zong Y, et al
Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.
Diagn Pathol. 2023;18:94.
Abstract

KIM DK, Kim JH, Park JY, Gwon YN, et al
Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features.
Clin Genitourin Cancer. 2023 Jul 8:S1558-7673(23)00172.
Abstract

ELSALEM L, Al Shatnawi A, A Alfaqih M, Alshoh A, et al
Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
Acta Biochim Pol. 2023 Aug 18. doi: 10.18388/abp.2020_6590.
Abstract

CHEN X, Liao C, Zou X, Zhang B, et al
A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer.
Clin Transl Oncol. 2023 Aug 18. doi: 10.1007/s12094-023-03270.
Abstract

KIM S, Park J, Ho JN, Kim D, et al
3D vascularized microphysiological system for investigation of tumor-endothelial crosstalk in anti-cancer drug resistance.
Biofabrication. 2023;15.
Abstract

KONOREV D, Bellamri M, Wu CF, Wu MT, et al
High-Field Asymmetric Waveform Ion Mobility Spectrometry Analysis of Carcinogenic Aromatic Amines in Tobacco Smoke with an Orbitrap Tribrid Mass Spectrometer.
Chem Res Toxicol. 2023;36:1419-1426.
Abstract

LIU Z, Wei S, Tang J
Clinicopathologic Features of Noninvasive Inverted Urothelial Papillary Tumor.
Am J Clin Oncol. 2023;46:409-413.
Abstract

LU J, Cai S, Wang F, Wu PY, et al
Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI.
Acad Radiol. 2023;30:1823-1831.
Abstract

ZHANG J, Li Z
Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review and meta-analysis.
Medicine (Baltimore). 2023;102:e34828.
Abstract

CHICK J, Alexander S, Herbert T, Huddart R, et al
Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy.
Phys Imaging Radiat Oncol. 2023;27:100481.
Abstract

MA X, Wei X, Yang G, Li S, et al
A novel Natural killer cell-related gene signature for improving the prediction of prognosis and immunotherapy response in bladder cancer.
Comb Chem High Throughput Screen. 2023.
Abstract

CUI Y, Yu L, Ma G, Wu J, et al
Construction of enhanced CT radiomics model for noninvasive prediction of CXCL13's expression and immune infiltrates in bladder cancer based on logistic regression and support vector machine algorithm.
Asian J Surg. 2023 Aug 29:S1015-9584(23)01299.
Abstract

HOU L, Li H, Dong Q
Clinical experience of modified percutaneous ureterostomy in bladder cancer patients receiving radical cystectomy.
Asian J Surg. 2023 Aug 29:S1015-9584(23)01281.
Abstract

NOH JI, Ahn EJ, Noh MG, Moon KS, et al
Orthotopic Mouse Models of Urinary Bladder Cancer.
In Vivo. 2023;37:2039-2043.
Abstract

LI H, Wang L, Li H, Zheng P, et al
Analysis of risk factors for recurrence after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer: 2-year follow-up outcomes.
Oncology. 2023 Aug 30. doi: 10.1159/000533410.
Abstract

LIU X, Qiu Z, Zhang X, Su Z, et al
Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
Environ Toxicol. 2023 Aug 30. doi: 10.1002/tox.23949.
Abstract

PLAMBECK BD, Tazegul TE, McElree IM, Steinberg RL, et al
Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS.
Urol Case Rep. 2023;50:102516.
Abstract

SAKAI D, Hirami Y, Sugita S, Maeda A, et al
A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA.
Retin Cases Brief Rep. 2023;17:630-634.
Abstract

LIU L, Sun FZ, Zhang PY, Xiao Y, et al
Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
Aging Male. 2023;26:2252102.
Abstract

HENDRI AZ, Soerohardjo I, Heriyanto DS, Khalilullah SA, et al
Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder.
Asian Pac J Cancer Prev. 2023;24:2673-2679.
Abstract

SU X, Dong C, Liao W, Liu W, et al
Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
World J Surg Oncol. 2023;21:271.
Abstract

MOON S, Pandya V, McDonald A, Basu A, et al
Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy.
Urol Oncol. 2023 Aug 26:S1078-1439(23)00264.
Abstract

MARIOTTI A, Spatafora P, Sessa F, Saieva C, et al
Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience.
Eur J Surg Oncol. 2023;49:107034.
Abstract

ZHANG Y, Chen Y, Wen W
Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.
Front Immunol. 2023;14:1152806.
Abstract

HUANG LK, Lin YC, Chuang HH, Chuang CK, et al
Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor.
Front Oncol. 2023;13:1180888.
Abstract

JIA X, Zhang D, Zhou C, Yan Z, et al
Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
Front Oncol. 2023;13:1175183.
Abstract

CHAN K, Hampson A, Hayes J, Rabinowitz J, et al
Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study.
BJUI Compass. 2023;4:568-574.
Abstract

ZNAIDER VK, Mikkelsen LH, Jensen CFS, Sonksen J, et al
Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
Scand J Urol. 2023;58:52-59.
Abstract

WONG K, Abascal F, Ludwig L, Aupperle-Lellbach H, et al
Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer.
Genome Biol. 2023;24:191.
Abstract

ALFANO M, Alchera E, Sacchi A, Gori A, et al
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on alpha5beta1-targeted gold nanorods.
J Nanobiotechnology. 2023;21:301.
Abstract

DEVLIES W, de Jong JJ, Hofmann F, Bruins HM, et al
The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office.
Eur Urol Focus. 2023 Aug 24:S2405-4569(23)00184.
Abstract

WANG W, Wang K, Qiu J, Li W, et al
MRI-based radiomics analysis of bladder cancer: prediction of pathological grade and histological variant.
Clin Radiol. 2023 Aug 12:S0009-9260(23)00327-6. doi: 10.1016/j.crad.2023.
Abstract

LALANI AA
How I Do It: Maintenance avelumab.
Can J Urol. 2023;30:11633-11638.
Abstract

TAN Z, Fu S, Zuo J, Wang J, et al
Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

YOO D, Min KW, Pyo JS, Kim NY, et al
Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.
Medicina (Kaunas). 2023;59:1452.
Abstract

RADIC SAVIC Z, Coric V, Vidovic S, Vidovic V, et al
GPX3 rs8177412 Polymorphism Modifies Risk of Upper Urothelial Tumors in Patients with Balkan Endemic Nephropathy.
Medicina (Kaunas). 2023;59:1421.
Abstract

CLAPS F, Pavan N, Ongaro L, Tierno D, et al
BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.
Int J Mol Sci. 2023;24:12596.
Abstract

CHIN FW, Chan SC, Veerakumarasivam A
Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.
Diagnostics (Basel). 2023;13:2641.
Abstract

CHIN FW, Hussin H, Chau DM, Ong TA, et al
Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression.
Diagnostics (Basel). 2023;13:2636.
Abstract

KOUKOURIKIS P, Papaioannou M, Georgopoulos P, Apostolidis I, et al
A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients with Neurogenic Lower Urinary Tract Dysfunction.
Biology (Basel). 2023;12:1126.
Abstract

WALZ S, Pollehne P, Vollmer P, Aicher WK, et al
Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids from Bladder Cancer Patients.
Cells. 2023;12:2108.
Abstract

WANG D, Qiu Z, Wu C
Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer.
World J Surg Oncol. 2023;21:267.
Abstract

SHAO F, Jin K, Li B, Liu Z, et al
Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
Urol Oncol. 2023 Aug 23:S1078-1439(23)00254.
Abstract

LI S, Pan M, Wu X, Bai Y, et al
miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP Bladder Cancer Cell Lines via Suppressing HMGA2 Expression.
Ann Clin Lab Sci. 2023;53:607-618.
Abstract

LUO Q, Huang C, Chen M
Comprehensive analysis of N1-methylandenosine regulators and m1A-related mRNAs and lncRNAs as prognostic factors in bladder cancer.
Gene. 2023 Aug 23:147735. doi: 10.1016/j.gene.2023.147735.
Abstract

MINAMI T, Inoue M, Yamaji T, Iwasaki M, et al
Reproductive factors in the risk of bladder cancer and upper urinary tract cancer: The Japan Public Health Center-based Prospective Study.
Cancer Epidemiol Biomarkers Prev. 2023 Aug 25:EPI-23-0201.
Abstract

HUI G, Stefanoudakis D, Zektser Y, Isaacs DJ, et al
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
Curr Oncol. 2023;30:7398-7411.
Abstract

MAO C, Xu N
Single-cell sequencing data reveals aggressive CD68-type macrophages and prognostic models in bladder cancer.
Curr Med Chem. 2023 Aug 24. doi: 10.2174/0929867331666230824093312.
Abstract

WU X, Xu L, Li X, Zhou Y, et al
A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
Cell Death Dis. 2023;14:550.
Abstract

PETTIT MS, Crowder SL, Ackerman RS, Hafez O, et al
Preoperative Nutritional Status and Enhanced Recovery after Surgery (ERAS) Prior to Radical Cystectomy: A Review of the Literature.
Nutr Cancer. 2023;75:1743-1751.
Abstract

SCHWARZOVA L, Varchulova Novakova Z, Danisovic L, Ziaran S, et al
Molecular classification of urothelial bladder carcinoma.
Mol Biol Rep. 2023;50:7867-7877.
Abstract

TUDERTI G, Mastroianni R, Chiacchio G, Anceschi U, et al
Long-term oncologic and functional outcomes following robot-assisted radical cystectomy and intracorporeal Padua ileal bladder: results from a single high-volume center.
World J Urol. 2023;41:2359-2366.
Abstract

FERREIRO-PANTIN M, Anido-Herranz U, Betancor YZ, Cebey-Lopez V, et al
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
ESMO Open. 2023;8:101611.
Abstract

LEBRET T, Paoletti X, Pignot G, Roumiguie M, et al
Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
World J Urol. 2023;41:2381-2388.
Abstract

BAHLBURG H, Schuster F, Tully KH, Butea-Bocu MC, et al
Prospective evaluation of functional outcomes in 395 patients with an ileal neobladder 1 year after radical cystectomy.
World J Urol. 2023;41:2367-2374.
Abstract

CHO BC, Penkov K, Bondarenko I, Kurochkin A, et al
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
ESMO Open. 2023;8:101589.
Abstract

KIM M, Lee JL, Shin SJ, Bae WK, et al
Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
ESMO Open. 2023;8:101588.
Abstract

LUO Z, Jiao B, Huang T, Zhao H, et al
Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.
J Cancer Res Clin Oncol. 2023;149:11223-11231.
Abstract

SONG J, Sun X, Wang T, Yan L, et al
Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
J Cancer Res Clin Oncol. 2023;149:11207-11221.
Abstract

WU M, Pang Y, Zheng X, Zhao J, et al
Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV.
Int J STD AIDS. 2023;34:720-727.
Abstract

KOVACS SA, Fekete JT, Gyorffy B
Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Acta Pharmacol Sin. 2023;44:1879-1889.
Abstract

SANCHEZ CANOVAS M, Fernandez Garay D, Adoamnei E, Guirao Garcia E, et al
Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
Clin Transl Oncol. 2023;25:3021-3031.
Abstract

ZWAKENBERG MA, Westra JM, Halmos GB, Wedman J, et al
Narrow-Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A Randomized Controlled Trial.
Otolaryngol Head Neck Surg. 2023;169:606-614.
Abstract

SU C, Xue J, Liu N
Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy in Patients with Bladder Cancer.
Arch Esp Urol. 2023;76:411-417.
Abstract

YU Q, Lan T, Ma Z, Wang Z, et al
Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
Transl Androl Urol. 2023;12:1296-1307.
Abstract

SUNG WW
Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In pres
Eur Urol Oncol. 2023 Sep 5:S2588-9311(23)00171-2. doi: 10.1016/j.euo.2023.
Abstract

CATTO JW, North B, Goff M, Carter A, et al
Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk.
BMJ Open. 2023;13:e076612.
Abstract

HWANG TJ, Davies BJ, Preston MA
Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer.
JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3304.
Abstract

LIU X, Chen C, Xu P, Chen B, et al
Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Funct Integr Genomics. 2023;23:291.
Abstract

LI B, Li X
A preliminary study on the establishment of a cyst and cystic neoplasm tissue-mimicking model.
J Cancer Res Ther. 2023;19:988-994.
Abstract

ZHENG J, Liu F, Zhang K, Xiang Y, et al
High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application.
J Cancer Res Ther. 2023;19:945-950.
Abstract

BENJAMIN DJ, Hsu R
Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
Front Immunol. 2023;14:1258388.
Abstract

WANG J, Xiao Y, Yu Q, Zhang C, et al
HSD17B1 could serve as a prognostic biomarker for bladder cancer patients.
Asian J Surg. 2023 Sep 4:S1015-9584(23)01094.
Abstract

RODEL C
[Radical cystectomy or trimodal therapy for bladder cancer: where do we stand?].
Urologie. 2023 Sep 5. doi: 10.1007/s00120-023-02194.
Abstract

NIE Z, Guo N, Peng Y, Gao Y, et al
Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.
Sci Rep. 2023;13:14595.
Abstract

MA Z, Li Z, Mao Y, Ye J, et al
AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.
Nat Commun. 2023;14:5415.
Abstract

REN C, Wang Q, Xu Z, Pan Y, et al
Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05352.
Abstract

SONG Y, Xu T
Letter to the editor for the article "Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes".
World J Urol. 2023 Sep 5. doi: 10.1007/s00345-023-04575.
Abstract

KIM GH, Yuk HD, Jeong CW, Kwak C, et al
Renal function change after radical cystectomy for urothelial carcinoma patients with a solitary kidney may be independent of urinary diversion type.
Investig Clin Urol. 2023;64:457-465.
Abstract

CHAAYA C, Zgheib G, El Karak F
Pharmacotherapy developments in Autophagy inhibitors for bladder cancer.
Expert Opin Pharmacother. 2023 Sep 5. doi: 10.1080/14656566.2023.2254697.
Abstract

OKA S, Sakaguchi K, Hayashida M, Ito S, et al
First case report of robot-assisted radical cystectomy for bladder cancer that developed after salvage radiotherapy following radical prostatectomy for prostate cancer.
IJU Case Rep. 2023;6:310-313.
Abstract

LARIZADEH MH, Arabnejad F, Ebadzadeh MR
Sequential Chemotherapy Followed by Radiotherapy Versus Concurrent Chemo-Radiation in Muscle Invasive Bladder Cancer.
Urol J. 2023 Jul 31. doi: 10.22037/uj.v20i.7525.
Abstract

DOSHI B, Athans SR, Woloszynska A
Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions.
Oncogenesis. 2023;12:44.
Abstract

FAN YW, Lu IC, Hsu MY, Kuo WT, et al
Synthetic lethality in human bladder cancer cells by curcumin via concurrent Aurora A inhibition and autophagy induction.
J Nutr Biochem. 2023 Sep 2:109438. doi: 10.1016/j.jnutbio.2023.109438.
Abstract

SAHIB AS, Fawzi A, Zabibah RS, Koka NA, et al
miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer progression and metastasis: A focus on gastric and bladder cancers.
Cell Signal. 2023 Sep 2:110881. doi: 10.1016/j.cellsig.2023.110881.
Abstract

LI S, Ruan B, Wang Z, Xia J, et al
Glucose dysregulation promotes oncogenesis in human bladder cancer by regulating autophagy and YAP1/TAZ expression.
J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17943.
Abstract

LIU Y, Fan M, Xian S, Hu P, et al
RBP7 Regulated by EBF1 Affects Th2 Cells and the Oocyte Meiosis Pathway in Bone Metastases of Bladder Urothelial Carcinoma.
Front Biosci (Landmark Ed). 2023;28:189.
Abstract

WU Z, Li X, Gu Z, Xia X, et al
Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer.
Front Oncol. 2023;13:1102518.
Abstract

LIU J, Yang TY, Dai LQ, Shi K, et al
Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer.
Bioact Mater. 2023;31:315-332.
Abstract

DING Z, Jiao B, Chen X, Chen X, et al
The function of Foxp1 represses beta-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity.
Open Med (Wars). 2023;18:20230647.
Abstract

FENG H, Deng Z, Huang Y, Liu Z, et al
A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
Front Immunol. 2023;14:1219209.
Abstract

BAMIAS A, Stenzl A, Zagouri F, Andrikopoulou A, et al
Defining Oligometastatic Bladder Cancer: A Systematic Review.
Eur Urol Open Sci. 2023;55:28-37.
Abstract

FENG Y, Hao Y, Wang Y, Song W, et al
Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B Fibronectin-Targeted Biosynthetic GVs.
Int J Nanomedicine. 2023;18:4871-4884.
Abstract

TATE T, Plumber SA, Al-Ahmadie H, Chen X, et al
Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis.
bioRxiv. 2023 Aug 21:2023.08.19.553961. doi: 10.1101/2023.08.19.553961.
Abstract

LI K, Raveendran A, Xie G, Zhang Y, et al
Prediction for recurrent non-muscle invasive bladder cancer.
Cancer Biomark. 2023 Aug 15. doi: 10.3233/CBM-220373.
Abstract

ZONG R, Ma X, Shi Y, Geng L, et al
The assessment of pathological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review and meta-analysis.
Br J Radiol. 2023 Sep 3:20230239. doi: 10.1259/bjr.20230239.
Abstract

GREBOWSKI R, Saluk J, Bijak M, Szemraj J, et al
The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology.
Sci Rep. 2023;13:14491.
Abstract

ANTHONY R, Rajandram R, Yap NY, Mun KS, et al
Demethylases of H3 lysine 27 (H3K27) expression in urothelial carcinoma (UC) of the urinary bladder.
Malays J Pathol. 2023;45:261-269.
Abstract

NAWAF C, Shiang A, Chauhan PS, Chaudhuri AA, et al
Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials.
Transl Oncol. 2023;37:101763.
Abstract

ARAD U, Werren C, White D
Paraneoplastic sacroiliitis.
BMJ Case Rep. 2023;16:e252572.
Abstract

ZANG J, Zhang R, Jin D, Xie F, et al
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
J Pathol. 2023;261:198-209.
Abstract

KUJDOWICZ M, Perez-Guaita D, Chlosta P, Okon K, et al
Fourier transform IR imaging of primary tumors predicts lymph node metastasis of bladder carcinoma.
Biochim Biophys Acta Mol Basis Dis. 2023;1869:166840.
Abstract

TAOKA R, Yamada K, Sawanobori Y, Honda T, et al
Oral 5-aminolevulinic acid administration before transurethral resection of bladder tumor induces perioperative nausea and vomiting.
Photodiagnosis Photodyn Ther. 2023;43:103707.
Abstract

LI H, Chen J, Li Z, Chen M, et al
S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8(+) T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma.
Adv Sci (Weinh). 2023;10:e2300110.
Abstract

FACCHINETTI F, Hollebecque A, Braye F, Vasseur D, et al
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
Cancer Discov. 2023;13:1998-2011.
Abstract

BABOUDJIAN M, Territo A, Gallioli A, Verri P, et al
Long-Term Oncologic Outcomes of Endoscopic Management of High-Risk Upper Tract Urothelial Carcinoma: The Fundacio Puigvert's Experience.
J Endourol. 2023;37:973-977.
Abstract

KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
Dual immunocytochemical staining of annexin A10 and p53 in low-grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology.
Cancer Cytopathol. 2023;131:548-560.
Abstract

POYRY E, Nykanen V, Pulkkinen J, Viljanen E, et al
Atypical urothelial cells classified according to the Paris System for Reporting Urinary Cytology: A 2-year experience with histological correlation from a Finnish tertiary care center-low rate and high risk of malignancy.
Cancer Cytopathol. 2023;131:574-580.
Abstract

LI P, Meng C, Peng L, Gan L, et al
Perioperative comparison between robot-assisted and laparoscopic radical cystectomy: An update meta-analysis.
Asian J Surg. 2023;46:3464-3479.
Abstract

MESNARD B, de Vergie S, Chelghaf I, Bouchot O, et al
Robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: Peri and postoperative outcomes.
Actas Urol Esp (Engl Ed). 2023;47:441-449.
Abstract

PEREZ JH, Faba OR, Gaya Sopena JM, Palou Redorta J, et al
An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association.
Actas Urol Esp (Engl Ed). 2023;47:395-397.
Abstract

TEKE K, Avci IE, Cinar NB, Baynal EA, et al
Immune-inflammatory-nutritional status predicts oncologic outcomes after radical cystectomy for urothelial carcinoma of bladder.
Actas Urol Esp (Engl Ed). 2023;47:430-440.
Abstract

MEHMANDAR-OSKUIE A, Tohidfar M, Hajikhani B, Karimi F, et al
Anticancer Effects of Cell-Free Culture Supernatant of Escherichia coli in Bladder Cancer Cell Line: New Insight into the Regulation of Inflammation.
Gene. 2023 Sep 12:147795. doi: 10.1016/j.gene.2023.147795.
Abstract

DE ARAUJO SOUZA LC, Ribeiro EC, Pinto TDA, de Ulhoa Barbosa TMJ, et al
Urothelial bladder cancer with cardiac metastasis: Literature review and case report.
Int J Surg Case Rep. 2023;111:108630.
Abstract

SLUSARCZYK A
ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2023 Sep 14. doi: 10.1245/s10434-023-14301.
Abstract

YAO X, Xu Z, Duan C, Zhang Y, et al
Role of human papillomavirus and associated viruses in bladder cancer: An updated review.
J Med Virol. 2023;95:e29088.
Abstract

ZHANG P, Xie X, Li C, Zhang C, et al
LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer.
Cancer Med. 2023 Sep 14. doi: 10.1002/cam4.6542.
Abstract

MARTINI A, Tholomier C, Mokkapati S, Dinney CPN, et al
Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.
Front Immunol. 2023;14:1260498.
Abstract

ZHENG R, Gao F, Mao Z, Xiao Y, et al
LncRNA BCCE4 Genetically Enhances the PD-L1/PD-1 Interaction in Smoking-Related Bladder Cancer by Modulating miR-328-3p-USP18 Signaling.
Adv Sci (Weinh). 2023 Sep 13:e2303473. doi: 10.1002/advs.202303473.
Abstract

YAO Z, Xu N, Shang G, Wang H, et al
Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.
Nat Commun. 2023;14:5670.
Abstract

LI L, Yang J, Peng D, Zhang Y, et al
177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple Metastatic Lesions.
Clin Nucl Med. 2023 Sep 13. doi: 10.1097/RLU.0000000000004865.
Abstract

DENG Y, Deng Y, Wang H, Xie H, et al
Solitary Axillary Lymph Node Metastasis From Bladder Cancer Detected by FDG PET/CT.
Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004827.
Abstract

MULLER G, Butea-Bocu MC, Beyer B, Tully KH, et al
Prospective evaluation of return to work, health-related quality of life and psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed German bladder cancer patients.
World J Urol. 2023 Sep 13. doi: 10.1007/s00345-023-04570.
Abstract

ZENG Y, Lv C, Wan B, Gong B, et al
The current landscape of m6A modification in urological cancers.
PeerJ. 2023;11:e16023.
Abstract

ABDEL-HAFIZ HA, Kailasam Mani SK, Huang W, Gouin KH 3rd, et al
Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance.
iScience. 2023;26:107703.
Abstract

ISLAM NU, Jehangir M, Parry AH, Nazir SS, et al
Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer.
Pol J Radiol. 2023;88:e356-e364.
Abstract

ZHANG ZG, Shi ZD, Dong JJ, Chen YA, et al
Novel potential urinary biomarkers for effective diagnosis and prognostic evaluation of high-grade bladder cancer.
Transl Cancer Res. 2023;12:1992-2007.
Abstract

ZHANG C, Kang Y, Miao P, Chang D, et al
A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies.
Transl Cancer Res. 2023;12:2063-2070.
Abstract

LI W, Xiong Y, Zhu J, Jin X, et al
Establishing a prognostic model with ferroptosis-related long non-coding RNAs in bladder cancer.
Transl Cancer Res. 2023;12:2023-2032.
Abstract

TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
Cancer Cell. 2023;41:1680-1688.
Abstract

SONG Y, Xu T
Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".
World J Urol. 2023 Sep 12. doi: 10.1007/s00345-023-04607.
Abstract

QIN Y, Zu X, Li Y, Han Y, et al
A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.
iScience. 2023;26:107722.
Abstract

HAN C, Wang J, Chen YL, Guan CP, et al
The role of Bacillus Calmette-Guerin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis.
Front Aging Neurosci. 2023;15:1243588.
Abstract

TREHAN D, Kumari R, Sharma J, Satuluri SH, et al
Inhibition of protein kinase C isozymes causes immune profile alteration and possibly decreased tumorigenesis in bladder cancer.
Am J Cancer Res. 2023;13:3832-3852.
Abstract

WANG X, Luo L, Xu J, Lu Q, et al
Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/beta-catenin pathways.
Genes Dis. 2023;11:1050-1065.
Abstract

WANG W, Zhang X, Jiang S, Xu P, et al
A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
Front Immunol. 2023;14:1187286.
Abstract

YANG F, Liu G, Wei J, Dong Y, et al
Relationship between Bladder Cancer, Nutritional Supply, and Treatment Strategies: A Comprehensive Review.
Nutrients. 2023;15:3812.
Abstract

PURNOMO AF, Daryanto B, Seputra KP, Budaya TN, et al
Methylenetetrahydrofolate Reductase C677T (rs1801133) Polymorphism Is Associated with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision Medicine Approach.
Cancers (Basel). 2023;15:4402.
Abstract

SUN D, Hadjiiski L, Gormley J, Chan HP, et al
Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors.
Cancers (Basel). 2023;15:4372.
Abstract

YAO Q, Jiang H, Niu H, Hu G, et al
Rotatable Bi-Channel En Bloc Resection of Bladder Tumor for Non-Muscle-Invasive Bladder Cancer in an Ex Vivo Porcine Model.
Cancers (Basel). 2023;15:4255.
Abstract

KARIMI M, Mendez-Pineda S, Blanche H, Boland A, et al
A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort.
Cancers (Basel). 2023;15:4218.
Abstract

REYNOLDS T, Gordon M, Monar GVF, Moon D, et al
Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection.
Int J Mol Sci. 2023;24:13651.
Abstract

XIE B, Lin J, Chen X, Zhou X, et al
CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer.
Mol Cancer. 2023;22:151.
Abstract

YU QX, Wang JC, Liu JF, Ye LX, et al
Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
Sci Rep. 2023;13:14803.
Abstract

WANG J, Xiao Y, Wu R, Zhang C, et al
TGM1 could predict overall survival for patients with bladder cancer.
Asian J Surg. 2023 Sep 6:S1015-9584(23)01104.
Abstract

HMAIDY O, Jamal BR, Mayo M, Haidar M, et al
Non-muscle invasive urothelial bladder cancer in a 17-year-old male: A rare case report.
Int J Surg Case Rep. 2023;110:108728.
Abstract

WALZ S, Pollehne P, Geng R, Schneider J, et al
A Protocol for Organoids from the Urine of Bladder Cancer Patients.
Cells. 2023;12:2188.
Abstract

LAPUENTE M, Conway D, Wood LS, Kehoe K, et al
Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
Clin J Oncol Nurs. 2023;27:71-80.
Abstract

MANSINHO A, Cruz A, Marconi L, Pinto C, et al
Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
Adv Ther. 2023;40:4134-4150.
Abstract

KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
Pathol Int. 2023;73:444-455.
Abstract

LI J, Zhang H, Wu J, Li L, et al
Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
Cancer Biomark. 2023;38:77-102.
Abstract

MAYER M, Nachtsheim L, Prinz J, Shabli S, et al
Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
Clin Exp Metastasis. 2023;40:395-405.
Abstract

LI J, Liu X
Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression.
Chem Biol Drug Des. 2023;102:805-814.
Abstract

BILEN MA, Robinson SB, Schroeder A, Peng J, et al
Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
Oncologist. 2023;28:790-798.
Abstract

MIAO S, He Q, Zhang Y, Wang L, et al
Management of urinary incontinence after radical cystectomy and orthotopic neobladder: A scoping review of international practices.
Nurs Open. 2023;10:6618-6634.
Abstract

ROCCO B, Sighinolfi MC, Sarchi L, Assumma S, et al
First case of robot-assisted radical cystectomy and intracorporeal neobladder reconstruction with the Hugo RAS system: step-by-step surgical setup and technique.
J Robot Surg. 2023;17:2247-2251.
Abstract

KURITZA V, Pei S
Zosteriform cutaneous metastases from urothelial carcinoma: Report of a rare case and literature review.
J Cutan Pathol. 2023 May 29. doi: 10.1111/cup.14471.
Abstract

KAIMAKLIOTIS HZ, Tachibana I, Woldu S, Labbate C, et al
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Urol Oncol. 2023;41:387.
Abstract

CHUA KJ, Patel HV, Srivastava A, Doppalapudi SK, et al
Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database.
Urol Oncol. 2023;41:390.
Abstract

SOBHANI S, Alsyouf M, Ahmadi H, Ghoreifi A, et al
Association between early postradical cystectomy kidney injury and perioperative outcome in enhanced recovery era.
Urol Oncol. 2023;41:389.
Abstract

DAVARO F, Davaro E, Rose K, Murthy P, et al
Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma.
Urol Oncol. 2023;41:389.
Abstract

SANGOI AR, Akgul M, Williamson SR
Artifactual Cystic Spaces in Prostatic Transurethral Resections and Related Specimens: A Potential Diagnostic Confounder.
Int J Surg Pathol. 2023;31:1048-1056.
Abstract

LAI S, Liu J, Lai C, Seery S, et al
Prognostic variations between "primary" and "progressive" muscle-invasive bladder cancer following radical cystectomy: A novel propensity score-based multicenter cohort study.
Int J Surg. 2023 Sep 22. doi: 10.1097/JS9.0000000000000790.
Abstract

LOPEZ-BELTRAN A, Raspollini MR, Hansel D, Comperat E, et al
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer.
Am J Surg Pathol. 2023 Sep 22. doi: 10.1097/PAS.0000000000002121.
Abstract

MALIK RF, Berry R, Lau BD, Busireddy KR, et al
Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed Tomography Performed before Pathologic Diagnosis.
Tomography. 2023;9:1734-1744.
Abstract

AHMADIEH N, Zeidan T, Chebel JA, Haddad FG, et al
Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in a Lebanese experience: in all aspects.
Gulf J Oncolog. 2023;1:33-39.
Abstract

NAVARRO-DOMENECH I, Arulanantham S, Liu ZA, Tjong M, et al
Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.
Radiat Oncol. 2023;18:154.
Abstract

COE C, Chirputkar K, Joseph L, Jude EB, et al
Pedal acrometastasis secondary to urothelial carcinoma masquerading as Charcot arthropathy in a patient with diabetes.
BMJ Case Rep. 2023;16:e254468.
Abstract

PISZCZEK R, Krajewski W, Subiela JD, Del Giudice F, et al
Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guerin immunotherapy.
Minerva Urol Nephrol. 2023;75:591-599.
Abstract

WANG S, Ge C
Chronic Obstructive Pulmonary Disease Mortality in Bladder Cancer Patients: A SEER-Based Competing Risk Analysis.
Urol J. 2023 Sep 17. doi: 10.22037/uj.v20i.7644.
Abstract

VAN DORP J, van der Heijden MS
The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.
Front Immunol. 2023;14:1235884.
Abstract

HEISHIMA K, Sugito N, Abe C, Hirata A, et al
Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model.
Mol Ther Nucleic Acids. 2023;33:960-982.
Abstract

HUANG H, Liu A, Liang Y, Xin Y, et al
A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
BMC Med. 2023;21:357.
Abstract

GAO D, Wang R, Gong Y, Yu X, et al
CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
Free Radic Biol Med. 2023 Sep 17:S0891-5849(23)00641.
Abstract

SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
ASO Visual Abstract: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer-A Population-Based Analysis.
Ann Surg Oncol. 2023 Sep 19. doi: 10.1245/s10434-023-14286.
Abstract

SONG H, Yang S, Yu B, Li N, et al
CT-based deep learning radiomics nomogram for the prediction of pathological grade in bladder cancer: a multicenter study.
Cancer Imaging. 2023;23:89.
Abstract

BREYER J, Eckstein M, Sikic D, Wezel F, et al
Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
Sci Rep. 2023;13:15437.
Abstract

MONDA S, Pratsinis M, Lui H, Noel O, et al
Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery.
Eur Urol Focus. 2023 Sep 16:S2405-4569(23)00199.
Abstract

CHEN Y, Zeng S, Jiao B, Zhang H, et al
Adherence to the Diabetes Risk Reduction Diet and bladder cancer risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) cohort.
Cancer Epidemiol Biomarkers Prev. 2023.
Abstract

KADHUM T, Selinski S, Blaszkewicz M, Reinders J, et al
Bladder cancer course, four genetic high-risk variants, and histopathological findings.
EXCLI J. 2023;22:867-879.
Abstract

MA SY, An Y, Sun JX, Xu MY, et al
The effect of different timing of blood transfusion on oncological outcomes of patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2023;13:1223592.
Abstract

FAHMY O, Kochergin M, Asimakopoulos AD, Gakis G, et al
Practice change: No benefit of extended lymphadenectomy at radical cystectomy in patients with muscle invasive bladder cancer.
Semin Oncol. 2023 Sep 14:S0093-7754(23)00064.
Abstract

DING Q, Tang W, Li X, Ding Y, et al
Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
J Control Release. 2023 Sep 15:S0168-3659(23)00611.
Abstract

BOLL LM, Perera-Bel J, Rodriguez-Vida A, Arpi O, et al
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Sci Rep. 2023;13:15287.
Abstract

YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
Urol Oncol. 2023 Sep 13:S1078-1439(23)00263.
Abstract

ZHANG Y, Rumgay H, Li M, Yu H, et al
The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.
J Glob Health. 2023;13:04109.
Abstract

LUO P, Zheng L, Zou J, Chen T, et al
Insights into vitamin A in bladder cancer, lack of attention to gut microbiota?
Front Immunol. 2023;14:1252616.
Abstract

STOCKEM CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, et al
Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
Front Oncol. 2023;13:1246603.
Abstract

QU Y, Yao Z, Xu N, Shi G, et al
Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma.
Cell Rep Med. 2023;4:101166.
Abstract

SOUKUP J, Manethova M, Stejskal V, Hornychova H, et al
Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
Endocr Pathol. 2023;34:333-341.
Abstract

ASERO V, Scornajenghi CM, Carino D, Pandolfo SD, et al
Comment on: "Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy".
Minerva Urol Nephrol. 2023;75:649-651.
Abstract

LUO HL, Lee YC, Chang YL, Hsu WC, et al
MicroRNA-145-5p suppresses cell proliferation, migration, and invasion in upper tract urothelial carcinoma by targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase.
J Cell Biochem. 2023;124:1324-1345.
Abstract

HUANG W, Warrick JI, Chen G
Clinical and pathological characteristics of metastatic tumors to the urinary bladder.
Ann Diagn Pathol. 2023;66:152179.
Abstract

QIU H, Wang J, Zhi Y, Yan B, et al
Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer.
ACS Appl Mater Interfaces. 2023 Sep 28. doi: 10.1021/acsami.3c09564.
Abstract

ZOU F, Chen W, Song T, Xing J, et al
SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3beta signaling pathway through P53.
Cancer Cell Int. 2023;23:221.
Abstract

ZHAN Y, Liu Y, Lin J, Fu X, et al
Author Correction: Synthetic Tet-inducible artificial microRNAs targeting beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and 5637.
Sci Rep. 2023;13:16331.
Abstract

ZHANG W, Cai K, Sun Z, Xiang Q, et al
Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer.
ACS Nano. 2023 Sep 28. doi: 10.1021/acsnano.3c04175.
Abstract

YANOVA MR, Zhiyanov AP, Antipenko ID, Slobodov SA, et al
Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.
Dokl Biochem Biophys. 2023 Sep 29. doi: 10.1134/S1607672923700503.
Abstract

PETEINARIS A, Perros P, Prokopakis I, Fasoulakis Z, et al
Bladder Cancer during Pregnancy: A Review of the Literature.
J Pers Med. 2023;13:1418.
Abstract

SCHULZ HAGERSTEN E, Ottosson K, Pelander S, Johansson M, et al
The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer before and after Cystectomy Depending on Blood Group and Neoadjuvant Chemotherapy-A Multicentre Retrospective Cohort Study.
J Pers Med. 2023;13:1355.
Abstract

YE L, Wang Y, Xiang W, Yao J, et al
Radiomic Analysis of Quantitative T2 Mapping and Conventional MRI in Predicting Histologic Grade of Bladder Cancer.
J Clin Med. 2023;12:5900.
Abstract

FLORES MONAR GV, Reynolds T, Gordon M, Moon D, et al
Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.
Int J Mol Sci. 2023;24:14374.
Abstract

ELAHI NAJAFI MA, Yasui M, Teramoto Y, Tatenuma T, et al
GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
Int J Mol Sci. 2023;24:13733.
Abstract

KHORAMINIA F, Fuster S, Kanwal N, Olislagers M, et al
Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.
Cancers (Basel). 2023;15:4518.
Abstract

ELKARTA A, Awadalla A, El-Hefnawy A, Mosbah A, et al
Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
Clin Genitourin Cancer. 2023 Aug 10:S1558-7673(23)00186.
Abstract

SACHKO AM, Goryainova OS, Ivanova TI, Nikolaeva IY, et al
Analysis of Transferrin in the Urine of Patients with Bladder Cancer Using Nanobodies.
Biochemistry (Mosc). 2023;88:1105-1115.
Abstract

TAN M, Pan Q, Gong H, Zhai X, et al
Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway.
Pharmacol Res. 2023 Sep 25:106940. doi: 10.1016/j.phrs.2023.106940.
Abstract

SLUSARCZYK A, Zapala P
Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2023 Sep 27. doi: 10.1245/s10434-023-14360.
Abstract

SABATE ORTEGA J, Fort Culillas R, Escoda Garcia M, Vasquez-Dongo CA, et al
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
Curr Oncol. 2023;30:7802-7809.
Abstract

KOGA F
Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
Expert Rev Anticancer Ther. 2023 Sep 27:1-13. doi: 10.1080/14737140.2023.2257389
Abstract

ZHENG K, Li M
Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO.
Mol Biotechnol. 2023 Sep 25. doi: 10.1007/s12033-023-00892.
Abstract

LIND AK, Liedberg F, Aljabery F, Blackberg M, et al
Health-related quality of life prior to and 1 year after radical cystectomy evaluated with FACT-G and FACT-VCI questionnaires.
Scand J Urol. 2023;58:76-83.
Abstract

MAGALHAES JC, Sousa M, Basto R, Fraga T, et al
Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
Cureus. 2023;15:e45672.
Abstract

LIANG T, Tao T, Wu K, Liu L, et al
Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.
Adv Sci (Weinh). 2023 Sep 24:e2303230. doi: 10.1002/advs.202303230.
Abstract

WANG L, Song R, Ma M, Chen Y, et al
Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway.
Chem Biol Interact. 2023 Sep 21:110725. doi: 10.1016/j.cbi.2023.110725.
Abstract

LIU J, Wu P, Lai S, Wang J, et al
Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics.
J Cancer Res Clin Oncol. 2023 Sep 23. doi: 10.1007/s00432-023-05266.
Abstract

LIU T, Fan MQ, Xie XX, Shu QP, et al
Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.
J Transl Med. 2023;21:656.
Abstract

WANG X, Liu J, Azoitei A, Eiseler T, et al
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
Cell Mol Life Sci. 2023;80:299.
Abstract

ZOU F, Rao T, Chen W, Song T, et al
DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7.
Cell Signal. 2023;112:110893.
Abstract

KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.
Diagn Pathol. 2023;18:106.
Abstract

JIANG R, Wang X, Li Z, Cai H, et al
Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
BMC Urol. 2023;23:150.
Abstract

LI W, Li C, Liu T, Wang Y, et al
Self-reported sleep disorders and the risk of all cancer types: evidence from the Kailuan Cohort study.
Public Health. 2023;223:209-216.
Abstract

SPAAS M, Sundahl N, Kruse V, Rottey S, et al
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
JAMA Oncol. 2023;9:1205-1213.
Abstract

GODARD L, Lee L, McGuinness B, Shirsat H, et al
Mycotic Abdominal Aortic Aneurysm Secondary to BCG Therapy for Non-muscle Invasive Urothelial Carcinoma of the Bladder.
Vasc Endovascular Surg. 2023;57:776-780.
Abstract

SEKIGUCHI Y, Nishimura Y, Kanda H, Kawamura M, et al
A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer.
Gan To Kagaku Ryoho. 2023;50:985-992.
Abstract

METHODS IN MEDICINE CAM
Retracted: MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in Bladder Cancer.
Comput Math Methods Med. 2023;2023:9763968.
Abstract

METHODS IN MEDICINE CAM
Retracted: The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
Comput Math Methods Med. 2023;2023:9761783.
Abstract

KIM Y, Ju H, Yoo SY, Jeong J, et al
Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
Cell Rep Med. 2023 Sep 27:101224. doi: 10.1016/j.xcrm.2023.101224.
Abstract

HUSSEIN AA, Bhat TA, Jing Z, Gomez EC, et al
Does the urinary microbiome profile change after treatment of bladder cancer?
World J Urol. 2023 Oct 5. doi: 10.1007/s00345-023-04627.
Abstract

HATTORI Y, Kato M, Imamura T, Inaba S, et al
[Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against Locally Recurrent Bladder Cancer : A Case Report].
Hinyokika Kiyo. 2023;69:255-258.
Abstract

KIM CJ, Ide H, Nakamura M, Hanada E, et al
[Occurrence of Distant Metastasis During Bladder Presevation in T1 high-grade Bladder Cancer: Report of Three Cases].
Hinyokika Kiyo. 2023;69:249-254.
Abstract

LI R
Organ-sparing precision treatment for muscle-invasive bladder cancer.
Nat Med. 2023 Oct 4. doi: 10.1038/s41591-023-02575.
Abstract

MOREO E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, et al
Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
Nat Commun. 2023;14:6090.
Abstract

VIEIRA HM, Kasper DP, Wang R, Smith LM, et al
Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.
Radiat Oncol J. 2023;41:154-162.
Abstract

XIONG S, Li S, Zeng J, Nie J, et al
Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Front Immunol. 2023;14:1253586.
Abstract

PAN G, Jiang B, Yi Z, Yin J, et al
Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer.
BMC Urol. 2023;23:155.
Abstract

INOUE Y, Yamada T, Fujihara A, Miyashita M, et al
Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.
Sci Rep. 2023;13:16580.
Abstract

OKADA M, Shindo T, Fujino K, Maeda T, et al
Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
Support Care Cancer. 2023;31:607.
Abstract

NORGAARD M, Mailhac A, Fagerlund K, Strunz-McKendry T, et al
Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
Acta Oncol. 2023 Oct 3:1-7. doi: 10.1080/0284186X.2023.2263154.
Abstract

WANG M, Zhang C, Ying Y, Hua M, et al
PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23643.
Abstract

ZAIDI N, Siddiqui Z, Sankhwar SN, Srivastava AN, et al
Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
J Cancer Res Ther. 2023;19:1324-1329.
Abstract

WU T, Li N, Wu X, Du Y, et al
LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer.
Open Med (Wars). 2023;18:20230788.
Abstract

ZHENG J, Lu S, Huang Y, Chen X, et al
Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
J Transl Med. 2023;21:685.
Abstract

GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02568.
Abstract

WANG G, He X, Dai H, Lin L, et al
WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2.
Oncogenesis. 2023;12:47.
Abstract

ZUO M, Chen H, Liao Y, He P, et al
Sulforaphane and bladder cancer: a potential novel antitumor compound.
Front Pharmacol. 2023;14:1254236.
Abstract

WANG X, Pan J, Guan Q, Ren N, et al
Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer.
Front Pharmacol. 2023;14:1215296.
Abstract

FRERICHS LM, Frerichs B, Petzsch P, Kohrer K, et al
Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.
Front Oncol. 2023;13:1228185.
Abstract

WU Z, Feng Z, Wei H, Lin C, et al
Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.
Front Med (Lausanne). 2023;10:1193133.
Abstract

ROSLAN A, Said DS, Sulaiman N, Mohd Ghani KA, et al
Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells.
J Pharm Biomed Anal. 2023;236:115729.
Abstract

XU JH, Shao GZ, Yang YF, Fan ZQ, et al
Comment on: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2023 Sep 30. doi: 10.1245/s10434-023-14355.
Abstract

YAN H, Zhang L, Li R
Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
Sci Rep. 2023;13:16457.
Abstract

SONG Y, Peng Y, Qin C, Wang Y, et al
Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
J Immunother Cancer. 2023;11:e006643.
Abstract

BUDAYA TN, Permatasari HK, Widodo N, Prawiro SR, et al
The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of Bladder Cancer.
Asian Pac J Cancer Prev. 2023;24:3155-3164.
Abstract

ASGARI M, Firouzi F, Abolhasani M, Bahadoram M, et al
The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder.
Asian Pac J Cancer Prev. 2023;24:3125-3131.
Abstract

CHALHOUB IG, Boulos RT, Dagher YG, El Helou S, et al
Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study.
Medicine (Baltimore). 2023;102:e34562.
Abstract

TORON M, Woloszyn A
[Organ-sparing treatment of node-positive bladder cancer].
Strahlenther Onkol. 2023 Sep 29. doi: 10.1007/s00066-023-02156.
Abstract

YANG J, Tan Y, Yao C
Study on anxiety, depression, and subjective wellbeing of patients with bladder cancer in their different chemotherapy stages.
Front Psychol. 2023;14:1226712.
Abstract

LIU Y, Pang ZQ, Wang JS, Wang JF, et al
Heat shock protein family A member 8 is a prognostic marker for bladder cancer: Evidences based on experiments and machine learning.
J Cell Mol Med. 2023 Sep 28. doi: 10.1111/jcmm.17977.
Abstract

ZHANG X, Hu X, Xie Y, Xie L, et al
Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.
Molecules. 2023;28:6720.
Abstract

YOO D, Min KW, Pyo JS, Kim NY, et al
Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
Medicina (Kaunas). 2023;59:1609.
Abstract

LU XJ, Lai HF, Wu SC, Chen CL, et al
Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma.
Int J Mol Sci. 2023;24:14081.
Abstract

NAKAMURA M, Tsuru I, Izumi T, Ono A, et al
Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy.
Sci Rep. 2023;13:16237.
Abstract

GAMBA T, Paparo J, Panepinto O, Dionisio R, et al
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
Clin Genitourin Cancer. 2023;21:509-516.
Abstract

NISHIYAMA H, Tsuzuki T, Ohyama C, Matsuyama H, et al
Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
Int J Clin Oncol. 2023;28:1398-1410.
Abstract

BETTOLI P, Liu Z, Jara N, Bakal F, et al
Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network.
Arch Ital Urol Androl. 2023;95:11533.
Abstract

RAO N, Starrett GJ, Piaskowski ML, Butler KE, et al
Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
Cancer Prev Res (Phila). 2023;16:561-570.
Abstract

MANCIULLI T, Marangoni D, Salas-Coronas J, Bocanegra C, et al
Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.
Infection. 2023;51:1185-1221.
Abstract

COTE G, Alqaisi H, Chan CT, Jiang DM, et al
Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma.
Kidney360. 2023;4:e1203-e1211.
Abstract

KONDO Y, Nagamine Y, Yoshikawa N, Echigo N, et al
Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study.
J Anesth. 2023;37:703-713.
Abstract

FERRO M, Crocetto F, Tataru S, Barone B, et al
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Clin Genitourin Cancer. 2023;21:574-583.
Abstract

BAKALOUDI DR, Talukder R, Lin GI, Makrakis D, et al
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Clin Genitourin Cancer. 2023;21:584-593.
Abstract

LEVY JJ, Chan N, Marotti JD, Kerr DA, et al
Large-scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis-X.
Cancer Cytopathol. 2023;131:637-654.
Abstract

ZHONG W, Xia K, Liu L, Cheng S, et al
Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
Int J Surg. 2023;109:2742-2750.
Abstract

JINDAL T, Zhang L, Deshmukh P, Reyes K, et al
Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
Clin Genitourin Cancer. 2023;21:e394-e404.
Abstract

GREENLAND NY, Khorsandi N, Peng Y, Balassanian R, et al
Utility and performance of cell blocks in urine cytology: Experience at three teaching hospitals.
Cancer Cytopathol. 2023;131:614-625.
Abstract

PEAK T, Spiess PE, Li R, Grivas P, et al
Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.
Oncologist. 2023;28:e910-e920.
Abstract

PIERANTONI F, Dionese M, Basso U, Lai E, et al
The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma.
Clin Genitourin Cancer. 2023;21:e378-e385.
Abstract

DANESHPAJOUHNEJAD P, Morrison C, Zhao X, Daniel RE, et al
Primary Alveolar Soft-Part Sarcoma (ASPS) of the Prostate: Report of a Deceptive Case.
Int J Surg Pathol. 2023;31:1359-1363.
Abstract

STOCKLE M
[Cystectomy versus trimodal therapy for bladder cancer].
Urologie. 2023 Oct 12. doi: 10.1007/s00120-023-02195.
Abstract

LIU K, Zhao H, Chen X, Nicoletti R, et al
A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guerin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Oct 10:S2588-9311(23)00206.
Abstract

HONG Y, Li Z, Su Y, Pu H, et al
The ceRNA Mechanism of lncRNA MEG3/miR-21-5p/SPRY2 in Cell Proliferation and Apoptosis in Bladder Cancer.
Crit Rev Eukaryot Gene Expr. 2024;34:55-68.
Abstract

HONG X, Chen X, Wang H, Xu Q, et al
A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
Adv Sci (Weinh). 2023 Oct 12:e2302377. doi: 10.1002/advs.202302377.
Abstract

VAN STRATEN CGJI, Caris C, Grimm MO, Colombel M, et al
Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guerin Instillations: The EAU-RF NIMBUS Trial.
Eur Urol Open Sci. 2023;56:15-24.
Abstract

ZHOU YX, Hu QC, Zhu YJ, Mu XL, et al
Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
Eur J Med Res. 2023;28:422.
Abstract

KONG L, Wen Z, Cai Q, Lin Y, et al
Amide Proton Transfer-Weighted MRI and Diffusion-Weighted Imaging in Bladder Cancer: A Complementary Tool to the VI-RADS.
Acad Radiol. 2023 Oct 9:S1076-6332(23)00472-5. doi: 10.1016/j.acra.2023.
Abstract

LI R, Jiang B, Zhu Y, Gao L, et al
Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
Endocr Metab Immune Disord Drug Targets. 2023.
Abstract

JENA R, Bhargava P, Tripathi S, Taywade S, et al
18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.
BJUI Compass. 2023;4:662-667.
Abstract

AN H, Liu K, Shirai K, Kawasaki R, et al
Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study.
Cancer Res Treat. 2023 Oct 6. doi: 10.4143/crt.2023.
Abstract

ZHENG Y, Shi D, Chen L, Yang Y, et al
UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells.
Aging (Albany NY). 2023;15.
Abstract

ZHANG X, Wu H, Wang S
[SLC12A8 promotes proliferation, invasiveness, migration and epithelial-mesenchymal transition of bladder cancer cells by activating JAK/STAT singaling].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1613-1621.
Abstract

ZHOU Q, Huang W, Xiong J, Guo B, et al
CDCA8 promotes bladder cancer survival by stabilizing HIF1alpha expression under hypoxia.
Cell Death Dis. 2023;14:658.
Abstract

ECKSTEIN M, Matek C, Wagner P, Erber R, et al
Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
Eur Urol Oncol. 2023 Oct 7:S2588-9311(23)00215-8. doi: 10.1016/j.euo.2023.
Abstract

TAARNHOJ GA, Johansen C, Carus A, Dahlrot RH, et al
The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
J Patient Rep Outcomes. 2023;7:99.
Abstract

FRESHOUR SL, Chen TH, Fisk B, Shen H, et al
Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
iScience. 2023;26:107937.
Abstract

ZHANG Y, Xu Z, Wu S, Zhu T, et al
Construction of 3D and 2D contrast-enhanced CT radiomics for prediction of CGB3 expression level and clinical prognosis in bladder cancer.
Heliyon. 2023;9:e20335.
Abstract

HUANG L, Xie Q, Deng J, Wei WF, et al
The role of cancer-associated fibroblasts in bladder cancer progression.
Heliyon. 2023;9:e19802.
Abstract

LIU HR, Peng X, Li SL, Gou X, et al
[Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment].
Beijing Da Xue Xue Bao Yi Xue Ban. 2023;55:793-801.
Abstract

WEICKHARDT A, Foroudi F, Lawrentschuk N, Xie J, et al
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00201-8. doi: 10.1016/j.euo.2023.
Abstract

CONTIERI R, Hensley PJ, Kamat AM
Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscl
Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00210-9. doi: 10.1016/j.euo.2023.
Abstract

YANG Y, Miao L, Lu Y, Sun Y, et al
Exosome, the glass slipper for Cinderella of cancer-bladder cancer?
J Nanobiotechnology. 2023;21:368.
Abstract

HUANG WB, Cheng L
[Research progress in molecular pathology of bladder cancer].
Zhonghua Bing Li Xue Za Zhi. 2023;52:1074-1078.
Abstract

MOSSANEN M, Smith AB, Onochie N, Matulewicz R, et al
Bladder cancer patient and provider perspectives on smoking cessation.
Urol Oncol. 2023 Oct 5:S1078-1439(23)00292-2. doi: 10.1016/j.urolonc.2023.
Abstract

VALDEZ-FLORES C, Erraguntla N, Budinsky R, Cagen S, et al
Corrigendum to "An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem. Biol. Interact. 366 (2022) 1-10].
Chem Biol Interact. 2023;385:110736.
Abstract

FAN ZC, Zhang L, Yang GQ, Li S, et al
MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study.
Abdom Radiol (NY). 2023 Oct 7. doi: 10.1007/s00261-023-04028.
Abstract

AZZAROUALI S, Goudschaal K, Visser J, Hulshof M, et al
Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers.
Radiat Oncol. 2023;18:165.
Abstract

YU A, Hu J, Fu L, Huang G, et al
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition.
J Immunother Cancer. 2023;11:e007230.
Abstract

CHEN J, Li H, Wu Y, Li Y, et al
Shared genetic links between bladder cancer and obesity-related traits: A conjunctional false discovery rate study.
Medicine (Baltimore). 2023;102:e35145.
Abstract

VAN ZUTPHEN M, Beeren I, Aben KKH, van der Heijden AG, et al
Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.
Cancer Med. 2023 Oct 6. doi: 10.1002/cam4.6620.
Abstract

BELSEY J
A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix(R) in patients diagnosed with non-muscle-invasive bladder cancer in France.
J Med Econ. 2023 Oct 6:1-10. doi: 10.1080/13696998.2023.2267929.
Abstract

LI WM, Chan TC, Wei YC, Li CF, et al
Downregulation of CRTAC1 in Urothelial Carcinoma Promotes Tumor Aggressiveness and Confers Poor Prognosis.
Front Biosci (Landmark Ed). 2023;28:217.
Abstract

TONG G, Wang X, Chen S, Jin Y, et al
Astragalus polysaccharide inhibits the development of urothelial carcinoma by activating AMPK signaling to induce BENC1-xCT complex formation.
Aging (Albany NY). 2023;15:9438-9452.
Abstract

ROCH C, Para S, Brandhofer C, Seitz AK, et al
Successful use of Rectal Pregabalin for the Treatment of Chemotherapy-Induced Neuropathic Pain-a Case Report.
J Palliat Care. 2023;38:412-415.
Abstract

DAYCO JS, DeSouza N, Cardozo S
A cluster of grapes: Right atrial masses of uncertain origin.
J Vasc Access. 2023;24:821-823.
Abstract

ZENG T, Ye J, Wang H, Tian W, et al
Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer.
Medicine (Baltimore). 2023;102:e35195.
Abstract

HEALTHCARE ENGINEERING JO
Retracted: Multi-Slice Spiral Computed Tomography Image Features under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
J Healthc Eng. 2023;2023:9791241.
Abstract

LI H, Long G, Tian J
Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
Front Oncol. 2023;13:1255632.
Abstract

OZDEMIR H, Azamat S, Sam Ozdemir M
Can Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder Cancer Has Invaded Muscles?
Cureus. 2023;15:e45488.
Abstract

YUAN F, Sun Y, Dai GC, Yao Q, et al
Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2 Family Members in Bladder Cancer from Database and FFPE Sample.
J Cancer. 2023;14:3050-3065.
Abstract

KHETRAPAL P, Bains PS, Jubber I, Ambler G, et al
Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer: Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled Trial.
Eur Urol Oncol. 2023 Oct 16:S2588-9311(23)00213.
Abstract

DURANT AM, Choudry MM, Madura G, Mi L, et al
Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
Urol Oncol. 2023 Oct 16:S1078-1439(23)00323.
Abstract

SHEN C, Han C, Li Z, Yan Y, et al
Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer.
Comb Chem High Throughput Screen. 2023.
Abstract

WANG W, Yang F, Zhang L, Wang M, et al
Targeting Dna Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate Sting Pathway for Maximizing Chemo-immunotherapy in Bladder Cancer.
Adv Mater. 2023 Oct 17:e2308762. doi: 10.1002/adma.202308762.
Abstract

ZHOU J, Dong C, Tan J, Wang G, et al
Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-kappaB pathways.
Apoptosis. 2023 Oct 17. doi: 10.1007/s10495-023-01898.
Abstract

KANG KA, Kim MJ, Kwon GY, Kim CK, et al
Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer.
Abdom Radiol (NY). 2023 Oct 17. doi: 10.1007/s00261-023-04069.
Abstract

BRYAN RT, Pirrie SJ, Abbotts B, Maycock S, et al
Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.
JAMA Netw Open. 2023;6:e2337494.
Abstract

ZOU Z, Li Z, Sun W, Gao W, et al
Establishment of prognostic model of bladder cancer based on apoptosis-related genes, in which P4HB promotes BLCA progression.
BMC Urol. 2023;23:167.
Abstract

ZHU CZ, Ting HN, Ng KH, Mun KS, et al
Dielectric properties of urine in relation to bladder cancer.
Phys Eng Sci Med. 2023 Oct 16. doi: 10.1007/s13246-023-01341.
Abstract

ABOU CHAKRA M, Packiam VT, O'Donnell MA
Real-word efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.
Expert Opin Pharmacother. 2023 Oct 16:1-11. doi: 10.1080/14656566.2023.2271396.
Abstract

LIATSOS GD, Manousopoulou G, Poulaki A, Iliaki A, et al
Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure.
Access Microbiol. 2023;5:000670.
Abstract

NGUYEN TT, Thanh HD, Do MH, Jung C, et al
Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells.
Chonnam Med J. 2023;59:160-166.
Abstract

PRINCE MR, Shaish H
Editorial for "Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System".
J Magn Reson Imaging. 2023 Oct 15. doi: 10.1002/jmri.29054.
Abstract

CARAPITO A, Roque ACA, Carvalho F, Pinto J, et al
Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review of metabolomics and sensor-based approaches.
Talanta. 2023;268.
Abstract

AVUDAIAPPAN AP, Prabhakar P, Ganapathi H, VanderVeer-Harris N, et al
Propensity score matched survival analysis of octogenarians with muscle-invasive bladder cancer: chemoradiation compared to radical cystectomy.
Can J Urol. 2023;30:11686-11691.
Abstract

MONTORSI F, Rosiello G, Gandaglia G
Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00208.
Abstract

DI GIANFRANCESCO L, Crestani A, Amodeo A, Corsi P, et al
The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.
Diagnostics (Basel). 2023;13:3119.
Abstract

LEE J, Yoo S, Choo MS, Cho MC, et al
Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette-Guerin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer.
Diagnostics (Basel). 2023;13:3114.
Abstract

MORI K, Matsumoto K, Ikeda M, Koguchi D, et al
Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.
Diagnostics (Basel). 2023;13:3067.
Abstract

JUENGEL E, Rutz J, Meiborg M, Markowitsch SD, et al
Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation.
Cancers (Basel). 2023;15:4849.
Abstract

LIOSIS KC, Marouf AA, Rokne JG, Ghosh S, et al
Genomic Biomarker Discovery in Disease Progression and Therapy Response in Bladder Cancer Utilizing Machine Learning.
Cancers (Basel). 2023;15:4801.
Abstract

COURBOIN E, Mathieu R, Panetta V, Mjaess G, et al
Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis.
Cancers (Basel). 2023;15:4732.
Abstract

DAVALIEVA K, Kiprijanovska S, Ivanovski O, Trifunovski A, et al
Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Int J Mol Sci. 2023;24:14938.
Abstract

KATSUMATA H, Matsumoto K, Yanagita K, Shimizu Y, et al
Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy.
Int J Mol Sci. 2023;24:14536.
Abstract

LUO J, Guo L, Chen L, Zhou J, et al
Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
Asian J Surg. 2023 Oct 11:S1015-9584(23)01573.
Abstract

LI H, Lv Z, Liu M
A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
Medicine (Baltimore). 2023;102:e35196.
Abstract

GOZUKUCUK R, Cakiroglu B
[Miliary Pulmonary Tuberculosis After Intravesical BCG Instillation in a Patient with High-Grade Bladder Cancer].
Mikrobiyol Bul. 2023;57:675-681.
Abstract

HAM WS, Park JS, Jang WS, Kim J, et al
Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
Ann Surg Oncol. 2023 Oct 26. doi: 10.1245/s10434-023-14449.
Abstract

Bladder cancer.
Nat Rev Dis Primers. 2023;9:59.
Abstract

DYRSKJOT L, Hansel DE, Efstathiou JA, Knowles MA, et al
Bladder cancer.
Nat Rev Dis Primers. 2023;9:58.
Abstract

TAN X, Liu Z, Cai T, Wang Y, et al
Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2023 Oct 24:S2588-9311(23)00219.
Abstract

SRETENOVIC M, Bojanic N, Grozdic Milojevic I, Bumbasirevic U, et al
Diagnostic and prognostic impact of preoperative thrombocytosis in muscle invasive bladder cancer: Any role in clinical practice?
J Clin Ultrasound. 2023 Oct 26. doi: 10.1002/jcu.23600.
Abstract

LUO Z, Yan Y, Jiao B, Huang T, et al
Prognostic value of the systemic immune-inflammation index in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
World J Surg Oncol. 2023;21:337.
Abstract

SHEN C, Bi Y, Chai W, Zhang Z, et al
Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
BMC Med Genomics. 2023;16:264.
Abstract

FAROUK SM, Khafaga AF, Abdellatif AM
Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics.
Cancer Cell Int. 2023;23:251.
Abstract

LI R, Naidu S, Fan W, Rose K, et al
Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
Urol Oncol. 2023 Oct 23:S1078-1439(23)00332.
Abstract

UCHIDA Y, Yokoyama M, Fujiwara M, Nakamura Y, et al
Preservation of Erectile and Ejaculatory Functions After Tetramodal Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against Muscle Invasive Bladder Cancer.
Urol Res Pract. 2023;49:162-168.
Abstract

ALKANLI N, Ay A
Investigation of the Roles of MTHFR (C677T and A1298C) and MMP-2 (-1306C>T ) Variations in Bladder Cancer Development.
Urol Res Pract. 2023;49:33-39.
Abstract

EFILOGLU O, Cakici MC, Kir G, Iplikci A, et al
The Impact of Histological Variants on Oncological Outcomes in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy.
Urol Res Pract. 2023;49:246-252.
Abstract

BERKOVA A, Chovanec Z, Krejcova I, Katolicka J, et al
A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis.
Klin Onkol. 2023;36:401-404.
Abstract

KHAN SM, Das T, Chakraborty S, Choudhury AMAR, et al
A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.
Heliyon. 2023;9:e21058.
Abstract

HAO L, Mu D, Mu H
Sakuranin represses the malignant biological behaviors of human bladder cancer cells by triggering autophagy via activating the p53/mTOR pathway.
BMC Urol. 2023;23:170.
Abstract

WEI Y, Yang X, Zhu H, Zhuang J, et al
Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter real-world study.
J Int Med Res. 2023;51:3000605231204465.
Abstract

CATTO JWF, Tran B, Roupret M, Gschwend JE, et al
Erdafitinib in BCG-treated high-risk non-muscle invasive bladder cancer.
Ann Oncol. 2023 Oct 5:S0923-7534(23)04015-2. doi: 10.1016/j.annonc.2023.09.3116.
Abstract

LI B, Li X, Li Z, Yang P, et al
Magnetic resonance radiographic features which might lead to misdiagnosis of muscle-invasive bladder cancer based on vesical imaging reporting and data system: the application experience of a single center.
Quant Imaging Med Surg. 2023;13:7258-7268.
Abstract

WARLI SM, Prapiska FF, Siregar DIS, Seja IA, et al
Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.
World J Oncol. 2023;14:423-429.
Abstract

KIM HJ, Kim KH, Lee SW, Swan H, et al
Familial Risk and Interaction With Smoking and Alcohol Consumption in Bladder Cancer: A Population-Based Cohort Study.
World J Oncol. 2023;14:382-391.
Abstract

ZHANG X, Huang W, Huang T, Zhang J, et al
Integrative analysis of triphenyl phosphate: contextual interpretation of bladder cancer cohort.
Front Oncol. 2023;13:1260114.
Abstract

ZHANG Z, Wang Y, Liang Z, Meng Z, et al
Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.
iScience. 2023;26:108142.
Abstract

WENG M, Deng Z, Huang S, Lin X, et al
Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through the Akt pathway in vitro and in vivo.
J Biochem Mol Toxicol. 2023 Oct 23:e23556. doi: 10.1002/jbt.23556.
Abstract

ZHANG X, Liu Q
Systemic Immune Inflammation Index and T-Staging Predict Prognosis in Patients with Muscle-Invasive Bladder Cancer.
Arch Esp Urol. 2023;76:511-518.
Abstract

XIA Y, Xiang L, Yao M, Ai Z, et al
Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis.
Mol Cell Proteomics. 2023 Oct 20:100672. doi: 10.1016/j.mcpro.2023.100672.
Abstract

WANG X, Juncker-Jensen A, Huang G, Nagy ML, et al
Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy.
Cancer Commun (Lond). 2023 Oct 20. doi: 10.1002/cac2.12491.
Abstract

WU J, Guo Q, Li J, Yuan H, et al
Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer.
Biochem Pharmacol. 2023;218:115870.
Abstract

WANG Z, Wei B, Ma S
EGR1/LINC00839/SOX5 axis modulates migration, invasion and Gemcitabine resistance of bladder cancer cells.
Cancer Biol Ther. 2023;24:2270106.
Abstract

KURBANOV AA, Kryukov SR, Chernov DV, Votyakov AY, et al
[Robot-assisted left-side partial nephrectomy with a segmental resection of left lower ureter and Boari reconstruction].
Urologiia. 2023;:125-128.
Abstract

KOLPACINIDI FG, Sergeev VP, Kyzlasov PS, Volokitin EV, et al
[Experience of using Experience of using NefroBest-N for rehabilitation of patients undergoing radical laparoscopic cystectomy].
Urologiia. 2023;:62-68.
Abstract

DAMIEV AD, Shpot EV, Akopyan GN, Dymov AM, et al
[Carboxycryobiopsy and carboxycryoextraction of bladder tumor. Experimental study].
Urologiia. 2023;:24-29.
Abstract

HERRMANN TRW
En bloc resection of bladder tumors (ERBT) revisited 12 years after reintroduction: too good to be further ignored.
World J Urol. 2023;41:2577-2582.
Abstract

MAISCH P, Hwang EC, Kim K, Narayan VM, et al
Immunotherapy for advanced or metastatic urothelial carcinoma.
Cochrane Database Syst Rev. 2023;10:CD013774.
Abstract

GOTFREDSEN K, Jandorf S, Zangenberg M, Faber C, et al
[Not Available].
Ugeskr Laeger. 2023;185:V04230244.
Abstract

WAN S, Li KP, Wang CY, Chen SY, et al
Exploring potential targets of HPV&BC based on network pharmacology and urine proteomics.
J Pharm Biomed Anal. 2023;236:115694.
Abstract

FIALA O, Buti S, Takeshita H, Okada Y, et al
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
Cancer Immunol Immunother. 2023;72:3665-3682.
Abstract

GALLIOLI A, Basile G, Territo A, Verri P, et al
The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma.
World J Urol. 2023;41:2743-2749.
Abstract

WHITE RE, Linscott JA, Hayn MT, Ryan ST, et al
Distance to Treatment With Radical Cystectomy in a Rural State: Long Car Rides, Equivalent Outcomes.
Urol Pract. 2023;10:588-594.
Abstract

SU PJ, Xiao Y, Lin AY, Goh C, et al
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Cancer Rep (Hoboken). 2023;6:e1887.
Abstract

QIU J, Deng R, Yu C, Gong K, et al
The long-term outcome of nephron-sparing surgery versus radical nephroureterectomy for organ-localized upper urinary tract urothelial carcinoma: a population-based study of 1969 patients.
J Cancer Res Clin Oncol. 2023;149:14869-14878.
Abstract

TEOH JY, D'Andrea D, Gallioli A, Yanagisawa T, et al
En bloc resection of bladder tumour: the rebirth of past through reminiscence.
World J Urol. 2023;41:2599-2606.
Abstract

CHEN YT, Yeh HC, Lee HY, Hsieh PF, et al
Endoscopic management of upper tract urothelial cancer in a highly endemic area: A Taiwan nationwide collaborative study.
Asian J Surg. 2023;46:3058-3065.
Abstract

BANDARA NA, Zhou XR, Alhamam A, Black PC, et al
The genitourinary impacts of electronic cigarette use: a systematic review of the literature.
World J Urol. 2023;41:2637-2646.
Abstract

SONG Y, Peng Y, Xu T
Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".
World J Urol. 2023;41:2869-2870.
Abstract

YANG K, Yu W, Liu H, Lou F, et al
Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.
Cancer Med. 2023;12:15304-15316.
Abstract

LIU J, Lai S, Wu P, Wang J, et al
Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.
J Cancer Res Clin Oncol. 2023;149:10893-10909.
Abstract

DOUGLAWI A, Ghoreifi A, Carbonara U, Yip W, et al
Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group.
Clin Genitourin Cancer. 2023;21:563-568.
Abstract

ENIKEEV D, Morozov A, Shpikina A, Fajkovic H, et al
A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we approaching the peak or is it back to the trough?
World J Urol. 2023;41:2607-2615.
Abstract

KOBAYASHI Y, Arai H, Hamamoto Y, Yoshida K, et al
High Infiltration of CD163-Positive Macrophages in Intratumor Compartment Predicts Poor Prognosis in Patients With Upper Urinary Tract Urothelial Carcinoma and Radical Nephroureterectomy.
Clin Genitourin Cancer. 2023;21:e386-e393.
Abstract

MORALES-BARRERA R, Villacampa G, Vidal N, Figols M, et al
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Clin Transl Oncol. 2023;25:3556-3564.
Abstract

WANG X, Wang Y, Che X, Zhou Z, et al
The prognosis and safety of continuous saline bladder irrigation in patients after transurethral resection of bladder tumors: a systematic review and meta-analysis of comparative study.
Updates Surg. 2023;75:1795-1806.
Abstract

NAGASAKI N, Watanabe T, Edamura K, Araki M, et al
Bladder Tumors with Multiple Cardiac Metastases, with Elevated Serum Granulocyte Colony-Stimulating Factor.
Am J Med. 2023;136:e161-e162.
Abstract

LAZO JF, Rosa B, Catellani M, Fontana M, et al
Semi-Supervised Bladder Tissue Classification in Multi-Domain Endoscopic Images.
IEEE Trans Biomed Eng. 2023;70:2822-2833.
Abstract

CHEIKHROUHOU T, Ben Dhaou M, Charfi S, Hbaieb M, et al
Phyllodes Tumor of the Bladder in a 2-Year-Old Boy - An Exceptional Finding.
Fetal Pediatr Pathol. 2023;42:699-705.
Abstract

MATSUZAWA ADACHI M, Sugawara H, Ishii A, Chiba E, et al
Malignancy-related Hypercalcemia Caused by Metameric Cutaneous Metastasis of Parathyroid Hormone-related Protein-producing Bladder Carcinoma with Squamous Cell Differentiation: An Autopsy Case of Cobb Syndrome.
Intern Med. 2023 Mar 1. doi: 10.2169/internalmedicine.0893.
Abstract

BREDA A, Gallioli A, Diana P, Fontana M, et al
The DEpth of Endoscopic Perforation scale to assess intraoperative perforations during transurethral resection of bladder tumor: subgroup analysis of a randomized controlled trial.
World J Urol. 2023;41:2583-2589.
Abstract

DIANA P, Gallioli A, Fontana M, Territo A, et al
Energy source comparison in en-bloc resection of bladder tumors: subanalysis of a single-center prospective randomized study.
World J Urol. 2023;41:2591-2597.
Abstract

GUVEN S, Colecchia M, Oltulu P, Bonfante G, et al
How do endoscopic bladder tumor resection techniques affect pathology practice? EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey.
World J Urol. 2023;41:2617-2625.
Abstract

CHEN Z, Deng K, Sun L, Qu L, et al
3D laparoscopic treatment of bladder cancer with pelvic multi-organ invasion: a case report and literature review.
Front Oncol. 2023;13:1249389.
Abstract

GARIONI M, Tschan VJ, Blukacz L, Nuciforo S, et al
Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.
NPJ Precis Oncol. 2023;7:112.
Abstract

WEI L, Ji L, Han S, Xu M, et al
Construction and Validation of a Prognostic Model of Metabolism-Related Genes Driven by Somatic Mutation in Bladder Cancer.
Front Biosci (Landmark Ed). 2023;28:242.
Abstract

KIM SW, Yu H, Kim Y, Nam K, et al
HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: A retrospective cohort study.
Int J Surg. 2023 Nov 2. doi: 10.1097/JS9.0000000000000859.
Abstract

QIN C, Tian Q, Zhou H, Qin Y, et al
Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System.
J Magn Reson Imaging. 2023 Nov 2. doi: 10.1002/jmri.29053.
Abstract

HU WM, Li M, Ning JZ, Tang YQ, et al
FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression.
J Exp Clin Cancer Res. 2023;42:290.
Abstract

SHUAI H, Duan X, Zhou JJ, Liu Y, et al
Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.
BMC Urol. 2023;23:177.
Abstract

UEKI Y, Kobayashi K, Hashimoto K, Tanaka T, et al
[Urological Comorbidities in an HIV-Infected Patient: A Case Report].
Hinyokika Kiyo. 2023;69:299-303.
Abstract

PATEL HD, Naha U, Chen VS, Ko C, et al
Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization.
Urol Pract. 2023 Oct 30:101097UPJ0000000000000467.
Abstract

SINGH R, Sharma G, Priyadarshi S, Fauzdar G, et al
Prognostic significance of preoperative pyuria & Neutrophil to lymphocyte ratio in patients with non-muscle-invasive bladder cancer: A prospective cohort study.
Urologia. 2023 Nov 1:3915603231203780. doi: 10.1177/03915603231203780.
Abstract

SAVCHENKO E, Rosenfeld A, Bunimovich-Mendrazitsky S
Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics.
Sci Rep. 2023;13:18754.
Abstract

ZHOU Q, Chen X, Chen Q, Hao L, et al
Factors Influencing Quality of Life and Functional Outcomes in Patients With Bladder Cancer.
Cancer Control. 2023;30:10732748231212353.
Abstract

NARAYAN VM, Siolas D, Meadows ES, Turzhitsky V, et al
Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
JCO Clin Cancer Inform. 2023;7:e2300096.
Abstract

DA SILVA AC, Scholl JN, de Fraga Dias A, Weber AF, et al
Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme.
Purinergic Signal. 2023 Oct 31. doi: 10.1007/s11302-023-09975.
Abstract

ZAZA MMA, Salem TAE, El-Sadat AM, Hassan Ali M, et al
Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer.
Urologia. 2023 Oct 31:3915603231206603. doi: 10.1177/03915603231206603.
Abstract

ABOU CHAKRA M, Shore ND, Dillon R, O'Donnell MA, et al
US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guerin-Unresponsive and Bacillus Calmette-Guerin-Exposed Nonmuscle-Invasive Bladder Cancer.
Urol Pract. 2023 Oct 30:101097UPJ0000000000000481.
Abstract

LV Z, Hou J, Wang Y, Wang X, et al
Knowledge-map analysis of bladder cancer immunotherapy.
Hum Vaccin Immunother. 2023;19:2267301.
Abstract

FAWZY MS, El Faiomy ARM, El Desoky AMZ, Hussein S, et al
The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa expressions in bladder cancer tissues.
Mol Biol Rep. 2023 Oct 30. doi: 10.1007/s11033-023-08818.
Abstract

ZHAO L, Han D, Zhu J, Bi D, et al
The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2 Macrophage Infiltration in Muscle-Invasive Bladder Cancer.
Clin Med Insights Oncol. 2023;17:11795549231203150.
Abstract

BAZARGAN S, Bunch B, Ojwang' AME, Blauvelt J, et al
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Front Immunol. 2023;14:1275375.
Abstract

LU J, Zhou W, He H, Chen J, et al
Duodenal stenosis caused by locally advanced upper tract urothelial carcinoma: a case report.
J Int Med Res. 2023;51:3000605231206958.
Abstract

LIU J, Lai S, Wu P, Wang J, et al
Systematic oxidative stress indices predicts prognosis in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy.
Eur J Med Res. 2023;28:469.
Abstract

LIN JH, Hung CH, Huang YC, Chen CS, et al
The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in Leonurus artemisia Extract-Induced Inhibition of the Proliferation of Human Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro.
Pharmaceuticals (Basel). 2023;16:1338.
Abstract

ALI W, Xiao W, Jacobs D, Kajdacsy-Balla A, et al
Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma.
Genes (Basel). 2023;14:1899.
Abstract

EMINAGA O, Leyh-Bannurah SR, Shariat SF, Krabbe LM, et al
Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images.
Cancers (Basel). 2023;15:4998.
Abstract

POTTGEN C, Hoffmann C, Gauler T, Guberina M, et al
Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry.
Cancers (Basel). 2023;15:4933.
Abstract

HU CY, Hung CF, Chen PC, Hsu JY, et al
Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.
Biomedicines. 2023;11:2598.
Abstract

ALFAQIH MA, Elsalem L, Nusier M, Mhedat K, et al
Serum Leptin Receptor and the rs1137101 Variant of the LEPR Gene Are Associated with Bladder Cancer.
Biomolecules. 2023;13:1498.
Abstract

YU SH, Kim SS, Lee H, Kim S, et al
Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence.
Diagnostics (Basel). 2023;13:3201.
Abstract

FRISHBERG A, Milman N, Alpert A, Spitzer H, et al
Reconstructing disease dynamics for mechanistic insights and clinical benefit.
Nat Commun. 2023;14:6840.
Abstract

LI Z, Zhou L, Lin C, Pan X, et al
Corrigendum to "MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018) 15-23].
Life Sci. 2023 Oct 25:122169. doi: 10.1016/j.lfs.2023.122169.
Abstract

YUE M, Yang Z, Sun J, Liu Z, et al
A candidate prognostic biomarker: TFEB inhibits tumor progression via elevating CDKN1A in bladder cancer.
Int Immunopharmacol. 2023;125.
Abstract

ZEMLA J, Szydlak R, Gajos K, Kozlowski L, et al
Plasma Treatment of PDMS for Microcontact Printing (muCP) of Lectins Decreases Silicone Transfer and Increases the Adhesion of Bladder Cancer Cells.
ACS Appl Mater Interfaces. 2023 Oct 27. doi: 10.1021/acsami.3c09195.
Abstract

VARCHULOVA NOVAKOVA Z, Kuniakova M, Ziaran S, Harsanyi S, et al
Molecular Biomarkers of Bladder Cancer: A Mini-Review.
Physiol Res. 2023;72.
Abstract

PARK HK
Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer?
Curr Oncol. 2023;30:9078-9089.
Abstract

PRIJOVIC N, Acimovic M, Santric V, Stankovic B, et al
The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
Curr Oncol. 2023;30:8841-8852.
Abstract

GLUTH L, Ochsenfarth C, Pham PNV, Wischermann JM, et al
Influence of the Anesthetic Technique on Circulating Extracellular Vesicles in Bladder Cancer Patients Undergoing Radical Cystectomy: A Prospective, Randomized Trial.
Cells. 2023;12:2503.
Abstract

SHAN Z, Tang W, Shi Z, Shan T, et al
Ferroptosis: An Emerging Target for Bladder Cancer Therapy.
Curr Issues Mol Biol. 2023;45:8201-8214.
Abstract

STARRETT GJ, Foster H, Sigel K, Liu Y, et al
Brief Report: The Virome of Bladder Tumors Arising in People Living With HIV.
J Acquir Immune Defic Syndr. 2023;94:337-340.
Abstract

LOPEZ-BELTRAN A, Gonzalez-Peramato P, Sanz-Ortega J, Prieto Cuadra JD, et al
[Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP].
Rev Esp Patol. 2023;56:261-270.
Abstract

KLUMPER N, Wust L, Saal J, Ralser DJ, et al
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Oncoimmunology. 2023;12:2267744.
Abstract

VARADI M, Horvath O, Modos O, Fazekas T, et al
Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
Sci Rep. 2023;13:17378.
Abstract

MARAZ A, Nagy B, Macher T, Jesko J, et al
Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
Adv Ther. 2023;40:5475-5488.
Abstract

WANG H, Ding Y, He Y, Yu Z, et al
LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.
Arch Biochem Biophys. 2023;748:109783.
Abstract

LI Y, Wu Q, Lv J, Gu J, et al
A comprehensive pan-cancer analysis of CDH5 in immunological response.
Front Immunol. 2023;14:1239875.
Abstract

LI M, Fu X, Zu X, Chen J, et al
Modified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical Cystectomy and its Long-Term Clinical Outcomes.
Technol Cancer Res Treat. 2023;22:15330338231192906.
Abstract

SACHDEVA S, Suresh PK, Basavaiah SH, Sahu KK, et al
p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
J Cancer Res Ther. 2023;19:1330-1334.
Abstract

LIANG H, Yang Q, Zhang Y, Sun H, et al
Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging.
J Cancer Res Clin Oncol. 2023;149:15867-15877.
Abstract

SHRIVASTAVA N, Jena R, Choudhary GR, Bhargava P, et al
Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder.
J Cancer Res Clin Oncol. 2023;149:15795-15804.
Abstract

ISCAIFE A, Socarras MR, Gonzalez LL, Rivas JG, et al
En Bloc Resection of Bladder Tumors (ERBT) using different lasers - Hybrid and Holmium Laser.
Int Braz J Urol. 2023;49:783-784.
Abstract

GAYA JM, Uleri A, Sanz I, Basile G, et al
Robot-assisted radical cystectomy and ileal conduit with Hugo(TM) RAS system: feasibility, setting and perioperative outcomes.
Int Braz J Urol. 2023;49:787-788.
Abstract

PIVOVARCIKOVA K, Pitra T, Alaghehbandan R, Buchova K, et al
Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: an opportunity to revisit urology clinical guidelines.
Virchows Arch. 2023;483:517-526.
Abstract

KIM JM, Lee J, Sung SH
Application of The Paris System in neobladder washing cytology: Comparison between the original diagnosis and correlation with histopathology.
Diagn Cytopathol. 2023;51:744-750.
Abstract

FOLARIN OS, Siddiqui MT
Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria.
Cancer Cytopathol. 2023;131:708-715.
Abstract

WANG Y, Yan S, Liu Y, Yan Z, et al
Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-associated diseases after renal transplantation.
Am J Transplant. 2023;23:1694-1708.
Abstract

GOUBET AG, Rouanne M, Derosa L, Kroemer G, et al
From mucosal infection to successful cancer immunotherapy.
Nat Rev Urol. 2023;20:682-700.
Abstract

REN K, Feng J, Bi H, Sun Q, et al
AFM-Based Poroelastic@Membrane Analysis of Cells and its Opportunities for Translational Medicine.
Small. 2023;19:e2303610.
Abstract

GRANT CR, de Kouchkovsky D, Kalebasty AR, Mar N, et al
Drug extravasation with Enfortumab vedotin.
J Oncol Pharm Pract. 2023;29:1789-1792.
Abstract

PEI L, Yan D, He Q, Kong J, et al
LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
Cell Oncol (Dordr). 2023;46:1509-1527.
Abstract

JONES H, Bhakta A, Jia L, Wojciechowski D, et al
An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma Arising in the Allograft, Persisting After Transplant Nephrectomy.
Int J Surg Pathol. 2023;31:1586-1592.
Abstract

PESCIA C, Pini G, Lopez G, Malfatto M, et al
A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature.
Int J Surg Pathol. 2023;31:1572-1579.
Abstract

MINATO H, Yoshikawa A, Tsuyama S, Katayanagi K, et al
Ureteral Metastasis of Colonic Adenocarcinoma with Enteroblastic Differentiation: A Rare Case to be Distinguished from Clear Cell Adenocarcinoma of the Urinary Tract.
Int J Surg Pathol. 2023;31:1553-1558.
Abstract

METHODS IN MEDICINE CAM
Retracted: Computed Tomography Image Features under Deep Learning Algorithm Applied in Staging Diagnosis of Bladder Cancer and Detection on Ceramide Glycosylation.
Comput Math Methods Med. 2023;2023:9842436.
Abstract

AND BIOMECHANICS AB
Retracted: Applications of Bladder Cancer Data Using a Modified Log-Logistic Model.
Appl Bionics Biomech. 2023;2023:9789308.
Abstract

OGURA R, Ito S, Ueda T, Gabata Y, et al
Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
Sci Rep. 2023;13:19517.
Abstract

LAURIE MA, Zhou SR, Islam MT, Shkolyar E, et al
Bladder Cancer and Artificial Intelligence: Emerging Applications.
Urol Clin North Am. 2024;51:63-75.
Abstract

CAO Y, Zou Z, Wu X, Li W, et al
LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of STAT3.
Gene. 2023 Nov 7:147974. doi: 10.1016/j.gene.2023.147974.
Abstract

WANG X, Wang Z, Wei Q, Wang H, et al
Anoikis-associated signatures predict prognosis and immune response in bladder cancer.
Epigenomics. 2023 Nov 9. doi: 10.2217/epi-2023-0240.
Abstract

FARNAZ T, Bhattacharjee P, Ahamad MSU, Rima SA, et al
The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care Hospital of Chattogram, Bangladesh.
Iran J Pathol. 2023;18:306-311.
Abstract

MOHAMED NE, Leung TM, Benn EK, Korn TG, et al
Depression and anxiety among patients treated for bladder cancer: examining clinical, demographic, and psychosocial predictors.
Am J Clin Exp Urol. 2023;11:401-413.
Abstract

JIA ZY, Yang F, Zhang W, Li WW, et al
Application of contrast-enhanced ultrasound in renal space-occupying lesion puncture biopsy.
BMC Med Imaging. 2023;23:178.
Abstract

TANIUCHI M, Yanagi M, Kiriyama T, Akatsuka J, et al
Primary leiomyoma of the bladder radiologically mimicking a retroperitoneal tumor - a case report.
J Med Invest. 2023;70.
Abstract

CUI A, Li X, Ma X, Song Z, et al
Quantitative transcriptomic and proteomic analysis reveals corosolic acid inhibiting bladder cancer via suppressing cell cycle and inducing mitophagy in vitro and in vivo.
Toxicol Appl Pharmacol. 2023 Nov 6:116749. doi: 10.1016/j.taap.2023.116749.
Abstract

CHEN B, Shu B, Liu Z, Zhu J, et al
The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer.
Bladder (San Franc). 2023;10:e21200006.
Abstract

GU Y, Lu Y, Xiong Y, Zhan X, et al
Advances in the bladder cancer research using 3D culture models.
Bladder (San Franc). 2023;10:e21200005.
Abstract

FU W, Zhang X
Laparoscopic and Robotic-Assisted Extended Pelvic Lymph Node Dissection for Invasive Bladder Cancer: A Review.
Bladder (San Franc). 2023;10:e21200004.
Abstract

LIU T, Gu J, Li C, Guo M, et al
Alternative polyadenylation-related genetic variants contribute to bladder cancer risk.
J Biomed Res. 2023 Nov 15:1-13. doi: 10.7555/JBR.37.20230063.
Abstract

WEI X, Jiang Y, Yang G, Chang T, et al
MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and invasion of bladder cancer cells and increases cisplatin sensitivity.
J Cancer Res Clin Oncol. 2023 Nov 8. doi: 10.1007/s00432-023-05484.
Abstract

CHEN H, Ma L, Yang W, Li Y, et al
POLR3G promotes EMT via PI3K/AKT signaling pathway in bladder cancer.
FASEB J. 2023;37:e23260.
Abstract

WANG J, Luo J, Wu X, Li Z, et al
WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.
Histol Histopathol. 2023 Oct 23:18671. doi: 10.14670.
Abstract

LI G, Song Z, Ru Y, Zhang J, et al
Small-molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual-inhibiting properties for bladder cancer treatment.
Exploration (Beijing). 2023;3:20220141.
Abstract

JEON J, Ha JS, Shin SJ, Ham WS, et al
Differences in clinical features between focal and extensive types of cystitis glandularis in patients without a previous history of urinary tract malignancy.
Investig Clin Urol. 2023;64:597-605.
Abstract

DURSUN F, Elshabrawy A, Wang H, Kaushik D, et al
Impact of rural residence on the presentation, management and survival of patients with non-metastatic muscle-invasive bladder carcinoma.
Investig Clin Urol. 2023;64:561-571.
Abstract

EL AZAB A, Abdelbary A, El Faqeh M Okasha A, Aboulkassem H, et al
The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guerin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial.
Investig Clin Urol. 2023;64:554-560.
Abstract

JAI-UA C, Limpaiboon C, Siriboonrid S, Binsri N, et al
Accuracy of Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer detection from multiparametric magnetic resonance imaging.
Investig Clin Urol. 2023;64:546-553.
Abstract

JANEV A, Ramuta TZ, Jerman UD, Obradovic H, et al
Human amniotic membrane inhibits migration and invasion of muscle-invasive bladder cancer urothelial cells by downregulating the FAK/PI3K/Akt/mTOR signalling pathway.
Sci Rep. 2023;13:19227.
Abstract

SINGH V, Singh MK, Jain M, Pandey AK, et al
The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer.
Urol Oncol. 2023 Nov 4:S1078-1439(23)00321-6. doi: 10.1016/j.urolonc.2023.
Abstract

ADEMAJ A, Puric E, Marder D, Timm O, et al
Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results.
Int J Hyperthermia. 2023;40:2275540.
Abstract

RIVEROS C, Ranganathan S, Haque W, Huang E, et al
Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
Can Urol Assoc J. 2023 Oct 23. doi: 10.5489/cuaj.8386.
Abstract

ARAI Y, Goto Y, Sazuka T, Fujimoto A, et al
A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation.
IJU Case Rep. 2023;6:471-474.
Abstract

KARAN C, Yaren A, Demirel BC, Dogan T, et al
Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
Cancer Diagn Progn. 2023;3:706-715.
Abstract

XU X, Huang Y, Liu Y, Cai Q, et al
Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of bladder cancer?
Eur Radiol. 2023 Nov 6. doi: 10.1007/s00330-023-10387.
Abstract

ZHANG L, Shao G, Shao J, Zhao J, et al
Corrigendum to "PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-kappaB pathway" [Tissue Cell 76 (2022) 101788].
Tissue Cell. 2023 Nov 1:102221. doi: 10.1016/j.tice.2023.102221.
Abstract

SORIA F, Rosazza M, Livoti S, Dutto D, et al
Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
Eur Urol Focus. 2023 Nov 1:S2405-4569(23)00236-5. doi: 10.1016/j.euf.2023.
Abstract

YANG M, Wang J, Quan S, Xu Q, et al
High-precision bladder cancer diagnosis method: 2D Raman spectrum figures based on maintenance technology combined with automatic weighted feature fusion network.
Anal Chim Acta. 2023;1282:341908.
Abstract

LI D, Liu F, Chen Y, Li P, et al
Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review.
Diagn Pathol. 2023;18:120.
Abstract

LEDFORD H
Cancer trial results show power of weaponized antibodies.
Nature. 2023;623:231-232.
Abstract

VAN DER HEIJDEN MS, Sonpavde G, Powles T, Necchi A, et al
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
N Engl J Med. 2023;389:1778-1789.
Abstract

FALTAS B
A new era in the treatment of urothelial carcinoma.
Urol Oncol. 2023;41:395-397.
Abstract

KSHATTRY S, Parker TL, Huntington SF
Peripheral Blasts in a Patient Receiving Chemotherapy.
JAMA. 2023;330:1581-1582.
Abstract

ORTNER G, Somani BK, Guven S, Kitzbichler G, et al
Experts' recommendations in laser use for the treatment of upper tract urothelial carcinoma: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training Research in Urological Surgery and Technology (T.R.U.S.T.) group.
World J Urol. 2023;41:3367-3376.
Abstract

GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma.
World J Urol. 2023;41:3001-3007.
Abstract

KLUMPER N, Eckstein M, Kunath F, Heidegger I, et al
[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
Urologie. 2023;62:1193-1199.
Abstract

YING Y, Zhang Z, Xing N, Qian Z, et al
Preoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis.
Urol Oncol. 2023;41:433.
Abstract

KATIMS AB, Gaffney C, Firouzi S, Yip W, et al
Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma.
Urol Oncol. 2023;41:433.
Abstract

RESNIK N, Visnjar T, Smrkolj T, Kreft ME, et al
Selective targeting of lectins and their macropinocytosis in urothelial tumours: translation from in vitro to ex vivo.
Histochem Cell Biol. 2023;160:435-452.
Abstract

MORENO MF, Kaul S, Fleishman A, Korets R, et al
Conditional survival following radical cystectomy for urothelial carcinoma of the bladder.
Urol Oncol. 2023;41:432.
Abstract

HE B, Ye L, Zeng H, Yao J, et al
Differentiation of urothelial carcinoma and neuroendocrine carcinoma in the urinary bladder based on CT texture analysis.
Asian J Surg. 2023;46:5053-5054.
Abstract

THOMAS J, Sun M, Getz T, Ho B, et al
Antibody-drug conjugates for urothelial carcinoma.
Urol Oncol. 2023;41:420-428.
Abstract

XIA M, Xiong S, He F, Li X, et al
Pelvic lipomatosis with mucinous adenocarcinoma: A case report and literature review.
Asian J Surg. 2023;46:4889-4890.
Abstract

YANG B, Wang D, Niu Y, Liu J, et al
A carcinoma in situ was inadvertently discovered after surgery for urinary bladder contracture.
Asian J Surg. 2023;46:4897-4898.
Abstract

SONG S, Smith A, Hu B
The patient experience with localized upper tract urothelial cancer.
Urol Oncol. 2023;41:431.
Abstract

PINAR U, Calleris G, Grobet-Jeandin E, Grande P, et al
The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
World J Urol. 2023;41:3205-3230.
Abstract

ATIQ S, Hirshman N, Shariff A, Zhang T, et al
The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
Urol Oncol. 2023;41:410-419.
Abstract

HAN X, Zhang T, Ma Q, Chang R, et al
Gene expression profiles to analyze the anticancer and carcinogenic effects of arsenic in bladder cancer.
Am J Transl Res. 2023;15:5984-5996.
Abstract

CAO P, Chen M, Zhang T, Zheng Q, et al
A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.
Eur J Med Res. 2023;28:515.
Abstract

BEDKE J, Black PC, Szabados B, Guerrero-Ramos F, et al
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
Urol Oncol. 2023 Nov 13:S1078-1439(23)00342.
Abstract

SHEN C, Chai W, Han J, Zhang Z, et al
Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Front Immunol. 2023;14:1213947.
Abstract

WOO S, Becker AS, Das JP, Ghafoor S, et al
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
Cancer Imaging. 2023;23:110.
Abstract

GUO P, Dai P, Yang S, Wang Z, et al
Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy.
Small. 2023 Nov 14:e2306699. doi: 10.1002/smll.202306699.
Abstract

KLEE M, Roesch MC, Eggers H, Ivanyi P, et al
Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer.
Aktuelle Urol. 2023 Nov 14. doi: 10.1055/a-2148-5799.
Abstract

WANG Y, Song Y, Qin C, Zhang C, et al
Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
Ann Med. 2023;55:2281654.
Abstract

LIU T, Tang Q, Shan Q, Wang Z, et al
Identification of potential phytochemical for the inhibition of non-muscle invasive bladder cancer (NMIBC).
J Biomol Struct Dyn. 2023 Nov 14:1-9. doi: 10.1080/07391102.2023.2280914.
Abstract

YU T, Cui X, Liang N, Wu S, et al
Postoperative Metachronous Metastasis of Bladder Cancer to Penis: A Case Report.
Arch Esp Urol. 2023;76:622-626.
Abstract

LI C, Wan Z, Deng Q, Li Z, et al
Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Arch Esp Urol. 2023;76:605-621.
Abstract

KRISHNAN J, Symington A, Kernohan N, Bray S, et al
HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.
Scott Med J. 2023 Nov 13:369330231213935. doi: 10.1177/00369330231213935.
Abstract

D'ANDREA VD, Melnick K, Yim K, Ernandez J, et al
Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.
J Clin Med. 2023;12:6845.
Abstract

STROBACH D, Haimerl L, Mannell H, Stief CG, et al
The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
J Clin Med. 2023;12:6749.
Abstract

XIAO LY, Su YL, Huang SY, Chen YH, et al
Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer.
Int J Mol Sci. 2023;24:15990.
Abstract

RUIZ DE PORRAS V, Font A
Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
Int J Mol Sci. 2023;24:15795.
Abstract

ALSOFYANI AA, Nedjadi T
Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma.
Int J Mol Sci. 2023;24:15763.
Abstract

GARCIA-VALLICROSA C, Falcon-Perez JM, Royo F
The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.
Int J Mol Sci. 2023;24:15668.
Abstract

GAO Y, Wang X, Luo H, Chen C, et al
Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates Tumorigenesis via the miR-206
Cancers (Basel). 2023;15:5305.
Abstract

HUANG N, Peng L, Yang J, Li J, et al
FAM111B Acts as an Oncogene in Bladder Cancer.
Cancers (Basel). 2023;15:5122.
Abstract

YILDIZ AK, Oktem C, Keseroglu BB, Kacan T, et al
A New Scoring System to Differentiate Bladder Cancer from Intravesical Prostatic Protrusion in the Bladder Neck: BCa-IPP Score.
Curr Med Imaging. 2023 Nov 10. doi: 10.2174/0115734056241577231023064014.
Abstract

STRAUB M, Auderset A, de Leval L, Piazzon N, et al
Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio.
Sci Rep. 2023;13:19796.
Abstract

SUNGU N, Kiran MM
Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
Pol J Pathol. 2023;74:161-170.
Abstract

ZHOU G, Qin G, Zhang Z, Zhao H, et al
Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
Front Immunol. 2023;14:1283792.
Abstract

MOLLER CT, Tafjord G, Blindheim A, Berge V, et al
Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway.
Scand J Urol. 2023;58:101-108.
Abstract

SODAGUM L, Passarelli R, Pfail J, Patel HV, et al
Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
Urol Oncol. 2023 Nov 10:S1078-1439(23)00324.
Abstract

WANG J, Li X, Chen S, Cao J, et al
Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
Life Sci. 2023;335:122253.
Abstract

WANG J, Zuo Z, Yu Z, Chen Z, et al
Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the bladder cancer intratumor heterogeneity and prognostic model development for bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

WAN H, Zhan X, Li X, Chen T, et al
Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.
BMC Urol. 2023;23:182.
Abstract

LI Y, Liu Y, Kang Z, Guo J, et al
Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses.
Sci Rep. 2023;13:19563.
Abstract

LIANG H, Yang Q, Sun H, Xu Y, et al
The vascular and morphological characteristics of tumors under narrow-band imaging as predictors for the grade and stage of bladder cancer: a prospective and multi-center study.
Ann Med. 2023;55:2281656.
Abstract

SANTINI D, Banna GL, Buti S, Isella L, et al
Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
Curr Oncol Rep. 2023;25:1345-1362.
Abstract

KIM JM, Choi E, Sung SH, Kang H, et al
Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
Pathol Res Pract. 2023;251:154839.
Abstract

DLUBAK A, Karwacki J, Logon K, Tomecka P, et al
Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.
Curr Oncol Rep. 2023;25:1327-1344.
Abstract

EMINAGA O, Lee TJ, Laurie M, Ge TJ, et al
Efficient Augmented Intelligence Framework for Bladder Lesion Detection.
JCO Clin Cancer Inform. 2023;7:e2300031.
Abstract

RICH JM, Tillu N, Grauer R, Busby D, et al
Robot-Assisted Repair of Ureteroenteric Strictures After Cystectomy with Urinary Diversion: Technique Description and Outcomes from the European Robotic Urology Section Scientific Working Group.
J Endourol. 2023;37:1209-1215.
Abstract

IWASAKI S, Takahashi K, Katano H, Suzuki T, et al
BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient.
Nephron. 2023;147 Suppl 1:53-60.
Abstract

WU B, Zhou X
LncRNA UCA1 could regulate the progression of neuropathic pain by regulating miR-135a-5p.
Mutat Res. 2023;827:111833.
Abstract

CELIK S, Aktas T, Gokbayrak O, Erol A, et al
Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-muscle Invasive Bladder Cancer.
Cancer Invest. 2023 Nov 24:1-10. doi: 10.1080/07357907.2023.2288640.
Abstract

JIANG Z, Wang Y, Tuo Z
Comprehensive analysis of Transferrin receptor (TFRC): A prognostic biomarker for patients with bladder cancer.
Asian J Surg. 2023 Nov 22:S1015-9584(23)01835.
Abstract

BEEREN I, Klerks NE, Aben KK, Oddens JR, et al
Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort.
Eur Urol Oncol. 2023 Nov 22:S2588-9311(23)00252.
Abstract

WANG D, Ning H, Wu H, Song Y, et al
Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer.
Curr Urol. 2023;17:236-245.
Abstract

GADELKAREEM RA, Abdelraouf AM, Ahmed AI, El-Taher AM, et al
Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer.
Curr Urol. 2023;17:246-250.
Abstract

IEMURA Y, Miyake M, Fukui S, Fujii T, et al
Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.
Curr Urol. 2023;17:229-235.
Abstract

DI GIANFRANCESCO L
The association between postvoid residual and response to standard therapy in male and female patients with non-muscle-invasive bladder cancer.
Curr Urol. 2023;17:251-256.
Abstract

JIANG Y, Sun X, Song X, Li Z, et al
Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.
Curr Urol. 2023;17:221-228.
Abstract

LIEDBERG F, Xylinas E, Gontero P
Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?
Eur Urol Focus. 2023 Nov 21:S2405-4569(23)00249.
Abstract

MYERS A, Ristau B, Mossanen M, Tyson MD, et al
Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer.
Urol Oncol. 2023 Nov 21:S1078-1439(23)00306.
Abstract

ZHENG B, Niu L, Xu H, Yang Y, et al
Engineering redirected NF-kappaB/OIP5 expression programs to enhance tumor responses to chemotherapy in bladder cancer.
Sci Bull (Beijing). 2023 Nov 14:S2095-9273(23)00781.
Abstract

ZHOU Y, Borcsok J, Adib E, Kamran SC, et al
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
Sci Adv. 2023;9:eadg2263.
Abstract

HERZEEL C, D'Hondt E, Vandeweerd V, Botermans W, et al
A software package for efficient patient trajectory analysis applied to analyzing bladder cancer development.
PLOS Digit Health. 2023;2:e0000384.
Abstract

WANG Z, He W, Ying Y, Wang M, et al
Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy.
Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00234.
Abstract

ZENGZHAO W, Xuan L, Xiaohan M, Encun H, et al
Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer.
Urol Oncol. 2023 Nov 20:S1078-1439(23)00351.
Abstract

KOLL FJ, Doring C, Herwig L, Hoeh B, et al
Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
J Clin Pathol. 2023 Nov 21:jcp-2023-208973. doi: 10.1136/jcp-2023-208973.
Abstract

LIU G, Zhang T, Gui D, Liu Q, et al
Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

BALINT IB, Erdodi BT
Is there a promoting role for artificial sweeteners in the evolution of bladder cancer? A meta-analysis of current literature.
Minerva Surg. 2023 Nov 21. doi: 10.23736/S2724-5691.23.10000.
Abstract

POSFAI B, Santa F, Schubert A, Semjen D, et al
[Morphological variants of the invasive urothelial cell carcinoma.].
Orv Hetil. 2023;164:1567-1582.
Abstract

SAHU R, Shah K, Malviya R, Paliwal D, et al
E-Cigarettes and Associated Health Risks: An Update on Cancer Potential.
Adv Respir Med. 2023;91:516-531.
Abstract

MALMSTROM PU, Truls G
Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up.
Scand J Urol. 2023;58:109-114.
Abstract

MALLET R
Thulium fiber laser as a novel technique with shallow and accurate cutting, high-quality hemostasis, and no ballistic effect in the treatment of non-muscle invasive bladder cancer.
Urologia. 2023 Nov 20:3915603231211982. doi: 10.1177/03915603231211982.
Abstract

DAUNGSUPAWONG H, Wiwanitkit V
Knowledge-map analysis and bladder cancer immunotherapy: Comment.
Hum Vaccin Immunother. 2023;19:2285094.
Abstract

DENG W, Chen R, Xiong S, Nie J, et al
CircFSCN1 induces tumor progression and triggers epithelial-mesenchymal transition in bladder cancer through augmentation of MDM2-mediated p53 silencing.
Cell Signal. 2023 Nov 17:110982. doi: 10.1016/j.cellsig.2023.110982.
Abstract

VAISHAMPAYAN UN, Heilbrun L, Vaishampayan N, Harper FW, et al
Phase II trial of Concurrent Nivolumab and Radiation therapy in Elderly or Chemotherapy ineligible Muscle Invasive Bladder Cancer.
Int J Radiat Oncol Biol Phys. 2023 Nov 17:S0360-3016(23)08152.
Abstract

KOMURA K, Hirosuna K, Tokushige S, Tsujino T, et al
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Mol Cancer. 2023;22:185.
Abstract

LIU CH, Zhang JJ, Zhang QJ, Dong Y, et al
METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4.
Cell Signal. 2023;113:110971.
Abstract

BASILE G, Pradere B, Lenfant L, Roupret M, et al
Re: Katharina Bruck, Richard P. Meijer, Joost L. Boormans, et al. Disease-free Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys
Eur Urol Oncol. 2023 Nov 15:S2588-9311(23)00238.
Abstract

XU C, Cao J, Zhou T
Radiogenomics uncovers an interplay between angiogenesis and clinical outcomes in bladder cancer.
Environ Toxicol. 2023 Nov 17. doi: 10.1002/tox.24038.
Abstract

CIVI CETIN K, Oner S, Erdogan B, Simsek G, et al
Young population bladder neoplasms.
Eur Rev Med Pharmacol Sci. 2023;27:10454-10461.
Abstract

ZHONG X, Pan Y, Wu K, Wang L, et al
A novel nomogram based on body composition and nutritional indicators to predict the prognosis of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
Cancer Med. 2023 Nov 16. doi: 10.1002/cam4.6712.
Abstract

GARG T, Frank K, Johns A, Rabinowitz K, et al
Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer.
J Am Geriatr Soc. 2023 Nov 16. doi: 10.1111/jgs.18676.
Abstract

SRETENOVIC M, Lisicic N, Bulat P, Radisavcevic D, et al
Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer.
J Surg Oncol. 2023 Nov 16. doi: 10.1002/jso.27517.
Abstract

KIKUCHI H, Abe T, Miyake M, Miyata H, et al
The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin therapy.
Jpn J Clin Oncol. 2023 Nov 16:hyad155. doi: 10.1093.
Abstract

[Not Available].
Aktuelle Urol. 2023;54:438-440.
Abstract

[Not Available].
Aktuelle Urol. 2023;54:428-430.
Abstract

[Not Available].
Aktuelle Urol. 2023;54:428.
Abstract

ZHANG H, Li D, Chen C
Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
J Clin Anesth. 2024;92:111273.
Abstract

HUANG H, Xu Q, Zhang Y, Zhou Y, et al
miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
Curr Pharm Des. 2023;29:2477-2488.
Abstract

LORIOT Y, Matsubara N, Park SH, Huddart RA, et al
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
N Engl J Med. 2023;389:1961-1971.
Abstract

CHAPUR J, Kojic K, Kula M, Flexman AM, et al
Perioperative cortical hand stroke syndrome mimicking peripheral neuropathy: a case report.
Can J Anaesth. 2023;70:1839-1844.
Abstract

QIANG Z, Jubber I, Lloyd K, Cumberbatch M, et al
Gene of the month: GATA3.
J Clin Pathol. 2023;76:793-797.
Abstract

GHATALIA P, Plimack ER
Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
Nat Rev Clin Oncol. 2023;20:818-819.
Abstract

WANG J, Wang T, Feng YK, Liu Y, et al
Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of RAB1A stabilization.
Cell Signal. 2023 Nov 29:110996. doi: 10.1016/j.cellsig.2023.110996.
Abstract

CHEN H, Qi Y, Yang C, Tai Q, et al
Heterogeneous MXene Hybrid-Oriented Exosome Isolation and Metabolic Profiling for Early Screening, Subtyping and Follow-up Evaluation of Bladder Cancer.
ACS Nano. 2023 Dec 1. doi: 10.1021/acsnano.3c08391.
Abstract

LU G, Qiu Y
SPI1-mediated CXCL12 expression in bladder cancer affects the recruitment of tumor-associated macrophages.
Mol Carcinog. 2023 Dec 1. doi: 10.1002/mc.23663.
Abstract

HANNOUNEH ZA, Hijazi A, Alsaleem AA, Hami S, et al
Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Cancer Med. 2023 Dec 1. doi: 10.1002/cam4.6768.
Abstract

LUO KW, Chen W, Lung WY, Wei XY, et al
Corrigendum to "EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9" [Journal of Nutritional Biochemistry 41 (2017) 56-64].
J Nutr Biochem. 2023 Nov 29:109530. doi: 10.1016/j.jnutbio.2023.109530.
Abstract

SYNELNYK T, Vovk T, Halenova T, Tytarenko V, et al
Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.
Front Med (Lausanne). 2023;10:1276882.
Abstract

MAVRIDIS C, Venihaki M, Dermitzaki E, Deiktakis M, et al
mRNA expression of CRF family members in urothelial bladder cancer.
Oncol Lett. 2023;27:13.
Abstract

DONG Y, Cheng Y, Guo H, Sun J, et al
Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study.
Ther Adv Urol. 2023;15:17562872231213720.
Abstract

RANGEL MMM, Linhares LCM, de Oliveira KD, Suzuki DOH, et al
Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
Sci Rep. 2023;13:21078.
Abstract

LIAO J, Zhou Z
Long-term cardiovascular mortality risk in patients with bladder cancer: a real-world retrospective study of 129,765 cases based on the SEER database.
Front Cardiovasc Med. 2023;10:1142417.
Abstract

LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p [Retraction].
Cancer Manag Res. 2023;15:1267-1268.
Abstract

KOURIE HR, Zouein J, Succar B, Mardirossian A, et al
Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.
Oncol Rev. 2023;17:10603.
Abstract

HODARA E, Mades A, Swartz L, Iqbal M, et al
m(6)A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer.
NAR Cancer. 2023;5:zcad054.
Abstract

CHORBINSKA J, Krajewski W, Nowak L, Bardowska K, et al
Is the Urinary and Gut Microbiome Associated With Bladder Cancer?
Clin Med Insights Oncol. 2023;17:11795549231206796.
Abstract

TAMADA S, Ikarashi D, Yanagawa N, Toyoshima M, et al
Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report.
Front Oncol. 2023;13:1274494.
Abstract

WANG Y, Wang J, He J, Ji B, et al
Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer.
Front Immunol. 2023;14:1289198.
Abstract

MA YT, Hua F, Zhong XM, Xue YJ, et al
Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
Front Immunol. 2023;14:1269097.
Abstract

DONG L, Lin F, Wu W, Huang W, et al
Erratum: Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell: Erratum.
J Cancer. 2023;14:3521-3522.
Abstract

HESSWANI C, Jackson CL, Marcq G, Hardy C, et al
Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
Eur Urol Open Sci. 2023;57:22-29.
Abstract

BOHNER P, Pal M, Crettenand F, Roth B, et al
[Bladder cancer : a comprehensive follow-up for an efficient and personalized care].
Rev Med Suisse. 2023;19:2250-2253.
Abstract

REALE S, Bohner P, Crettenand F, Roth B, et al
[Radical cystectomy in the geriatric population. Tools for screening postoperative complications].
Rev Med Suisse. 2023;19:2247-2249.
Abstract

CHEN H, Shi D, Guo C, Zhang W, et al
Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.
Mol Carcinog. 2023 Nov 29. doi: 10.1002/mc.23664.
Abstract

LIU Z, Sun L, Zheng B, Wang H, et al
The value of ATAD3A as a potential biomarker for bladder cancer.
Cancer Med. 2023 Nov 28. doi: 10.1002/cam4.6759.
Abstract

ZHOU G, Li Y, Ren X, Qin G, et al
Identifying prognostic characteristics of m6A-related glycolysis gene and predicting the immune infiltration landscape in bladder cancer.
Cancer Cell Int. 2023;23:300.
Abstract

MYOEN S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, et al
CD271 promotes proliferation and migration in bladder cancer.
Genes Cells. 2023 Nov 28. doi: 10.1111/gtc.13087.
Abstract

JIN H, Liu B, Guo X, Qiao X, et al
MYLK and CALD1 as molecular targets in bladder cancer.
Medicine (Baltimore). 2023;102:e36302.
Abstract

LI J, Zhuang C, Liu Y, Chen M, et al
Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.
J Exp Clin Cancer Res. 2023;42:321.
Abstract

WANG L, Deng JY, Li KP, Shan-Yin, et al
Inflammatory bowel disease and bladder cancer risk: based on a Mendelian randomization study.
BMC Urol. 2023;23:195.
Abstract

YUE R, Dutta A
Reparameterized multiobjective control of BCG immunotherapy.
Sci Rep. 2023;13:20850.
Abstract

GUO C, Li P, Guo X, Wang X, et al
Identification of bladder cancer subtypes and predictive model for prognosis, immune features, and immunotherapy based on neutrophil extracellular trap-related genes.
Sci Rep. 2023;13:20791.
Abstract

KOBAYASHI Y, Iijima K, Kondo Y, Yamamoto K, et al
Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
Acta Neurol Belg. 2023 Nov 27. doi: 10.1007/s13760-023-02439.
Abstract

KISHI S, Mori S, Fujiwara-Tani R, Ogata R, et al
ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production.
Int J Mol Sci. 2023;24:16367.
Abstract

SAMARA M, Vlachostergios PJ, Thodou E, Zachos I, et al
Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.
Int J Mol Sci. 2023;24:16243.
Abstract

FAHEY CC, Nebhan CA, York S, Davis NB, et al
Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
Int J Mol Sci. 2023;24:16109.
Abstract

BERNDT-PAETZ M, Han S, Weimann A, Reinhold A, et al
Cell Line-Based Human Bladder Organoids with Bladder-like Self-Organization-A New Standardized Approach in Bladder Cancer Research.
Biomedicines. 2023;11:2958.
Abstract

AKIN O, Lema-Dopico A, Paudyal R, Konar AS, et al
Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies.
Cancers (Basel). 2023;15:5468.
Abstract

ZHANG Z, Yu Y, Zhang Z, Li D, et al
Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1.
J Exp Clin Cancer Res. 2023;42:316.
Abstract

KHEDR OS, Wahed ME, Al-Attar AR, Abdel-Rehim EA, et al
The classification of the bladder cancer based on Vision Transformers (ViT).
Sci Rep. 2023;13:20639.
Abstract

FUJIWARA M, Tanaka H, Kobayashi M, Nakamura Y, et al
Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00232.
Abstract

KNAPP DW, Dhawan D, Ruple A, Cooper BR, et al
Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study.
Vet J. 2023 Nov 22:106044. doi: 10.1016/j.tvjl.2023.106044.
Abstract

LIU L, Xiao Y, Wei D, Wang Q, et al
Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: A population-based retrospective study.
J Affect Disord. 2023;347:124-133.
Abstract

YU J, Lee CU, Chung JH, Song W, et al
Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: Propensity score matched and weighted analyses of retrospective cohort.
Int J Surg. 2023 Nov 23. doi: 10.1097/JS9.0000000000000904.
Abstract

TSILI AC
VI-RADS scoring system for predicting 1- to 5-year recurrence of bladder cancer.
Eur Radiol. 2023 Nov 24. doi: 10.1007/s00330-023-10458.
Abstract

TEMPO J, Bolton D, O'Callaghan M
Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
BMC Urol. 2023;23:194.
Abstract

MEDORI MC, Micheletti C, Madeo G, Maltese PE, et al
Omics sciences and precision medicine in Urothelial Carcinoma.
Clin Ter. 2023;174.
Abstract

TANG X, Zhan X, Chen X
Incidence, mortality and survival of transitional cell carcinoma in the urinary system: A population-based analysis.
Medicine (Baltimore). 2023;102:e36063.
Abstract

[Not Available].
Aktuelle Urol. 2023;54:434.
Abstract

SCHALLENBERG S, Plage H, Hofbauer S, Furlano K, et al
Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
Acta Oncol. 2023;62:1880-1889.
Abstract

DHALL A, Patiyal S, Kaur H, Raghava GPS, et al
Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Comput Biol Med. 2023;167:107594.
Abstract

STONE L
Bladder-sparing neoadjuvant therapy for MIBC.
Nat Rev Urol. 2023;20:703.
Abstract

SANO T, Saito R, Aizawa R, Watanabe T, et al
Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
Int J Clin Oncol. 2023;28:1573-1584.
Abstract

MARJERRISON N, Grimsrud TK, Hansen J, Martinsen JI, et al
Occupational exposures of firefighting and urinary tract cancer risk among men in the Norwegian Fire Departments Cohort.
Occup Environ Med. 2023;80:659-666.
Abstract

TOYODA T, Kobayashi T, Miyoshi N, Matsushita K, et al
Mucosal damage and gamma-H2AX formation in the rat urinary bladder induced by aromatic amines with structures similar to o-toluidine and o-anisidine.
Arch Toxicol. 2023;97:3197-3207.
Abstract

LIAO PJ, Lee CH, Wang SL, Chiou HY, et al
Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area.
J Epidemiol Glob Health. 2023;13:807-815.
Abstract

SAVIN Z, Yossepowitch O, Lazarovich A, Rosenzwieg B, et al
11-item modified frailty index and outcomes after radical cystectomy.
J Geriatr Oncol. 2023;14:101627.
Abstract

ANDRUSKA N, Waters MR, Fischer-Valuck BW, Smith ZL, et al
Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
Clin Genitourin Cancer. 2023;21:653-659.
Abstract

ROSENBERG JE, Powles T, Sonpavde GP, Loriot Y, et al
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
Ann Oncol. 2023;34:1047-1054.
Abstract

BASCIO LS, Chiappa V, Paolini B, Chiarello G, et al
Urothelial bladder carcinoma recurrence in the uterine cervix: Cytological findings on a cervical cytology test.
Cytopathology. 2023;34:645-648.
Abstract

KIR G, Cecikoglu GE, Topal CS, Sorkun MH, et al
Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma.
Virchows Arch. 2023;483:621-634.
Abstract

NOGRADI AL, Cope I, Arany-Toth A, Muller L, et al
Primary Urinary Bladder Tumors in Three Guinea Pigs (Cavia Porcellus).
Top Companion Anim Med. 2023;56-57:100805.
Abstract

AHN H, Kim TM, Hwang SI, Lee HJ, et al
Tumor contact length with bladder wall provides effective risk stratification for lesions with a VIRADS score of 2-3.
Eur Radiol. 2023;33:8417-8425.
Abstract

KLOSE C, Gordon O, Sparks A, Whalen M, et al
Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive Urothelial Carcinoma of the Bladder.
Clin Genitourin Cancer. 2023;21:703-709.
Abstract

AGRAWAL P, Rostom M, Alam R, Florissi I, et al
Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder.
Clin Genitourin Cancer. 2023;21:631-638.
Abstract

ACAR O, Ayhan M, Demir B, Ekinci F, et al
HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer.
J Coll Physicians Surg Pak. 2023;33:1405-1409.
Abstract

LIU T, Xu X, Li J, Bai M, et al
ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape.
Cell Death Dis. 2023;14:800.
Abstract

NOEL ODV, Hassouneh Z, Svatek RS, Mukherjee N, et al
Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.
Cancer Immunol Res. 2023 Dec 7:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0414.
Abstract

WANG Z, Ying Y, Wang M, Chen Q, et al
Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event.
iScience. 2023;26:108482.
Abstract

YANG J, Jiang X, Chen Y, Teng L, et al
EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-beta Signaling Pathway.
Discov Med. 2023;35:1167-1176.
Abstract

AN WX, Gupta R, Zhai K, Wang YR, et al
Current and Potential Roles of Ferroptosis in Bladder Cancer.
Curr Med Sci. 2023 Dec 7. doi: 10.1007/s11596-023-2814.
Abstract

ZHUANG J, Cai L, Sun H, Wu Q, et al
Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy.
Sci Rep. 2023;13:21502.
Abstract

LI W, Shen Y, Yang C, Ye F, et al
Identification of a novel ferroptosis-inducing micropeptide in bladder cancer.
Cancer Lett. 2023 Dec 4:216515. doi: 10.1016/j.canlet.2023.216515.
Abstract

TENG C, Liu Z, Wang J, Shi S, et al
C15:0 and C17:0 partially mediate the association of milk &dairy products with bladder cancer risk.
J Dairy Sci. 2023 Dec 4:S0022-0302(23)00830-5. doi: 10.3168/jds.2023-24186.
Abstract

HOOGEVEEN F, Blanker MH, Cauberg E, Steffens MG, et al
Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
Scand J Urol. 2023;58:120-125.
Abstract

ZHENG J, Peng L, Zhang S, Liao H, et al
Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.
Front Immunol. 2023;14:1275033.
Abstract

EBNER B, Fleckenstein F, Volz Y, Eismann L, et al
Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching?
Transfusion. 2023 Dec 6. doi: 10.1111/trf.17618.
Abstract

DONG X, Wang Y, Wang S, Li C, et al
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
Arch Esp Urol. 2023;76:657-665.
Abstract

HAN Y, Kim U, Jung KJ, Lee JY, et al
Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.
Cancer Metab. 2023;11:23.
Abstract

WU JM, Qiu WR, Liu Z, Xu ZC, et al
Integrative approach for classifying male tumors based on DNA methylation 450K data.
Math Biosci Eng. 2023;20:19133-19151.
Abstract

JIANG YK, Shuai YJ, Ding HM, Zhang H, et al
Erratum to: ARID1A Inactivation Increases Expression of circ0008399 and Pro-motes Cisplatin Resistance in Bladder Cancer.
Curr Med Sci. 2023 Dec 4. doi: 10.1007/s11596-023-2819.
Abstract

LI H, Lin G, Cui M, Wang L, et al
Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon.
Medicine (Baltimore). 2023;102:e36414.
Abstract

ZHU S, Zhao Q, Fan Y, Tang C, et al
Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
BMC Urol. 2023;23:199.
Abstract

CHI BJ, Duan ZL, Hasan AHAM, Yin XZ, et al
Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer.
Biochem Genet. 2023 Dec 5. doi: 10.1007/s10528-023-10584.
Abstract

MAITRE P, Choudhury A
Bladder Preservation and Immunotherapy: Rebel Without A Cause?
Int J Radiat Oncol Biol Phys. 2024;118:50-51.
Abstract

LIVERINGHOUSE C, Netzley A, Bryant JM, Linkowski LC, et al
Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer.
Adv Radiat Oncol. 2023;8:101268.
Abstract

SINGH P, Parida GK, Bishnoi K, Singhal T, et al
Delayed Recurrence of Gall Bladder Cancer as Port-site Metastases with Occult Primary Detected on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: A Tale of Two Cases.
Indian J Nucl Med. 2023;38:273-275.
Abstract

SOLOWAY MS
Inflection points in urology as witnessed by Mark Soloway. Part 1: bladder cancer.
Cent European J Urol. 2023;76:263-268.
Abstract

WIELAND VLS, Uysal D, Probst P, Grilli M, et al
Framework for a living systematic review and meta-analysis for the surgical treatment of bladder cancer: introducing EVIglance to urology.
Int J Surg Protoc. 2023;27:9-15.
Abstract

FURUYA H, Sakatani T, Tanaka S, Murakami K, et al
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
Res Sq. 2023 Nov 25:rs.3.rs-3635581. doi: 10.21203/rs.3.rs-3635581.
Abstract

CAI X, Ruan L, Wang D, Zhang J, et al
Boosting chemotherapy of bladder cancer cells by ferroptosis using intelligent magnetic targeting nanoparticles.
Colloids Surf B Biointerfaces. 2023;234:113664.
Abstract

LIU Y, Ye F, Yang C, Jiang H, et al
Use of in vivo Raman spectroscopy and cryoablation for diagnosis and treatment of bladder cancer.
Spectrochim Acta A Mol Biomol Spectrosc. 2023;308:123707.
Abstract

KIM JM, Choi E, Sung SH, Jo J, et al
Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
Clin Genitourin Cancer. 2023 Nov 10:S1558-7673(23)00240.
Abstract

FRANCOLINI G, Ghoshal A, Caini S, Piazzini T, et al
Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.
Radiother Oncol. 2023;190:110038.
Abstract

MA C, Zhong X, Liu R, Yang X, et al
Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Guerin for chemo-immunotherapy of orthotopic bladder cancer.
J Control Release. 2023;365:640-653.
Abstract

JOBST M, Hossain M, Kiss E, Bergen J, et al
Autophagy modulation changes mechano-chemical sensitivity of T24 bladder cancer cells.
Biomed Pharmacother. 2023;170:115942.
Abstract

QIU Y, Ye W, Wang C, Zang J, et al
Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
Aging (Albany NY). 2023;15:13312-13328.
Abstract

CHEN J, Chen S, Luo H, Wan X, et al
The complementary and alternative roles of elemene injection in cancer: An umbrella review.
Pharmacol Res. 2023;198:107007.
Abstract

FIGAROA OJA, Hendriks N, Kamphuis GM, van Moorselaar RJA, et al
Positioning the role of urine cytology within the diagnostic pathway for UTUC: supportive but inconclusive.
World J Urol. 2023;41:3429-3435.
Abstract

TSUJINO T, Komura K, Inamoto T, Maenosono R, et al
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
World J Urol. 2023;41:3585-3591.
Abstract

CHEN JC, Huang TH, Wei TC, Huang IS, et al
Influence of preoperative body mass index on prognosis for patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
World J Urol. 2023;41:3575-3583.
Abstract

KOELKER M, Bradtke M, Klemm J, von Deimling M, et al
Rational peri-operative management of antithrombotic therapy in patients undergoing radical cystectomy: A 30-day morbidity analysis based on the updated European Association of Urology guidelines for standardized complication reporting.
Eur J Surg Oncol. 2023;49:107123.
Abstract

RICH JM, Geduldig J, Cumarasamy S, Ranti D, et al
Eliminating the routine use of postoperative drain placement in patients undergoing robotic-assisted radical cystectomy with intracorporeal urinary diversion.
Urol Oncol. 2023;41:457.
Abstract

WANG B, Ou Z, Zhong W, Huang L, et al
Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
Cancer Immunol Res. 2023;11:1656-1670.
Abstract

ALHALABI O, Wilson N, Xiao L, Lin Y, et al
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Eur Urol Oncol. 2023;6:611-620.
Abstract

GRAHN A, Coleman JA, Eriksson Y, Gabrielsson S, et al
Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's around the corner?
World J Urol. 2023;41:3405-3411.
Abstract

MU N, Jylha C, Axelsson T, Syden F, et al
Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
World J Urol. 2023;41:3421-3427.
Abstract

CALLERIS G, Roupret M, Seisen T, Bendjeddou L, et al
Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
World J Urol. 2023;41:3413-3420.
Abstract

YIM K, Melnick K, Mott SL, Carvalho FLF, et al
Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
Urol Oncol. 2023;41:458.
Abstract

SYDEN F, Baard J, Bultitude M, Keeley FX Jr, et al
Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?
World J Urol. 2023;41:3395-3403.
Abstract

BLACHMAN-BRAUN R, Gurayah AA, Mason MM, Hougen HY, et al
Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy.
Urol Oncol. 2023;41:455.
Abstract

NYAME YA, Baker KK, Montgomery B, Grivas P, et al
Racial and sex differences in tumor genomics in urothelial carcinoma.
Urol Oncol. 2023;41:456.
Abstract

KAZAN O, Gunduz N, Bakir B, Iplikci A, et al
Diagnostic validity of the vesical imaging-reporting and data system (VI-RADS): a real-world study.
Actas Urol Esp (Engl Ed). 2023;47:638-644.
Abstract

ROSE KM, Murray KS, Labbate C, Woldu S, et al
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Eur Urol Focus. 2023;9:807-812.
Abstract

RYAN PC, Kelly C, Afridi I, Fawaz A, et al
Surgical treatment of urachal remnants in an adult population-a single-centre experience.
Ir J Med Sci. 2023;192:3023-3027.
Abstract

MARTINI A, Touzani A, Ploussard G
Lower Detrusor Apron-sparing Robot-assisted Radical Cystectomy and Intracorporeal Neobladder Reconstruction: Technique and Preliminary Outcomes.
Eur Urol Focus. 2023;9:760-764.
Abstract

ZHANG X, Wen Z, Xing Z, Zhou X, et al
The causal relationship between osteoarthritis and bladder cancer: A Mendelian randomization study.
Cancer Med. 2023 Dec 15. doi: 10.1002/cam4.6829.
Abstract

BAZARKIN A, Morozov A, Androsov A, Fajkovic H, et al
Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
Curr Urol Rep. 2023 Dec 15. doi: 10.1007/s11934-023-01193.
Abstract

CARRASCO R, Ingelmo-Torres M, Oriola J, Roldan FL, et al
Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
Front Oncol. 2023;13:1270962.
Abstract

TIAN X, Liu D, He P, Li L, et al
DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer.
Aging (Albany NY). 2023;15.
Abstract

KHAN AR, Awan NUH, Tchier F, Alahmari SD, et al
An estimation of physiochemical properties of bladder cancer drugs via degree-based chemical bonding topological descriptors.
J Biomol Struct Dyn. 2023 Dec 14:1-9. doi: 10.1080/07391102.2023.2292792.
Abstract

ZHOU Y, Xu W, Zeng Y, Li H, et al
Global research trends of the application of artificial intelligence in bladder cancer since the 21st century: a bibliometric analysis.
Front Oncol. 2023;13:1227152.
Abstract

METHODS IN MEDICINE CAM
Retracted: CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.
Comput Math Methods Med. 2023;2023:9867274.
Abstract

WANG H, Zhang M, Miao J, Hou F, et al
Deep learning signature based on multiphase enhanced CT for bladder cancer recurrence prediction: a multi-center study.
EClinicalMedicine. 2023;66:102352.
Abstract

WANG H, Lv Z, Xia H, Tang R, et al
Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.
Heliyon. 2023;9:e21153.
Abstract

MICHAUD E, Mansure JJ, Kassouf W
INTEGRATING NOVEL IMMUNOTHERAPEUTIC APPROACHES IN ORGAN-PRESERVING THERAPIES FOR BLADDER CANCER.
Br J Pharmacol. 2023 Dec 13. doi: 10.1111/bph.16300.
Abstract

REN Y, Wang G, Wang P, Liu K, et al
MM-SFENet: multi-scale multi-task localization and classification of bladder cancer in MRI with spatial feature encoder network.
Phys Med Biol. 2023 Dec 13. doi: 10.1088/1361-6560/ad1548.
Abstract

WANG S, Ji Y, Liu Y, Du P, et al
The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study.
Front Oncol. 2023;13:1243118.
Abstract

WANG L, Wang W
Symptom management and nursing interventions for postoperative bladder instillation chemotherapy in bladder cancer patients.
Minerva Surg. 2023 Dec 13. doi: 10.23736/S2724-5691.23.10162.
Abstract

GORE JL, Follmer K, Reynolds J, Nash M, et al
Interruptions in bladder cancer care during the COVID-19 public health emergency.
Urol Oncol. 2023 Dec 11:S1078-1439(23)00362.
Abstract

YU X, Li W, Sun S, Li J, et al
Investigating the prognostic value of mTORC1 signaling in bladder cancer via bioinformatics evaluation.
Sci Rep. 2023;13:22066.
Abstract

SLUSARCZYK A, Zapala P, Piecha T, Zapala L, et al
Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy.
Ann Surg Oncol. 2023 Dec 12. doi: 10.1245/s10434-023-14710.
Abstract

ZOUEIN J, Boueri M, Kourie HR, Kattan J, et al
Advanced bladder cancer management: history in the making.
Future Oncol. 2023 Dec 12. doi: 10.2217/fon-2023-0908.
Abstract

ZHENG X, Chen J, Deng M, Ning K, et al
G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K/Akt Activation in Bladder Cancer.
Adv Sci (Weinh). 2023 Dec 12:e2305922. doi: 10.1002/advs.202305922.
Abstract

LEE S, Jue M, Lee K, Paulson B, et al
Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy combined with machine learning algorithms in a rat model.
Biosens Bioelectron. 2023;246:115915.
Abstract

HEALTHCARE ENGINEERING JO
Retracted: Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
J Healthc Eng. 2023;2023:9801404.
Abstract

METHODS IN MEDICINE CAM
Retracted: Effects of Nursing Care for the Treatment of Patients with Bladder Cancer: A Systematic Review and Meta-analysis.
Comput Math Methods Med. 2023;2023:9876720.
Abstract

MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer.
medRxiv. 2023 Nov 29:2023.11.28.23299093. doi: 10.1101/2023.11.28.23299093.
Abstract

CHEN X, Zhang Z, Liao W, Zhao Y, et al
Assessment tool based on fatty acid metabolic signatures for predicting the prognosis and treatment response in bladder cancer.
Heliyon. 2023;9:e22768.
Abstract

FALLATAH M, Alkahtani AS, Alrumayyan M, Alotaibi MF, et al
Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.
Urol Ann. 2023;15:406-411.
Abstract

MARX AH, Nowicki DN, Carlson RB, Schultz KM, et al
Bacille Calmette-Guerin preparation and intravesical administration to patients with bladder cancer: Risks to healthcare personnel and patients, and mitigation strategies.
Infect Control Hosp Epidemiol. 2023 Dec 11:1-6. doi: 10.1017/ice.2023.
Abstract

LIU Y, Han YS, Wang JF, Pang ZQ, et al
A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer.
Cancer Biomark. 2023 Nov 7. doi: 10.3233/CBM-230190.
Abstract

LIU Z, Du D, Zhang S
Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1.
Cancer Biol Ther. 2024;25:2290033.
Abstract

EL-AGRODY E, Abol-Enein H, Mortada WI, Awadalla A, et al
Does the Presence of Heavy Metals Influence the Gene Expression and Oxidative Stress in Bladder Cancer?
Biol Trace Elem Res. 2023 Dec 11. doi: 10.1007/s12011-023-03950.
Abstract

CHEN X, Qin Z, Zhu X, Wang L, et al
Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Sci Rep. 2023;13:21816.
Abstract

MENG F, Zhang Z
MicroRNA-152 specifically targets kinesin family member 14 to suppress the advancement of bladder cancer cells via PI3K/AKT pathway.
Biochem Biophys Res Commun. 2023;692:149337.
Abstract

CARRASCO R, Ingelmo-Torres M, Trullas R, Roldan FL, et al
Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
Int J Mol Sci. 2023;24:16578.
Abstract

NEDJADI T, Ahmed ME, Ansari HR, Aouabdi S, et al
Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis.
Cancers (Basel). 2023;15:5704.
Abstract

KHOUYA A, Pottgen C, Hoffmann C, Ringbaek TP, et al
Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer.
Cancers (Basel). 2023;15:5629.
Abstract

RODRIGUEZ-IZQUIERDO M, Del Canizo CG, Rubio C, Reina IA, et al
Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:5554.
Abstract

SANCHEZ-PELLICER P, Boix-Rodriguez C, Hernandez-Belmonte A, Encarnacion-Castellano C, et al
Bladder Cancer and Probiotics: What Do We Know So Far?
Cancers (Basel). 2023;15:5551.
Abstract

SEMENIUK-WOJTAS A, Modzelewska M, Poddebniak-Strama K, Kolaczynska S, et al
CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer.
Cancers (Basel). 2023;15:5529.
Abstract

OH CH
Clinical efficacy and safety of percutaneous drainage for post-operative fluid collection in patients with bladder cancer undergoing radical cystectomy and urinary diversion.
Medicine (Baltimore). 2023;102:e36488.
Abstract

LIU R, Yang J, Du Y, Yu X, et al
A "One Arrow Three Eagle" Strategy to Improve CM-272 Primed Bladder Cancer Immunotherapy.
Adv Mater. 2023 Dec 8:e2310522. doi: 10.1002/adma.202310522.
Abstract

LI Z, Li Y, Liu L, Zhang C, et al
Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Environ Toxicol. 2023 Dec 8. doi: 10.1002/tox.24066.
Abstract

CHEN H, Zhang Y, Chen X, Xu R, et al
Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
Cancer Med. 2023 Dec 8. doi: 10.1002/cam4.6617.
Abstract

ZHANG YH, Xie JJ, Wang JG, Wang Y, et al
[Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
Zhonghua Bing Li Xue Za Zhi. 2023;52:1216-1222.
Abstract

CHANG S, Bermoy ME, Chang SS, Scarpato KR, et al
Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal.
Sci Rep. 2023;13:21484.
Abstract

KWON AG, Brinzevich D, Borovik A, Bhalla R, et al
Ileal conduit to small intestine fistula following extensive abdominopelvic resection and radiation for metastatic colon cancer.
BMJ Case Rep. 2023;16:e254170.
Abstract

TAKAHASHI K, Urabe F, Suhara Y, Nakano J, et al
Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
Jpn J Clin Oncol. 2023;53:1208-1214.
Abstract

AL-QUDIMAT AR, Singh K, Ojha LK, Moustafa DA, et al
Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.
Front Surg. 2023;10:1276746.
Abstract

SHI X, Peng X, Chen Y, Shi Z, et al
Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Front Immunol. 2023;14:1326509.
Abstract

MATSON M, Tien T, Yardy G, Allchorne P, et al
The Use of Hospital Services by Patients With Muscle Invasive Bladder Cancer in the Last Year of Life: Identifying the Areas to Improve Care.
Cureus. 2023;15:e49175.
Abstract

HU H, Lai S, Wang M, Tang X, et al
Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis.
BMC Urol. 2023;23:212.
Abstract

CHEN Z, Liu Y, He A, Li J, et al
Author Correction: Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells.
Sci Rep. 2023;13:22896.
Abstract

LEBRET T, Bonastre J, Fraslin A, Neuzillet Y, et al
Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
BMJ Open. 2023;13:e075942.
Abstract

BAHLBURG H, Roghmann F
[Overall survival and cancer-specific mortality in patients with very high-risk non-muscle-invasive bladder cancer (NMIBC) : Retrospective analysis of a US American single-center cohort].
Urologie. 2023 Dec 21. doi: 10.1007/s00120-023-02252.
Abstract

SONG Y, Xu T
Letter to the editor for the article "Does the urinary microbiome profile change after treatment of bladder cancer?".
World J Urol. 2023;42:2.
Abstract

GALLIOLI A, Baboudjian M, Diana P, Moschini M, et al
Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
Minerva Urol Nephrol. 2023;75:672-682.
Abstract

INTELLIGENCE AND NEUROSCIENCE
Retracted: Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.
Comput Intell Neurosci. 2023;2023:9824189.
Abstract

HIMURA R, Kawano S, Nagata Y, Kawai M, et al
Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
Chem Biol Interact. 2023 Dec 18:110840. doi: 10.1016/j.cbi.2023.110840.
Abstract

SARAY KILIC H, Pazar B, Ibrahimoglu O, Naldan ME, et al
Quality of care perceived by patients during cystoscopy and affecting factors.
Medicine (Baltimore). 2023;102:e36314.
Abstract

XU Y, Li Q, Lin H
Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Cell Signal. 2023 Dec 17:111012. doi: 10.1016/j.cellsig.2023.111012.
Abstract

DIAZ ACEDO R, Galvan Banqueri M, Artacho Criado S, Fernandez Parra EM, et al
Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
Int J Clin Pharm. 2023 Dec 19. doi: 10.1007/s11096-023-01667.
Abstract

MATSUSHITA Y, Miyake M, Nishimura N, Nishimoto K, et al
Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
Int J Clin Oncol. 2023 Dec 19. doi: 10.1007/s10147-023-02447.
Abstract

PIERINI A, Criscuolo MC, Caccamo R, Bottero E, et al
A case series of urinary bladder rhabdomyosarcoma in seven dogs.
Open Vet J. 2023;13:1498-1503.
Abstract

PENG M, Chu X, Peng Y, Li D, et al
Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
MedComm (2020). 2023;4:e455.
Abstract

PENG J, Weng Z, Zhang C, Zhou G, et al
Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization.
Transl Androl Urol. 2023;12:1697-1707.
Abstract

WANG KR, Simhal RK, Dinatale GG, Li L, et al
Recurring cystitis cystica and cystitis glandularis masquerading as urothelial carcinoma.
Can J Urol. 2023;30:11752-11755.
Abstract

QIAN Z, Ye J, Friedlander DF, Koelker M, et al
Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries.
Can J Urol. 2023;30:11714-11723.
Abstract

OGURA R, Ito S, Ueda T, Gabata Y, et al
Author Correction: Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
Sci Rep. 2023;13:22350.
Abstract

DERRE L, Lucca I, Cesson V, Bohner P, et al
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
J Immunother Cancer. 2023;11:e008020.
Abstract

WONG C
The cancer physician who helped to deliver a life-extending treatment.
Nature. 2023;624:508.
Abstract

OBI H, Nagao K, Aoki M, Nagura S, et al
[Thoracic Endovascular Aortic Repair for Mycotic Thoracic Aortic Aneurysm After BCG Intravesical Therapy].
Kyobu Geka. 2023;76:1083-1089.
Abstract

NAVRIYA SC, Singh V, Choudhary GR, Tripathi S, et al
Postradical cystectomy delayed urethral recurrence: a rare presentation posing diagnostic dilemma.
BMJ Case Rep. 2023;16:e256700.
Abstract

LIN S, Chai Y, Zheng X, Xu X, et al
The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.
Mol Biol Rep. 2023;51:14.
Abstract

JAIN K, Datta C, Sengupta M, Pal DK, et al
Quest to develop a standard screening method for urothelial carcinoma using liquid-based cytology (The Paris System) and CK20.
Indian J Pathol Microbiol. 2023;66:720-726.
Abstract

BAI Y, Wu X, Weng M, Han Q, et al
The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
Indian J Pathol Microbiol. 2023;66:702-707.
Abstract

YUE R, Dutta A
Koopman-based Impulsive Model Predictive Control of BCG Immunotherapy.
Annu Int Conf IEEE Eng Med Biol Soc. 2023;2023:1-4.
Abstract

SUN J, Zhang Y, Yang L, Zhou L, et al
[High expression of long noncoding RNA UCA1 promotes invasion, migration and epithelial-mesenchymal transition of trophoblasts in vitro].
Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1984-1988.
Abstract

LESLIE M
Tumor-killing viruses score rare success in late-stage trial.
Science. 2023;382:1101-1102.
Abstract

ELLIS JL, Dalimov Z, Chew L, Quek ML, et al
Preoperative optimization of the radical cystectomy patient: Current state and future directions.
J Surg Oncol. 2024;129:138-144.
Abstract

WU P, Liu J, Wang X, Lai S, et al
Development and validation of a nomogram based on geriatric nutritional risk index for predicting prognosis and postoperative complications in surgical patients with upper urinary tract urothelial carcinoma.
J Cancer Res Clin Oncol. 2023;149:18185-18200.
Abstract

VARVIL MS, Clark SL, Bailey TW, Ramos-Vara JA, et al
Canine urothelial carcinoma: a pilot study of microRNA detection in formalin-fixed, paraffin-embedded tissue samples and in normal urine.
J Vet Diagn Invest. 2024;36:70-77.
Abstract

LI J, Huang X, Wang L, Wang X, et al
Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions.
Ultrasound Med Biol. 2024;50:295-303.
Abstract

HAN F, Wu Z, Chen J, Liu M, et al
The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.
Cancer Med. 2023;12:21129-21137.
Abstract

WEISS K, Gessner KH, Demzik A, Moreton E, et al
Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications.
Cancer Treat Res Commun. 2023;37:100779.
Abstract

CAI TN, Lu JL, Chen Z, Liu ZH, et al
Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette-Guerin perfusion.
Cancer Med. 2023;12:21279-21286.
Abstract

NADAL R, Valderrama BP, Bellmunt J
Progress in systemic therapy for advanced-stage urothelial carcinoma.
Nat Rev Clin Oncol. 2024;21:8-27.
Abstract

XU J, Zhang H, Zhang L, Chu X, et al
Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
Cancer Med. 2023;12:21159-21171.
Abstract

SANTONI M, Massari F, Takeshita H, Tapia JC, et al
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
Clin Exp Med. 2023;23:5413-5422.
Abstract

UC Trials Get Standing Ovation.
Cancer Discov. 2023;13:2496.
Abstract

TYSON MD, Abouassaly R, Durant A, Smith AB, et al
Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients.
Urol Pract. 2024;11:54-60.
Abstract

ZHANG WJ, Huang XY, Lin B, Zheng WC, et al
The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy.
Cancer Med. 2023;12:20930-20939.
Abstract

OHTSU A, Arai S, Fujizuka Y, Miyazawa Y, et al
Predictive models of long-term survival outcomes following radical cystectomy.
Cancer Med. 2023;12:21118-21128.
Abstract

GHELANI GH, Zerdan MB, Jacob J, Spiess PE, et al
HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
Urol Oncol. 2023;41:486.
Abstract

HOU Y, Du W, Wu Q, Chai X, et al
PDGFRA exhibits potential as an indicator of angiogenesis within the tumor microenvironment and is up-regulated in BLCA.
Microvasc Res. 2024;151:104614.
Abstract

SOLTANTABAR P, Alhadab A, Hibma J, Roychoudhury S, et al
Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma.
CPT Pharmacometrics Syst Pharmacol. 2023;12:2001-2012.
Abstract

LIU Y, Wang J
Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female.
Asian J Surg. 2023;46:5567-5568.
Abstract

KOMURA K, Tokushige S, Ishida M, Hirosuna K, et al
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Cancer Sci. 2023;114:4622-4631.
Abstract

JIANG Y, Tang Y, Zhang Q, Liang S, et al
Development of a nomogram for predicting overall survival in patients with urinary bladder carcinoma in situ based on SEER database analysis.
Asian J Surg. 2023;46:6015-6017.
Abstract

XIAO P, Liu J, Sun W, Wang J, et al
Large cell neuroendocrine carcinoma of the urinary bladder: A case report and literature review.
Asian J Surg. 2023;46:6049-6050.
Abstract

MAI Z, Yuan R, Wu L, Yan W, et al
Genetic testing and innovative surgery for familial urinary bladder paraganglioma: Report of two cases and literature review.
Asian J Surg. 2023;46:6053-6055.
Abstract

HE B, Chen Y, Hui Z
Primary pure bladder large cell neuroendocrine carcinoma: A case report.
Asian J Surg. 2023;46:5454-5455.
Abstract

WANG H, Fei J, Yu X
Synchronous renal pelvic urothelial carcinoma and oncocytoma: A case report.
Asian J Surg. 2023;46:5952-5953.
Abstract

CIVRIZ AH, Teke K, Akdas EM, Dillioglugil O, et al
The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
Urol Oncol. 2023;41:486.
Abstract

CANNON E, Ntala C, Joss N, Rahilly M, et al
High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia - Just a coincidence?
Clin Transplant. 2023 Aug 31:e15113. doi: 10.1111/ctr.15113.
Abstract

YU CC, Chang CH, Fang JK, Huang SK, et al
Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapy.
J Formos Med Assoc. 2023;122:1274-1281.
Abstract

UCCELLO M, Adeleke S, Moschetta M, Ghose A, et al
Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.
Ann Palliat Med. 2023;12:1345-1354.
Abstract

SANDA GE, Shabto JM, Goyal S, Liu Y, et al
Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
Oncologist. 2023;28:1072-1078.
Abstract

LINEHAN J, Gottlieb J, Woldu SL, Labbate C, et al
Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
Eur Urol Focus. 2023;9:1052-1058.
Abstract

KATSIMPERIS S, Tzelves L, Tandogdu Z, Ta A, et al
Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis.
Eur Urol Focus. 2023;9:920-929.
Abstract

SAKURAI Y, Furuto Y, Saito T, Namikawa A, et al
Disseminated Bacillus Calmette-Guerin Infection with Rhabdomyolysis, Acute Kidney Injury, and Interstitial Pneumonia after Bacillus Calmette-Guerin Intravesical Instillation Therapy.
Intern Med. 2023;62:3707-3712.
Abstract

LAUKHTINA E, Quhal F, von Deimling M, Kawada T, et al
For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy.
Eur Urol Focus. 2023;9:900-902.
Abstract

JAHANGIRIAN E, Zargan J, Rabbani H, Zamani J, et al
Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation.
J Biomol Struct Dyn. 2023;41:15354-15385.
Abstract

CHEN X, Chen H, Lin R, Li Y, et al
Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
J Clin Pathol. 2023;77:61-67.
Abstract

KIM HJ, Sim JY, Kim MB, Chang SW, et al
Unusual Cervical Lymph Node Metastasis of Papillary Urothelial Carcinoma.
Ear Nose Throat J. 2024;103:NP4-NP6.
Abstract

WANG Z, Kwan ML, Haque R, Pratt R, et al
Environmental and Occupational Exposures and Prognosis in Patients with Non-Muscle Invasive Bladder Cancer in the Be-Well Study.
Am J Epidemiol. 2023 Dec 5:kwad236. doi: 10.1093.
Abstract

CHEN SY, Chao CN, Huang HY, Zhao PW, et al
Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
Anticancer Res. 2023;43:1175-1184.
Abstract

LI JR, Wang SS, Lu K, Chen CS, et al
First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
Anticancer Res. 2023;43:1331-1339.
Abstract

YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
Anticancer Res. 2023;43:1725-1730.
Abstract

LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
Anticancer Res. 2023;43:1437-1448.
Abstract

LEE YH, Wu RC, Mai HC, Huang WL, et al
The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
Anticancer Res. 2023;43:1521-1531.
Abstract

SANO T, Aizawa R, Ito K, Nakamura K, et al
Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
Anticancer Res. 2023;43:2119-2126.
Abstract

TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
Anticancer Res. 2023;43:3607-3613.
Abstract

ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
Anticancer Res. 2023;43:3615-3621.
Abstract

MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
Anticancer Res. 2023;43:4055-4060.
Abstract

KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
Anticancer Res. 2023;43:4249-4254.
Abstract

SOMMER U, Grosser M, Aust D, Joehrens K, et al
PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
Anticancer Res. 2023;43:4365-4371.
Abstract

NISHIYAMA N, Kita Y, Ito K, Kato M, et al
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
Anticancer Res. 2023;43:5041-5050.
Abstract

FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
Anticancer Res. 2023;43:5689-5698.
Abstract

NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
BJU Int. 2023;131:306-312.
Abstract

BESIROGLU H
Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
Abstract

SMELSER WW, Wang J, Ogden KM, Chang SS, et al
Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
Abstract

ROSE KM, Narang G, Rosen G, Labatte C, et al
Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
BJU Int. 2023;131:471-476.
Abstract

UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
BJU Int. 2023;131:477-485.
Abstract

FREGO N, Contieri R, Diana P, Mancon S, et al
Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
Abstract

YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
Abstract

LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
BJU Int. 2023;131:571-580.
Abstract

BENJAMIN DJ, Lythgoe MP, Rezazadeh A
Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
BJU Int. 2023;131:691-693.
Abstract

CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
BJU Int. 2023;131:734-744.
Abstract

TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
BJU Int. 2023;131:755-762.
Abstract

DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
BJU Int. 2023;131:712-719.
Abstract

TAN WS, Grajales V, Bree K, Li R, et al
BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
Abstract

RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
Abstract

Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
BJU Int. 2023;132:2-3.
Abstract

DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
BJU Int. 2023;132:84-91.
Abstract

JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
Abstract

CONTIERI R, Grajales V, Tan WS, Martini A, et al
Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
Abstract

LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
Abstract

ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
BJU Int. 2023;132:291-297.
Abstract

VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
BJU Int. 2023;132:428-434.
Abstract

NECCHI A, Basile G, Gibb EA, Raggi D, et al
VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
Abstract

MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
Abstract

VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
Abstract

ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
Abstract

MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
BJU Int. 2023;132:671-677.
Abstract

HACK J, Douglas J, Makaroff L, Costin M, et al
Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
Abstract

VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
Abstract

VASDEV N
Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.
Abstract

YAMAMOTO S, Kato M, Takeyama Y, Azuma Y, et al
Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
Br J Cancer. 2023;128:2197-2205.
Abstract

SHALA NK, Stenehjem JS, Babigumira R, Liu FC, et al
Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
Abstract

LU J, Lai J, Xiao K, Peng S, et al
A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.
Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
Abstract

LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
Abstract

VIERGEVER BJ, Raats DAE, Geurts V, Mullenders J, et al
Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
Abstract

ZHUANG J, Shen L, Li M, Sun J, et al
Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance.
Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213.
Abstract

ZHANG L, Li Y, Zhou L, Zhou H, et al
The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response.
Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485.
Abstract

XIE R, Cheng L, Huang M, Huang L, et al
NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer.
Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233.
Abstract

OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
Cancer Res. 2023;83:1159.
Abstract

OUYANG Y, Ou Z, Zhong W, Yang J, et al
FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
Abstract

ZHAO Y, Chen J, Zheng H, Luo Y, et al
SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer.
Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
Abstract

LIU B, Fu X, Du Y, Feng Z, et al
Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Carcinogenesis. 2023;44:525-534.
Abstract

AGGEN DH, Chu CE, Rosenberg JE
Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
Clin Cancer Res. 2023;29:1377-1380.
Abstract

KLUMPER N, Ralser DJ, Ellinger J, Roghmann F, et al
Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
Clin Cancer Res. 2023;29:1496-1505.
Abstract

JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
Clin Cancer Res. 2023;29:2052-2065.
Abstract

ZHANG R, Zang J, Jin D, Xie F, et al
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
Abstract

JIANG D, Lan X, Cai W
PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
Clin Cancer Res. 2023;29:3259-3261.
Abstract

DUAN X, Xia L, Zhang Z, Ren Y, et al
First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
Clin Cancer Res. 2023;29:3395-3407.
Abstract

SALARI K, Sundi D, Lee JJ, Wu S, et al
Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
Clin Cancer Res. 2023;29:3668-3680.
Abstract

LI R, Sexton WJ, Dhillon J, Berglund A, et al
A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
Clin Cancer Res. 2023;29:3875-3881.
Abstract

KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
Abstract

MITRA A, Thompson B, Strange A, Amato CM, et al
A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
Clin Cancer Res. 2023;29:4242-4255.
Abstract

DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Clin Cancer Res. 2023;29:4373-4384.
Abstract

LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
Abstract

GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
Clin Cancer Res. 2023;29:4586-4595.
Abstract

LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Clin Cancer Res. 2023;29:4797-4807.
Abstract

MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
PET in bladder cancer imaging.
Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
Abstract

KATIMS AB, Bochner BH
Extended pelvic lymph node dissection in muscle invasive bladder cancer.
Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
Abstract

BERNDL F, Frerichmann J, Berndl T
Prevention and management of urinary tract infections after cystectomy.
Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
Abstract

KRAJEWSKI W, Laszkiewicz J, Nowak L, Szydelko T, et al
Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review.
Curr Opin Urol. 2023;33:230-238.
Abstract

MELLEMA JJ, van Rhijn BWG, van der Heijden MS
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
Abstract

YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
Curr Opin Urol. 2023;33:258-268.
Abstract

DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
Abstract

CANCEL-TASSIN G, Koutros S
Use of genomic markers to improve epidemiologic and clinical research in urology.
Curr Opin Urol. 2023;33:414-420.
Abstract

GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
AI-powered radiomics: revolutionizing detection of urologic malignancies.
Curr Opin Urol. 2024;34:1-7.
Abstract

IKEDA A, Nosato H
Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
Curr Opin Urol. 2024;34:27-31.
Abstract

CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
Eur J Cancer. 2023;187:58-64.
Abstract

SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
Abstract

STENZL A, Roupret M, Witjes JA, Gontero P, et al
High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
Eur Urol. 2023;83:193-194.
Abstract

GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
Abstract

MAITRE P, Sangar V, Choudhury A
ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
Abstract

MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
Eur Urol. 2023;83:377-378.
Abstract

BERGEROT CD, Gupta S
Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
Eur Urol. 2023;83:329-330.
Abstract

GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
Eur Urol. 2023;83:320-328.
Abstract

LENFANT L, Pinar U, Roupret M, Seisen T, et al
First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?
Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
Abstract

MOSCHINI M, Salonia A, Briganti A, Montorsi F, et al
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
Abstract

CERRATO C, Roupret M, Mir MC
Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
Abstract

CHENG C, Hu J, Chen J
Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
Abstract

LENFANT L, Pinar U, Roupret M, Seisen T, et al
Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
Abstract

GALSKY MD, Bajorin DF, Witjes JA, Gschwend JE, et al
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
Eur Urol. 2023;83:432-440.
Abstract

JUBBER I, Ong S, Bukavina L, Black PC, et al
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
Abstract

MOSCHINI M, Montorsi F
Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
Eur Urol. 2023;83:582.
Abstract

BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
Abstract

KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
Abstract

MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
Abstract

LAUKHTINA E, Shariat SF
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
Abstract

O'CALLAGHAN M
Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
Abstract

GRIVAS P, Park SH, Voog E, Caserta C, et al
Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
Eur Urol. 2023;84:95-108.
Abstract

ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
Eur Urol. 2023;84:49-64.
Abstract

SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
Eur Urol. 2023;84:117-126.
Abstract

FENG M, Matoso A, Epstein G, Fong M, et al
Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
Abstract

GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
Abstract

BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
Abstract

KOTI M, Robert Siemens D
A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
Abstract

FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
Abstract

LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
Oligometastatic Bladder Cancer: Defining a Novel Entity.
Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
Abstract

CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
Abstract

BASILE G, Audenet F, Seisen T, Pradere B, et al
The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
Abstract

SUSSMAN J, Konety B, Ahmadi H
Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
Abstract

BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
Abstract

ZLOTTA AR, Lajkosz K, Efstathiou JA
Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
Abstract

SEISEN T, Roupret M, Blanchard P
Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
Abstract

INAMURA K
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
Abstract

STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
Abstract

KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
Eur Urol. 2023;84:393-405.
Abstract

FENG M, Matoso A, Epstein G, Fong M, et al
Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
Abstract

KULKARNI GS, Wettstein MS
SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
Abstract

KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
Eur Urol. 2023;84:514-515.
Abstract

ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
Abstract

SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
Abstract

SWINTON M, Hoskin P, Choudhury A
Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
Abstract

MEEKS JJ, Black PC, Galsky M, Grivas P, et al
Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
Eur Urol. 2023;84:473-483.
Abstract

MARTINI A, Falagario UG, Russo A, Mertens LS, et al
Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
Eur Urol. 2023;84:484-490.
Abstract

WANG Z, Zeng S, Xu C
Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
Abstract

HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
Abstract

BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
Abstract

XIE Q, Shen D
Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
Eur Urol. 2024;85:e17-e18.
Abstract

PRASAD RAI B, Violette PD, Imran Omar M
Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
Eur Urol. 2024;85:e15-e16.
Abstract

HIEN TT, Ambite I, Wan MLY, Cavalera M, et al
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
Int J Cancer. 2023 Mar 9. doi: 10.1002/ijc.34500.
Abstract

HOSSEINI B, Zendehdel K, Bouaoun L, Hall AL, et al
Bladder cancer risk in relation to occupations held in a nationwide case-control study in Iran.
Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34560.
Abstract

YU EY, Tang QY, Chen YT, Zhang YX, et al
Genome-wide exploration of genetic interactions for bladder cancer risk.
Int J Cancer. 2023 Aug 28. doi: 10.1002/ijc.34690.
Abstract

SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
Abstract

PRADHAN P, Jia G, Khankari NK, Zheng W, et al
Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34736.
Abstract

ZHANG S, Zhang C, Liu W, Zheng W, et al
[Retracted] MicroRNAâ€‘24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3.
Int J Oncol. 2023;62:67.
Abstract

HWANG TI, Cuiu YC, Chen YC, Chen PC, et al
Tumor suppressive functions of hsaâ€‘miRâ€‘34a on cell cycle, migration and protective autophagy in bladder cancer.
Int J Oncol. 2023;62:66.
Abstract

LI Z, Jiang Y, Liu J, Fu H, et al
Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway.
Int J Oncol. 2023;63:84.
Abstract

WANG Z, Li L, Chu C, Wei X, et al
CUDC?101 is a potential target inhibitor for the EGFR?overexpression bladder cancer cells.
Int J Oncol. 2023;63:131.
Abstract

MOEEN AM
Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
Int J Urol. 2023;30:270-271.
Abstract

CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
Int J Urol. 2023;30:258-263.
Abstract

MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
Int J Urol. 2023;30:328-330.
Abstract

SINGH A, Kayina CA, Naik N, Ganesh V, et al
Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
Int J Urol. 2023;30:264-270.
Abstract

MATSUMOTO K
Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
Abstract

MASTROIANNI R, Torregiani G, Simone G
Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
Int J Urol. 2023;30:373-374.
Abstract

TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
Int J Urol. 2023;30:366-373.
Abstract

LIU Z, Leow JJ, Yong DZP
Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
Abstract

CHOO ZW, Leow JJ, Vong E, Chia PL, et al
Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
Int J Urol. 2023;30:471-472.
Abstract

TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
Int J Urol. 2023;30:464-471.
Abstract

MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
Abstract

GOTO Y
Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:647-648.
Abstract

YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:634-647.
Abstract

KONDO T
Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:657.
Abstract

SAZUKA T
Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:658.
Abstract

OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
Int J Urol. 2023;30:649-657.
Abstract

HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
Int J Urol. 2023;30:579-584.
Abstract

ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
Int J Urol. 2023;30:572-578.
Abstract

GOTO Y
Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
Abstract

NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
Abstract

LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
Abstract

SZARVAS T
Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
Abstract

SATO T, Sano T, Kawamura S, Ikeda Y, et al
Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
Abstract

KIKUCHI E, Hayakawa N
Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
Int J Urol. 2023;30:786-787.
Abstract

HARA T, Furukawa J, Okamura Y, Bando Y, et al
The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
Int J Urol. 2023;30:779-786.
Abstract

TOMISAKI I, Harada M, Sakano S, Terado M, et al
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
Int J Urol. 2023;30:738-745.
Abstract

ITO K, Kita Y, Kobayashi T
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Int J Urol. 2023;30:696-703.
Abstract

GOTO Y
Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Int J Urol. 2023;30:704.
Abstract

KIKUCHI E, Hayakawa N
Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
Abstract

FUKUSHIMA H
Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
Abstract

SHIGETA K
Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
Int J Urol. 2023;30:859.
Abstract

KU JH, Lee LS, Lin TP, Kikuchi E, et al
Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
Abstract

TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
Int J Urol. 2023;30:936-938.
Abstract

SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
Int J Urol. 2023;30:853-858.
Abstract

MORI K
Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:1059.
Abstract

CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
Int J Urol. 2023;30:1014-1019.
Abstract

KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
Int J Urol. 2023;30:1056-1058.
Abstract

TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
Abstract

ROSAZZA M, Soria F, Gontero P
Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
Abstract

NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
Abstract

HASHIMOTO T
Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Int J Urol. 2023;30:1186-1187.
Abstract

TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
Int J Urol. 2023;30:1180-1186.
Abstract

KATO M, Uchida J
Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
Int J Urol. 2023;30:1068-1077.
Abstract

GOTO Y
Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
Abstract

ARAI S
Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
Abstract

DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
Int Urol Nephrol. 2023;55:541-546.
Abstract

QIU Y, Zhang X, Dong Z, Zhang Y, et al
Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
Int Urol Nephrol. 2023;55:579-588.
Abstract

GRIZZI F, Hegazi MAAA, Taverna G
Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
Abstract

NISHIHARA D, Kijima T, Arai K, Kamai T, et al
Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
Int Urol Nephrol. 2023;55:867-874.
Abstract

FU W, Liu D, Xiong Y, Liu C, et al
The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
Int Urol Nephrol. 2023;55:1073-1079.
Abstract

YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
Int Urol Nephrol. 2023;55:1459-1465.
Abstract

SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
Abstract

KABA M, Pirincci N, Demir M, Kaba S, et al
The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
Abstract

MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
Int Urol Nephrol. 2023;55:1719-1726.
Abstract

KIM SH, Choi BG, Oh JS, Chun HJ, et al
Upper tract heparin instillation for maintenance of ureteral stent patency.
Int Urol Nephrol. 2023;55:1893-1897.
Abstract

OPPOLZER IA, Riester J, Buttner R, Burger M, et al
Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
Int Urol Nephrol. 2023;55:1943-1949.
Abstract

WANG Z, Yang Z, Qu C, Li J, et al
Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
Int Urol Nephrol. 2023;55:1957-1970.
Abstract

OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
Int Urol Nephrol. 2023;55:2161-2167.
Abstract

WANG IK, Yu TM, Yen TH, Lin CL, et al
Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
Int Urol Nephrol. 2023;55:2267-2274.
Abstract

ASSEM A, Kassem A, Sherif M, Lotfi A, et al
Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
Abstract

YOU C, Li Q, Qing L, Li R, et al
Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
Abstract

KHALIFA SE
Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
Int Urol Nephrol. 2023;55:2473-2481.
Abstract

XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
Abstract

KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
Abstract

GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
Int Urol Nephrol. 2023;55:2765-2772.
Abstract

GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
Abstract

WEI C, Deng C, Dong R, Hou Y, et al
Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
Abstract

PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
Abstract

MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
Abstract

BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
Abstract

COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
J Clin Oncol. 2023;41:1618-1625.
Abstract

SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
J Clin Oncol. 2023;41:3225-3235.
Abstract

POWLES T, Park SH, Caserta C, Valderrama BP, et al
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
J Clin Oncol. 2023;41:3486-3492.
Abstract

STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
J Clin Oncol. 2023;41:3772-3781.
Abstract

JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
J Clin Oncol. 2023;41:3771.
Abstract

BOSL GJ
Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
J Clin Oncol. 2023;41:3769-3770.
Abstract

SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
Abstract

VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
J Clin Oncol. 2023;41:3881-3890.
Abstract

SMALL EJ
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
J Clin Oncol. 2023;41:3879-3880.
Abstract

SIEFKER-RADTKE AO, Cauley D, Alhalabi O
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
J Clin Oncol. 2023;41:4084-4086.
Abstract

KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
Abstract

CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
J Clin Oncol. 2023;41:5131-5139.
Abstract

HE W, Zeng S, Xu C
Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
Abstract

PENG CK, Sung WW, Chen SL
Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
Abstract

PENG CK, Sung WW
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
J Urol. 2023;209:676-677.
Abstract

LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
J Urol. 2023;209:762-772.
Abstract

STEINBERG RL, O'Donnell MA, Packiam VT
Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
Abstract

MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
Abstract

TYSON MD, Morris D, Palou J, Rodriguez O, et al
Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
J Urol. 2023;209:890-900.
Abstract

GILBERT SM
Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
J Urol. 2023;209:833-835.
Abstract

GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
J Urol. 2023;209:854-862.
Abstract

KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
J Urol. 2023;209:882-889.
Abstract

YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
J Urol. 2023;209:863-871.
Abstract

CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
J Urol. 2023;209:901-910.
Abstract

LABBATE C, Woldu S, Murray K, Rose K, et al
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
J Urol. 2023;209:872-881.
Abstract

COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
J Urol. 2023;209:1071-1081.
Abstract

WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
J Urol. 2023;209:1202-1209.
Abstract

BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
Abstract

PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
J Urol. 2023;210:222.
Abstract

JI J, Lai CH, Wang Q, Hu H, et al
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
Abstract

TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
Abstract

PRASAD SM, Huang WC, Shore ND, Hu B, et al
Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
Abstract

CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
J Urol. 2023;210:408.
Abstract

WONG N, So WZ, Tiong HY
Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
J Urol. 2023;210:407-408.
Abstract

PRASAD SM
Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
Abstract

MURTHY PB, Sexton WJ
Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
Abstract

BREE KK, Navai N
Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
Abstract

BREE K, Navai N
Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
Abstract

SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
Abstract

SUN J, Zhang H, Wei W, Xiao X, et al
Regulation of CD8(+) T cells infiltration and immunotherapy by circMGA/HNRNPL complex in bladder cancer.
Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02637.
Abstract

NEYRET-KAHN H, Fontugne J, Meng XY, Groeneveld CS, et al
Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
Oncogene. 2023 Mar 22. doi: 10.1038/s41388-023-02662.
Abstract

JIA Y, Ding X, Zhou L, Zhang L, et al
Retraction Note: Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.
Oncogene. 2023 May 30. doi: 10.1038/s41388-023-02726.
Abstract

XIE J, Zhang H, Wang K, Ni J, et al
M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
Oncogene. 2023 Aug 23. doi: 10.1038/s41388-023-02814.
Abstract

RAMAL M, Corral S, Kalisz M, Lapi E, et al
The urothelial gene regulatory network: understanding biology to improve bladder cancer management.
Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02876.
Abstract

YU J, Li M, Ju L, Zhou F, et al
TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC.
Oncogene. 2023 Dec 20. doi: 10.1038/s41388-023-02922.
Abstract

CHEN JX, Chen DM, Wang D, Xiao Y, et al
METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
Oncol Rep. 2023;49:94.
Abstract

LIU X, Tong Y, Huang Q, He Y, et al
CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway.
Oncol Rep. 2023;49:103.
Abstract

ZHANG C, Wang R, Li M, Yang Q, et al
Long nonâ€‘coding RNA BLACAT2/miRâ€‘378aâ€‘3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Oncol Rep. 2023;49:108.
Abstract

HO JN, Jeon JS, Kim DH, Ryu H, et al
CUDCâ€‘907 suppresses epithelialâ€‘mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
Oncol Rep. 2023;49:130.
Abstract

HAO Y, He W, Wang H, Rui W, et al
Forkhead box F1 functions as a novel prognostic biomarker and induces caspaseâ€‘dependent apoptosis in bladder cancer.
Oncol Rep. 2023;50:173.
Abstract

SONG W, Li Z, Xia M, Xiao W, et al
Regulation of Drp1 and enhancement of mitochondrial fission by the deubiquitinating enzyme PSMD14 facilitates the proliferation of bladder cancer cells.
Oncol Rep. 2024;51:6.
Abstract

YE G, Tu L, Li Z, Li X, et al
SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy.
Oncol Rep. 2024;51:14.
Abstract

CHEN F, Chen X, Yang D, Che X, et al
[Retracted] Isoquercitrin inhibits bladder cancer progression in vitro and in vivo by regulating the PI3K/Akt and PKC signaling pathways.
Oncol Rep. 2024;51:25.
Abstract

GABRIEL PE, Pinar U, Parra J, Vaessen C, et al
[Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review].
Prog Urol. 2023;33:145-154.
Abstract

CIMIER A, Thach S, Lacroix B, Mariat C, et al
[Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer].
Prog Urol. 2023 Mar 9:S1166-7087(23)00062-3. doi: 10.1016/j.purol.2023.
Abstract

SOOROJEBALLY Y, Neuzillet Y, Lebret T, Allory Y, et al
Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
Prog Urol. 2023 Apr 21:S1166-7087(23)00083-0. doi: 10.1016/j.purol.2023.
Abstract

GABRIEL PE, Lambert T, Dumont C, Gauthier H, et al
[Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function].
Prog Urol. 2023;33.
Abstract

ARNAUD Q, Sebe P, Colau A, Mouton M, et al
Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
Prog Urol. 2023 Nov 16:S1166-7087(23)00238-5. doi: 10.1016/j.purol.2023.
Abstract

GALLON J, LeMaoult J, Verine J, Dumont C, et al
[Profile and immune environment of upper tract urothelial carcinoma].
Prog Urol. 2023;33.
Abstract

BRUNEAUX E, Iborra F, Trouche-Sabatier SG, Foucan AS, et al
[Bladder tumors in the Herault department: Results of the Herault tumor registry registration from1987 to 2019].
Prog Urol. 2023;33.
Abstract

FU Y, Liu K, Jiang X, Zhao L, et al
Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through miR-1184/RAP2B Axis.
Urol Int. 2023 Mar 23:1-14. doi: 10.1159/000527873.
Abstract

HAAS M, Knobloch C, Mayr R, Gierth M, et al
Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications.
Urol Int. 2023;107:246-256.
Abstract

MEYER HJ, Wienke A, Zamsheva M, Surov A, et al
Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
Urol Int. 2023;107:219-229.
Abstract

CHEN S, Gao Y, Chen F, Wang TB, et al
ANLN Serves as an Oncogene in Bladder Urothelial Carcinoma via Activating JNK Signaling Pathway.
Urol Int. 2023;107:310-320.
Abstract

HAEUSER L, Marchese M, Noldus J, Kibel AS, et al
Association between Operative Time and Short-Term Radical Cystectomy Complications.
Urol Int. 2023;107:273-279.
Abstract

GRUNE B, Menold H, Lenhart M, Muhlbauer J, et al
Patient Compliance in Assessing Electronic Patient-Reported Outcome Measures after Urologic Surgery.
Urol Int. 2023;107:280-287.
Abstract

BOLENZ C, Kunath F, Zengerling F, Wezel F, et al
Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials.
Urol Int. 2023;107:480-488.
Abstract

DU J, Zhan H, Chen J, Wang J, et al
The Influence of Preoperative Hydronephrosis on the Prognosis after Radical Cystectomy among Patients with Different Pathological Stages of Bladder Cancer.
Urol Int. 2023 Jun 2:1-8. doi: 10.1159/000531080.
Abstract

GRUNE B, Kowalewski KF, Weiss C, Neuberger M, et al
Predicting Complexity in Transurethral Resection of Bladder Tumours: External Validation and Modification of the Bladder Complexity Score.
Urol Int. 2023;107:583-590.
Abstract

WU YL, Li ZQ, Wu AM
The Misdiagnosis of Intravesical Ectopic Prostatic Tissue as a Tumor.
Urol Int. 2023;107:738-741.
Abstract

JIAO H, Wang L, Zhou X, Wu J, et al
Prognostic Ability of Nutritional Indices for Outcomes of Bladder Cancer: A Systematic Review and Meta-Analysis.
Urol Int. 2023 Aug 29:1-9. doi: 10.1159/000531884.
Abstract

CHEN Z
The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway.
Urol Int. 2023 Sep 4:1-9. doi: 10.1159/000532128.
Abstract

STRUCK JP, Ozimek T, Schnoor M, Offermann A, et al
The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours.
Urol Int. 2023;107:792-800.
Abstract

BOKARICA P, Alfirevic M, Hrkac A, Glas AM, et al
Letter to the Editor regarding the Article "Postoperative Mortality Rate after Radical Cystectomy: A Systematic Review of Epidemiologic Series".
Urol Int. 2023;107:839-840.
Abstract

SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
Urol Int. 2023;107:841-847.
Abstract

YUAN P, Li X, Yuan Y, Xu P, et al
Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma Case.
Urol Int. 2023;107:895-898.
Abstract

GUO L, Zhang T, Taisheng L, Chen J, et al
Laparoscopic Radical Cystectomy With Ileal Orthotopic Neobladder for Bladder Cancer: Current Indications and Outcomes.
Urol Int. 2023 Nov 23. doi: 10.1159/000535032.
Abstract

GUO Y, Li C, Zhang S, Zhu G, et al
U-Net-Based Assistive Identification of Bladder Cancer: A Promising Approach for Improved Diagnosisc.
Urol Int. 2023 Dec 11. doi: 10.1159/000535652.
Abstract

WANG C, Yu H, Fu W, Chen G, et al
Transurethral Hem-o-lok Clip Ligation of the Distal Ureter in Retroperitoneal Laparoscopic Radical Nephroureterectomy.
Urol Int. 2023;107.
Abstract

TULONE G, Pavan N, Giannone S, Abrate A, et al
Double-Layered Hand-Sewn versus Stapled Intestinal Anastomosis in Patients Who Underwent Ileal Urinary Diversion in Radical Cystectomy: A Comparative and Cost Effective Study.
Urol Int. 2023;107.
Abstract

CHUN B, He M, Jones C, Vasan R, et al
Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
Urology. 2023 Mar 25:S0090-4295(23)00267-4. doi: 10.1016/j.urology.2023.
Abstract

DONAT SM, Sonoda Y, Al-Ahmadie H, Murali R, et al
Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary Tract.
Urology. 2023;173:10-16.
Abstract

RAM P, Mandal S, Das MK, Nayak P, et al
Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Res
Urology. 2023;173:229.
Abstract

MILLER DT, Sun Z, Grajales V, Pekala KR, et al
Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer.
Urology. 2023 Apr 5:S0090-4295(23)00270-4. doi: 10.1016/j.urology.2023.
Abstract

ZHANG JH, Starr SL, Chamie K
Contemporary Systemic Therapies in Urothelial Carcinoma.
Urology. 2023;174:150-158.
Abstract

JUE JS, Armenakas NA
Upper Tract Tumor En Bloc Enucleation: A Novel Approach to the Diagnosis and Management of Upper Tract Urothelial Carcinoma.
Urology. 2023;174:196-200.
Abstract

SONG SH, Kim JH, Lee S, Hong SK, et al
Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
Urology. 2023;174:111-117.
Abstract

PASTER IC, Zeng J, Recio-Boiles A, Chipollini J, et al
Gender, racial and ethnic differences in pathologic response following neoadjuvant chemotherapy for bladder cancer patients.
Urology. 2023 May 23:S0090-4295(23)00446-6. doi: 10.1016/j.urology.2023.
Abstract

WAHLEN MM, McElree IM, Packiam VT
Editorial Comment On: Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
Urology. 2023 May 19:S0090-4295(23)00371-0. doi: 10.1016/j.urology.2023.
Abstract

GROOTEMAAT M, Tjiam I, Sampimon D, Bot F, et al
Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes Complicated.
Urology. 2023;175:e11-e12.
Abstract

TAN WP
An Atypical Bladder Mass: Extra Adrenal Paraganglioma.
Urology. 2023;176:e8-e9.
Abstract

ERGUN O, Alperen Ozturk S, Kircicek F, Gurdal O, et al
Increased Plasma Ignition Distance Practice may Prevent the Obturator Reflex Occurrences and Compare of its Effectiveness Versus Obturator Block: A Prospective, Randomized, Controlled Study.
Urology. 2023;176:226-231.
Abstract

PASTER IC, Chipollini J
Reply: Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients.
Urology. 2023 Jul 11:S0090-4295(23)00448-X. doi: 10.1016/j.urology.2023.
Abstract

SEKAR RR, Maganty A
Impact of Race, Ethnicity, and Gender on Response to Neoadjuvant Chemotherapy and Survival in Patients With Muscle-invasive Bladder Cancer.
Urology. 2023 Jul 11:S0090-4295(23)00447-8. doi: 10.1016/j.urology.2023.
Abstract

JEVNIKAR B, Slopnick E, Almassi N
Clinical Challenge in Urology: Late Genitourinary Toxicity Following Intravesical Bacillus Calmette-Guerin.
Urology. 2023;177:e8-e9.
Abstract

GELDMAKER LE, Baird BA, Hasse CH, Haehn DA, et al
Analysis of Transurethral Resection of Bladder Tumor Efficiency Utilizing Nonprocedural Operating Room Times.
Urology. 2023;177:6-11.
Abstract

KANABOLO DL, Park S
Prophylactic Mesh Placement With Ileal Conduit: A Cost-effectiveness Analysis.
Urology. 2023;177:197-203.
Abstract

FENG S, Yang Y, Yu Z, Xiong Q, et al
Survival and Analysis of Prognostic Factors for Bladder Malignancies in Children and Adolescents: A Population-based Study.
Urology. 2023;177:156-161.
Abstract

SOYSTER ME, Arnold PJ, Burns RT, Zappia JL, et al
Ileal Ureter Utilization in Patients With Previous Urinary Diversions.
Urology. 2023;177:184-188.
Abstract

RANTI D, Dey L, Bieber C, Grauer R, et al
Surveillance for Non-Muscle Invasive Bladder Cancer: Identifying the point of Diminishing Returns.
Urology. 2023 Aug 19:S0090-4295(23)00697-0. doi: 10.1016/j.urology.2023.
Abstract

HYMAN MJ, Skolarus TA, Litwack K, Meltzer DO, et al
Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists.
Urology. 2023;178:67-75.
Abstract

LYALL V, Aziz Ould Ismail A, Haggstrom DA, Issa MM, et al
Accurate Documentation Contributes to Guideline-concordant Surveillance of Non-Muscle Invasive Bladder Cancer: a Multi-site VA Study.
Urology. 2023 Sep 1:S0090-4295(23)00729-X. doi: 10.1016/j.urology.2023.
Abstract

NABAVIZADEH R, Pessoa RR, Dumbrava MG, Packiam VT, et al
Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary Series.
Urology. 2023 Sep 7:S0090-4295(23)00733-1. doi: 10.1016/j.urology.2023.
Abstract

PENN T, Borza T, Liou JI, Jason Abel E, et al
The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes.
Urology. 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.
Abstract

HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
Abstract

VEJLGAARD M, Maibom SL, Joensen UN, Moser C, et al
Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer.
Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
Abstract

MAJDALANY SE, Yaguchi G, Arora S, Ray C, et al
Genital Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Neobladder & Paravaginal Repair.
Urology. 2023;179:202-203.
Abstract

HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
Reply by Authors: Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
Urology. 2023 Oct 21:S0090-4295(23)00810-5. doi: 10.1016/j.urology.2023.
Abstract

GRECO F, Domanico L, Lembo F
Editorial Comment to Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
Urology. 2023 Oct 21:S0090-4295(23)00809-9. doi: 10.1016/j.urology.2023.
Abstract

GALOSI AB, Fave RFD, Perpepaj L, Milanese G, et al
Does Alexis(c) wound protector/retractor reduce the risk of surgical site infections after open radical cystectomy for bladder cancer? Results from a single center, comparative study.
Urology. 2023 Nov 6:S0090-4295(23)00951-2. doi: 10.1016/j.urology.2023.
Abstract

ARCEO-OLAIZ R, Smith EA, Stokes C, Eaton BR, et al
Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report.
Urology. 2023;181:136-140.
Abstract

TUA-CARACCIA R, Livingston A, Routh JC
Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
Urology. 2023;181:133-135.
Abstract

GUL ZG, Wu S, Raver M, Vasan R, et al
A Multipronged Intervention to Reduce Readmissions and Readmission Intensity After Radical Cystectomy.
Urology. 2023;182:155-160.
Abstract

ZHU A, Srivastava A
Editorial Comment: Does Alexis Wound Protector/Retractor Reduce the Risk of Surgical Site Infections After Open Radical Cystectomy for Bladder Cancer? Results From a Single Center, Comparative Study.
Urology. 2023 Dec 14:S0090-4295(23)00958-5. doi: 10.1016/j.urology.2023.
Abstract

YANG X, Zhang S, Cui Y, Li Y, et al
Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
BMC Cancer. 2023;23:320.
Abstract

TANG Y, Lei Y, Gao P, Jia J, et al
Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
BMC Cancer. 2023;23:328.
Abstract

HUI P, Ni F, Zheng L, Jia L, et al
Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
BMC Cancer. 2023;23:355.
Abstract

KOLL FJ, Doring C, Olah C, Szarvas T, et al
Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
BMC Cancer. 2023;23:504.
Abstract

RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
BMC Cancer. 2023;23:539.
Abstract

NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
BMC Cancer. 2023;23:565.
Abstract

LIU J, Wu P, Lai S, Wang J, et al
Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
BMC Cancer. 2023;23:574.
Abstract

KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
BMC Cancer. 2023;23:605.
Abstract

LIANG PI, Lai HY, Chan TC, Li WM, et al
Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
BMC Cancer. 2023;23:599.
Abstract

LI W, Liu Z, Jin K, Shao F, et al
Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
BMC Cancer. 2023;23:661.
Abstract

JIANG Y, Zhu C, Huang H, Huang G, et al
TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
BMC Cancer. 2023;23:716.
Abstract

CAI Y, Cheng Y, Wang Z, Li L, et al
A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
BMC Cancer. 2023;23:725.
Abstract

NASR S, Haddad FG, Khazen J, Kattan J, et al
PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
BMC Cancer. 2023;23:817.
Abstract

TSAI TH, Su PJ, Huang SY, Kuo MC, et al
The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
BMC Cancer. 2023;23:871.
Abstract

WANG Y, Pan J, An F, Chen K, et al
GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
BMC Cancer. 2023;23:925.
Abstract

ALT M, Stecca C, Lin Y, Kazeem G, et al
Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
BMC Cancer. 2023;23:919.
Abstract

HE Q, Wu S, Zhou Y, Liu Y, et al
Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
BMC Cancer. 2023;23:965.
Abstract

ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
BMC Cancer. 2023;23:956.
Abstract

TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
BMC Cancer. 2023;23:940.
Abstract

LUO L, Xie Q, Wu Y, Li P, et al
Circular RNA CCT3 is a unique molecular marker in bladder cancer.
BMC Cancer. 2023;23:977.
Abstract

CHEN JX, Huang WT, Zhang QY, Deng CE, et al
The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
BMC Cancer. 2023;23:1018.
Abstract

LI Y, Xu K, Zhang Y, Mao H, et al
Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
BMC Cancer. 2023;23:1021.
Abstract

LU L, Chen C, Cheng H, Ding H, et al
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
BMC Cancer. 2023;23:1066.
Abstract

ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
BMC Cancer. 2023;23:1080.
Abstract

GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
BMC Cancer. 2023;23:1127.
Abstract

THOMAS R, Wiley CA, Droste EL, Robertson J, et al
Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
PLoS Genet. 2023;19:e1010575.
Abstract

WEINBERG L, Aitken SAA, Kaldas P, Fletcher L, et al
Postoperative complications and hospital costs following open radical cystectomy: A retrospective study.
PLoS One. 2023;18:e0282324.
Abstract

LIU CL, Tsai HW, Peng SL, Chang CP, et al
CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
PLoS One. 2023;18:e0281873.
Abstract

SMITH-TOGOBO C, Mprah R, Yeboah EA, Anyidoho HK, et al
Detection of cytological abnormalities in urothelial cells from individuals previously exposed or currently infected with Schistosoma haematobium.
PLoS One. 2023;18:e0278202.
Abstract

Expression of Concern: The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
PLoS One. 2023;18:e0284938.
Abstract

HAMID ARAH, Syadza YZ, Yausep OE, Christanto RBI, et al
The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: A systematic review.
PLoS One. 2023;18:e0269214.
Abstract

VAINER G, Huang L, Emancipator K, Nuti S, et al
Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
PLoS One. 2023;18:e0285764.
Abstract

SATO N, Mori KP, Sakai K, Miyata H, et al
Exploring the mechanism of BK polyomavirus-associated nephropathy through consensus gene network approach.
PLoS One. 2023;18:e0282534.
Abstract

YUAN Q, Hu J, Yuan F, An J, et al
Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.
PLoS One. 2023;18:e0288077.
Abstract

LEE J, Kim E, Park J, Choi S, et al
Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis.
PLoS One. 2023;18:e0291198.
Abstract

LEONARDO K, Mirza H, Seno DH, Purnomo N, et al
Transperitoneal vs extraperitoneal radical cystectomy: A systematic review and meta-analysis.
PLoS One. 2023;18:e0294809.
Abstract

WANG E, Hagberg O, Malmstrom PU
The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
PLoS One. 2023;18:e0292174.
Abstract

WONG JL, Smith P, Angulo-Lozano J, Ranti D, et al
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
Proc Natl Acad Sci U S A. 2023;120:e2306782120.
Abstract

ZHAO Z, Aoi Y, Philips CN, Meghani KA, et al
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
Proc Natl Acad Sci U S A. 2023;120:e2310063120.
Abstract

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.

;